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Abstract	
Hydrogels	 are	of	 great	 interest	due	 to	 their	 ability	 to	encapsulate	and	deliver	bioactive	
molecules,	mimic	the	extracellular	matrix	(ECM)	and	act	as	an	artificial	3D	scaffold.	Here	
we	report	multi-component	hydrogels	based	on	low-molecular-weight	gelators	(LMWGs)	
and	 polymer	 gelators	 (PGs)	 incorporating	 heparin	 that	 can	 bind	 to	 self-assembled	
molecules,	and	their	potential	for	controlled	release	and	to	mimic	the	ECM.	These	multi-
component	 systems	 were	 characterised	 and	 the	 orthogonality	 of	 each	 individual	
component	investigated.		
	
Firstly,	three	cationic	surfactants	were	synthesised	and	their	ability	to	self-assemble	and	
bind	to	polyanionic	heparin	was	 investigated.	The	systems	consisted	of	an	amine-based	
head	 group	 connected	 via	 an	 amide	 linkage	 to	 different	 saturated	 fatty	 acids.	 Self-
assembled	 C14-DAPMA	 and	 C16-DAPMA	 formed	 highly	 organised	 polycrystalline	
assemblies	with	heparin,	proving	 that	 the	micelles	 remain	 intact	during	 the	hierarchical	
assembly	process.	C16-DAPMA	proved	to	be	the	most	charge-efficient	heparin	binder,	also	
with	 the	 lowest	 critical	 aggregation	 concentration,	 with	 high	 stability	 when	 free	 and	
solution	and	when	electrostatically	interacting	with	heparin.		
	
Two	 dibenzylidene-D-sorbitol	 (DBS)	 derivatives	 capable	 of	 forming	 hydrogels	 are	 then	
introduced:	 a	 pH-activated	 LMWG	 (DBS-COOH)	 and	 a	 thermally-activated	 LWMG	 (DBS-
CONHNH2).	The	 incorporation	and	release	of	heparin	 from	the	LMWGs	hydrogels	 in	the	
presence	and	absence	of	C16-DAPMA,	and	from	hybrid	hydrogels	consisting	of	one	of	the	
LMWGs	 and	 a	 PG	 -	 agarose	 is	 reported.	 The	 rate	 of	 heparin	 release	 can	 be	 controlled	
through	 network	 density	 and	 composition,	 and	 control	 of	 the	 release	 surface	 area	 to	
volume	ratio,	while	the	presence	of	C16-DAPMA	inhibits	heparin	release.	Characterisation	
of	 this	 multi-component	 complexes	 (LMWG	 +	 Heparin	 +	 C16-DAPMA)	 showed	 the	
orthogonal	 self-assembly	 of	 each	 individual	 component	 within	 one	 single	 system.	
Cytocompatilibity	 of	 the	 multi-component	 hydrogels	 is	 reported.	 Heparin	 was	 then	
incorporated	and	released	from	three	different	hydrogels	based	on	triamide	cyclohexane	
derivatives.	From	these,	a	positively	charged	LMWG	able	to	directly	interact	with	heparin,	
resulted	 in	 the	 triggered	 release	 of	 heparin	 by	 hydrogel	 disruption	 through	 enzymatic	
cleavage.				
3	
	
Table	of	Contents	
Abstract	........................................................................................................................	2	
Table	of	Contents	..........................................................................................................	3	
List	of	Figures	................................................................................................................	7	
List	of	Tables	................................................................................................................	23	
List	of	Schemes	.............................................................................................................	24	
List	of	Equations	...........................................................................................................	25	
Acknowledgements	......................................................................................................	27	
Declaration	...................................................................................................................	28	
1.	 Introduction	..........................................................................................................	29	
1.1.	 Introduction	to	Gels	...........................................................................................	29	
1.1.1.	 Supramolecular	Chemistry	.........................................................................	29	
1.1.2.	 Self-Assembly	.............................................................................................	30	
1.1.3.	 Supramolecular	Gels	...................................................................................	33	
1.2.	 Typical	Hydrogelators	.........................................................................................	37	
1.3.	 Multicomponent	Gels	.........................................................................................	46	
1.4.	 Controlled	Release	from	Gels	.............................................................................	52	
1.5.	 Tissue	Engineering	in	Gels	..................................................................................	57	
1.6.	 Heparin	and	its	Applications	...............................................................................	63	
1.6.1.	 Multivalency	...............................................................................................	68	
1.6.2.	 Self-Assembling	Multivalency	(SAMul)	.......................................................	70	
1.7.	 Project	Aims	.......................................................................................................	71	
2.	 DAPMA-based	Self-Assembling	Multivalent	Ligands	for	Heparin	Binding	..............	73	
2.1.	 Introduction	........................................................................................................	73	
2.2.	 Synthesis	of	Amphiphilic	Heparin	Binders	..........................................................	74	
2.3.	 Nile	Red	Assay	....................................................................................................	76	
4	
	
2.4.	 Mallard	Blue	Assay	.............................................................................................	79	
2.5.	 Dynamic	Light	Scattering	(DLS)	and	Zeta	Potential	............................................	83	
2.6.	 Transmission	Electron	Microscopy	(TEM)	..........................................................	87	
2.7.	 Modelling	Heparin	Binding	.................................................................................	89	
2.8.	 Small	Angle	X-Ray	Scattering	(SAXS)...................................................................	91	
2.9.	 Degradation	Studies	...........................................................................................	95	
2.10.	 Conclusions	.....................................................................................................	99	
3.	 Orthogonal	Self-Assembly	of	DBS-COOH	Hydrogels	with	C16-DAPMA	and	Heparin
	 100	
3.1.	 Introduction	......................................................................................................	100	
3.2.	 Synthesis	of	DBS-COOH	Gelator	and	pH-induced	Hydrogelation	.....................	101	
3.3.	 Study	of	Orthogonal	Self-Assembly	of	DBS-COOH	with	C16-DAPMA	and	Heparin
	 103	
3.3.1.	 Thermal	Stability	and	Tgel	Determination	.................................................	107	
3.3.2.	 Infrared	Characterisation	(IR)	...................................................................	107	
3.3.3.	 Study	of	Gel	Formation	Kinetics	...............................................................	108	
3.3.4.	 Mallard	Blue	Diffusion	Assay	....................................................................	112	
3.3.5.	 Electron	Microscopy	.................................................................................	114	
3.3.6.	 Rheology	...................................................................................................	118	
3.4.	 Release	Studies	.................................................................................................	122	
3.5.	 Cytocompatibility	of	DBS-COOH	Hydrogels	......................................................	130	
3.5.1.	 2D	Cell	Culture	with	Cells	on	Top	.............................................................	132	
3.5.2.	 2D	Cell	Culture	in	Transwells	....................................................................	138	
3.5.3.	 3D	Cell	Culture	..........................................................................................	143	
3.6.	 Summary,	Conclusions	and	Future	Work	.........................................................	143	
5	
	
4.	 Orthogonal	 Self-Assembly	 of	 DBS-CONHNH2	 Hydrogels	 with	 C16-DAPMA	 and	
Heparin	......................................................................................................................	147	
4.1.	 Introduction	......................................................................................................	147	
4.2.	 Synthesis	 of	 DBS-CONHNH2	 Gelator	 and	 Temperature	 Induced	 Hydrogelation
	 148	
4.3.	 Study	 of	 Orthogonal	 Self-Assembly	 of	 DBS-CONHNH2	 with	 C16-DAPMA	 and	
Heparin	.........................................................................................................................	149	
4.3.1.	 Thermal	Stability	and	Tgel	Determination	.................................................	154	
4.3.2.	 Infrared	Characterisation	.........................................................................	154	
4.3.3.	 Study	of	Gel	Formation	Kinetics	...............................................................	155	
4.3.4.	 Mallard	Blue	Diffusion	Assay	....................................................................	157	
4.3.5.	 Electron	Microscopy	.................................................................................	160	
4.3.6.	 Rheology	...................................................................................................	166	
4.4.	 Release	Studies	.................................................................................................	171	
4.5.	 Cytocompatibility	of	DBS-CONHNH2	Hydrogels	................................................	177	
4.5.1.	 2D	Cell	Culture	with	Cells	on	Top	.............................................................	178	
4.5.2.	 2D	Cell	Culture	in	Transwells	....................................................................	186	
4.5.3.	 3D	Cell	Culture	..........................................................................................	198	
4.6.	 Summary,	Conclusions	and	Future	Work	.........................................................	198	
5.	 Orthogonal	Self-Assembly	of	Cyclohexane-Based	Low-Molecular-Weight	Hydrogels
	 202	
5.1.	 Introduction	......................................................................................................	202	
5.2.	 Orthogonal	 Self-Assembly	 of	 Cyclohexane	 Hydrogels	 with	 C16-DAPMA	 and	
Heparin	.........................................................................................................................	204	
5.2.1.	 Thermal	Stability	and	Tgel	Determination	.................................................	206	
5.2.2.	 Transmission	Electron	Microscopy	...........................................................	207	
5.2.3.	 Rheology	Studies	......................................................................................	212	
6	
	
5.3.	 Release	Studies	.................................................................................................	216	
5.4.	 Positively	Charged	Cyclohexane	LMWG	...........................................................	220	
5.5.	 Summary,	Conclusions	and	Future	Work	.........................................................	224	
6.	 Conclusions	and	Future	Work	.............................................................................	226	
6.1.	 Conclusions	.......................................................................................................	226	
6.2.	 Future	Work	.....................................................................................................	228	
7.	 Experimental	......................................................................................................	229	
7.1.	 General	Reagents	and	Methods	.......................................................................	229	
7.2.	 Synthesis	...........................................................................................................	230	
7.3.	 Chapter	2	–	Characterisation	and	Assay	Methods	...........................................	238	
7.4.	 Chapters	3	and	4	–	Characterisation	and	Assay	Methods	................................	242	
7.5.	 Chapter	3	and	4	-	Cytocompatiblity	Studies	.....................................................	250	
7.6.	 Chapter	5	–	Characterisation	and	Assay	Methods	...........................................	253	
Abbreviations	.............................................................................................................	258	
References	.................................................................................................................	262	
	
	
7	
	
List	of	Figures	
Figure	 1.1	 Supramolecular	 structures	 based	 on	 (a)	 host-guest	 complexes	 and	 (b)	 self-
assembled	materials.	[Adapted	from	reference	10]	............................................................	30	
Figure	1.2.	Morphology	of	amphiphilic	aggregates	in	aqueous	solution	depending	on	the	
hydrophobic-hydrophilic	balance	of	the	monomers,	by	Isreaelachvili.	.............................	31	
Figure	 1.3.	 AuNPs	 with	 high	 grafting	 density	 interact	 primarily	 through	 solvophobic	
interactions	between	polymer	coatings,	favouring	the	formation	of	planar	assemblies	(2D	
arrays).	 AuNPs	with	 low	 grafting	 interact	 primarily	 through	 van	 der	Waals	 interactions	
between	particle	cores,	favouring	the	formation	of	particle	chains	(1D	strings).	[Adapted	
from	reference	18].	.............................................................................................................	32	
Figure	1.4.	Gel	classification.	[Adapted	from	reference	28]	................................................	33	
Figure	 1.5.	 Representation	 of	 the	 hierarchical	 self-assembly	 of	 a	 supramolecular	 gel.	
[Adapted	from	reference	29]	...............................................................................................	35	
Figure	 1.6.	 Molecular	 structures	 of	 stimuli	 responsive	 LMWGs:	 1.1)	 N-acetyl-
galactosamine-appended	 amino	 acid	 (GalNAc-aa)	 derivative;	 1.2)	 Dimeric	 cholesterol-
based	A(LS)2	derivative	(A	-	aromatic	component,	S	-	steroid	moiety,	L	-	linker	connecting	
the	 two	 units);	 1.3)	 Melamine	 (M),	 6,7-dimethoxy-2,4[1H,3H]-	 quinazolinedione	 (Q),	
Riboflavin	(R)	and	1.4)	Cationic	hyperbranched	polycarbonate.	.......................................	36	
Figure	 1.7.	 Molecular	 structure	 of	 dibenzoyl-l-cystine	 (1.5),	 first	 small	 molecule	
hydrogelator	reported.	......................................................................................................	38	
Figure	1.8.	Molecular	structure	of	tyrosine-lysine	based	cyclodipeptide	1.6.	...................	39	
Figure	1.9.	Molecular	structure	of	a	representative	PA	designed	by	Stupp’s	research	group.
............................................................................................................................................	40	
Figure	1.10.	Generic	molecular	structure	of	aromatic	PAs.	...............................................	40	
Figure	 1.11.	 Molecular	 structure	 of	 1.9)	 Fmoc-FF	 and	 1.10)	 naphthalene-conjugated	
dipeptide.	...........................................................................................................................	41	
Figure	1.12.	Molecular	structures	of	selected	urea-based	LMWGs	1.11	-1.13.	.................	42	
Figure	1.13.	Molecular	structures	of	saccharide-based	hydrogelators	1.14	and	1.15.	......	43	
Figure	1.14.	Molecular	structures	of	sorbitol-based	LMWGs	1.16	and	1.17.	....................	44	
Figure	1.15.	Molecular	structure	of	DBS.	...........................................................................	45	
8	
	
Figure	 1.16.	 Molecular	 structures	 of	 DBS-based	 LMWGs:	 a)	 DBS-COOH	 and	 b)	 DBS-
CONHNH2.	..........................................................................................................................	46	
Figure	1.17.	Schematic	representation	of	the	self-assembling	of	two	LMWGs:	a)	randomly;	
b)	co-assembly;	c)	self-sorting.	[Adapted	from	reference	90]	.............................................	47	
Figure	 1.18.	 a)	 Molecular	 structures	 of	 naphthalene-based	 LMWGs	 1.18	 and	 1.19.	 b)	
Schematic	representation	of	partial	co-assembly	of	a	mixture	of	the	LMWG	1.18	(blue)	and	
LMWG	 1.19	 (red)	 with	 the	 decrease	 of	 pH.	 LMWG	 1.19	 is	 not	 fully	 incorporated	 and	
assembles	alone	as	the	pH	decreases.105	...........................................................................	48	
Figure	1.19.	a)	Molecular	structures	of	LMWG	and	PGs	used	to	obtain	responsive	hybrid	
gels	b)	Schematic	representation	of	a	LMWG-polymer	hybrid	gel.97	.................................	49	
Figure	1.20.	Molecular	structure	of	a	cyclohexane-based	LMWG	functionalised	with	an	l-
phenylalalanyl-amidoquinoline	 moiety	 (OG2)	 (top)	 and	 cryo-transmission	 electron	
microscopy	(cryo-TEM)	images	of	stable	dioleoylphosphocholine	(DOPC)	vesicles	coexisting	
with	OG2	gel	network	(bottom	left)	–	vesicles	shape	influenced	by	confined	gel	network	
and	DOPC	 vesicles	 deformed	by	 the	 growth	 of	 the	OG2	 gel	 nanofibers	 directly	 in	 their	
aqueous	compartment	(bottom	right).102	..........................................................................	50	
Figure	 1.21.	 Transmission	 electron	 microscopy	 (TEM)	 images	 of	 DBS-CONHNH2-AuNPs	
(right)	and	DBS-CONHNH2-AgNPs	(left)	hydrogels.	Scale	bars:	200	nm.108	........................	52	
Figure	 1.22.	 a)	 Molecular	 structure	 of	 multi-stimuli	 responsive	 phosphate-based	
hydrogelator	1.20.	b)	Schematic	representation	of	hierarchical	self-assembly	of	phosphate-
based	hydrogelator	and	gel-sol	transition	triggered	by	different	stimuli	(temperature,	pH,	
Ca2+	and	light).121	................................................................................................................	54	
Figure	1.23.	Molecular	structures	of	Fmoc-phenylalanine	(1.21)	and	Fmoc-tyrosine	(1.22)	
hydrogelators.	....................................................................................................................	55	
Figure	 1.24.	 a)	 Molecular	 structure	 of	 l-proline	 based	 hydrogelator	 1.23.	 b)	 Hydrogel	
disassembly	after	reacting	with	aldehydes.125	...................................................................	55	
Figure	1.25.	Molecular	structure	of	(C16)-VVAAEE-(NH2)	(V:	valine,	A:	alanine,	E:	glutamic	
acid)	PA	used	to	form	highly	aligned,	monodomain	hydrogels.	.........................................	56	
Figure	1.26.	a)	Molecular	structure	of	cationic	lipidic	LMWG	coupled	with	Vitamin	B7.	b)	
Schematic	representation	of	LMWG	coupled	with	B	vitamins	self-assembly	in	lamellar-type	
structures.	c)	Fluorescence	images	of	(i)	liver,	(ii)	spleen,	(iii)	kidney	and	(iv)	tumor	from	a	
9	
	
rat	treated	with	only	siRNA	(right)	and	siRNA	incorporated	in	the	hydrogel	of	lipidic	LMWG	
with	Vitamin	B7	(left).129	.....................................................................................................	57	
Figure	1.27.	Tissue	engineering	concept	involving	cell	seeding.	[Adapted	from	reference	132]
............................................................................................................................................	58	
Figure	1.28.	Chemical	structure	of	lysine-based	hydrogelator	1.26.	.................................	59	
Figure	1.29.	Chemical	structure	of	glycosyl-nucleosyl-fluorinated	hydrogelator	1.27.	.....	60	
Figure	1.30.	Schematic	representation	of	interactions	between	GFs	with	the	ECM	and	cells.	
The	producer	cell	secretes	GFs	into	the	ECM,	where	they	are	bound,	held	and	stabilised	
until	required.	Partial	cell	degradation	of	the	ECM	allows	the	local	release	of	GFs,	which	
bind	 to	 GF	 receptors	 on	 the	 surface	 of	 the	 cell,	 initiating	 the	 signalling	 which	 will	 be	
translated	into	a	specific	biological	response.	[Adapted	from	reference	156]	....................	61	
Figure	 1.31.	 Schematic	 representation	 of	 1)	 supramolecular	 MDP	 hydrogel	 and	
supramolecular	orthogonal	 self-assembly	of	 	2)	MDP	hydrogel	 incorporated	with	PlGF-1	
and	3)	MDP	hydrogel	loaded	with	liposomes	encapsulating	PlGF-1.172	.............................	63	
Figure	 1.32.	 Heparin	 predominant	 disaccharide	 repeat	 unit	 (top)	 and	 heparin	 partial	
structure	(X	=	H	or	SO3-;	Y	=	Ac,	SO3-	or	H)	(bottom).	.........................................................	64	
Figure	1.33.	 Structure	of	 2:2:1	 FGF-FGFR-heparin	 complex.	 FGFR	 is	 represented	 as	 gold	
ribbons	and	FGF	as	green	ribbons.	Heparin	is	shown	as	space-filling	models:	sulfur	(yellow),	
oxygen	(red)	and	nitrogen	(blue).180	..................................................................................	65	
Figure	 1.34.	 Schematic	 representation	 of	 PEG-heparin	 hydrogel.	 Left:	 TGF-b	 are	
immobilised	 within	 the	 hydrogel	 scaffold	 and	 released	 over	 time	 to	 induce	 cell	
differentiation.	 Right:	 Network	 structure	 of	 PEG-heparin	 hydrogel.	 Electrostatic	
interactions	between	heparin	and	TGF-b	allows	the	protection	and	controlled	release	of	
TGF-b.	[Adapted	from	reference	200]	..................................................................................	67	
Figure	1.35.	Molecular	 structure	of	 the	PA	1.28	designed	 to	bind	heparin	chains	by	 the	
Stupp	research	group	(top).	Schematic	representation	of	nanofibers	(blue)	with	adsorbed	
heparin	 (red)	 which	 is	 binding	 to	 growth	 factors	 (VEGF	 (purple);	 FGF	 (yellow)	 and	 FGF	
receptors	(green))	(bottom).195	..........................................................................................	68	
Figure	1.36.	 Schematic	 representation	of	a)	monovalent	 interactions	and	b)	multivalent	
interactions.	[Adapted	from	reference	208]	........................................................................	69	
10	
	
Figure	1.37.	Molecular	structures	of	self-assembling	multivalent	C12-RGD,	non-assembling	
dendritic	 G1-RGD3	 and	 non-assembling	 PEG-RGD	monomer,	 from	 Smith	 and	 coworkers	
work.	..................................................................................................................................	71	
Figure	1.38.	Representation	of	the	orthogonal	self-assembled	bioactive	hydrogel.	.........	72	
Figure	2.1.	 Structure	of	 the	self-assembling	heparin	binder	C22G1DAPMA	and	schematic	
representation	its	self-assembly.207	...................................................................................	74	
Figure	 2.2.	 Fluorescence	 intensity	 of	Nile	 Red	 (2.5	mM	 in	 PBS,	 pH	7.4)	 at	 635	nm	with	
increasing	concentration	of	C14-DAPMA.	..........................................................................	77	
Figure	 2.3.	 Fluorescence	 intensity	 of	Nile	 Red	 (2.5	mM	 in	 PBS,	 pH	7.4)	 at	 635	nm	with	
increasing	concentration	of	C16-DAPMA.	..........................................................................	78	
Figure	 2.4.	 Fluorescence	 intensity	 of	Nile	 Red	 (2.5	mM	 in	 PBS,	 pH	7.4)	 at	 635	nm	with	
increasing	concentration	of	C18-DAPMA.	..........................................................................	78	
Figure	2.5.	Uv-vis	spectra	of	C14-DAPMA	replacing	MalB.	................................................	80	
Figure	2.6.	Uv-vis	spectra	of	C16-DAPMA	replacing	MalB.	................................................	80	
Figure	2.7.	Uv-vis	spectra	of	C18-DAPMA	replacing	MalB.	................................................	81	
Figure	 2.8.	 Charge	 ratio	 versus	 normalised	 absorbance	 at	 615	 nm	 from	 the	 MalB	
displacement	assay	for	C14-DAPMA.	.................................................................................	81	
Figure	 2.9.	 Charge	 ratio	 versus	 normalised	 absorbance	 at	 615	 nm	 from	 the	 MalB	
displacement	assay	for	C16-DAPMA.	.................................................................................	82	
Figure	 2.10.	 Charge	 ratio	 versus	 normalised	 absorbance	 at	 615	 nm	 from	 the	 MalB	
displacement	assay	for	C18-DAPMA.	.................................................................................	82	
Figure	2.11.	Size	distribution	by	intensity	from	DLS	of	C16-DAPMA	in	10	mM	Tris-HCl/	150	
mM	NaCl	buffer.	.................................................................................................................	85	
Figure	2.12.	Size	distribution	by	volume	from	DLS	of	C16-DAPMA	in	10	mM	Tris-HCl/	150	
mM	NaCl	buffer.	.................................................................................................................	85	
Figure	2.13.	 TEM	 images	of	C14-DAPMA	 (left,	 scale	bar:	200	nm)	and	C14-DAPMA	with	
heparin	(right,	scale	bar:	100	nm)	in	aqueous	solution.	.....................................................	88	
Figure	2.14.	 TEM	 images	of	C16-DAPMA	 (left,	 scale	bar:	100	nm)	and	C16-DAPMA	with	
heparin	(right,	scale	bar:	100	nm	-	inset:	200	nm)	in	aqueous	solution.	............................	89	
Figure	2.15.	 TEM	 images	of	C18-DAPMA	 (left,	 scale	bar:	200	nm)	and	C18-DAPMA	with	
heparin	(right,	scale	bar:	100	nm)	in	aqueous	solution.	.....................................................	89	
11	
	
Figure	2.16.	DPD	snapshots	of	C14-DAPMA	(left)	and	C16-DAPMA	(right)	self-assembly	in	
presence	of	heparin	(2:1	binder:heparin	ratio).	The	hydrophobic	micellar	core	is	highlighted	
as	 green	 and	blue	 isosurfaces,	 respectively.	Hydrophilic	moieties	 of	 each	 aggregate	 are	
shown	as	white	sticks,	while	heparin	molecules	are	shown	as	orange	rods.	A	continuous	
light	grey	field	portrays	the	aqueous	medium.	..................................................................	90	
Figure	 2.17.	 SAXS	 characterisation	 of	 C14-DAPMA	 and	 C16-DAPMA	 in	 the	 presence	 of	
heparin.	 a)	 Integrated	SAXS	curve	measured	 from	self-assembled	C14-DAPMA	and	C16-
DAPMA	in	the	presence	of	heparin.		Inset:	2D-scattering	pattern	of	C14-DAPMA	and	C16-
DAPMA	with	heparin.	b,	c)	Quadractic	Miller	indices	of	assigned	reflections	for	fcc	structure	
versus	measured	q-vector	positions	for	indexed	peaks,	related	with	(b)	C14-DAPMA	and	(c)	
C16-DAPMA,	both	binding	heparin.	...................................................................................	93	
Figure	2.18.	a)	TEM	image	of	C14-DAPMA	heparin	complex.	b)	A	crystalline	area	(left,	inset:	
fast	 Fourier	 transform)	 and	 a	 line	 profile	 analysis	 (right)	 along	 the	 red	 line.	 c)	 Filtered	
inverse	Fourier	transform	from	selected	Fourier	components	(left),	overlay	of	the	image	
and	fcc	unit	cell	(middle)	and	model	of	the	fcc	unit	cell	with	key	dimension	(right).	Micelles	
shown	in	yellow,	diameter	reduced	for	clarity.	.................................................................	94	
Figure	2.19.	a)	TEM	image	of	C16-DAPMA	heparin	complex.	b)	A	crystalline	area	(left,	inset:	
fast	 Fourier	 transform)	 and	 a	 line	 profile	 analysis	 (right)	 along	 the	 red	 line.	 c)	 Filtered	
inverse	Fourier	transform	from	selected	Fourier	components	(left),	overlay	of	the	image	
and	fcc	unit	cell	(middle)	and	model	of	the	fcc	unit	cell	with	key	dimension	(right).	Micelles	
shown	in	yellow,	diameter	reduced	for	clarity.	.................................................................	95	
Figure	2.20.	Mass	spectra	of	C14-DAPMA	at	0	(top)	and	24	hours	(bottom)	in	the	presence	
of	Gly-Ala	and	incubated	at	37	°C.	.....................................................................................	96	
Figure	2.21.	Mass	spectra	of	C16-DAPMA	at	0	(top)	and	24	hours	(bottom)	in	the	presence	
of	Gly-Ala	and	incubated	at	37	°C.	.....................................................................................	97	
Figure	2.22.	Normalised	fluorescence	intensity	of	Nile	Red	at	635	nm	in	the	presence	of	
C14-DAPMA	(circles)	and	C14-DAPMA	with	heparin	(triangles),	over	time.	......................	97	
Figure	2.23.	Normalised	fluorescence	intensity	of	Nile	Red	at	635	nm	in	the	presence	of	
C16-DAPMA	(circles)	and	C16-DAPMA	with	heparin	(triangles),	over	time.	......................	98	
Figure	3.1.	Chemical	structures	of	LMWG	DBS-COOH	and	PG	agarose,	used	in	the	formation	
of	a	hybrid	hydrogel.	........................................................................................................	101	
12	
	
Figure	3.2.	DBS-COOH	gel	 formation	using	different	concentration	of	gelator:	0.2%	w/v;	
0.15%	w/v	and	0.1%	w/v	(from	left	to	right)	in	10	mM	Tris-	HCl/	150	mM	NaCl.	............	103	
Figure	3.3.	0.2%	w/v	DBS-COOH	gel	formation	with	addition	of	150	µM	C16-DAPMA	/38	
µM	Heparin	solution	20	minutes	after	the	addition	of	GdL,	in	10	mM	Tris-HCl/	150	mM	NaCl	
(pH	7.4).	............................................................................................................................	104	
Figure	3.4.	0.2%	w/v	DBS-COOH	gel	formation	with	38	µM;	50	µM;	100	µM;	150	µM;	300	
µM;	400	µM;	500	µM	(from	left	to	right)	of	heparin.	......................................................	105	
Figure	3.5.	0.2%	w/v	DBS-COOH	gel	formation	with	150	µM;	300	µM;	400	µM;	500	µM;	600	
µM;	700µM;	800	µM;	900	µM;	1000	µM	(from	left	to	right)	of	C16-DAPMA.	.................	105	
Figure	3.6.	IR	spectra	of	xerogels	formed	by	DBS-COOH	gel	(blue	line);	DBS-COOH	gel	with	
300	µM	of	heparin	(red	line)	and	DBS-COOH	gel	with	800	µM	of	C16-DAPMA	and	300	µM	
of	heparin	(green	line).	.....................................................................................................	108	
Figure	3.7.	%	Gelation	over	time	for	DBS-COOH	(0.2%	w/v)	(blue	circles);	DBS-COOH	(0.2%	
w/v)	with	heparin	(300	µM)	(red	triangles)	and	DBS-COOH	(0.2%	w/v)	in	the	presence	of	
heparin	 (300	 µM)	 and	 C16-DAPMA	 (800	 µM)	 (green	 squares),	 as	 monitored	 by	 NMR	
spectroscopy.	...................................................................................................................	109	
Figure	3.8.	Kinetic	studies	of	the	growth	of	DBS-COOH	fibrillar	network	over	time,	using	CD	
spectroscopy.	(a)	DBS-COOH	(0.02%	w/v);	(b)	DBS-COOH	(0.02%	w/v)	 in	the	presence	of	
heparin	(38	µM)	and	(c)	DBS-COOH	(0.02%	w/v)	in	the	presence	of	C16-DAPMA	(150	µM)	
and	heparin	(38	µM).	.......................................................................................................	111	
Figure	3.9.	Absorbed	polarized	light	at	260	nm	of	DBS-COOH	(blue	circles),	DBS-COOH	in	
the	presence	of	heparin	(red	triangles)	and	DBS-COOH	in	the	presence	of	heparin	and	C16-
DAPMA	(green	squares),	over	6	hours.	............................................................................	112	
Figure	3.10.	DBS-COOH	gel	with	MalB	solution	on	top.	...................................................	112	
Figure	3.11.	Normalised	absorbance	of	MalB	at	615	nm	over	time	when	placed	on	top	of	
DBS-COOH;	DBS-COOH	with	heparin	and	DBS-COOH	with	heparin	and	C16-DAPMA.	....	113	
Figure	3.12.	DBS-COOH	gel	with	MalB	solution	on	top	after	1	week.	..............................	113	
Figure	3.13.	TEM	image	of	DBS-COOH	gel	(0.2%	w/v).	Scale	bar:	1	µM.	.........................	115	
Figure	3.14.	TEM	image	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM).	
Scale	bar:	200	nm.	............................................................................................................	115	
Figure	3.15.	TEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM)	
and	C16-DAPMA	(150	µM).	Scale	bar:	200	nm.	...............................................................	116	
13	
	
Figure	3.16.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v).	...................................................	116	
Figure	3.17.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM).
..........................................................................................................................................	117	
Figure	3.18.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM)	
and	C16-DAPMA	(150	µM).	..............................................................................................	118	
Figure	3.19.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	 for	 DBS-COOH	 gel	 (),	 DBS-COOH	 gel	 with	 heparin	 (r)	 and	 DBS-COOH	 gel	 with	
heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.	............................................................	119	
Figure	3.20.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBS-COOH	gel	with	agarose	()	and	DBS-COOH	gel	with	agarose	and	heparin	(r).	
Frequency	=	1	Hz.	.............................................................................................................	120	
Figure	3.21.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	for	
DBS-COOH	gel	(),	DBS-COOH	gel	with	heparin	(r)	and	DBS-COOH	gel	with	heparin	and	
C16-DAPMA	(£).	Amplitude	strain	=	0.1%.	......................................................................	121	
Figure	3.22.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	for	
DBS-COOH	 gel	 with	 agarose	 ()	 and	 DBS-COOH	 gel	 with	 agarose	 and	 heparin	 (r).	
Amplitude	strain	=	0.1%.	..................................................................................................	121	
Figure	 3.23.	 DBS-COOH	 hydrogel	 containing	 1	 mM	 of	 heparin	 with	 buffer	 on	 top	 for	
monitoring	the	release	of	heparin.	..................................................................................	122	
Figure	3.24.	Heparin	release	from	DBS-COOH	hydrogel	(0.2%	w/v)	with	1	mM	of	heparin	
(p)	and	DBS-COOH	hydrogel	(0.2%	w/v)	with	1	mM	of	heparin	interacting	with	2	mM	of	
C16-DAPMA(¢).	...............................................................................................................	123	
Figure	3.25.	Heparin	release	from	0.2%	w/v	(p)	and	2%	w/v	()	of	DBS-COOH	hydrogels	
with	1	mM	of	heparin.	......................................................................................................	124	
Figure	3.26.	Heparin	release	from	2%	w/v	(),	5%	w/v	(¿)	and	10%	w/v	(¯)	DBS-COOH	
hydrogels	containing	1	mM	of	heparin.	...........................................................................	125	
Figure	3.27.	Heparin	release	from	1.0%	w/v	(yellow),	2.5%	w/v	(blue),	5.0%	w/v	(orange),	
7.5%	w/v	(green)	and	10%	w/v	(purple)	of	agarose	gels	with	1	mM	of	heparin.	.............	126	
Figure	3.28.	Heparin	release	from	DBS-COOH	hydrogel	(2%	w/v)	with	1	mM	of	heparin	in	
the	absence	of	agarose	(p),	with	0.5%	of	agarose	()	and	1%	w/v	of	agarose	(¢).	.....	126	
Figure	3.29.	Assay	design	for	heparin	release	from	hybrid	gel	cylinders	containing	2.0%	w/v	
DBS-COOH,	1.0%	w/v	agarose	and	17	mM	heparin.	1	mL	gels	were	prepared	in	small	sample	
14	
	
vials.	 The	 gel	 cylinders	were	 then	 transferred	 to	 large	 glass	 jars	 and	 35	mL	 buffer	was	
added.	65	μL	of	buffer	was	removed	over	time,	added	to	1935	μL	MalB	and	a	UV-Visible	
spectrum	recorded.	..........................................................................................................	127	
Figure	3.30.	Different	methods	of	heparin	release	from	DBS-COOH	hydrogel	(2%	w/v)	and	
agarose	(1%	w/v).	():	Buffer	on	top	of	the	gel.	(¢):	Gel	cylinder.	................................	128	
Figure	3.31.	NMR	spectra	of	aromatic	protons	of	DBS-COOH	prior	 to	gelation,	after	 full	
gelation,	 and	 after	 19.5,	 26,	 45,	 and	 68/69	 hours	 exposure	 to	 NaOH	 a)	 in	 presence	 of	
agarose	and	absence	of	heparin,	and	b)	in	presence	of	agarose	and	heparin.	................	129	
Figure	3.32.	Schematic	representation	of	2D	cell	culture	performed	in	96	well	plates.	..	131	
Figure	3.33.	Schematic	representation	of	2D	cell	culture	performed	in	transwells.	.......	131	
Figure	3.34.	Optical	microscopy	images	of	DBS-COOH	hydrogels	with	cells	on	top,	at	day	1	
and	5.	Magnification:	10x.	................................................................................................	133	
Figure	3.35.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	cells	on	top	of	
DBS-COOH	hydrogels,	at	day	1	and	5.	Magnification:	40x.	..............................................	134	
Figure	 3.36.	 Fluorescence	 microscopy	 images	 of	 calcein-AM/PI	 staining	 of	 DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	
and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1	and	7.	Magnifcation:	20x.	135	
Figure	3.37.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	
and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1,	5	and	7.	Magnifcation:	20x.
..........................................................................................................................................	136	
Figure	 3.38.	 Fluorescence	microscopy	 images	 of	 cell	 in	DBS-COOH	hydrogels	with	 1330	
µg/mL	heparin	at	day	1	(left)	and	5	(right).	Magnifcation:	20x.	.......................................	137	
Figure	 3.39.	 Absorbance	 of	 formazan	 at	 440	 nm	with	DBS-COOH	hydrogels,	 DBS-COOH	
hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	and	control	(medium	
with	cells),	with	cells	on	top,	at	day	1,	5	and	7.	...............................................................	138	
Figure	3.40.	Optical	microscopy	images	of	DBS-COOH	hydrogels	in	transwells,	at	day	1	and	
5.	Magnification:	10x.	.......................................................................................................	139	
Figure	 3.41.	 Fluorescence	microscopy	 images	 of	 phalloidin/DAPI	 staining	 of	 DBS-COOH	
hydrogels	in	transwells,	at	day	1	and	5.	Magnification:	40x.	...........................................	139	
15	
	
Figure	 3.42.	 Fluorescence	 microscopy	 images	 of	 calcein-AM/PI	 staining	 of	 DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	 in	the	presence	of	heparin	(667	µg/mL	and	667	µg/mL)	
and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	Magnifcation:	20x.	..	140	
Figure	3.43.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	
and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	Magnifcation:	20x.	..	141	
Figure	 3.44.	 Fluorescence	microscopy	 images	 of	 cell	 in	DBS-COOH	hydrogels	with	 1330	
µg/mL	heparin	at	day	1.	Magnifcation:	20x.	....................................................................	142	
Figure	 3.45.	 Absorbance	 of	 formazan	 at	 440	 nm	with	DBS-COOH	hydrogels,	 DBS-COOH	
hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	and	control	(medium	
with	cells),	in	transwells,	at	day	1,	5	and	7.	......................................................................	143	
Figure	4.1.	Chemical	structure	of	LMWG	DBS-CONHNH2.	...............................................	147	
Figure	4.2.UV-Vis	spectra	of	MalB	free	in	solution,	with	heparin	and	in	the	presence	of	C16-
DAPMA,	at	25	°C	and	85	°C.	.............................................................................................	151	
Figure	4.3.	DBS-CONHNH2	(0.4%	w/v)	gel	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer:	stable	
and	uniform	gel	(left),	non-uniform	gel	(centre)	and	unstable	gel	(right).	......................	153	
Figure	4.4.	IR	spectra	of	xerogels	formed	by	DBS-CONHNH2	gel	(blue	line);	DBS-CONHNH2	
gel	 with	 300	 µM	 of	 heparin	 (red	 line);	 DBS-CONHNH2	 gel	 with	 1200	 µM	 C16-DAPMA	
(dashed	orange	line)	and	DBS-CONHNH2	gel	with	1200	µM	of	C16-DAPMA	and	300	µM	of	
heparin	(green	line).	.........................................................................................................	155	
Figure	4.5.	Kinetic	studies	of	the	growth	of	DBSCONHNH2	fibrillar	network	over	time,	using	
CD	spectroscopy.	(a)	DBS-CONHNH2;	(b)	DBS-CONHNH2	in	the	presence	of	heparin;	(c)	DBS-
CONHNH2	in	the	presence	of	C16-DAPMA	and	(d)	DBS-CONHNH2	in	the	presence	of	C16-
DAPMA	and	heparin.	........................................................................................................	156	
Figure	4.6.	CD	 intensity	at	275	nm	of	DBS-CONHNH2,	DBS-CONHNH2	 in	 the	presence	of	
heparin,	DBS-CONHNH2	in	the	presence	of	C16-DAPMA	and	DBS-CONHNH2	in	the	presence	
of	C16-DAPMA	and	heparin,	over	15	minutes.	................................................................	157	
Figure	4.7.	DBS-CONHNH2	gel	with	MalB	solution	on	top.	..............................................	158	
Figure	4.8.	DBS-CONHNH2	gel	with	MalB	solution	on	top	after	72	h.	..............................	158	
Figure	4.9.	DBS-CONHNH2	gel	in	the	presence	of	heparin	with	MalB	solution	on	top	after	
72	h.	..................................................................................................................................	159	
16	
	
Figure	4.10.	Normalised	absorbance	of	MalB	at	615	nm	over	time	when	placed	on	top	of	
DBS-CONHNH2;	DBS-CONHNH2	with	 heparin;	DBS-CONHNH2	with	 C16-DAPMA	and	DBS-
CONHNH2	with	heparin	and	C16-DAPMA.	.......................................................................	160	
Figure	4.11.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel.	Scale	bars:	100	nm	(left)	and	200	
nm	(right).	........................................................................................................................	161	
Figure	4.12.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	heparin	(38	
µM).	Scale	bars:	1	µM	(left)	and	200	nm	(right).	..............................................................	161	
Figure	4.13.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM).	Scale	bars	=	200	nm	(left)	and	50	nm	(right).	..................................................	162	
Figure	4.14.	TEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM)	and	heparin	(38	µM).	Scale	bar	=	1	µM.	...........................................................	162	
Figure	4.15.	TEM	image	of	the	aggregates	observed	in	the	DBS-CONHNH2	(0.4%	w/v)	gel	in	
the	presence	of	C16-DAPMA	(150	µM)	and	heparin	(38	µM).	Scale	bar:	100	nm.	..........	163	
Figure	4.16.	TEM	images	of	Scale	bars	=	500	nm	(left)	and	200	nm	(right).	....................	163	
Figure	4.17.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel.	..............................................	164	
Figure	4.18.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	 in	the	presence	of	heparin	(38	
µM).	..................................................................................................................................	164	
Figure	4.19.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM).	..........................................................................................................................	165	
Figure	4.20.	SEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM)	and	heparin	(38	µM).	........................................................................................	166	
Figure	4.21.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBSCONHNH2	gel	(),	DBSCONHNH2	gel	with	heparin	(△),	DBSCONHNH2	gel	with	
C16-DAPMA	(◇)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	Frequency	=	1	
Hz.	....................................................................................................................................	167	
Figure	4.22.	DBS-CONHNH2	gel	with	C16-DAPMA.	..........................................................	168	
Figure	4.23.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBSCONHNH2	gel	with	agarose	()	and	DBSCONHNH2	gel	with	agarose	and	heparin	
(△).	Frequency	=	1	Hz.	.....................................................................................................	168	
Figure	4.24.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	for	
DBSCONHNH2	gel	 (),	DBSCONHNH2	gel	with	heparin	 (△),	DBSCONHNH2	gel	with	C16-
17	
	
DAPMA	(¯)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	Amplitude	strain	=	
0.1%.	.................................................................................................................................	169	
Figure	4.25.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	for	
DBSCONHNH2	gel	with	agarose	(○)	and	DBSCONHNH2	gel	with	agarose	and	heparin	(△).
..........................................................................................................................................	170	
Figure	4.26.	Temperature	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBSCONHNH2	gel	(),	DBSCONHNH2	gel	with	heparin	(△),	DBSCONHNH2	gel	with	C16-
DAPMA	(◇)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	Amplitude	strain	=	
0.1%,	Frequency	=	1	Hz.	...................................................................................................	171	
Figure	4.27.	DBS-CONHNH2	hydrogel	containing	1	mM	of	heparin,	with	10	mM	Tris-HCl/	
150	mM	NaCl	buffer	on	top	for	monitoring	the	release	of	heparin.	................................	172	
Figure	4.28.	Heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	heparin	
(▲)	and	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	heparin	interacting	with	2	mM	
C16-DAPMA	(■).	.............................................................................................................	173	
Figure	4.29.	Chemical	structure	of	sodium	dodecylsulfonate.	........................................	173	
Figure	4.30.	Chemical	structure	of	sodium	dodecylbenzenesulfonate.	...........................	174	
Figure	 4.31.	 Heparin	 release	 from	 DBS-CONHNH2	 hydrogel	 (0.4%	 w/v)	 with	 1	 mM	 of	
heparin	and	2	mM	of	C16-DAPMA	over	 time,	by	adding	10	mM	Tris-HCl/	150	mM	NaCl	
buffer	(pH	7.4)	(¢)	and	borax/NaOH	buffer	(pH	10)	()	on	top	of	the	hydrogel.	..........	175	
Figure	4.32.	Heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	heparin	
in	the	absence	of	agarose	(),	with	0.5%	w/v	of	agarose	()	and	1%	w/v	of	agarose	(■).
..........................................................................................................................................	176	
Figure	4.33.	Hybrid	gel	cylinder	containing	0.4%	w/v	of	DBS-CONHNH2,	1%	w/v	of	agarose	
and	17	mM	of	heparin,	immersed	in	35	mL	of	buffer.	.....................................................	176	
Figure	4.34.	Different	methods	of	heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	
and	agarose	(1%	w/v).	():	Buffer	on	top	of	the	gel.	(■):	Gel	cylinder.	.........................	177	
Figure	4.35.	Optical	microscopy	images	of	DBS-CONHNH2	hydrogels	with	cells	on	top	(top)	
and	controls	(medium	with	cells)	at	day	1	and	5	(bottom).	Magnification:	10x.	.............	179	
Figure	4.36.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels,	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	 heparin	 (667	 µg/mL	 and	 1330	
18	
	
µg/mL)	and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1	and	5.	Magnification:	
20x.	...................................................................................................................................	180	
Figure	 4.37.	 Fluorescence	 microscopy	 images	 of	 mitotraker/hoechst	 staining	 of	 DBS-
CONHNH2	hydrogels,	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	 µg/mL)	 and	 controls	 (medium	 with	 cells),	 with	 cells	 on	 top,	 at	 day	 1	 and	 5.	
Magnification:	20x.	...........................................................................................................	180	
Figure	 4.38.	 Absorbance	 of	 WST-1	 reagent	 at	 440	 nm	 with	 (from	 left	 to	 right):	 DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL,	respectively)	and	control	(medium	with	cells),	with	cells	on	top,	at	day	1,	5	
and	7.	................................................................................................................................	181	
Figure	 4.39.	 Absorbance	 of	 WST-1	 reagent	 at	 440	 nm	 with	 (from	 left	 to	 right):	 DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	 in	the	presence	of	heparin	 (50	µg/mL,	25	
µg/mL	and	10	µg/mL);	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	
C16-DAPMA	(140	µg/mL;	DBS-CONHNH2	hydrogels	with	agarose	(1%	w/v);	DBS-CONHNH2	
hydrogels	 with	 agarose	 (1%	 w/v)	 and	 heparin	 (50	 µg/mL);	 agarose	 (1%)	 and	 control	
(medium	with	cells),	with	cells	on	top	of	the	gels,	at	day	1,	3	and	7.	..............................	182	
Figure	4.40.	Optical	microscope	image	of	cells	on	top	of	1%	w/v	agarose	hydrogel	at	day	3.
..........................................................................................................................................	184	
Figure	 4.41.	 Schematic	 representation	 of	 the	 cell	 migration	 assay.	 (a)	 DBS-CONHNH2	
hydrogel	was	formed	in	the	transwell	insert	and	cells	were	added	on	top	of	the	hydrogel.	
Medium	was	added	in	the	well.	(b)	Cells	migration	through	the	gel	network	into	the	well.	
Adhesion	of	cells	on	the	bottom	of	the	well	can	be	followed	by	optical	microscopy.	.....	185	
Figure	4.42.	Example	of	an	optical	microscope	image	obtained	on	the	migration	assay	for	
the	well	were	DBS-CONHNH2	hydrogels	were	present	(left	–	no	cells	present)	and	control	
(right	 -	 cells	 added	directly	 into	 the	well	 and	attached	 to	 the	bottom	of	 the	well)	 after	
washing	the	membrane	with	trypsin,	on	day	7.	...............................................................	186	
Figure	 4.43.	 Fluorescence	 microscopy	 images	 of	 mitotraker/hoechst	 staining	 of	 DBS-
CONHNH2	hydrogels,	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	5.	Cell	density:	
40000	cells/mL.	Magnification:	20x.	................................................................................	187	
Figure	4.44.	Optical	microscopy	images	of	DBS-CONHNH2	hydrogels	in	transwells,	at	day	1	
3	and	7	and	control	(medium	with	cells).	Magnification:	20x.	.........................................	188	
19	
	
Figure	 4.45.	 Optical	microscopy	 images	 of	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	
heparin	 (50	 µg/mL,	 25	 µg/mL	 and	 10	 µg/mL)	 and	 controls	 (medium	 with	 cells),	 in	
transwells,	at	day	1,	3	and	7.	Magnifcation:	20x.	.............................................................	189	
Figure	4.46.	Optical	microscopy	images	of	agarose	hydrogels,	DBS-CONHNH2	and	agarose	
hybrid	 hydrogels	 and	 DBS-CONHNH2	 and	 agarose	 hybrid	 hydrogels	 in	 the	 presence	 of	
heparin	 (50	 µg/mL)	 and	 controls	 (medium	with	 cells),	 in	 transwells,	 at	 day	 1,	 3	 and	 7.	
Magnifcation:	20x.	...........................................................................................................	189	
Figure	4.47.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	DBS-CONHNH2	
hydrogels	in	transwells,	at	day	1	and	5.	Magnification:	40x.	...........................................	190	
Figure	4.48.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	DBS-CONHNH2	
hydrogels	and	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	
µg/mL)	in	transwells	at	day	1	and	5.	Magnification:	40x.	................................................	191	
Figure	4.49.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels	 (0.4%	w/v)	and	controls	 (medium	with	cells),	 in	 transwells,	at	day	1,	3	and	7.	
Magnification:	20x.	...........................................................................................................	192	
Figure	4.50.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels	 in	 the	presence	of	heparin	 (50	µg/mL,	25	µg/mL	and	10	µg/mL)	and	controls	
(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	Magnification:	20x.	......................	193	
Figure	 4.51.	 Fluorescence	 microscopy	 images	 of	 calcein-AM/PI	 staining	 of	 agarose	
hydrogels,	DBS-CONHNH2	and	agarose	hybrid	hydrogels	and	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	controls	(medium	with	cells),	
in	transwells,	at	day	1,	3	and	7.	Magnification:	20x.	........................................................	193	
Figure	 4.52.	 Fluorescence	 microscopy	 images	 of	 mitotraker/hoechst	 staining	 of	 DBS-
CONHNH2	hydrogels	(0.4%	w/v)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	3	
and	7.	Magnification:	40x.	................................................................................................	194	
Figure	 4.53.	 Fluorescence	 microscopy	 images	 of	 mitotraker/hoechst	 staining	 of	 DBS-
CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	and	
controls	(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	Magnification:	40x.	........	195	
Figure	4.54.	 Fluorescence	microscopy	 images	of	mitotraker/hoechst	 staining	of	 agarose	
hydrogels,	DBS-CONHNH2	and	agarose	hybrid	hydrogels	and	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	controls	(medium	with	cells),	
in	transwells,	at	day	1,	5	and	7.	Magnification:	40x.	........................................................	196	
20	
	
Figure	 4.55.	 Absorbance	 of	 WST-1	 reagent	 at	 440	 nm	 with	 (from	 left	 to	 right):	 DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	 in	the	presence	of	heparin	 (50	µg/mL,	25	
µg/mL	 and	 10	 µg/mL);	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	 C16-DAPMA	 (140	
µg/mL);	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	C16-DAPMA	
(140	µg/mL);	DBS-CONHNH2	hydrogels	with	 agarose	 (1%	w/v);	DBS-CONHNH2	hydrogels	
with	agarose	(1%	w/v)	and	heparin	(50	µg/mL);	agarose	(1%)	and	control	 (medium	with	
cells),	in	transwells,	at	day	1,	3	and	7.	..............................................................................	197	
Figure	 4.56.	 Absorbance	 of	 WST-1	 reagent	 at	 440	 nm	 with	 (from	 left	 to	 right):	 DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL)	and	control	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	.............	198	
Figure	 5.1.	 Chemical	 structure	 of	 cyclohexane-based	 LMWGs.	 Light	 grey:	 hydrophilic	
regions;	dark	grey:	hydrophobic	regions.	AA:	aminoacid;	X:	hydrophilic	substituent.296	 202	
Figure	5.2.	Chemical	structure	of	cyclohexane-based	hydrogelators.	OG1:	heat-cool	gelator	
and	OG2:	pH	responsive	gelator.	.....................................................................................	203	
Figure	5.3.	Schematic	representation	of	a	two-step	release	system	with	the	dissociation	of	
self-assembled	 nanofibers	 followed	 by	 enzymatic	 cleavage	 for	 OG2-drug	 conjugate	
hydrogels.	∆:	trigger	of	gel-sol	transition	(temperature,	pH).[Adapted	from	reference	298]
..........................................................................................................................................	204	
Figure	5.4.	Dropping	ball	method:	Steel	balls	are	placed	on	top	of	gels,	that	subsequently	
are	placed	in	a	heating	block,	where	the	temperature	is	monitored	and	recorded.	.......	207	
Figure	5.5.	TEM	images	of	OG1	(0.5%	w/v)	gel.	Scale	bars:	1	µm	(left)	and	500	nm	(right).
..........................................................................................................................................	208	
Figure	5.6.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	heparin	(38	µM).	Scale	
bars:	1	µm	(left)	and	200	nm	(right).	................................................................................	209	
Figure	5.7.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	C16-DAPMA	(150	µM).	
Scale	bars:	500	nm	(left)	and	200	nm	(right).	...................................................................	209	
Figure	5.8.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	heparin(38µM)	and	C16-
DAPMA	(150	µM).	............................................................................................................	209	
Figure	5.9.	TEM	images	of	OG2	(0.5%	w/v)	gel.	Scale	bars:		1	µm	(left)	and	500	nm	(right).
..........................................................................................................................................	211	
21	
	
Figure	5.10.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	heparin	(38	µM).	Scale	
bars:	500	nm	(left)	and	200	nm	(right).	............................................................................	211	
Figure	5.11.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	C16-DAPMA	(150	µM).	
Scale	bars:	500	nm	(left)	and	200	nm	(right).	...................................................................	211	
Figure	5.12.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	heparin(38µM)	and	C16-
DAPMA	(150	µM).	Scale	bars:	200	nm	(left)	and	100	nm	(right).	....................................	212	
Figure	5.13.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	OG1	gel	(),	OG1	gel	with	heparin	(△),	OG1	gel	with	C16-DAPMA	(◇)	and	OG1	
gel	with	heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.	..............................................	213	
Figure	5.14.	Time	sweep	oscillatory	rheology	measurements	 (frequency	=	1Hz	and	0.5%	
strain)	for	OG1	gel	(),	OG1	gel	with	heparin	(△),	OG1	gel	with	C16-DAPMA	(◇)	and	OG1	
gel	with	heparin	and	C16-DAPMA	(£).	............................................................................	214	
Figure	5.15.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	OG2	gel	(),	OG2	gel	with	heparin	(△),	OG2	gel	with	C16-DAPMA	(◇)	and	OG2	
gel	with	heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.	..............................................	215	
Figure	5.16.	Time	sweep	oscillatory	rheology	measurements	 (frequency	=	1Hz	and	0.5%	
strain)	for	OG2	gel	(),	OG2	gel	with	heparin	(△),	OG2	gel	with	C16-DAPMA	(◇)	and	OG2	
gel	with	heparin	and	C16-DAPMA	(£).	............................................................................	216	
Figure	5.17.	Heparin	release	from	OG1	hydrogel	(0.5%	w/v)	containing	1	mM	of	heparin	
(▲)	and	1	mM	of	heparin	with	2	mM	of	C16-DAPMA	(¢).	.............................................	217	
Figure	5.18.	Heparin	release	from	OG1	hydrogel	(0.5%	w/v)	with	1	mM	of	heparin	in	the	
absence	of	agarose	()	and	in	the	presence	of	1%	w/v	of	agarose	(¢).	........................	218	
Figure	 5.19.	 Different	methods	 of	 heparin	 release	 from	OG1	hydrogel	 (0.5%	w/v).	 ():	
Buffer	on	top	of	the	gel.	(■):	Gel	cylinder.	......................................................................	218	
Figure	5.20.	Heparin	release	from	OG2	hydrogel	(0.5%	w/v)	containing	1	mM	of	heparin	
(▲)	and	1mM	of	heparin	and	2	mM	of	C16-DAPMA	(¢).	...............................................	220	
Figure	5.21.	Positively	charged	cyclohexane	gelator	(OG+).	............................................	221	
Figure	5.22.	TEM	image	of	OG+	(0.5%	w/v)	gel.	Scale	bar:	200	nm.	................................	222	
Figure	5.23.	TEM	images	of	OG+	gel	(0.5%	w/v)	in	the	presence	of	heparin	(78	µM).	Scale	
bars:	2	µm	(top);	200	nm	(bottom	left)	and	100	nm	(bottom	right).	...............................	222	
22	
	
Figure	5.24.	Heparin	release	from	OG+	hydrogels:	()	OG+	hydrogel	with	heparin	without	
a-chy;	(¯)	OG+	hydrogel	with	heparin	and	a-chy	at	room	temperature;	(¿)	OG+	hydrogel	
with	heparin	and	a-chy	at	37	°C.	.....................................................................................	223	
23	
	
List	of	Tables	
Table	2.1.CMC	values	of	C14-DAPMA,	C16-DAPMA	and	C18-DAPMA.	..............................	79	
Table	 2.2.	 CE50,	 EC50	 and	 dose	 values	 obtained	 for	 C14-DAPMA,	 C16-DAPMA	 and	 C18-
DAPMA	using	MalB	assay	(25	µM	MalB,	27	µM	Heparin	in	10	mM	Tris-HCl,	150	mM	NaCl,	
pH	7.0).	...............................................................................................................................	83	
Table	2.3.	Average	hydrodynamic	diameter	(volume	distribution)	and	zeta	potential	of	C14-
DAPMA,	C16-DAPMA	and	C18-DAPMA	in	the	presence	and	absence	of	heparin.	............	86	
Table	3.1.	Test	of	different	heparin/binder	ratio	in	gel	formation.	.................................	106	
Table	 3.2.	 Binder/Heparin	 molar	 ratio	 and	 charge	 ratio	 +/-	 with	 increasing	 heparin	
concentration.	..................................................................................................................	107	
Table	3.3.	Media	tested	in	DBS-COOH	gels.	.....................................................................	132	
Table	4.1.	Average	hydrodynamic	diameter,	zeta	potential	and	polydispersity	index	(PdI)	of	
C16-DAPMA	micelles	at	25	°C	and	70	°C.	.........................................................................	150	
Table	4.2.	Test	of	different	heparin/binder	ratio	in	gel	formation.	.................................	152	
Table	 4.3.	 Binder/Heparin	 molar	 ratio	 and	 charge	 ratio	 +/-	 with	 increasing	 heparin	
concentration.	..................................................................................................................	153	
Table	5.1.	Test	of	different	heparin/	binder	ratios	on	OG1	gel	formation.	......................	206	
Table	5.2.	Test	of	different	heparin/	binder	ratios	in	OG2	gel	formation.	.......................	206	
Table	7.1.	Binder/Heparin	ratios	used	in	DLS	measurements.	........................................	240	
Table	 7.2.	 Concentrations	 of	 C14-DAPMA,	 C16-DAPMA,	 C18-DAPMA	 with	 and	 without	
heparin	used	to	record	TEM	images	in	water.	.................................................................	240	
Table	7.3.	Concentrations	of	DBS-COOH,	C16-DAPMA	and	heparin	used	to	record	infrared	
spectra.	.............................................................................................................................	246	
Table	 7.4.	 Concentrations	 of	 DBS-CONHNH2,	 C16-DAPMA	 and	 heparin	 used	 to	 record	
infrared	spectra.	...............................................................................................................	246	
Table	7.5.	Concentrations	of	DBS-COOH,	C16-DAPMA	and	heparin	used	to	record	TEM	and	
SEM	images	of	gels	prepared	in	ultra-pure	H2O.	..............................................................	248	
Table	7.6.	Concentrations	of	DBS-CONHNH2,	Heparin	and	C16-DAPMA	used	to	record	TEM	
and	SEM	images	of	gels	prepared	in	ultra-pure	water.	....................................................	248	
Table	 7.7.	 Concentrations	 of	 OG1,	 OG2,	 Heparin	 and	 C16-DAPMA	 used	 to	 obtain	 TEM	
images	of	gels	prepared	in	ultra-pure	water.	...................................................................	255	
24	
	
List	of	Schemes	
Scheme	2.1.	Boc	protection	of	N,N-di-(3-aminopropyl)-N-methylamine.	.........................	75	
Scheme	2.2.	TBTU	coupling	of	DAPMA	with	saturated	fatty	acids	followed	by	Boc	group	
removal.	.............................................................................................................................	76	
Scheme	3.1.	Synthesis	of	DBS-COOCH3.	...........................................................................	102	
Scheme	3.2.	Synthesis	of	DBS-COOH.	..............................................................................	102	
Scheme	3.3.	Hydrolysis	of	GdL.	........................................................................................	103	
Scheme	4.1.	Synthesis	of	DBS-CONHNH2.	........................................................................	148	
	
25	
	
List	of	Equations	
Equation	1.1.	Calculation	of	 the	binding	enhancement	 factor	a	 to	obtain	 the	degree	of	
cooperativity	of	multivalent	systems.	................................................................................	70	
26	
	
Dedication	
	
	
	
	
	
	
	
	
	
	
	
To	my	father	
	
	
	
	
27	
	
Acknowledgements	
I	would	like	to	thank	my	supervisor	Professor	David	Smith	for	all	the	guidance	and	advice,	
for	helping	me	building	up	my	confidence	and	for	the	great	scientific	enthusiasm	and	ideas.	
I	 would	 also	 like	 to	 acknowledge	 Professor	 Jan	 van	 Esch	 and	 Dr	 Menno	 de	 Jong	 for	
welcoming	me	 in	Delft	 and	Groningen	 for	my	 placements,	 allowing	me	 to	 improve	my	
scientific	experience	and	adaptability.	
	
I	am	very	grateful	to	all	the	members	of	Smith’s	group	for	the	great	work	environment,	
making	my	adaptation	to	a	new	country	so	much	easier.	I	would	like	to	thank	Stephen	and	
Tunde	for	all	the	help	and	support	when	I	started.	Rex	for	the	NMR	advices	and	computer	
tips.	I	would	also	like	to	thank	my	brilliant	MChem	student	Laura,	for	contributing	to	this	
thesis.	Jorge	for	being	a	good	neighbour,	in	country,	fume	hood	and	desk	(por	favor),	and	
for	together	with	Phill	having	the	craziest	conversations.	To	Lizzie	for	all	the	English	lessons	
and	allowing	me	to	have	some	dog	therapy	moments.	Nicole,	my	favourite	Scottish	person,	
for	her	great	work	and	for	bringing	an	industrial	point	of	view	to	the	group.	Buthaina,	the	
kindest	 person	 I	 ever	 met,	 for	 being	 a	 truly	 friend	 and	 for	 the	 nicest	 and	 funniest	
conversations.	Ana	for	being	more	than	a	postdoc,	a	really	good	friend	and	for	cheering	me	
up	when	I	feel	like	a	‘pasa’.	I	would	also	like	to	thank	all	the	SmartNet	members	for	the	
amazing	 and	 unforgettable	meetings	 around	 Europe.	 In	 addition,	 I	 would	 like	 to	 thank	
Vicent	le	Sage	and	Ana	Catarina	Lima	for	all	the	help	and	availability	during	my	placements	
in	Netherlands.	
	
I	must	also	acknowledge	the	collaborators	who	have	contributed	to	this	project;	Professor	
Sabrina	Pricl	(Italy)	and	Professor	Mauri	Kostiainen	(Finland).	Additionally,	I	would	like	to	
thank	 all	 the	 technical	 support	 received	 from	 Karl	 Heaton	 (MS),	 Heather	 Fish	 (NMR),	
Andrew	Leech	(CD)	and	Meg	Stark	(TEM	and	SEM).		
		
Finally,	 a	 special	 thanks	 to	my	 family.	 To	my	mother	 for	 always	 supporting	me	 in	 new	
adventures	and	encouraging	me	to	explore	the	world.	To	my	sister	and	Alexandre	for	giving	
me	the	best	gift	I	could	ever	ask	during	my	PhD,	my	little	nephew	Pedro.	To	Bruno,	for	being	
the	most	supportive	boyfriend	and	for	always	being	by	my	side.	And	lastly	to	my	father,	I	
am	sure	he	would	be	proud	of	my	achievements.			
28	
	
Declaration	
	
I	 declare	 that	 the	 work	 presented	within	 this	 thesis	 is	 entirely	my	 own,	 except	 where	
otherwise	acknowledged.	This	work	has	not	been	submitted	in	part	or	fully	for	examination	
towards	any	other	degrees	or	qualifications.		
	
	
Vânia	Margarida	Pinto	Vieira	
	
	 	 Chapter	1	
	
29	
	
1. Introduction	
1.1. Introduction	to	Gels	
1.1.1. Supramolecular	Chemistry	
Supramolecular	 chemistry	 studies	 the	 noncovalent	 interactions	 between	 molecular	
building	 blocks	 which	 generate	 different	 self-assembled	 materials	 in	 different	
dimensions.1,2	Back	 in	the	1990s,	Lehn	as	described	 it	as	 ‘the	designed	chemistry	of	the	
intermolecular	 bond’.3	 These	 intermolecular	 bonds	 include	 solvophobic	 effects,	
electrostatic	 interactions,	 hydrogen	 bonding,	 p-p	 interactions	 and	 van	 der	 Waals	
interactions.	Despite	non-covalent	 interactions	being	weaker	than	covalent	 interactions,	
they	 give	 supramolecular	 materials	 unique	 properties,	 such	 as	 mechanical	 tunability,	
responsiveness	 and	directionality,	 allowing	 control	 over	 composition	 and	 functionality.4	
Additionally,	supramolecular	materials	can	play	an	important	role	in	mimicking	biological	
systems,	 as	 supramolecular	 assemblies	 are	naturally	 present	 in	 biological	 systems	 from	
bilayer	membranes	to	ribosomes	and	self-assembly	of	 lipids	 in	the	formation	of	the	cell	
membrane.	 The	 replacement	 of	 natural	 materials	 with	 biocompatible	 supramolecular	
scaffolds	 can	 be	 particularly	 useful	 for	 tissue	 engineering	 and	 in	 fact	 supramolecular	
materials	can	be	used,	for	example,	in	the	replication	of	the	structure	of	collagen	(the	main	
component	 of	 the	 extracellular	 matrix	 (ECM)),	 or	 as	 muscle-like	 supramolecular	
polymers.5–7	Hence,	it	is	immediately	noteworthy	that	this	field	requires	a	multidisciplinary	
knowledge	across	chemistry,	physics	and	biology.		
	
Supramolecular	chemistry	can	be	divided	into	two	main	categories:	host-guest	interactions	
and	self-assembly	(Figure	1.1).	Host-guest	complexes,	as	the	name	suggests,	consist	of	a	
larger	molecule	(a	host)	that	can	surround	a	smaller	molecule	(a	guest)	via	non-covalent	
interactions,	 forming	 a	 stable	 host-guest	 complex	 based	 on	 the	 interactions	 between	
them.8,9	 Self-assembly	 processes	 are	 based	 on	 non-covalent	 interactions	 between	
molecules,	often	with	similar	size	and	shape.	In	the	present	work,	we	will	be	focused	on	
self-assembly	processes,	which	will	be	explained	in	more	detail	in	the	next	section	and	in	
section	1.6.	
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Figure	1.1	Supramolecular	structures	based	on	(a)	host-guest	complexes	and	(b)	self-
assembled	materials.	[Adapted	from	reference	10]	
	
1.1.2. Self-Assembly	
Self-assembly	 refers	 to	 the	 spontaneous	 association	 of	 molecules	 under	 equilibrium	
conditions	into	stable,	structurally	well-defined,	aggregates	held	together	by	non-covalent	
bonds.11	 Self-assembly	 processes	 are	 vital	 in	 nature	 and	 the	 use	 of	weak	 non-covalent	
interactions,	means	 that	 it	 is	a	 reversible	process	with	a	 thermodynamically	 stable	 final	
product.	This	allows	natural	systems	to	correct	any	errors	that	may	arise	from	the	multiple	
intermolecular	interactions	present	in	such	complex	structures.10,12	A	well-known	example	
of	a	molecule	spontaneously	held	together	by	non-covalent	interactions	is	the	DNA	double-
helix.13,14	 The	 two	 single	 strands	 come	 together	 by	 hydrogen	bonding	 and	p-p	 stacking	
interactions	 between	 complementary	 nucleobases	 of	 each	 strand.	 Assembly	 and	
disassembly	 allows	 the	 structure	 to	 correct	 any	matching	 errors	 and	 to	 form	 the	most	
thermodynamically	stable	structure.			
	
The	most	 common	molecular	 structure	 used	 in	 self-assembled	 systems	 corresponds	 to	
amphiphilic	molecules,	which	 aggregate	 in	 aqueous	 solution	 in	processes	driven	by	 the	
hydrophobic	effect.	As	the	non-polar	regions	of	the	molecule	aggregate,	their	associated	
	 	 Chapter	1	
	
31	
	
surface	water	molecules	become	free	in	solution,	resulting	in	an	increase	of	entropy,	which	
more	 than	 compensates	 the	 entropic	 cost	 associated	 with	 the	 aggregation	 of	 the	
hydrophobic	 components.15	 The	 type	 of	 aggregates	 formed	 from	 the	 assembly	 of	 the	
individual	monomers	depends	on	different	factors,	such	as	monomer	concentration	and	
morphology.16	Israelachvili	et	al.17	reported	the	effect	of	the	degree	of	hydrophobicity	of	
an	amphiphile	on	the	self-assembly	process.	The	morphology	of	the	aggregates	changes	
with	 the	 relative	 sizes	 of	 the	 hydrophobic	 and	 hydrophilic	 components,	 in	 order	 to	
geometrically	maximise	packing	and	minimise	unfavourable	solvent	interactions,	resulting	
in	 different	 geometries	 (Figure	 1.2).	 When	 hydrophilic	 heads	 are	 larger	 than	 the	
hydrophobic	tails,	this	favours	the	formation	of	spherical	micelles.	As	the	hydrophilic	heads	
become	 smaller	 in	 comparison	 to	 the	 hydrophobic	 tails,	 self-assembly	 into	 cylindrical	
shapes	is	favoured.	With	a	further	increase	in	hydrophobicity,	usually	by	the	addition	of	a	
second	 aliphatic	 tail,	 vesicles	 or	 liposomes	 become	 preferred.	 If	 the	 hydrophobic	 and	
hydrophilic	domain	are	comparable	in	size	it	tends	to	form	a	planar	bilayer	structure.	When	
the	hydrophobic	tails	are	larger	than	the	hydrophilic	heads,	inverted	micelles	are	formed.									
	
	
Figure	1.2.	Morphology	of	amphiphilic	aggregates	in	aqueous	solution	depending	on	the	
hydrophobic-hydrophilic	balance	of	the	monomers,	by	Isreaelachvili.	
	
It	is	common	for	a	self-assembled	system	to	form	after	successive	self-assembly	processes	
where	one	stage	of	complexity	cannot	be	achieved	without	the	previous	one.	This	process	
is	 called	 hierarchical	 self-assembly	 and	 can	 give	 rise	 to	 the	 design	 of	 multifunctional	
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structures.	 As	 an	 example,	 the	 hierarchical	 self-assembly	 of	 functionalised	 gold	
nanoparticles	(AuNPs)	with	promising	applications	in	theranostic	tools	has	been	reported.	
Firstly,	the	AuNPs	functionalised	with	amphiphilic	copolymers	self-assembled	into	vesicles.	
With	the	slow	addition	of	water	into	the	system	it	was	verified	that	the	grafting	density	of	
the	 copolymers	 affected	 the	 hierarchical	 self-assembly.	 While	 high	 copolymer	 density	
resulted	 in	 the	self-assembly	of	 the	hollow	vesicles	with	membranes	composed	of	 two-
dimensional	(2D)	AuNP	arrays,	when	the	grafting	density	was	reduced	the	vesicles	were	
composed	of	one-dimensional	(1D)	linear	AuNP	strings	(Figure	1.3).	This	was	found	to	be	a	
result	of	the	fact	that	the	AuNPs	with	high	grafting	density	of	copolymer	were	interacting	
through	solvophobic	 interactions	 that	 favoured	 the	 formation	of	2D	assemblies.	On	 the	
other	hand,	AuNPs	with	 low	grafting	density	were	primarily	 interacting	through	van	der	
Waals	 interactions	which	 favoured	 the	 formation	 of	 1D	 strings.	 The	 different	 forms	 of	
assembly	resulted	in	an	important	shift	in	the	absorbance	of	the	AuNPs	from	visible	(AuNPs	
with	 high	 grafting	 density	 of	 polymer)	 to	 near-infrared	 (NIR)	 (AuNPs	 with	 low	 grafting	
density	of	polymer)	-	efficient	probes	for	bioimaging	are	required	to	absorb	at	NIR.18	
	
	
Figure	1.3.	AuNPs	with	high	grafting	density	interact	primarily	through	solvophobic	
interactions	between	polymer	coatings,	favouring	the	formation	of	planar	assemblies	(2D	
arrays).	AuNPs	with	low	grafting	interact	primarily	through	van	der	Waals	interactions	
between	particle	cores,	favouring	the	formation	of	particle	chains	(1D	strings).	[Adapted	
from	reference	18].	
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Self-assembly	can	therefore	be	applied	to	the	construction	of	nanosized	materials	by	the	
spontaneous	assembly	of	small	molecular	building	blocks	that	can	ultimately	result	in	3D	
macroscopic	products	with	a	vast	range	of	applications.19–24	
	
1.1.3. Supramolecular	Gels	
Back	in	1926,	Dorothy	Jordon	Lloyd	stated	that	‘the	colloidal	condition,	the	gel,	is	easier	to	
recognise	than	to	define’	and	that	it	should	be	‘built	up	from	two	components,	one	which	
is	a	liquid	(…)	and	the	other	(…)	often	spoken	as	the	gelator,	is	a	solid’.25	Indeed,	gels	are	
well	 known	 three-dimensional	 (3D)	 soft	 materials	 with	 solid-like	 rheology,	 mainly	
constituted	by	a	liquid	phase	(usually,	99%)	against	a	very	small	amount	of	gelator	(usually,	
1%).26	Gels	can	be	categorised	into	chemical	and	physical	gels	(Figure	1.4).	In	chemical	gels,	
the	3D	network	is	formed	through	permanent	and	non-reversible	covalent	crosslinking	of	
the	components.	Physical	gels	are	based	on	reversible	non-covalent	interactions	between	
the	 network	 components,	 that	 can	 consist	 for	 instance	 of	 polymers,	 proteins	 or	 small	
organic	molecules	as	gelators,	in	a	liquid	phase.27		
			
	
	
Figure	1.4.	Gel	classification.	[Adapted	from	reference	28]	
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Supramolecular	gels	are	a	type	of	physical	gel	consisting	of	small	organic	molecules	able	to	
self-assemble,	that	combined	with	the	existence	of	directionality	in	the	interactions,	can	
give	rise	to	nanomaterials	capable	of	immobilizing	an	impressive	amount	of	solvent.	These	
small	molecules	 are	 usually	 called	 low-molecular-weight	 gelators	 (LMWGs),	 which	 self-
assemble	 into	 1D	 fibers	 by	 noncovalent	 interactions,	 such	 as	 hydrogen	 bonds,	 van	 der	
Waals	forces,	π-π	stacking	interactions	and	solvophobic	interactions,	into	a	3D	entangled	
network,	 preventing	 the	 flow	 of	 bulk	 solvent	 (Figure	 1.5).20,29–32	 According	 to	 the	
composition	of	 the	 liquid	phase,	supramolecular	gels	are	organogels	 (if	 the	gelator	self-
assembles	in	an	organic	solvent)	or	hydrogels	(if	the	gelator	self-assembles	in	water).	In	the	
present	 work	 hydrogels	 are	 of	 great	 interest	 as	 they	 are	 usually	 biocompatible,	 non-
cytotoxic	 and	 biodegradable.	 These	 characteristics	make	 hydrogels	 suitable	 for	 diverse	
biomedical	applications,	such	as	drug	delivery	and	tissue	engineering.33–36	
	
Differently	from	the	covalent	crosslinked	polymer	gels	which	present	1D	structures	as	the	
most	 basic	 elements,	 supramolecular	 gels	 are	 composed	 by	 ‘zero-dimensional’	 (0D)	
building	blocks	which	undergo	nucleation	to	form	a	stable	nucleus,	prior	to	self-assembly	
to	 form	 1D	 nanofibers	 and	 subsequent	 noncovalent	 cross-linking	 to	 form	 the	 3D	
network.37,38	Supramolecular	gels	are	characterised	by	unique	properties	such	as	critical	
gelation	temperatures	(Tgel),	referring	to	the	temperature	at	which	gel-sol	transition	occurs,	
and	 the	 critical	 gelation	 concentration	 (CGC)	 which	 refers	 to	 the	minimum	 amount	 of	
gelator	required	to	form	a	gel	in	a	certain	solvent.	Almost	all	supramolecular	gels	present	
sol-to-gel	 thermal	 reversibility,	 with	 good	 solubility	 when	 heated	 and	 with	 gelation	
occurring	at	low	concentrations	of	gelator	(typically	<	50	g.l-1).27,38,39	
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Figure	1.5.	Representation	of	the	hierarchical	self-assembly	of	a	supramolecular	gel.	
[Adapted	from	reference	29]	
	
Apart	 from	 thermal	 responsiveness,	 supramolecular	 gels	 can	 respond	 to	 other	 external	
stimuli	such	as	mechanical	stress,	light	irradiation	and	pH,	giving	rise	to	smart	soft	materials	
that	can	be	used	for	a	diversity	of	applications.		
	
As	an	example,	Kiyonaka	et	al.40	introduced	a	hydrogelator	based	on	glycosylated	amino	
acid	with	 a	 unique	 thermoresponsive	 property	 (Figure	 1.6	 –	Gelator	 1.1).	 The	hydrogel	
undergoes	shrinking	or	swelling	as	a	response	to	thermal	changes	instead	of	exhibiting	the	
conventional	gel-sol	 transition.	This	hydrogel	can	be	used	to	successfully	 release	water-
soluble	drugs	trapped	within	the	gel	matrix,	as	upon	shrinking,	water	is	expelled,	releasing	
the	 drugs	 in	 a	 thermally-controlled	 manner.	 On	 the	 other	 hand,	 hydrophobic	 water	
pollutants	became	entrapped	in	the	hydrophobic	cavity	of	the	gel	and	precipitated	when	
the	temperature	increased	and	the	gel	shrunk.	
	
Self-healing	supramolecular	gels	are	a	class	of	smart	materials	that	are	thixotropic,	which	
means	that	after	applying	a	mechanical	stress,	the	gel	is	able	to	spontaneously	repair	the	
damage	and	be	restored	after	the	stress	being	removed.	This	property	makes	gels	highly	
useful	 for	 applications	 that	 require	 injectability	 and	 therefore,	 highly	 desirable	 in	 the	
biomedical	field.41,42	A	thixotropic	cholesterol-based	organogel	has	been	reported	by	Xue	
et	al.43	(Figure	1.6	–	Gelator	1.2)	where	it	was	demonstrated	that	the	LMWG	formed	stable	
gels	 in	different	organic	 solvents	and	after	 the	application	of	a	 stress	destroyed	 the	gel	
network,	its	elastic	gel	properties	spontaneously	recovered	after	20	seconds.	Currently,	it	
is	possible	to	synthesise	new	gelators	based	on	the	structure	of	known	thixotropic	LMWGs,	
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however	 a	 general	 explanation	 for	 this	 phenomenon	 is	 still	 needed	 as	 generally	 these	
LMWGs	(as	many	other	gelators)	are	discovered	serendipitously.38		
	
	
Figure	1.6.	Molecular	structures	of	stimuli	responsive	LMWGs:	1.1)	N-acetyl-
galactosamine-appended	amino	acid	(GalNAc-aa)	derivative;	1.2)	Dimeric	cholesterol-
based	A(LS)2	derivative	(A	-	aromatic	component,	S	-	steroid	moiety,	L	-	linker	connecting	
the	two	units);	1.3)	Melamine	(M),	6,7-dimethoxy-2,4[1H,3H]-	quinazolinedione	(Q),	
Riboflavin	(R)	and	1.4)	Cationic	hyperbranched	polycarbonate.	
	
Photoresponsive	supramolecular	gels	have	great	potential	for	electroluminescent	devices	
and	sensors.	Therefore,	the	incorporation	of	donor-acceptor	chromophores	within	the	gel	
matrix	has	been	widely	 investigated.44	For	example,	Nandi	and	coworkers	described	the	
energy	transfer	from	a	blue-emitting	gel	consisting	of	a	hydrogen	bonding	bi-complex	of	
melamine	and	a	quinazolinedione	derivative	to	a	green	emitting	gel	when	in	the	presence	
of	the	acceptor	riboflavin	(Figure	1.6	–	Gelators	1.3).	The	properties	of	this	co-assembled	
supramolecular	gel	can	be	useful	for	stimuli-responsive	optoelectronic	devices.45	
	
Another	interesting	property	that	some	supramolecular	gels	can	present	is	pH-sensitivity,	
which	 is	 highly	 attractive	 for	 drug	 delivery	 and	 biomedical	 applications.	 Jia	 et	 al.46	 has	
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reported	 a	 pH-sensitive	 supramolecular	 hydrogel	 based	 on	 the	 hydrogen	 bonding	 of	 a	
cationic	hyperbranched	polycarbonate	(Figure	1.6	–	Gelator	1.4).	While	the	hydrogel	was	
stable	at	neutral	pH	with	the	possibility	to	load	drugs,	it	showed	a	fast	response	when	the	
pH	was	decreased	from	7.4	to	6.6	due	to	charge	repulsion.	This	resulted	in	significant	gel	
volume	expansion,	favouring	local	drug	release	in	acidic	microenvironments.		
	
The	 examples	 described	 above	 are	 among	 a	 vast	 variety	 of	 LMWGs	 that	 form	 stimuli-
responsive	 supramolecular	 gels,	 involving	 also	 different	 types	 of	 stimuli	 such	 as	 redox	
reactions,47	 enzymes,48	metals	 and	anions49.	 Stimuli	 responsive	 supramolecular	 gels	 are	
very	 attractive	 due	 to	 their	 potential	 applications	 in	 a	 different	 range	 of	 fields.	 In	 the	
present	work,	we	are	particularly	interest	in	LMWGs	that	are	able	to	form	supramolecular	
gels	 in	 water,	 therefore	 we	 will	 focus	 the	 next	 section	 on	 the	 different	 types	 of	
hydrogelators.			
	
1.2. Typical	Hydrogelators	
Hydrogels	can	be	found	in	a	variety	of	objects,	such	as	contact	lenses,	vitamin	capsules	and	
baby	 diapers.	 As	 hydrogels	 consist	 of	 a	 3D	 supramolecular	 network	 in	which	 the	main	
constituent	is	water,	the	attention	they	have	received	is	not	surprising,	particularly	in	life	
sciences	as	the	only	solvent	that	maintains	life	forms	is	water.		
	
Back	in	1921,	Hoffman	reported	a	molecule	named	dibenzoyl-l-cystine,	which	is	believed	
to	be	the	first	small	molecule	hydrogelator	(Figure	1.7).50	The	molecule	was	able	to	form	a	
gel	with	only	a	0.1%	concentration,	that	was	‘rigid	enough	to	hold	its	shape	for	a	minute	or	
more	when	the	beaker	(…)	was	inverted’.50	Although	hydrogels	were	already	common,	they	
were	mainly	constituted	by	large	molecules,	such	as	proteins	and	polymers	with	complex	
intermolecular	interactions	and	with	molecular	structures	that	were	hard	to	define.	It	was	
not	until	the	1990s	with	the	rise	of	supramolecular	chemistry	that	small	molecules	able	to	
form	gels	started	to	be	studied	in	more	detail	in	academic	labs	and	only	in	2000,	did	Menger	
et	 al.51	 investigate	 the	molecular	 details	 of	 dibenzoyl-l-cystine.	 The	 study	 revealed	 the	
importance	of	aromatic	moieties	in	the	design	of	hydrogelators,	as	the	aromatic-aromatic	
	 	 Chapter	1	
	
38	
	
interactions	proved	to	be	effective	in	enhancing	hydrogen	bonds	and	other	interactions	in	
water,	promoting	molecular	self-assembly.							
	
	
Figure	1.7.	Molecular	structure	of	dibenzoyl-l-cystine	(1.5),	first	small	molecule	
hydrogelator	reported.	
	
The	 fact	 that	 supramolecular	 hydrogels	 are	 mainly	 discovered	 by	 serendipity	 makes	 it	
complicated	 to	 predict	 which	 molecules	 will	 self-assemble	 in	 water	 only	 based	 on	
molecular	 structure.	 However,	 they	 share	 some	 properties	 such	 as	 self-assembly	 by	
noncovalent	 interactions,	 as	 already	 described	 and	 the	 presence	 of	 amphiphilicity	 that	
allows	an	effective	bottom-up	fabrication	of	the	3D	gel	network	and	provides	the	balanced	
solubility	required	for	both	gelator	aggregation	and	compatibility	with	solvent.	Therefore,	
we	 will	 be	 focusing	 on	 the	 most	 classical	 examples	 of	 supramolecular	 hydrogelators,	
namely	hydrogelators	based	on	peptides	and	small	organic	molecules.		
	
Peptides	are	valuable	supramolecular	building	blocks	due	to	their	ability	to	mimic	natural	
architectures	 such	 as	 b-sheets	 and	 a-helices	 in	 solution	 and	 to	 form	 gels	 under	
physiological	 conditions,	 while	 being	 biocompatible	 and	 biodegradable.	 Peptide	
amphiphiles	(PAs)	consist	of	a	hydrophobic	region,	usually	an	alkyl	chain,	and	a	hydrophilic	
peptide	 sequence,	 with	 features	 of	 amphiphilic	 surfactants	 and	 functions	 of	 bioactive	
peptides.	 PAs	 can	 self-assemble	 in	 water	 into	 gels	 allowing	 the	 encapsulation	 of	 small	
hydrophobic	drugs	and	by	displaying	at	their	surfaces	charged	amino	acids,	PAs	can	also	
interact	electrostatically	with	a	variety	of	biomolecules.52,53	Feng	and	coworkers54	reported	
a	cyclopeptide	combining	lysine	and	tyrosine	able	to	gelate	in	water	at	a	CGC	of	0.6%	wt/vol	
(Figure	 1.8).	 The	 stabilisation	 of	 the	 gels	 was	 originated	 by	 intermolecular	 hydrogen	
bonding	between	the	amide	groups	of	the	diketopiperazine	ring	-	a	type	of	hydrogen	bond	
interaction	similar	to	that	found	in	nanofibers	of	cyclic	dipeptides.	Despite	being	able	to	gel	
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a	 number	 of	 organic	 solvents,	 the	 gelator	 was	 only	 able	 to	 form	 gels	 in	 water	 when	
ultrasound	was	applied	during	cooling,	yielding	a	hydrogel	with	relatively	low	mechanical	
strength.	In	an	attempt	to	enhance	the	mechanical	properties	of	the	hydrogel,	a	series	of	
n-alkyl	chains	(C2-C18)	were	introduced	in	the	lysine	residue.	The	outcome	revealed	that	
hydrogelation	ability	was	dependent	on	the	chain	length	and	only	short	alkyl	tails	yielded	
hydrogels.	Moreover,	 the	 addition	 of	 an	 alkyl	 chain	 with	 one	 carbon	 atom	 resulted	 in	
formation	of	a	robust	and	thermoreversible	hydrogel	at	2.5%	wt/vol.	This	modification	is	
believed	to	tune	the	solubility	and	hence	the	gelation	potential.	
	
	
Figure	1.8.	Molecular	structure	of	tyrosine-lysine	based	cyclodipeptide	1.6.	
	
Stupp	 and	 coworkers	 have	 introduced	 a	 family	 of	 cationic	 PAs	 able	 to	 gelate	 water,	
consisting	of	a	hydrophobic	alkyl	chain	contributing	to	the	strongly	amphiphilic	nature	of	
the	molecule,	 followed	by	 a	 short	 peptide	 sequence	 capable	 of	 forming	 intermolecular	
hydrogen	bonding,	typically	composed	by	hydrophobic	amino	acids,	that	leads	to	1D	self-
assembly.	 Additionally,	 charged	 amino	 acids	 are	 incorporated	 into	 the	 PA	 design,	
enhancing	 the	 solubility	 in	 water	 and	 the	 pH-response	 of	 the	 3D	 network.	 Finally,	 the	
incorporation	of	different	peptide	epitopes	introduces	bioactivity	by	their	ability	to	interact	
with	cells	or	proteins.53,55	The	chemical	 structure	of	a	 representative	PA	synthesised	by	
Stupp	and	coworkers	is	shown	in	Figure	1.9.	
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Figure	1.9.	Molecular	structure	of	a	representative	PA	designed	by	Stupp’s	research	
group.	
A	popular	class	of	hydrogelators	based	on	peptides	are	the	aromatic	PAs.	Aromatic	PAs	
have	gained	special	attention	due	to	their	structural	simplicity	while	maintaining	peptidic	
versatility.	This	class	of	self-assembling	materials	relies	on	aromatic	groups	to	provide	the	
amphiphilicity	required	to	promote	self-assembly.	The	aromatic	PA	structure	(Figure	1.10)	
is	based	on	a	short	peptide	sequence	(usually,	dipeptide	or	single	amino	acid)	stabilised	via	
hydrogen	bonding	 linked	to	an	aromatic	moiety	 (typically	a	9-fluorenylmethoxycarbonyl	
(Fmoc)	group56,57)	that	self-assembles	through	p-p	interactions.	The	linker	between	these	
two	segments	can	control	their	structural	orientation	and	hence	also	plays	an	important	
role	in	the	overall	structure.	Additionally,	the	C-terminus	can	be	funtionalised	or	contribute	
to	the	balance	between	protonated	and	ionised	forms.58		
	
	
Figure	1.10.	Generic	molecular	structure	of	aromatic	PAs.	
	
A	very	well	investigated	aromatic	PA	is	Fmoc-diphenylalanine	(Fmoc-FF),	shown	on	Figure	
1.11	–	Gelator	1.9.59–63	Xu	and	coworkers64	were	the	first	to	report	Fmoc-protected	amino	
acids	and	dipepetides	that	spontaneously	formed	fibrous	scaffolds.	Ulijn	and	coworkers65,66	
then	reported	the	Fmoc-FF	PA	as	a	hydrogelator	able	 to	self-assemble	 into	a	3D	fibrilar	
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network	under	physiological	conditions	by	adjusting	the	pH	of	the	aqueous	solution.	Later	
Adams	 et	 al.67	 concluded	 that	 the	 final	 pH	 of	 the	 Fmoc-FF	 hydrogels	 dictated	 the	
mechanical	properties	of	the	hydrogel,	due	to	the	presence	of	the	C-terminal	carboxylic	
group.	 Adams	 and	 coworkers68	 also	 studied	 the	 contribution	 of	 different	 parts	 of	
naphthalene-conjugated	 dipeptide	 to	 the	 overall	 structural	 architecture,	 by	 testing	
different	 dipeptide	 sequences	 conjugated	 to	 naphthalene	 with	 different	 substituents	
(Figure	1.11	–	Gelator	1.10).	Adams	and	co-workers	achieved	gelation	by	the	hydrolysis	of	
glucono-d-lactone	(GdL)	to	adjust	the	pH.	The	hydrolysis	of	GdL	 in	water	forms	gluconic	
acid	and	results	in	a	slow	decrease	in	pH.	This	controls	the	kinetics	of	protonation	to	make	
sure	that	it	is	not	faster	than	the	kinetics	of	self-assembly	–	which	leads	to	inhomogeneous	
materials.	 The	 hydrophobicity	 of	 the	 dipeptide	 influenced	 the	 pKa	 of	 this	 class	 of	
hydrogelators	and	consequently	the	final	pH	of	the	gels.68	Additionally,	it	was	found	that	
the	chirality	of	the	naphthalene	assemblies	was	governed	by	the	dipeptide	sequence	and		
the	molecular	packing	governed	by	the	nature	of	the	naphthalene	conjugate.					
							
	
Figure	1.11.	Molecular	structure	of	1.9)	Fmoc-FF	and	1.10)	naphthalene-conjugated	
dipeptide.	
	
In	 respect	 to	 hydrogels	 based	 on	 small	 organic	 molecules	 there	 is	 currently	 a	 diverse	
number	of	building	blocks	in	this	category	that	can	promote	gelation	in	water.	Therefore,	
some	examples	of	effective	hydrogelator	families	based	on	small	organic	molecules	will	be	
described.	
	
Urea	is	well-known	to	form	self-assembled	nano-architetures	and	to	have	a	gelation	ability	
dependent	on	the	hydrogen	bond	interactions,	having	self-complementary	hydrogen	bond	
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donors	 and	 acceptors.	 For	 that	 reason	 several	 hydrogelators	 based	 on	 urea	 have	 been	
developed.69–71	The	Dastidar	group72,73	has	demonstrated	that	composites	of	pyridyl-urea	
(Figure	1.12	–	Gelator	1.11)	 in	conjunction	with	carboxylic	acids	can	produce	a	range	of	
materials	that	can	either	form	gels	or	are	crystalline.	They	demonstrated	that	when	the	
urea	group	 is	at	 the	para	position	of	 the	pyridine	 it	hydrogelates,	whereas	at	 the	meta	
position	 is	 does	 not.	 This	 is	 thought	 to	 be	 due	 to	 the	 intramolecular	 CH-O	 interactions	
coupled	to	the	good	hydrogen	bond	acceptor	of	the	pyridinyl	nitrogen	atom	when	the	urea	
group	is	in	the	meta	position	making	it	a	poor	gelator	as	it	cannot	form	the	typical	urea	
tape	 motif	 responsible	 for	 one-dimensional	 fibre	 growth.74	 Different	 urea-based	
hydrogelators	 have	 also	 been	 developed	 by	 Steed	 and	 coworkers.75–77	 Specifically,	 an	
imidazole-urea	based	hydrogelator	was	developed	(Figure	1.12	–	Gelator	1.12)	in	which	the	
imidazole	nitrogen	atom	has	the	potential	to	hydrogen	bond	with	the	imidazole	NH	group,	
leaving	the	urea	moiety	free	to	form	the	typical	hydrogen	bonded	tape	motif	and	hence	
act	 as	 and	 effective	 gelator.77	 van	 Esch	 et	 al	 introduced	 a	 new	 class	 of	 effective	
hydrogelators	 based	 on	 the	 modification	 of	 the	 substituents	 of	 cyclohexane	 bis-urea	
organogelators	with	hydrophilic	hydroxy	or	 amino	 functionalities	 (Figure	1.12	–	Gelator	
1.13).	The	hydrogels	consist	of	a	network	of	fibers,	where	the	urea	groups	were	involved	
in	 intermolecular	 hydrogen	 bonding	 and	 the	 gelation	 was	 driven	 by	 hydrophobic	
interactions	 of	 the	 methylene	 groups,	 while	 urea	 hydrogen	 bonding	 provided	 the	
anisotropic	self-assembly	and	high	thermal	stability	of	the	gels.78		
	
	
Figure	1.12.	Molecular	structures	of	selected	urea-based	LMWGs	1.11	-1.13.	
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An	 alternative	 type	 of	 hydrogelator	 uses	 saccharide	 groups	 instead	 of	 urea	 to	 provide	
hydrogen	interactions,	as	the	multiple	hydroxyl	groups	contribute	to	the	presence	of	both	
hydrogen	 bond	 donors	 and	 acceptors	 for	 intermolecular	 interactions,	 essential	 for	 the	
molecular	self-assembly	in	water,	while	the	hydrophilic	saccharide	moieties	also	contribute	
to	the	solubility	of	the	gelator	in	water.79	Chen	et	al.80	reported	a	cysteine	and	pH-sensitive	
saccharide-derived	hydrogelator	bearing	an	aldehyde	group	(Figure	1.13	–	Gelator	1.14).	
The	 selective	 response	 to	 cysteine	was	 tested	 by	 comparing	with	 other	 eight	 different	
amino	acid	solutions	placed	on	top	of	the	hydrogels.	Only	when	in	contact	with	cysteine	
was	the	hydrogel	completely	transformed	into	solution	 indicating	that	this	hydrogelator	
responds	selectively	to	cysteine,	probably	due	to	the	specific	reaction	of	the	aldehyde	with	
cysteine	to	form	the	thiazolidine	derivative,	while	not	being	able	to	react	with	any	of	the	
other	amino	acids.	The	hydrogelator	also	proved	to	be	pH-sensitive	and	could	be	converted	
to	solution	after	exposure	to	acidic	medium	due	to	the	sensitivity	of	the	acetal	moiety	to	
acidic	 environments.	 In	 another	 approach,	 Mishra	 and	 coworkers81	 demonstrated	 a	
glucose-based	 gelator	 able	 to	 effectively	 form	 thermoreversible	 hydrogels	 at	 a	 CGC	 of	
0.03%	wt/vol	in	a	mixture	of	water	and	methanol	(50:50).	The	amphiphilic	gelator	design	
was	based	on	a	hydrophilic	glucose	head	connected	through	a	triazole	incorporated	linker	
to	 the	 benzene	 ring	with	 a	 hydrophobic	 hydrocarbon	 tail	 (Figure	 1.13	 –	 Gelator	 1.15).	
Intermicellar	 aggregation	 led	 to	 the	 formation	 of	 larger	 micellar	 structures	 and	 the	
interaction	of	larger	aggregates	to	form	sheet-like	spongy	gel	networks	which	entrap	the	
solvent	molecules	 by	 a	 surface	 tension	 effect.	 It	 should	 be	 noted	 that	mixed	 aqueous	
solvents	are	often	used	to	tune	the	solubility	of	a	system	to	achieve	effective	gelation.			
	
	
Figure	1.13.	Molecular	structures	of	saccharide-based	hydrogelators	1.14	and	1.15.	
	
The	use	of	sorbitol	as	a	supramolecular	building	block	has	also	resulted	in	the	development	
of	effective	hydrogelators.	 	An	effective	amphiphilic	hydrogelator	based	on	sorbitol	has	
been	reported	by	Li	et	al.82,	and	the	effect	of	salt	on	the	gelation	process	of	the	LMWG	
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2,4(3,4-dichlorobenzylidene)-D-sorbitol	 (Figure	 1.14	 –	Gelator	 1.16)	was	 studied.	 It	was	
demonstrated	that	the	addition	of	NaCl	affected	the	morphology	of	the	gels	changing	from	
globular	 aggregates	 to	 entangled	 long	 fibers.	 The	 presence	 of	 salt	 also	 contributed	 to	
slightly	 weaker	 hydrogen	 bonding	 interactions,	 probably	 due	 to	 the	 fact	 that	 the	 self-
assembly	of	the	hydrogelator	was	not	only	governed	by	 intermolecular	hydrogen	bonds	
but	 also	 by	 p-p	 interactions	 and	 van	 der	Waals	 interactions,	 which	 interfere	 with	 the	
hydrogen-bonding	interactions	because	of	steric	mismatching.	A	related	example	reported	
a	sorbitol-based	LMWG	(Figure	1.14	–	Gelator	1.17)	that	self-assembles	in	water	and	can	
be	used	as	a	gel	electrolyte.	The	hydrogel	is	formed	in	the	presence	of	6	M	KOH	and	has	a	
CGC	of	0.3%	wt/vol.	The	hydrogel	electrolyte	proved	to	be	thermoreversible,	with	a	very	
good	thermal	and	electrochemical	stability	that	make	it	suitable	for	applications	in	alkaline	
battery	systems.83		
	
	
Figure	1.14.	Molecular	structures	of	sorbitol-based	LMWGs	1.16	and	1.17.	
	
In	the	present	work,	hydrogels	are	formed	based	on	the	well-known	organogelator	1,3:	2,4-
dibenzylidene-D-sorbitol	 (DBS)	 (Figure	1.15).84	This	chiral	LMWG	amphipile	 is	capable	of	
self-assembling	into	1D	fibers	which	leads	to	an	intertwined	network	in	the	presence	of	a	
liquid	phase.	DBS	is	a	derivative	of	the	sugar	alcohol	D-sorbitol	and	presents	a	butterfly-like	
shape,	having	the	sorbitol	as	the	body	and	the	benzylidene	groups	as	the	wings.	The	ability	
of	DBS	to	self-assemble	is	endowed	by	the	aromatic	rings	through	the	solvophobic	effect	
and	π-π	stacking	supported	by	hydrogen	bonding	between	the	acetal	oxygens	and	hydroxyl	
groups.	 It	 is	 believed	 that	 the	 more	 internal	 5-hydroxy	 group	 forms	 intramolecular	
interactions	with	the	nearest	acetal	oxygen,	while	the	most	external	6-hydroxy	group	forms	
intermolecular	hydrogen	bonds	with	the	acetal	oxygens	of	DBS	“neighbours”,	hence	being	
crucial	for	the	self-assembly	event.85	Furthermore,	Lan	et	al.86	disclosed	how	solvents	can	
alter	or	 influence	the	gelation	of	DBS.	 It	was	stated	that	opaque	DBS	gels	 tended	to	be	
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constituted	by	bundles	of	 fibers	and	to	be	weaker	 than	the	 transparent	gels,	which	are	
more	likely	to	form	in	higher-polarity	solvents.	Besides	the	importance	of	the	polarity	of	
the	 solvent,	 their	 ability	 to	 accept	 or	 donate	 a	 hydrogen	 bond	 appeared	 to	 be	 very	
important	to	determine	whether	the	addition	of	DBS	will	result	in	a	solution,	clear	gel,	or	
opaque	gel,	with	 the	 latter	being	obtained	when	 the	DBS	 could	not	 accept	 a	hydrogen	
bond.	Therefore,	when	the	solvent	presented	stronger	hydrogen	bonding	than	DBS,	clear	
gels	were	formed	whereas	the	opposite	situation	led	to	the	formation	of	opaque	gels.	This	
reflects	the	fact	that	gelation	is	a	balance	between	solubility	and	aggregation.						
	
	
Figure	1.15.	Molecular	structure	of	DBS.	
	
The	presence	of	 aromatic	 rings	 introduces	hydrophobicity	 into	 the	molecule	which	 is	 a	
drawback	in	terms	of	the	formation	of	hydrogels.	In	order	to	overcome	this	problem,	our	
research	group	developed	DBS	derivatives	in	which	the	aromatic	rings	are	para	substituted.	
When	 substituted	 by	 carboxylic	 acid	 groups	 (Figure	 1.16–	 a),	 the	 hydrophilicity	 of	 the	
molecule	 is	 increased	 and	 allows	 the	 formation	 of	 efficient	 pH-controlled	 hydrogels.87	
Additionally,	 if	 functionalised	by	hydrazide	groups	(Figure	1.16	–	b),	which	also	provides	
hydrophilicity	to	support	hydrogelation,	the	system	effectively	self-assembles	in	water	by	
application	of	a	heat-cool	cycle	and	forms	pH-tolerant	hydrogels.88		
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Figure	1.16.	Molecular	structures	of	DBS-based	LMWGs:	a)	DBS-COOH	and	b)	DBS-
CONHNH2.	
	
1.3. Multicomponent	Gels	
Most	supramolecular	gels	consist	of	a	solvent	and	a	gelator.	However,	the	individual	self-
assembly	of	multi-component	supramolecular	structures	with	LMWGs	can	give	rise	to	new	
materials	 with	 complexity,	 containing	 independent	 functionalities,	 potentially	 able	 to	
mimic	multi-component	natural	systems.89–91	Multi-component	LMWGs	can	be	achieved	
using	 different	 approaches	 such	 as	 through	 mixing	 of	 different	 LMWGs,92–96	 or	 the	
combination	of	LMWGs	with	polymers,87,97–99	where	both	molecules	can	form	gels;	mixing	
two	 or	 more	 components	 that	 do	 not	 gel	 independently	 but	 form	 gels	 when	
combined;100,101	or	the	orthogonal	self-assembly	of	LMWGs	with	non-gelating	components	
such	as	surfactants.102–104	
	
Mixtures	of	two	different	LMWGs	can	originate	different	behaviours,	resulting	in	different	
structures,	as	shown	in	Figure	1.17.	The	LMWGs	can	associate	with	each	other,	so	the	fibers	
are	formed	with	an	exact	order	of	gelators	(ordered	co-assembly);	the	LMWGs	can	mix	in	
a	random	way	(random	co-assembly);	or	the	LMWGs	can	self-assemble	individually,	so	the	
fibers	are	formed	with	only	one	molecule	or	the	other	(self-sorting).90		
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Figure	1.17.	Schematic	representation	of	the	self-assembling	of	two	LMWGs:	a)	
randomly;	b)	co-assembly;	c)	self-sorting.	[Adapted	from	reference	90]	
	
Recently,	Adams	and	co-workers	studied	a	pH-triggered	mixture	of	two	naphthalene-based	
dipeptide	LMWGs	and	explored	whether	co-assembly	or	self-sorting	was	occurring	and	the	
effect	of	pH	on	gel	network	formation	(Figure	1.18).	As	described	previously,	they	lowered	
pH	in	a	controlled	manner	using	the	hydrolysis	of	GdL	to	gluconic	acid.	At	high	pH	both	
LMWGs	remained	independent	and	colloidal	structures	were	formed	(LMWG	1.18	forms	
wormlike	micelles,	whereas	LMWG	1.19	does	not).	When	the	pH	was	decreased	there	were	
two	main	stages	in	the	assembly	process	of	the	mixture	of	LMWG	1.18	and	1.19.	The	first	
stage	was	above	the	expected	pka	of	LMWG	1.19,	with	LMWG	1.18	starting	to	assemble	
into	fibers	first.	At	this	stage,	there	was	co-assembly	of	both	LMWGs.	As	the	pH	continued	
to	 decrease,	 there	 was	 a	 different	 rate	 of	 assembly	 and	 as	 LMWG	 1.19	 was	 not	 fully	
incorporated	it	formed	an	independent	network,	thus	self-sorting.	It	was	believed	that	the	
type	 of	micelle	 formed	 at	 high	 pH	may	 dictate	whether	 the	multicomponent	 system	 is	
driven	by	self-sorting	or	co-assembling.105			
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Figure	1.18.	a)	Molecular	structures	of	naphthalene-based	LMWGs	1.18	and	1.19.	b)	
Schematic	representation	of	partial	co-assembly	of	a	mixture	of	the	LMWG	1.18	(blue)	
and	LMWG	1.19	(red)	with	the	decrease	of	pH.	LMWG	1.19	is	not	fully	incorporated	and	
assembles	alone	as	the	pH	decreases.105	
	
Despite	the	responsiveness	and	tunability	of	LMWGs,	they	usually	form	weak	networks,	
which	can	make	them	less	applicable	than	covalently	cross-linked	gels.106	Therefore,	their	
combination	 with	 polymer	 gels	 is	 of	 increasing	 recent	 interest	 due	 to	 the	 enhanced	
mechanical	 properties	 which	 become	 possible.	 This	 combination	 can	 be	 achieved	 by	
polymerizing	the	LMWG	fibers;	capturing	the	LMWG	in	the	polymer	matrix;	adding	a	non-
gelling	polymer;	adding	a	polymer	that	will	drive	the	self-assembly	of	the	LMWG,	or	mixing	
a	polymer	with	a	LMWG,	where	both	are	able	to	form	gels.97	As	an	example	of	the	latter	
approach,	our	group	previously	demonstrated	the	combination	of	DBS-COOH	LMWG	with	
agarose	 as	 a	 polymer	 gelator	 (PG)	 (Figure	 1.19)	 that	 resulted	 in	 independent	 and	 non-
interacting	networks,	with	the	LMWG	providing	the	network	with	pH	responsiveness	while	
the	polymer	gel	ensured	the	robustness,	 integrity	and	porosity	of	the	overall	material.87	
The	same	LMWG	has	been	used	to	form	a	hybrid	hydrogel	with	a	photo-inducible	synthetic	
polymer	(poly(ethylene	glycol)	dimethacrylate	-	PEGDM)	(Figure	1.19).	The	hybrid	material	
proved	to	be	a	self-sorting	multicomponent	gel	where	different	regions	can	be	spatially	
patterned	 by	 photo-irradiation	 and	 with	 the	 LMWG	 being	 able	 to	 assemble	 and	
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disassemble	within	 the	PG	network	by	pH	 variation.	 Both	 gelator	 networks	 can	 control	
diffusion	rates	with	suggested	applications	in	drug	delivery	with	the	potential	for	different	
kinetics	of	drug	release	from	different	parts	of	the	gel.98	
	
	
Figure	1.19.	a)	Molecular	structures	of	LMWG	and	PGs	used	to	obtain	responsive	hybrid	
gels	b)	Schematic	representation	of	a	LMWG-polymer	hybrid	gel.97	
	
Multi-component	supramolecular	gels	can	also	be	obtained	from	small	molecules	which	
individually	are	not	able	to	form	gels.	Ding	and	coworkers101	reported	a	peptide	that	by	
itself	 forms	nanofibers	but	not	hydrogels	due	to	the	weak	 inter-fiber	 interactions.	 In	an	
attempt	to	use	the	nanofibers	as	a	vehicle	for	delivering	anticancer	drug	doxorubicin,	they	
discovered	that	the	drug	could	not	be	encapsulated	as	it	formed	nanospheres	that	were	
located	at	the	surface	of	the	peptide	nanofibers.	The	nanospheres	acted	as	cross-linkers	to	
increase	 the	 inter-fiber	 interactions	 due	 to	 the	 electrostatic	 interactions	 between	 the	
negatively	charged	nanofibers	and	the	positively	charged	doxorubicin,	contributing	to	the	
formation	of	a	stable	3D	hydrogel	network.	Additionally,	the	resulting	hydrogel	was	able	to	
release	the	drug	in	a	sustained	manner	while	showing	a	cytotoxicity	comparable	to	the	free	
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doxorubicin.	Therefore,	 the	use	of	nanospheres	as	cross-linkers	 to	 form	supramolecular	
hydrogels	with	potential	for	controlled	delivery	of	anticancer	drugs	was	demonstrated.			
	
In	a	different	approach,	van	Esch	and	co-workers102	reported	an	orthogonal	self-assembled	
architecture	 involving	 a	 1,3,5-cyclohexyltricarboxamide	 based	 hydrogelator	 (OG2)	 and	
surfactants	 that	 form	 compartmentalised	 structures.	 The	 thermoreversilibity	 of	 the	
hydrogels	allowed	them	to	be	dissolved	in	solutions	of	surfactants	at	a	temperature	above	
the	Tgel,	followed	by	cooling	to	obtain	the	hydrogels	with	the	surfactants	incorporated.	The	
surfactant	vesicles	were	stable	in	the	presence	of	the	gel	nanofibers,	with	the	vesicles	being	
accommodated	within	the	confined	space	of	the	gel	network	pores	(Figure	1.20).		
	
Figure	1.20.	Molecular	structure	of	a	cyclohexane-based	LMWG	functionalised	with	an	l-
phenylalalanyl-amidoquinoline	moiety	(OG2)	(top)	and	cryo-transmission	electron	
microscopy	(cryo-TEM)	images	of	stable	dioleoylphosphocholine	(DOPC)	vesicles	
coexisting	with	OG2	gel	network	(bottom	left)	–	vesicles	shape	influenced	by	confined	gel	
network	and	DOPC	vesicles	deformed	by	the	growth	of	the	OG2	gel	nanofibers	directly	in	
their	aqueous	compartment	(bottom	right).102	
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Additionally,	as	the	OG2	hydrogelator	can	also	form	reversible	hydrogels	by	adjusting	the	
pH	 value,	 the	 encapsulation	 of	 free	 OG2	monomers	 in	 unilamellar	 liposomes	 could	 be	
achieved	at	pH	2.	The	self-assembly	of	OG2	into	nanofibers	was	then	induced	by	increasing	
the	 pH	 to	 neutral.	 As	 a	 result,	 OG2	 nanofibers	 were	 observed	 within	 the	 aqueous	
compartment	of	the	unilamellar	vesicles,	with	the	growth	of	the	fibers	restricted	by	the	
membrane	wall,	and	its	anisotropic	growth	and	rigidity	deforming	the	spherical	shape	of	
the	 vesicles	 (Figure	 1.20).	 The	 orthogonal	 self-assembly	 of	 vesicles	 with	 encapsulated	
hydrogels,	usually	called	‘gellosomes’	is	very	attractive	as	a	mimic	of	natural	systems,	such	
as	the	cytoskeleton	and	for	drug	delivery.104		
	
Stupp	et	al107	 reported	aldehyde	 functionalised	PAs,	based	on	 the	amphiphile	 structure	
shown	in	Figure	1.9,	that	form	supramolecular	assemblies	capable	of	reducing	silver	ions	
and	nucleating	uniformly	sized	silver	metal	nanoparticles	in	water.	The	PA	was	modified	in	
order	to	display	aldehyde	moieties	on	its	surface,	which	are	known	to	reduce	two	silver	
ions	 to	 Ag2	 clusters.	 The	 fusion	 of	 silver	 clusters	 into	 larger	 nanoparticles	 was	 then	
promoted	 by	 rearrangement	 of	 PA	 molecules	 within	 the	 supramolecular	 structure,	
generating	monodispersed	silver	particles	at	regular	distances	along	the	length	of	the	PA	
nanofibers.	The	metallic	supramolecular	hydrogels	exhibited	antimicrobial	activity	which	
can	be	useful	for	applications	in	medicine.	Our	research	group	has	also	reported	a	hybrid	
hydrogel	 based	 on	 the	 pH-stable	 hydrogelator	 DBS-CONHNH2	 which	 extracts	 precious	
metal	 ions,	 such	 as	 gold	 and	 silver,	 and	 originates	 conductive	 hybrid	materials.	 In	 this	
example,	gold	and	silver	ions	were	spontaneously	reduced	in	the	gel	to	form	gold	and	silver	
nanoparticles	(AuNPs	and	AgNPs,	respectively)	(Figure	1.21).	The	diffusion	of	Au3+	and	Ag+	
into	the	gel	leads	to	its	change	in	colour	to	ruby	or	yellow,	respectively,	indicating	that	the	
gel	fibers	reduce	and	cap	the	nanoparticles	in	situ	within	the	network.	These	conductive	
hybrid	materials	may	be	useful	in	nanoelectronics,	with	modified	electrode	surfaces	and	
enhanced	electrocatalysis,	being	demonstrated.108				
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Figure	1.21.	Transmission	electron	microscopy	(TEM)	images	of	DBS-CONHNH2-AuNPs	
(right)	and	DBS-CONHNH2-AgNPs	(left)	hydrogels.	Scale	bars:	200	nm.108	
	
1.4. Controlled	Release	from	Gels	
The	 controlled	 release	of	 pharmaceutical	 drugs	 requires	 the	development	of	 optimized	
systems	 that	 will	 ensure	 biodegradability;	 the	 absence	 of	 side	 effects;	 drug	 loading	
capacity;	 control	 on	 drug	 release	 kinetics;	 and	 maintenance	 of	 the	 physical-chemical	
properties	 of	 the	 drug.109,110	 Biomaterials	 with	 nanoscale	 organisation	 have	 been	
successfully	used	as	controlled	release	vehicles	for	drug	delivery.	Promising	nanoscale	drug	
delivery	 systems	 include	 nanoparticles,	 nanocapsules,	 nanotubes,	 nanogels	 and	
dendrimers,	which	can	be	used	to	deliver	small-molecule	drugs	and	biomacromolecules	
(e.g.	peptides,	proteins).111		
	
Soft	materials	 such	as	hydrogels,	 can	 serve	as	 carriers	of	encapsulated	drugs	or	 can	be	
covalently	conjugated	with	therapeutics,	and	for	that	reason	have	been	widely	studied	to	
act	 as	 drug	 delivery	 vehicles.28,109,110,112–118For	 the	 release	 of	 drugs	 from	 a	 polymer	
hydrogel,	the	molecular	weight	of	the	drug	and	the	network	density	can	affect	the	release	
profile	of	the	drugs.119,120	For	example,	Menzel	et	al.120	studied	the	influence	of	the	network	
properties	of	polymer	hydrogel	cylinders	and	microspheres	on	the	release	rate	of	proteins.	
They	observed	that	the	degradation	of	the	network	leads	to	the	release	of	the	entrapped	
substances,	 but	 the	 encapsulation	 of	 small	 substances	 in	 hydrogels	with	 low	polymeric	
gelator	 concentrations	 (10	 wt%)	 resulted	 in	 an	 initial	 burst	 release.	 By	 increasing	 the	
density	of	the	network	(30	wt%	of	gelator)	and	the	drug	size,	the	initial	burst	disappeared	
and	a	continuous	release	occurred.	With	the	increase	of	network	density	and	associated	
decrease	in	pore	size	of	the	network,	the	substances	were	entrapped	more	evenly,	which	
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contributed	 to	 a	 more	 constant	 release.	 So,	 the	 network	 properties,	 the	 drug	
hydrodynamic	diameter	and	degradation	proved	to	be	essential	factors	for	the	efficiency	
of	controlled	release	by	polymer	hydrogels.		
	
In	hydrogels	formed	from	LMWGs,	the	self-assembly	process,	the	gelator	concentration,	
pH,	 temperature,	 etc.	 can	 be	 used	 to	 obtain	 a	 controlled	 release	 profile	 of	 bioactive	
molecules.	 In	 one	 example,	 Hamachi	 et	 al.	 have	 reported	 a	 multi-stimulus	 responsive	
phosphate-based	hydrogelator	which	responds	to	four	different	stimuli	(temperature,	pH,	
Ca2+	 and	 light)	 (Figure	 1.22).	 By	 using	 the	 multi-stimulus	 responsiveness,	 they	 formed	
supramolecular	hydrogels	in	the	presence	of	various	combinations	of	the	stimuli	and	found	
that	they	were	able	to	hold	and	release	bioactive	substances	(vitamin	B2	and	protein	Rh-
Con	 [rhodamine-labelled	 concanavalin	 A])	 in	 response	 to	 various	 input	 triggers.	 For	
example,	when	using	Ca2+	complexed	supramolecular	hydrogel	at	pH	2,	vitamin	B2	was	held	
in	the	network	 in	the	absence	of	 triggers,	even	when	exposed	to	aqueous	solution	or	a	
single	additional	input	(i.e.,	EDTA	or	NH3).	When	both	triggers	were	applied	simultaneously	
a	gel-sol	transition	occurred	and	a	gradual	release	of	vitamin	B2	was	observed.	Additionally,	
by	combining	this	hydrogel	with	a	photoresponsive	supramolecular	gel,	the	application	of	
UV	light	prior	or	after	to	the	other	2	inputs	resulted	in	different	behaviours,	with	the	former	
leading	to	the	rapid	release	of	vitamin	B2	and	the	later	temporarily	modulating	its	release.	
Therefore,	this	supramolecular	system	presents	powerful	responses	to	various	stimuli	that	
mean	 it	 has	 potential	 as	 a	 smart	 material	 for	 the	 controlled	 release	 of	 biological	
substances.121		
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Figure	1.22.	a)	Molecular	structure	of	multi-stimuli	responsive	phosphate-based	
hydrogelator	1.20.	b)	Schematic	representation	of	hierarchical	self-assembly	of	
phosphate-based	hydrogelator	and	gel-sol	transition	triggered	by	different	stimuli	
(temperature,	pH,	Ca2+	and	light).121	
	
Adams	 et	 al.122	 showed	 two	 Fmoc-aminoacid	 based	 hydrogels	 (Figure	 1.23)	 formed	 by	
adjusting	pH,	 that	were	able	 to	entrap	and	 release	model	dyes	and	may	be	 suitable	as	
controlled	 release	 systems.	 The	 release	 profiles	 showed	 typical	 sustained	 release	
behaviour	 and	 when	 plotting	 the	 released	 amount	 against	 the	 square	 root	 of	 time	 it	
indicated	 that	 the	 release	of	 dyes	 from	 the	hydrogels	was	under	 the	 control	 of	 Fickian	
diffusion.123	 Additionally,	 while	 the	 Fmoc-phenylalanine	 hydrogels	 presented	 similar	
diffusion	times	for	different	dyes	and	could	not	retain	even	the	larger	dyes	(5	nm),	Fmoc-
tyrosine	hydrogels	restricted	the	diffusion	of	larger	dyes,	which	was	expected	as	the	later	
proved	to	have	a	stronger	gel	network	and	therefore	there	is	a	greater	influence	on	the	
diffusion	 of	 larger	 molecules.	 This	 indicated	 that	 network	 properties	 control	 release	
kinetics	in	self-assembled	systems.			
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Figure	1.23.	Molecular	structures	of	Fmoc-phenylalanine	(1.21)	and	Fmoc-tyrosine	(1.22)	
hydrogelators.	
					
Escuder	 and	 coworkers	 reported	 an	 L-proline-based	 hydrogelator,	 which	 provides	 a	
nucleophilic	reactive	site	that	reacts	with	aliphatic	aldehydes	causing	the	disassembly	of	
the	hydrogel	network	(Figure	1.24).	They	reasoned	that	the	secondary	amine	group	of	the	
hydrogelator	reacts	with	the	electrophilic	carbonyl	group	of	the	aldehyde	yielding	a	soluble	
aminal.	This	feature	led	the	group	to	further	investigate	the	potential	of	these	hydrogels	
for	the	release	of	drugs.	Firstly,	it	was	shown	that	the	disassembly	of	the	hydrogels	depends	
on	the	aldehyde	structure	and	the	rate	of	response	increased	with	the	hydrophobicity	of	
the	 aldehyde.	 Additionally,	 the	 hydrogels	 proved	 to	 effectively	 entrap	 dyes	 and	 non-
steroidal	anti-inflammatory	drugs,	followed	by	their	controlled	release	in	response	to	the	
presence	of	 specific	aldehydes.	 It	was	 reasoned	 that	because	 the	hydrogelator	 is	highly	
biocompatible	 it	 may,	 via	 this	 mechanism,	 present	 a	 protective	 effect	 against	 toxic	
aldehydes.124,125								
	
	
Figure	1.24.	a)	Molecular	structure	of	l-proline	based	hydrogelator	1.23.	b)	Hydrogel	
disassembly	after	reacting	with	aldehydes.125	
	 	 Chapter	1	
	
56	
	
Stupp	et	al.126,127	have	reported	the	use	of	one	of	their	PA	nanofiber	hydrogels	(Figure	1.25)	
to	effectively	deliver	sonic	hedgehog	(SHH)	protein	to	the	cavernous	nerve	(CN)	to	promote	
regeneration	and	prevent	erectile	dysfunction	(majority	of	causes	due	to	injury	of	the	CN).	
SHH	proteins	are	essential	to	maintain	CN	integrity	and	therefore	the	group	developed	a	
PA	hydrogel	composed	by	highly	aligned	monodomain	nanofiber	bundles	with	SHH	protein	
entrapped	 within	 the	 gel	 network	 during	 cation-based	 assembly	 and	 crosslinking.	 The	
hydrogels	were	mechanically	strong	enough	to	be	manipulated	and	placed	on	top	of	CN	at	
the	time	of	surgery.	CN	preservation	and	regeneration	were	enhanced	as	the	SHH	protein	
was	 gradually	 released	 from	 the	 gel.	 The	 PA	 hydrogel	 acted	 as	 a	 scaffold	 for	 the	
regeneration	of	axons	(nerve	fibers)	and	allowed	the	direct	delivery	of	SHH	proteins	to	the	
crush	site	in	the	CN.	This	PA	hydrogel	allowed	customised,	controlled	protein	delivery	with	
a	biodegradable	vehicle.						
	
	
Figure	1.25.	Molecular	structure	of	(C16)-VVAAEE-(NH2)	(V:	valine,	A:	alanine,	E:	glutamic	
acid)	PA	used	to	form	highly	aligned,	monodomain	hydrogels.	
	
Fatouros	 et	 al.	 reported	 the	 design	 of	 amphiphilic	 self-assembling	 lipid-like	 peptides	
consisting	of	six	hydrophobic	alanines	(A)	and	an	aspartic	acid	(D)	or	lysine	(K)	hydrophilic	
head	group	(such	as,	Acetyl-A6K-CONH2	or	Acetyl-A6D-COOH).	These	 lipid-based	systems	
formed	turbid	suspensions	when	added	to	water	as	a	 result	of	 the	self-assembly	of	 the	
peptide	monomers	 to	minimise	 the	 interaction	between	hydrophobic	 domains	 and	 the	
polar	environment.	By	altering	the	amino	acid	sequence	and	the	charge	distribution,	the	
group	was	 able	 to	 obtain	 different	 loading	 capacities	 and	 drug	 release	 kinetics.	 Of	 the	
tested	nanovesicle	systems,	Acetyl-A6D-COOH	proved	to	be	more	suitable	for	drug	delivery.	
Negatively	 charged	 drug	 carriers	 are	 preferable	 for	 intravenous	 administration	 as	 they	
present	longer	circulation	in	the	bloodstream	due	to	electrostatic	repulsions	with	charged	
blood	 cells	 and	 vessel	 walls.128	 Kim	 and	 coworkers129	 designed	 and	 characterised	
hydrogelators	consisting	of	cationic	lipids	coupled	with	B	vitamins	(B2-B7)	(Figure	1.26	-	a),	
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which	are	overexpressed	on	the	surfaces	of	cancer	cells	and	thus,	their	specific	receptor	
can	be	involved	in	the	biological	mechanism	for	the	delivery	of	therapeutic	siRNA	into	cells.	
Therefore,	they	used	these	nanoassembled	LMWGs	to	effectively	deliver	siRNA	into	cancer	
cells,	to	silence	gene	expression.	The	group	suggested	that	the	hydrogels	self-assemble	into	
lamellar-type	structures	which	can	help	in	the	efficient	complexation	and	delivery	of	siRNA	
(Figure	 1.26	 -	 b).130	 Specifically,	 when	 coupling	 the	 cationic	 polar	 head	 groups	 and	
hydrophobic	 chains	with	 vitamin	 B7,	 the	 resulting	 transparent	 biocompatible	 hydrogels	
delivered	siRNA	to	tumor	tissue	and	not	to	other	major	organs	and	therefore,	may	be	used	
to	silence	gene	expression	specifically	in	cancer	cells	(Figure	1.26	-	c).		
	
	
Figure	1.26.	a)	Molecular	structure	of	cationic	lipidic	LMWG	coupled	with	Vitamin	B7.	b)	
Schematic	representation	of	LMWG	coupled	with	B	vitamins	self-assembly	in	lamellar-
type	structures.	c)	Fluorescence	images	of	(i)	liver,	(ii)	spleen,	(iii)	kidney	and	(iv)	tumor	
from	a	rat	treated	with	only	siRNA	(right)	and	siRNA	incorporated	in	the	hydrogel	of	
lipidic	LMWG	with	Vitamin	B7	(left).129	
	
1.5. Tissue	Engineering	in	Gels	
Tissue	engineering	is	an	interdisciplinary	field	that	uses	engineering	and	natural	sciences	
to	attempt	the	successful	repair	and	replacement	of	damaged	tissues	and	organs.131	For	
the	formation	of	functional	tissue,	cells	ideally	need	to	be	seeded	in	3D	scaffolds	before	
transplantation	(Figure	1.27).	These	3D	biomaterials	should	be	able	to	retain	cells,	direct	
cell	proliferation	and	differentiation,	while	allowing	the	appropriate	transport	of	nutrients	
and	metabolites	into	the	cell.	The	fact	that	cells	need	a	microenvironment	that	mimics	the	
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in	 vivo	 properties	 of	 the	 tissue	 and	 accurately	 replicates	 the	 ECM	 to	 undergo	 the	
morphogenic	process,i	makes	tissue	engineering	a	very	challenging	field.132–137	
	
	
Figure	1.27.	Tissue	engineering	concept	involving	cell	seeding.	[Adapted	from	reference	
132]	
	
Hydrogels	have	been	described	as	suitable	mimics	of	the	ECM	due	to	key	characteristics	
such	as	high	water	content,	porosity,	high	loading	capacity,	degradability,	responsiveness	
to	 certain	 stimuli	 and	 varied	 rigidity,	 being	 widely	 exploited	 to	 develop	 efficient	 3D	
scaffolds	for	cell-culture	applications.138–151	Polymer	hydrogels	are	very	widely	exploited	in	
this	 regard	 but	 supramolecular	 gels	 have	 been	 less	 extensively	 investigated.	 In	 one	
example,	 Pradas	 et	 al.139	 incorporated	 a	 self-assembling	 peptide	 (SAP)	 into	 a	 porous	
elastomer	 scaffold,	 creating	 a	 hydrogel	 with	 similar	 properties	 to	 those	 of	 ECM	 and	
observed	 that	 the	 presence	 of	 the	 SAP	 in	 the	 pores	 of	 the	 scaffold	 improved	 the	
colonization	of	 cells	with	 a	more	uniform	distribution	 compared	with	 the	 same	 system	
without	the	SAP.	Proliferation	also	proved	to	be	greater	in	the	pores	with	SAP	gel.	Thus,	
																																																						
i	Morphogenesis	describes	the	evolution	and	development	of	form.		
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the	existence	of	a	self-assembled	hydrogel	able	to	mimic	the	ECM	contributed	to	creating	
an	effective	medium	for	cell	growth.	In	another	example,	Suga	et	al152	synthesised	a	lysine	
amphiphilic	compound	(Figure	1.28)	that	forms	viscous	hydrogels	able	to	attach	onto	the	
96-well	plates	leading	to	10-fold	enhanced	cell	attachment	when	compared	to	the	control	
experiment	with	 no	 gel	 coating.	 This	 hydrogel	 interacts	with	 cells	 through	 electrostatic	
interactions	between	NH3+	positive	 charge	and	 the	negative	 charged	cell	membrane.	 In	
addition,	this	LMWG	attached	more	cells	than	conventional	materials	(e.g.	sodium	alginate,	
collagen,	 poly-L-lysine	 hydrochloride),	 most	 probably	 due	 to	 the	 high	 viscosity	 of	 the	
material	that	allowed	the	hydrogel	to	strongly	stick	to	the	wells	enabling	better	adhesion.	
The	 strong	 adhesive	 features	 of	 this	 hydrogel	may	 be	 useful	 in	 tissue	 engineering	 and	
biomedicine.	
	
	
Figure	1.28.	Chemical	structure	of	lysine-based	hydrogelator	1.26.		
	
Ziane	et	al.153	also	reported	a	promising	LMWG	for	bone	tissue	engineering,	consisting	of	a	
thermosensitive	hydrogel	based	on	a	glycosyl-nucleosyl-fluorinated	(GNF)	compound,	with	
a	hydrophobic	fluorinated	carbon	chain,	a	central	thymidine	group	and	a	glucose	moiety	
(Figure	 1.29),	 that	 self-assembles	 into	 organised	 supramolecular	 structures	 at	 room	
temperature.		This	study	revealed	a	slow	degradation	in	vitro	and	in	vivo,	that	is	desired	for	
bone	tissue	engineering,	with	the	degradation	of	the	hydrogel	being	replaced	with	newly	
formed	tissue.	Furthermore,	the	differentiation	and	growth	of	adipose	tissue	derived	stem	
cells	 (ASC)	 was	 achieved	 when	 ASC	 aggregates	 were	 incorporated	 in	 the	 GNF-based	
hydrogels.	
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Figure	1.29.	Chemical	structure	of	glycosyl-nucleosyl-fluorinated	hydrogelator	1.27.		
	
In	a	different	example,	Bai	et	al.154	introduced	a	self-reinforcing	injectable	hydrogel	used	
for	 bone	 repair.	 To	 enhance	 the	 mechanical	 strength	 of	 the	 hydrogel	 without	
compromising	 its	water	content,	the	group	developed	a	hydrogel	based	on	noncovalent	
and	Diels-Alder	chemical	dual	crosslinking.	The	noncovalent	crosslinking	was	obtained	by	
the	 supramolecular	 interaction	 of	 b-cyclodextrin	 and	 adamantane,	 which	 allowed	 the	
hydrogel	 to	 be	 formed	 in	 situ	 after	 injection.	 The	 covalent	 crosslinking	 then	 occurred	
following	 the	 injection	 of	 chondroitin	 sulfate	 (ChS-F)	 and	 maleimide-terminated	
poly(ethylene	 glycol)	 (PEG-AMI)	 via	 Diels-Alder	 reaction	 to	 reinforce	 the	 network.	 The	
resulting	hydrogel	 showed	high	mechanical	 strength	 (»25	MPa)	and	high	water	content	
(98%).	Additionally,	the	hydrogel	induced	bone	repair	without	using	cells	or	growth	factors	
(GFs)	indicating	that	the	dual	crosslinking	hydrogel	may	be	useful	as	an	injectable	skeleton	
to	encourage	bone	repair.							
	
These	examples	demonstrate	how	promising	LMWGs	can	be	as	artificial	3D	scaffolds,	and	
provide	the	physical	support	and	environment	needed	to	promote	cells	growth	and	tissue	
regeneration.		
	
Hydrogels	for	tissue	engineering	can	also	include	adhesion	sites	and	the	incorporation	of	
GFs.134	GFs	 are	 soluble	 signalling	 polypeptides	which	 induce	 cellular	 responses	 through	
their	 interactions	with	specific	 transmembrane	receptors	on	target	cells.155	Due	to	their	
short	biological	half-lives	and	slow	diffusion,	GFs	act	differently	to	hormones	and	rather	
	 	 Chapter	1	
	
61	
	
than	acting	in	an	endocrine	fashion	they	are	sequestered	in	the	ECM	until	required.	ECM	
stabilises	 GFs,	 enabling	 precise	 temporal	 and	 spatial	 control	 over	 their	 actions.	 Cell	
degradation	of	 the	ECM	 releases	 the	GFs	 allowing	 them	 to	diffuse	 locally	 and	 induce	a	
specific	response	in	nearby	cells	(Figure	1.30).156	The	integral	role	played	by	GFs	in	directing	
cellular	behaviour	makes	them	a	highly	desirable	tool	 for	 tissue	engineering,	and	a	vast	
amount	of	research	has	been	conducted	into	a	better	understanding	of	how	to	use	GFs	to	
direct	the	growth	and	regeneration	of	various	tissue	types,	such	as	nerve,	cartilage,	bone	
and	blood	vessels.157,158		
	
	
Figure	1.30.	Schematic	representation	of	interactions	between	GFs	with	the	ECM	and	
cells.	The	producer	cell	secretes	GFs	into	the	ECM,	where	they	are	bound,	held	and	
stabilised	until	required.	Partial	cell	degradation	of	the	ECM	allows	the	local	release	of	
GFs,	which	bind	to	GF	receptors	on	the	surface	of	the	cell,	initiating	the	signalling	which	
will	be	translated	into	a	specific	biological	response.	[Adapted	from	reference	156]	
	
GFs	can	be	incorporated	into	hydrogels	via	two	main	methods:	physical	entrapment,	where	
electrostatic	 forces	or	pore	size	prevents	the	GF	from	leaving	the	hydrogel;	or	chemical	
immobilisation,	where	the	GF	is	typically	covalently	linked	to	the	hydrogel	network.159	GF	
release	from	hydrogels	can	occur	by	diffusion160–164	or	external	stimuli	such	as	pH,165,166	
light167	or	enzymes.168,169		
	
Once	again	many	of	these	studies	have	been	performed	using	polymer	hydrogels.	Nguyen	
et	al.170	developed	a	3D	synthetic	hydrogel	cell	culture	by	testing	different	concentrations	
of	poly(ethylene	glycol)	(PEG)	including	different	concentrations	of	adhesion	peptides,	in	
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order	 to	 mimic	 the	 3D	 extracellular	 environment	 that	 exists	 in	 vivo	 and	 incorporated	
vascular	 endothelial	 growth	 factor	 (VEGF)	 in	 the	 presence	 of	 human	 umbilical	 vein	
endothelial	cells	(HUVEC).	Variations	of	the	composition	of	the	hydrogel	surrounding	the	
HUVECs	 influenced	 their	 viability	 and	proliferation,	 and	modulated	 the	 signalling	of	 the	
VEGF.	This	proved	that	the	combination	of	different	parameters	of	hydrogel	composition	
led	to	different	cell	behaviours	due	to	the	existence	of	different	cell-matrix	interactions.		
	
In	 the	 field	 of	 supramolecular	 materials,	 	 Stupp	 and	 coworkers171	 investigated	 how	
different	 degrees	 of	 intermolecular	 hydrogen	 bonding	 from	 PA	 nanofibers	 affect	 GF	
signalling	for	osteogenesis.	They	developed	two	supramolecular	PA	assemblies	formed	by	
primary	amino	acid	sequences	with	strong	b-sheets	and	weak	b-sheets.	It	was	observed	
that	weaker	b-sheet	hydrogen	bonding	promoted	cell	differentiation	by	enhancing	bone	
morphogenic	protein-2	(BMP-2)	signalling.	Differently,	the	presence	of	stronger	hydrogen	
bonding	 in	the	supramolecular	assemblies	reduced	BMP-2	signalling.	They	believed	that	
the	 intercalation	of	weak,	positively	charged	PA	nanostructures	 into	 the	cell	membrane	
increases	 the	 lipid	 raft	 mobility,	 which	 results	 in	 the	 enhancement	 of	 cell	 signalling.	
Therefore,	 by	 simply	 altering	 the	 nature	 of	 the	 supramolecular	 PA	 hydrogen-bond	
interactions	it	was	possible	to	potentiate	cell	signalling	by	GFs.		
	
Hartgerink	 and	 coworkers172	 reported	 the	 orthogonal	 self-assembly	 of	 multidomain	
peptide	 nanofibers	 (MDP)	 and	 GFs	 encapsulated	 in	 liposomes,	 as	 a	 supramolecular	
hydrogel	that	can	act	as	a	delivery	vehicle.	 	Hydrogels	were	incorporated	with	placental	
growth	factor-1	(PlGF-1),	which	plays	a	key	role	in	the	formation	of	blood	vessels,	and	their	
potential	as	scaffolds	for	cellular	infiltration	and	vascularisation	was	tested	(Figure	1.31).	
The	method	of	incorporation	of	PlGF-1	within	the	gel	network	resulted	in	different	in	vivo	
responses	 after	 being	 injected	 subcutaneously	 in	 rats.	 When	 PlGF-1	 was	 incorporated	
directly	in	the	hydrogel	network	it	contributed	to	an	early	and	fast	release	of	the	GFs	which	
led	to	an	immature	signalling	and	low	vessel	development	in	the	short	term.	On	the	other	
hand,	 when	 incorporated	 in	 the	 liposomes,	 PlGF-1	 release	 was	 delayed	 up	 to	 3	 days,	
allowing	high	levels	of	cellular	infiltration,	followed	by	the	formation	of	blood	vessels	when	
PlGF-1	 is	 released.	 The	 study	 revealed	 that	 the	 orthogonal	 self-assembly	 of	 the	 MDP	
hydrogels	with	liposomes	loaded	with	PlGF-1	contributed	to	a	higher	order	structure,	able	
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to	 drive	 controlled	 release	 and	 promote	 high	 vessel	 density	 while	 mimicking	 the	 ECM	
environment.		
	
	
Figure	1.31.	Schematic	representation	of	1)	supramolecular	MDP	hydrogel	and	
supramolecular	orthogonal	self-assembly	of		2)	MDP	hydrogel	incorporated	with	PlGF-1	
and	3)	MDP	hydrogel	loaded	with	liposomes	encapsulating	PlGF-1.172	
	
1.6. Heparin	and	its	Applications	
The	formation	of	new	blood	vessels	is	crucial	in	tissue	engineering	to	avoid	rejection	and	
due	 to	 the	 need	 for	 nutrients	 and	 oxygen	 for	 the	 growth	 of	 tissue	 and	 cell	 survival.173	
Therefore	 different	 approaches	 have	 been	 investigated	 such	 as	 dispersing	 signalling	
molecules	and/or	GFs	within	3D	scaffolds	as	previously	described	or	alternatively	by	using	
heparin	as	a	delivery	agent	of	GFs	to	promote	neo-tissue	formation.174–178	
	
Heparin	is	a	biological	macromolecule	with	high	negative	charge	density	that	belongs	to	
the	family	of	glycosaminoglycans	(GAG)	and	has	a	molecular	weight	range	between	2500	–	
25000	 Da.	 This	 polyanionic	 polysaccharide	 is	 polydisperse	 but	 is	 typically	 formed	 by	
repeated	units	of	uronic	acid	and	glucosamine	residues	and	owes	its	high	negative	charge	
to	 the	presence	of	 sulfate	 and	 carboxylic	 acid	 groups	 in	 its	 structure	 (Figure	1.32).	 The	
understanding	of	heparin	structure	has	allowed	the	development	of	low-molecular-weight	
heparins	 (LMWH)	 which	 consists	 of	 polysaccharides	 with	 molecular	 weights	 typically	
between	4000	–	6000	Da,	contributing	to	better	definition	of	 its	chemical	and	biological	
properties.179–182	
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Figure	1.32.	Heparin	predominant	disaccharide	repeat	unit	(top)	and	heparin	partial	
structure	(X	=	H	or	SO3-;	Y	=	Ac,	SO3-	or	H)	(bottom).		
	
Heparin	 interacts	with	 a	 vast	 number	 of	 proteins,	 such	 as	 proteases,	GFs,	 chemokines,	
lipoproteins	and	adhesion	proteins,	at	the	cell	surface	and	in	the	ECM.	Being	widely	known	
for	 its	 anticoagulant	 effect,183	 heparin	 has	 also	 generated	 special	 attention	 due	 to	 its	
interactions	 with	 GFs	 which	 are	 known	 to	 form	 stable	 complexes	 that	 regulate	 the	
proliferation,	 migration	 and	 angiogenesis	 of	 cells.184–188	 Angiogenesis	 is	 related	 to	 the	
formation	of	new	blood	vessels	 from	existing	ones.	Heparin	 is	known	to	bind	to	several	
angiogenic	growth	factors	such	as	fibroblast	growth	factor	(FGF),	VEGF	and	transforming	
growth	factor	beta	(TGFβ).	These	growth	factors	are	heparin-binding	proteins	in	which	the	
most	 obvious	 and	 common	 interaction	 between	 them	 is	 electrostatic,	where	 positively	
charged	 amino	 acids	 from	 the	protein	 growth	 factors	will	 interact	with	 the	 sulfate	 and	
carboxylate	 groups	 in	 heparin.180,189	 Figure	 1.33	 represents	 the	 2:2:1	 fibroblast	 growth	
factor	 receptor	 (FGFR)-FGF-heparin	 complex.	 To	 initiate	 signal	 transduction,	 the	 three	
compounds	 FGF,	 FGFR	 and	 heparin	 need	 to	 interact	 simultaneously.	 In	 this	 particular	
example,	 the	complex	assembles	around	a	heparin	chain	that	 is	bound	to	two	FGF.	The	
FGF-heparin	 complex	 then	 acts	 as	 a	 bridge	 between	 the	 two	 FGFR.	 Heparin	 plays	 an	
important	 role	 here	 due	 to	 the	 existence	 of	 very	 few	 protein-protein	 contacts.180,189	
Furthermore,	heparin-binding	epidermal	growth	factors	(EGFs)	mediate	the	earliest	cellular	
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response	to	proliferate	a	rapid	and	efficient	protection	to	tissue	damage	contributing	to	
wound	healing	and	regeneration.176,190		
	
	
Figure	1.33.	Structure	of	2:2:1	FGF-FGFR-heparin	complex.	FGFR	is	represented	as	gold	
ribbons	and	FGF	as	green	ribbons.	Heparin	is	shown	as	space-filling	models:	sulfur	
(yellow),	oxygen	(red)	and	nitrogen	(blue).180		
	
Several	 studies	 have	 reported	 the	 use	 of	 heparin	 bound	 to	 growth	 factors	 in	 diverse	
systems,	for	controlled	delivery	into	cell	cultures	and	subsequent	controlled	release	of	the	
growth	factors,	to	promote	cell	growth.191–195	For	instance,	d’Angelo	et	al.196	described	the	
influence	 of	 heparin	 on	 VEGF	 stability	 and	 bioactivity,	 and	 its	 ability	 to	 modulate	 the	
interaction	between	growth	factors	and	ECM.	The	fact	that	the	heparin-binding	domain	is	
localised	close	to	the	VEGF	receptor-binding,	allows	heparin	to	form	a	complex	with	VEGF,	
stabilizing	 it	 and	 extending	 its	 half-life.	 The	 stability	 of	 VEGF	 is	 shown	 to	 be	 crucial	 to	
effective	angeogenic	activity,	promoting	cell	proliferation	and	growth.	In	addition,	Johnson	
at	al.197	reported	the	importance	of	heparin-binding	EGF	in	wound	healing.	The	controlled	
release	of	heparin-EGF	enhanced	bioactivity	and	promoted	human	keratinocyte	migration	
with	wound	closure	within	17	days,	while	free	growth	factors	showed	no	influence	on	the	
closure	 rate	when	compared	 to	controls.	Zhao	et	al.191	developed	a	polyion	complex	 in	
which	 a	 cationic	 polymer	 bound	 electrostatically	 to	 heparin	 in	 order	 to	 enable	 the	
controlled	release	of	heparin	 into	cell	cultures	 in	the	presence	of	growth	factors.	 It	was	
found	 that	 the	 size	 of	 the	 cationic	 block	 copolymer	 and	 the	 heparin/polymer	 ratio	
influenced	the	biological	activity	of	heparin	as	well	as	the	cell	uptake,	demonstrating	that	
the	properties	of	the	block	copolymers	can	be	tuned	for	different	applications	including	GF	
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delivery	 and	heparin-binding	 drug	 uptake	 into	 cells.	Niu	 et	 al.198	 disclosed	 the	 use	 of	 a	
heparin-modified	gelatin	 scaffold	 for	 transplantation	of	human	corneal	endothelial	 cells	
(HCECs)	 into	 the	 anterior	 chamber	 of	 the	 eye,	 as	 an	 alternative	 for	 cadaveric	 cornea	
transplantation.	The	work	aimed	to	develop	a	transparent	and	flexible	scaffold	based	on	
gelatin,	due	to	its	high	cell	compatibility	and	biodegradability	in	vivo,	making	it	a	suitable	
medium	 to	 seed	 the	 HCECs.	 In	 order	 to	 improve	 the	 binding	 of	 growth	 factors	 that	
supported	HCEC	growth,	the	scaffolds	were	functionalized	with	heparin.	The	presence	of	
heparin	provided	a	greater	capacity	of	 the	scaffolds	 to	absorb	FGF	and	a	better	 release	
kinetics,	with	the	FGF	being	continuously	released	for	up	to	20	days,	while	 for	the	non-
modified	scaffolds	the	release	only	lasted	for	3	days.	The	presence	of	heparin	in	the	studied	
gelatin	scaffold	contributed	to	improved	HCECs	survival,	viability,	and	growth	and	reduced	
cellular	 loss.	Additionally,	 the	use	of	heparin	 to	 immobilize	VEGF	 into	 fibroblast-derived	
extracellular	matrix	(FDM)	as	a	novel	platform	for	angiogenic	growth	factor	delivery	has	
been	 reported.199	 VEGF	 bound	 effectively	 to	 heparin-modified	 FDM	 in	 2D	 and	 3D	
environments	 and	 was	 released	 in	 a	 sustained	 manner.	 The	 bioactivity	 of	 VEGF	 was	
retained	 by	 heparin	which	 also	 contributed	 to	 the	 immobilization	 of	 VEGF	 in	 the	 FDM	
resulting	in	an	increased	migration	of	the	human	umbilical	vein	endothelial	cells	toward	
the	FDM.	Furthermore,	VEGF	delivery	with	this	system	was	more	competitive	in	promoting	
neovascularization	when	compared	to	other	groups.	The	presence	of	heparin	in	the	FDM	
contributed	to	the	development	of	an	efficient	delivery	system	of	angiogenic	GFs.			
	
Other	approaches	have	been	exploited	in	which	heparin	is	incorporated	into	hydrogels	in	
order	to	create	a	biocompatible	3D	scaffold	that	mimics	the	ECM	and	carries	the	heparin,	
which	 in	 turn	binds	 to	 cell	 growth	 factors	 for	 controlled	 release,	 leading	 to	 the	perfect	
environment	and	conditions	for	cell	adhesion	and	proliferation	with	the	formation	of	blood	
vessels	 that	 are	 crucial	 for	 the	 cell	 survival	 and	 to	 avoid	 rejection.200–204	 Figure	 1.34200	
shows	a	schematic	representation	of	a	PEG-heparin	hydrogel	with	the	immobilization	of	
TGF-b	 to	promote	wound	healing.	The	design	was	thought	to	be	a	way	of	obtaining	cell	
responsiveness	 and	 adhesion	 independent	 of	 the	 gel	 network	 features,	 through	
incorporation	 of	 cleavable	 linkers	 and	 peptides;	with	 the	 degradability	 of	 the	 hydrogel	
contributing	 to	 the	 effective	 administration	 of	 GFs.	 	 On	 the	 other	 hand,	 the	 strong	
interactions	between	the	negatively	charged	heparin	and	the	basic	amino	acids	of	TGF-b	
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allowed	 the	 stabilization,	 protection	 and	 retention	 of	 the	 GFs	 in	 the	 hydrogel	 for	
subsequent	controlled	release.	
	
	
Figure	1.34.	Schematic	representation	of	PEG-heparin	hydrogel.	Left:	TGF-b	are	
immobilised	within	the	hydrogel	scaffold	and	released	over	time	to	induce	cell	
differentiation.	Right:	Network	structure	of	PEG-heparin	hydrogel.	Electrostatic	
interactions	between	heparin	and	TGF-b	allows	the	protection	and	controlled	release	of	
TGF-b.	[Adapted	from	reference	200]	
	
In	supramolecular	materials,	Stupp	et	al.195,205	described	the	use	of	heparin	to	nucleate	the	
self-assembly	of	a	PA	into	1D	nanofibers	and	trigger	gel	formation.	Through	electrostatic	
interactions	 heparin	 is	 adsorbed	 into	 the	 large	 surface	 area	 of	 the	 nanofibers	 and	 is	
available	to	interact	with	angiogenic	GFs	and	GF	receptors	(Figure	1.35).	The	self-assembled	
system	 forms	 a	 rigid	 scaffold	 allowing	 local	 retention	 of	 GFs,	 their	 protection	 from	
enzymatic	activity	and	orientation	of	the	GF	domains	for	an	adequate	binding	with	heparin.			
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Figure	1.35.	Molecular	structure	of	the	PA	1.28	designed	to	bind	heparin	chains	by	the	
Stupp	research	group	(top).	Schematic	representation	of	nanofibers	(blue)	with	adsorbed	
heparin	(red)	which	is	binding	to	growth	factors	(VEGF	(purple);	FGF	(yellow)	and	FGF	
receptors	(green))	(bottom).195		
	
Although	these	systems	revealed	successful	results	and	efficiency	in	the	promotion	of	cell	
growth	 and	 angiogenesis,	 the	 incorporation	 of	 heparin	 into	 hydrogels	 could	 lead	 to	 an	
initial	burst	release	of	heparin,	being	difficult	to	control	in	a	constant	way.	In	this	sense,	the	
incorporation	of	a	heparin/	heparin	binding	molecule	complex	into	a	biocompatible	and	
biodegradable	 hydrogel	 may	 overcome	 these	 issues.	 Our	 group	 has	 developed	 some	
heparin	ligands	for	purposes	related	to	the	anticoagulation	properties	of	heparin,	which	
have	been	revealed	to	be	very	efficient.	These	ligands	are	amphiphilic	systems	that	self-
assemble	into	micelles,	having	a	cationic	hydrophilic	head	which	efficiently	binds	to	heparin	
through	multivalent	electrostatic	interactions.206,207		
	
1.6.1. Multivalency	
Multivalency	 is	 often	 used	 in	 biological	 and	 chemical	 systems	 to	 achieve	 high	 affinity	
binding	and	is	related	with	the	simultaneous	interaction	of	multiple	binding	groups	on	one	
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molecule	 with	 the	 complementary	 receptors	 on	 another.	 Therefore,	 multivalent	
interactions	(Figure	1.36	-	b)	can	be	stronger	than	corresponding	monovalent	interactions	
(Figure	1.36	-	a)	and	while	rigid	multivalent	systems	form	highly	organised	structures	with	
lower	binding	entropic	cost,	flexible	multivalent	systems	can	benefit	from	the	possibility	of	
optimisation	 of	 individual	 interactions	 and	 screening	 from	 the	 surrounding	 competitive	
medium.208	
	
	
Figure	1.36.	Schematic	representation	of	a)	monovalent	interactions	and	b)	multivalent	
interactions.	[Adapted	from	reference	208]	
	
In	order	to	quantify	the	degree	of	cooperativity	of	a	multivalent	interaction,	Whitesides	et	
al	compared	the	binding	of	a	multivalent	ligand	with	equivalent	monovalent	counterparts	
and	calculated	the	‘enhancement	factor’,	a	(Equation	1.1).	A	successful	multivalent	system	
should	have	an	overall	binding	constant	for	a	multivalent	interaction	(Kmulti)	superior	to	the	
binding	 constant	 of	 the	 monovalent	 system	 (Kmono),	 indicating	 that	 the	 individual	
interactions	of	the	multivalent	system	bind	collectively	to	the	receptor	in	a	more	effective	
manner	than	multiple	copies	of	a	monovalent	ligand.	This	equation	allows	to	define	three	
types	of	multivalent	interactions:	positively	cooperative,	if	a	>	1	(where	the	second	binding	
is	more	favourable	than	the	first);	non-cooperative,	if	a	=	1	(where	the	second	binding	has	
the	 same	affinity	 as	 the	 first);	 and	negatively	 cooperative,	 if	 	a	 <	 1	 (where	 the	 second	
binding	to	the	receptor	is	inhibited	by	the	first	ligand).	Despite	truly	positively	cooperative	
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multivalent	interactions	being	rare,	for	a	successful	multivalent	system,	it	is	only	required	
to	have	a	higher	affinity	for	the	receptor	than	the	monovalent	counterpart.208–210			
	 𝛼	 = 	𝐾%&'()𝐾%*+*	
Equation	1.1.	Calculation	of	the	binding	enhancement	factor	a	to	obtain	the	degree	of	
cooperativity	of	multivalent	systems.	
	
1.6.2. Self-Assembling	Multivalency	(SAMul)	
It	 is	 perhaps	 not	 surprising	 that	 numerous	 examples	 of	 supramolecular	 systems	 with	
biological	 functions	 have	 arisen	 making	 use	 of	 self-assembly	 to	 organise	 molecules	 to	
generate	 multivalent	 recognition,	 this	 is,	 through	 self-assembling	 multivalency	
(SAMul).211,212	 Typically,	 synthetic	 SAMul	 systems	 are	 achieved	 by	 using	 amphiphilic	
molecules	 able	 to	 self-assemble	 in	 aqueous	 solutions.	 These	 building	 blocks	 present	 a	
number	of	advantages	over	covalent	structures	as	they	are	usually	simple	to	synthesise,	
the	design	of	 the	 individual	binding	 ligands	can	be	tuned	for	different	receptors	and	by	
changing	the	hydrophobic	tail,	different	aggregate	morphologies	can	be	obtained.	Another	
fundamental	 advantage	 is	 the	 reversibility	 of	 the	 SAMul	 systems	 that	 can	 lead	 to	
multivalent	binding	being	 switched	off	by	 triggering	disassembly,	which	 can	 reduce	 the	
toxicity	of	bioactive	SAMul	nanostructures	and	improve	specificity.	As	an	example,	Smith	
and	 co-workers	 compared	 the	 binding	 affinity	 of	 different	 amphiphilic	 molecules	
containing	a	hydrophilic	arginine-glycine-aspartic	acid	(RGD)	ligand	group.	RGD	tripeptides	
were	chosen	to	provide	 the	system	with	 integrinii	binding	ability	and	a	comparison	was	
performed	 between	 a	 large	 covalent	 RGD	 multivalent	 binder,	 the	 equivalent	 self-
assembled	 monomer	 and	 an	 analogous	 non-assembled	 monomer	 (Figure	 1.37).	 It	 was	
concluded	 that	 the	self-assembling	system	demonstrated	similar	 integrin	binding	 to	 the	
covalent	RGD	dendrimer,	revealing	higher	affinity	than	the	non-assembling	monomer,	due	
to	 the	 multivalency	 of	 the	 binding.213	 Other	 SAMul	 systems	 have	 been	 developed	 by	
Smith’s	research	group	for	DNA214	and	heparin	binding.207		
																																																						
ii	Integrins	are	transmembrane	proteins	which	play	an	important	role	in	cell	signalling	and	adhesion.	
	 	 Chapter	1	
	
71	
	
	
Figure	1.37.	Molecular	structures	of	self-assembling	multivalent	C12-RGD,	non-
assembling	dendritic	G1-RGD3	and	non-assembling	PEG-RGD	monomer,	from	Smith	and	
coworkers	work.	
	
1.7. Project	Aims	
Despite	the	importance	of	developing	structures	as	similar	as	possible	to	the	complex	and	
natural	systems	used	to	successfully	form	tissue,	advances	in	tissue	engineering	did	not	yet	
allow	a	full	understanding	and	development	of	orthogonal	self-assembled	biocompatible	
architectures	(specially	using	LMWGs	as	3D	scaffolds)	that	mimic	the	complexity	of	natural	
structures	and	allow	the	effective	proliferation	and	growth	of	cells.		
	
The	 aim	 of	 this	 project	was	 to	 study	 the	 orthogonal	 self-assembly	 of	multi-component	
hybrid	materials	using	LMWGs	as	3D	scaffolds,	which	incorporate	bioactive	heparin	(Figure	
1.38),	gain	a	detailed	understanding	of	their	activity,	and	explore	their	potential	high-tech	
applications.	 Understanding	 these	 multi-component	 materials	 assembled	 from	 the	
bottom-up	 is	 highly	 challenging	 and	 will	 require	 the	 development	 of	 innovative	
characterisation	techniques	to	probe	the	extent	of	orthogonal	self-sorting.		It	is	proposed	
that	this	family	of	gels	may	be	useful	for	tissue	engineering	given	the	key	role	of	heparin	in	
angiogenesis,	and	that	the	breakdown	of	the	nanospheres	within	the	gel	matrix	may	allow	
release	of	 the	bound	heparin	 in	a	 triggered	manner.	 	 This	may	allow	 the	gel	 to	 release	
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heparin	 in	 response	 to	 changes	 induced	 by	 cellular	 proliferation,	 endowing	 these	 soft	
materials	with	the	possibility	to	be	smart	matrices	for	multi-step	cell	growth,	which	may	
encourage	controlled	differentiation	of	stem	cells.	
	
	
Figure	1.38.	Representation	of	the	orthogonal	self-assembled	bioactive	hydrogel.	
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2. DAPMA-based	Self-Assembling	Multivalent	Ligands	for	Heparin	
Binding	
Results	from	this	chapter	have	been	published	in	J.	Mater.	Chem.	B,	2017,	5,	341-347.	
	
2.1. Introduction	
The	 development	 of	 amphiphilic	molecules	 that	 self-assemble	 into	micelles	 in	 aqueous	
media	has	been	widely	exploited	as	suitable	SAMul	systems	to	bind	to	biomolecules	such	
as	integrins213	and	DNA.215,216	These	building	blocks	have	a	general	structure	that	contains	
a	hydrophobic	unit	that	will	be	directed	towards	the	interior	of	the	nanostructure	and	a	
hydrophilic	ligand	unit	that	will	be	displayed	at	the	surface	towards	the	solvent.	Given	the	
efficiency	of	these	SAMul	structures	 in	 interacting	with	biomolecules	 it	became	of	great	
interest	to	explore	them	as	mimics	of	the	 large	covalent	structures	which	are	known	to	
bind	to	heparin,	such	as	protamine	and	dendrimers.206,217,218		
	
A	 good	 example	 of	 a	 self-assembling	 system	with	 high	 affinity	 to	 bind	 to	 heparin	 was	
developed	by	Smith’s	group	with	a	design	inspired	by	the	Fréchet	dendron	scaffold.219	The	
ligand	is	shown	in	Figure	2.1	and	contains	peripheral	amines	that	protonate	at	physiological	
pH	 and	 hence	 can	 interact	 electrostatically	 with	 polyanionic	 heparin.	 It	 also	 has	 a	
degradable	ester	linkage	and	a	hydrophobic	unit	that	drives	the	self-assembly	in	aqueous	
media	due	to	the	hydrophobic	effect.	This	molecular	building	block	self-assembles	into	a	
positively	charged	spherical	micelle	nanostructure	and	is	capable	of	efficient	multivalent	
heparin	 binding.	 This	 SAMul	 system	 can	 therefore	 be	 introduced	 as	 an	 alternative	 to	
covalent	proteins,	such	as	protamine	and	macromolecules	such	as	dendrimers,	with	equal	
or	improved	affinity	to	bind	to	heparin.207		
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Figure	2.1.	Structure	of	the	self-assembling	heparin	binder	C22G1DAPMA	and	schematic	
representation	its	self-assembly.207	
	
Considering	 the	 clinical	 importance	 of	 heparin	 binding,220	 and	 with	 the	 goal	 of	
incorporating	 such	 structures	 in	 controlled	 release	 gels,	 we	 were	 interested	 in	 better	
understanding	 the	 potential	 of	 this	 type	 of	 SAMul	 nanostructure.	 To	 this	 purpose,	 this	
chapter	will	focus	on	the	study	of	simple	cationic	SAMul	heparin	binders	in	order	to	achieve	
a	 detailed	 characterisation	 in	 terms	 of	 structure,	 hydrophobic	 region	 influence	 in	 self-
assembly	and	heparin	binding	and	hierarchical	assembly	processes.	In	particular,	we	aimed	
to	go	beyond	our	previous	research	by	synthesising	simple	binders,	which	can	be	easily	
made	 at	 scale	 and	 incorporated	 into	 gels.	Ultimately,	 the	most	 efficient	 system	will	 be	
selected	 as	 heparin	 binder	 to	 proceed	 with	 further	 investigations	 of	 orthogonal	 self-
assembled	soft	materials.	
	
2.2. Synthesis	of	Amphiphilic	Heparin	Binders	
Three	amphiphilic	heparin	binders	were	synthesised	with	a	polar	head	group	constituted	
by	amine	groups	and	an	apolar	tail	constituted	by	saturated	fatty	acids.	The	fatty	acids	used	
were	myristic	acid	with	14	carbon	atoms,	palmitic	acid	with	a	16	carbon	atoms	and	stearic	
acid	with	18	carbon	atoms.		
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In	the	first	step,	and	in	order	to	have	selective	coupling	of	only	one	amine	group	from	N,N-
di-(3-aminopropyl)-N-methylamine	(DAPMA)	and	the	carboxylic	group	of	the	fatty	acids,	
tert-butyl	dicarbonate	(Boc)	was	used	as	protecting	group	(Scheme	2.1).	Mono-	protection	
was	 achieved	 by	 using	 an	 excess	 of	 DAPMA	 and	 purification	 was	 achieved	 by	 simple	
washing	protocols.		
	
	
Scheme	2.1.	Boc	protection	of	N,N-di-(3-aminopropyl)-N-methylamine.	
	
The	 coupling	 between	 tert-butyl	 3-((3-aminopropyl)(methyl)amino)propyl	 carbamate	
(protected	DAPMA)	and	 the	 fatty	 acids	was	performed	using	a	highly	efficient	 coupling	
agent	 2-[(1H-Benzotriazole-1-yl)-1,1,3,3-	 tetramethyluroniumtetrafluoroborate]	 (TBTU).	
TBTU	 is	 an	 uronium	 salt	 frequently	 used	 as	 coupling	 agent	 in	 peptide	 chemistry,	 being	
stable	and	soluble	in	the	most	common	organic	solvents	and	water	and	producing	easily-
removed	by-products	with	low	toxicity.221	TBTU	coupling	was	performed	for	the	three	fatty	
acids,	followed	by	acid-mediated	Boc	group	removal	(Scheme	2.2),	achieved	by	bubbling	
HCl	 gas	 through	 a	 methanolic	 solution.	 This	 yielded	 the	 desired	 products	 as	 their	
hydrochloride	salts.			
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Scheme	2.2.	TBTU	coupling	of	DAPMA	with	saturated	fatty	acids	followed	by	Boc	group	
removal.	
	
From	here,	the	coupled	molecule	with	myristic	acid	as	apolar	chain	will	be	referred	as	C14-
DAPMA,	the	coupled	molecule	with	palmitic	acid	will	be	referred	to	as	C16-DAPMA	and	the	
coupled	molecule	with	stearic	acid	will	be	referred	as	C18-DAPMA.	These	molecules	were	
synthesised	 in	very	good	overall	yields	and	had	characterisation	data	fully	 in	agreement	
with	their	structures	(see	Experimental	Section).	
	
2.3. Nile	Red	Assay	
Nile	Red	was	used	to	determine	the	critical	micelle	concentration	(CMC)	of	the	synthesised	
amphiphilic	 molecules.	 Nile	 Red	 is	 a	 hydrophobic	 dye	 highly	 dependent	 on	 the	
environmental	 conditions.	 Its	 excitation	 and	 emission	 maxima	 can	 vary	 by	 ca.	 60	 nm,	
depending	on	the	hydrophobicity	of	the	solvent,	whereas	no	emission	is	detected	when	
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the	solvent	is	water	due	to	its	poor	solubility.222	This	makes	it	possible	to	use	Nile	Red	as	a	
fluorescent	 hydrophobic	 probe	 to	 identify	 the	 aggregation	of	 amphiphilic	molecules.	 In	
micelles	 or	 other	 amphiphilic	 aggregates	 in	 the	 presence	 of	 water,	 Nile	 Red	 tends	 to	
interact	with	the	hydrophobic	domains	of	the	self-assembled	structures,	and	is	hence	able	
to	emit	intense	fluorescence.	If	no	aggregation	occurs,	no	emission	is	detected,	making	it	
possible	to	determine	the	CMC	of	the	amphiphile.223	This	approach	was	used	to	obtain	the	
CMC	values	of	the	synthesised	amphiphiles	by	measuring	the	fluorescence	of	solutions	with	
constant	 concentration	of	Nile	Red	and	different	 concentrations	of	binder	 in	10	mM	of	
phosphate	buffered	saline	(PBS,	pH	7.4).		
	
The	CMC	values	were	obtained	from	the	graphs	 in	Figure	2.2-2.4,	 for	C14-DAPMA,	C16-
DAPMA	 and	 C18-DAPMA,	 respectively.	 To	 determine	 these	 values,	 the	 points	 were	
separated	into	two	groups,	each	of	which	were	fitted	linearly.	These	were	associated	with	
non-aggregating	and	aggregating	Nile	Red,	and	the	intercept	between	the	two	linear	fits	
was	considered	to	represent	the	CMC.		
	
	
Figure	2.2.	Fluorescence	intensity	of	Nile	Red	(2.5	mM	in	PBS,	pH	7.4)	at	635	nm	with	
increasing	concentration	of	C14-DAPMA.	
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Figure	2.3.	Fluorescence	intensity	of	Nile	Red	(2.5	mM	in	PBS,	pH	7.4)	at	635	nm	with	
increasing	concentration	of	C16-DAPMA.	
	
	
	
Figure	2.4.	Fluorescence	intensity	of	Nile	Red	(2.5	mM	in	PBS,	pH	7.4)	at	635	nm	with	
increasing	concentration	of	C18-DAPMA.	
			
The	 calculated	 CMC	 values	 are	 shown	 in	 Table	 2.1.	 As	 expected,	 C14-DAPMA	 has	 the	
highest	CMC	value	because	it	has	the	smallest	hydrophobic	chain	and	therefore	the	lowest	
driving	 force	 for	 self-assembly.	 The	 CMC	 of	 C16-DAPMA	was	 significantly	 lower	 as	 the	
longer	chain	assists	self-assembly.	Perhaps	surprisingly,	however,	the	CMC	value	for	C18-
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DAPMA	was	higher	than	for	C16-DAPMA.	We	suggest	this	is	a	result	of	the	relatively	low	
solubility	of	C18-DAPMA	in	PBS	buffer	caused	by	the	larger	hydrophobic	block	–	we	have	
noted	for	related	compounds	that	the	balance	between	hydrophobic	and	hydrophilic	block	
size	 is	 important	 in	 controlling	 solubility,218	 as	 is	 indeed	 well-known	 in	 surfactant	
chemistry.224	As	such,	C16-DAPMA	appears	optimised	in	this	family	in	terms	of	its	ability	to	
self-assemble.	
	
Table	2.1.CMC	values	of	C14-DAPMA,	C16-DAPMA	and	C18-DAPMA.	
Binder	 CMC	(µM)	
C14-DAPMA	 116.5	±	1.4	
C16-DAPMA	 38.5	±	0.4	
C18-DAPMA	 73.0	±	5.9	
	
2.4. Mallard	Blue	Assay	
Mallard	 Blue	 (MalB)	 assays	 were	 then	 performed	 in	 order	 to	 test	 the	 heparin	 binding	
effectiveness	of	each	system.	Mallard	Blue	is	a	cationic	dye	developed	by	the	Smith	group	
which	 has	 high	 affinity	 for	 heparin.225	 The	 success	 of	MalB	 in	 detecting	 heparin	 led	 to	
development	of	a	dye	displacement	competition	assay	to	probe	the	efficiency	of	synthetic	
molecules	to	bind	heparin.225,226	When	free	in	solution,	MalB	presents	a	characteristic	UV-
Vis	band	with	a	maximum	absorbance	at	615	nm.	When	interacting	with	heparin,	this	UV-
Vis	band	decreases	substantially	in	intensity.	Therefore,	if	MalB	is	being	displaced	from	its	
complex	with	heparin	by	 the	 interaction	of	heparin	with	another	molecule,	 this	 can	be	
easily	 verified	 by	 an	 increase	 in	 the	MalB	 absorbance.	 An	 assay	 is	 then	 performed	 by	
increasing	the	concentration	of	binder	and	monitoring	MalB	by	UV-Vis.				
	
Figures	 2.5,	 2.6	 and	 2.7	 confirm	 the	 gradual	 displacement	 of	MalB	with	 the	 increasing	
concentration	 of	 C14-DAPMA,	 C16-DAPMA	 and	 C18-DAPMA,	 respectively,	 proving	 the	
efficiency	of	the	binders	towards	heparin.		
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Figure	2.5.	Uv-vis	spectra	of	C14-DAPMA	replacing	MalB.	
	
	
	
Figure	2.6.	Uv-vis	spectra	of	C16-DAPMA	replacing	MalB.	
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Figure	2.7.	Uv-vis	spectra	of	C18-DAPMA	replacing	MalB.	
	
The	charge	ratio	was	then	calculated	after	each	addition	of	C14-DAPMA,	C16-DAPMA	or	
C18-DAPMA,	and	plotted	against	the	normalized	absorbance	at	615	nm	as	shown	in		Figure	
2.8	–	2.10.		
	
	
Figure	2.8.	Charge	ratio	versus	normalised	absorbance	at	615	nm	from	the	MalB	
displacement	assay	for	C14-DAPMA.	
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Figure	2.9.	Charge	ratio	versus	normalised	absorbance	at	615	nm	from	the	MalB	
displacement	assay	for	C16-DAPMA.	
	
	
	
Figure	2.10.	Charge	ratio	versus	normalised	absorbance	at	615	nm	from	the	MalB	
displacement	assay	for	C18-DAPMA.	
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displacement	of	MalB,	the	effective	concentration	(EC50)	that	is	the	concentration	of	binder	
needed	to	displace	50%	of	MalB	and	the	dose,	which	clinically	relevant	quantity	is	the	mass	
of	binder	required	to	bind	100	IU	of	heparin.		
	
All	three	binders	bind	heparin	and	displace	MalB	at	micromolar	concentrations,	indicative	
of	highly	effective	SAMul	binding	(Table	2.2).		Among	the	three	binders	C16-DAPMA	had	
the	 highest	 efficiency	 in	 terms	 of	MalB	 displacement	 and	 hence	 heparin	 binding.	 	 This	
would	suggest	that	in	the	same	way	that	self-assembly	was	optimised	for	this	molecular	
structure	as	a	result	of	it	possessing	the	optimal	hydrophobic/hydrophilic	balance,	these	
self-assembly	properties	are	translated	into	its	heparin	binding	capability.		Nonetheless,	all	
three	compounds	were	effective	heparin	binders	and	furthermore,	differences	between	
them	in	this	assay	were	relatively	small.		It	should	be	noted	that	heparin	binding	occurs	at	
concentrations	below	the	CMC	–	this	is	not	surprising	as	it	is	well-known	that	the	presence	
of	 polyanions	 can	 encourage	 the	 self-assembly	 of	 oppositely-charged	 polycations,	 and	
lower	the	effective	CMC.227,228	Furthermore,	this	provides	a	mechanism	by	which	optimised	
self-assembly,	as	observed	for	C16-DAPMA,	can	be	matched	with	heparin	binding,	as	these	
two	processes	act	to	reinforce	one	another.	
	
Table	2.2.	CE50,	EC50	and	dose	values	obtained	for	C14-DAPMA,	C16-DAPMA	and	C18-
DAPMA	using	MalB	assay	(25	µM	MalB,	27	µM	Heparin	in	10	mM	Tris-HCl,	150	mM	NaCl,	
pH	7.0).	
Sample	 CE50	 EC50	/	µM	 Dose	/	mg	100	IU-1	
C14-DAPMA	 0.88	±	0.05	 48	±	3	 0.59	±	0.03	
C16-DAPMA	 0.64	±	0.02	 34	±	1	 0.46	±	0.01	
C18-DAPMA	 0.68	±	0.09	 37	±	5	 0.52	±	0.07	
	
	
2.5. Dynamic	Light	Scattering	(DLS)	and	Zeta	Potential	
The	size	and	surface	charges	of	the	three	binders	in	the	presence	and	absence	of	heparin	
in	 10	 mM	 Tris-HCl/	 150	 mM	 NaCl	 buffer	 were	 then	 characterised	 using	 DLS	 and	 zeta	
potential	measurements.		
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DLS	 is	 a	 technique	 that	 measures	 the	 time-dependent	 fluctuations	 in	 the	 intensity	 of	
scattered	light	that	occur	because	particles	undergo	Brownian	motion.229	The	analysis	of	
these	 intensity	 fluctuations	 can	 determine	 the	 diffusion	 coefficients,	 which	 can	 be	
converted	into	a	size	distribution	using	the	Stokes-Einstein	equation:	
	 𝑅- = 	 𝐾𝑇6𝜋𝜂𝐷	
	
where	 RH	 is	 the	 hydrodynamic	 radius,	 D	 the	 diffusion	 coefficient,	 K	 is	 the	 Boltzmann’s	
constant,	 T	 is	 the	 temperature	 and	 h	 is	 the	 viscosity.229,230	 This	 approach	 makes	 the	
assumption	that	the	species	under	investigation	are	spherical	in	morphology.	
	
The	size	distribution	obtained	from	a	DLS	measurement	is	based	on	intensity	distribution,	
which	relates	with	the	intensity	of	light	scattered.	However,	intensity	distribution	can	be	
misleading,	as	larger	particles	scatter	significantly	more	light	than	smaller	particles,	and	can	
incorrectly	indicate	a	higher	contribution	of	larger	species	and	that	they	will	be	present	as	
the	majority	in	solution.	For	example,	Figure	2.11	shows	the	size	distribution	by	intensity	
obtained	 for	 C16-DAPMA,	 where	 it	 is	 clear	 the	 presence	 of	 two	 different	 size	 particle	
species.	The	larger	particle	size	appears	to	dominate	the	distribution.	However,	this	may	
not	correspond	to	the	most	realistic	view,	as	mentioned	above	larger	particles	scatter	more	
light.	In	this	case,	intensity	size	distribution	can	be	converted	to	volume	distribution	(based	
on	 the	 mass	 or	 volume	 of	 the	 particles	 instead	 of	 scattered	 light)	 to	 have	 a	 better	
understanding	 of	 the	 contribution	 of	 the	 larger	 aggregates.	 Figure	 2.12	 shows	 the	 size	
distribution	by	volume	for	C16-DAPMA,	with	the	presence	of	only	one	size	particle	species.	
The	larger	species	in	solution	observed	in	the	intensity	distribution	completely	disappear	
when	converted	to	volume	distribution.	This	proves	that	the	larger	species	observed	are	
present	in	insignificant	amounts	and	that	the	smaller	species	are	dominant	in	solution.	As	
such,	larger	aggregates	are	often	not	observed	in	the	volume	distribution	and	all	peaks	are	
shifted	to	smaller	diameters	as	the	larger	components	have	their	larger	contributions	re-
weighted.	We	therefore	use	volume	distribution	to	characterise	and	report	the	size	of	the	
dominant	species	in	solution.	The	results	are	shown	in	Table	2.3.	
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Figure	2.11.	Size	distribution	by	intensity	from	DLS	of	C16-DAPMA	in	10	mM	Tris-HCl/	150	
mM	NaCl	buffer.	
	
	
Figure	2.12.	Size	distribution	by	volume	from	DLS	of	C16-DAPMA	in	10	mM	Tris-HCl/	150	
mM	NaCl	buffer.	
	
C14-DAPMA	and	C16-DAPMA	assembled	into	micelles	with	diameters	of	ca.	5.8	nm	and	6.2	
nm	respectively.	The	aggregates	 formed	by	C16-DAPMA	were	slightly	bigger	 than	those	
formed	 by	 C14-DAPMA,	 as	 would	 be	 expected,	 due	 to	 the	 difference	 in	 length	 of	 the	
hydrocarbon	chain.	C16-DAPMA	has	2	additional	carbon-carbon	bonds	which	results	in	4	
additional	bonds	when	the	micelles	are	formed.	This	means	that	it	should	be	approximately	
6	Å,	0.6	nm,	bigger	than	C14-DAPMA.	Taking	into	account	experimental	error	it	is	possible	
to	 confirm	 that	 this	 is	 the	 size	 difference	 observed.	 On	 the	 other	 hand,	 C18-DAPMA	
revealed	the	presence	of	significantly	large	aggregates	(ca.	100	nm).	As	the	self-assembled	
micelles	were	 expected	 to	 have	 smaller	 sizes	 and	 C18-DAPMA	 has	 poor	 solubility,	 it	 is	
possible	 that	 the	 large	 population	 corresponds	 to	 relatively	 uncontrolled	 aggregation	
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associated	with	poor	solubility,	as	DLS	is	carried	out	at	relatively	high	concentrations,	which	
can	encourage	aggregation	into	larger	structures.		
	
Additionally,	high	zeta	potentials	were	obtained	for	each	of	the	three	binders,	indicating	
the	existence	of	highly-charged	cationic	nanoscale	surfaces	as	a	result	of	protonation	of	
DAPMA	at	physiological	pH	values.		The	zeta	potential	becomes	larger	as	the	hydrophobic	
block	becomes	bigger,	presumably	because	there	is	a	greater	driving	force	for	the	assembly	
of	positively	charged	molecular	building	blocks	into	close	proximity,	enabling	the	formation	
of	 micelles	 with	 higher	 surface	 charge	 density.	 Furthermore,	 the	 larger	 size	 of	
nanostructures	formed	by	C18-DAPMA	may	incorporate	a	greater	total	charge	and	support	
a	greater	charge	density.	
	
Table	2.3.	Average	hydrodynamic	diameter	(volume	distribution)	and	zeta	potential	of	
C14-DAPMA,	C16-DAPMA	and	C18-DAPMA	in	the	presence	and	absence	of	heparin.	
Sample	 Z-Average	(nm)	 ζ	Potential	(mV)	
C14-DAPMA	 5.8	±	1.6	 41.3	±	1.6	
C16-DAPMA	 6.2	±	1.3	 51.7	±	2.2	
C18-DAPMA	 93	±	26	 54.1	±	4.2	
C14-DAPMA+Heparin	 1321	±	249	 -8.0	±	0.5	
C16-DAPMA+Heparin	 1185	±	151	 26.6	±	0.8	
C18-DAPMA+Heparin	 480	±	59	 4.8	±	0.7	
	
When	 the	 binders	 were	 in	 the	 presence	 of	 heparin	 a	 significant	 increase	 of	 the	 size	
distribution	was	 observed	 (at	 2:1	 binder:heparin	 charge	 ratio).	 The	 presence	 of	 a	 very	
broad	and	large	population	when	the	binders	are	in	the	presence	of	heparin	suggests	the	
formation	 of	 agglomerates	 between	 them,	 providing	 evidence	 of	 the	 existence	 of	
hierarchical	interactions	between	the	binders	and	heparin	(see	TEM	images	in	the	following	
section).	Additionally,	 it	 is	noticeable	 that	when	heparin	 is	 interacting	with	C18-DAPMA	
smaller	aggregates	were	formed	when	compared	with	C14-DAPMA	and	C16-DAPMA,	which	
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may	correspond	to	decreased	levels	of	hierarchical	aggregation	of	the	C18-DAPMA	micelles	
(in	fact	this	will	later	be	confirmed	by	TEM	images).	However,	it	should	be	stated	that	the	
aggregate	dimensions	are	not	particularly	accurate,	as	clearly	the	hierarchical	aggregates	
are	not	spherical	(see	TEM	images	in	the	following	section)	and,	as	mentioned	above,	this	
approach	 makes	 the	 assumption	 that	 the	 species	 under	 investigation	 are	 spherical	 in	
morphology.		
	
Furthermore,	on	binding	 to	heparin,	 the	zeta	potential	decreased,	as	a	 result	of	 charge	
neutralisation	induced	by	heparin	binding	–	the	charge	neutralisation	was	greatest	for	the	
least	effective	binder	C14-DAPMA,	while	the	most	effective	binder	C16-DAPMA,	showed	
the	 lowest	 extent	 of	 charge	 neutralisation	 –	 in	 line	 with	 the	 view	 that	 C16-DAPMA	 is	
actually	very	efficient	in	using	its	positive	charge	to	bind	to	the	fixed	amount	of	heparin	
present.	 DLS	 therefore	 suggests	 a	 degree	 of	 nanoscale	 aggregation	 between	 the	
polycationic	self-assembled	micelles	and	heparin	polyanions.	The	evolution	of	hierarchical	
structures	 in	 micelle-	 polyelectrolyte	 systems	 is	 a	 known	 phenomenon,	 but	 has	 not	
previously	been	explored	in	detail	for	heparin	binding.231,232	
	
2.6. Transmission	Electron	Microscopy	(TEM)	
To	further	characterise	the	morphologies	of	the	nanostructures,	and	the	impact	of	heparin	
binding	on	them,	TEM	images	were	obtained	for	the	three	binders	before	and	after	binding	
to	heparin.		
	
TEM	images	of	C14-DAPMA	(Figure	2.13,	left)	and	C16-DAPMA	(Figure	2.14,	left)	showed	
the	presence	of	spherical	self-assembled	nanostructures,	in	agreement	with	DLS.	When	in	
the	presence	of	heparin	it	was	possible	to	verify	a	different	behaviour,	with	the	formation	
of	highly-organised	semi-crystalline	nanostructured	arrays	(Figure	2.13	and	2.14,	right).	It	
was	believed	that	a	hierarchical	nanoscale	self-assembly	process	is	taking	place	between	
the	spherical	cationic	micelles,	and	the	‘linear’	heparin	polyanions	(see	below).	These	TEM	
observations	clearly	suggest	that	the	self-assembled	micelles	formed	by	C14-DAPMA	and	
C16-DAPMA	have	excellent	 stability,	 and	appear	 to	 remain	 intact	without	disruption	or	
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reorganisation,	 even	 in	 the	presence	of	 heparin,	with	which	 they	 can	 form	 very	 strong	
electrostatic	interactions,	and	an	effective	2D	‘ionic	lattice’	on	the	TEM	grid.			
	
C18-DAPMA	 (Figure	 2.15,	 left)	 showed	 less	 obvious	 spherical-shaped	 self-assembled	
micelles,	and	although	when	in	the	presence	of	heparin	(Figure	2.15,	right)	the	formation	
of	aggregates	was	also	noticeable,	they	appear	to	be	somewhat	less	ordered	in	terms	of	
hierarchical	structuring.	This	is	in-line	with	the	DLS	observations	which	suggested	that	the	
self-assembly	of	this	compound	is	 less	well-defined,	presumably	as	a	consequence	of	 its	
lower	solubility	and	a	greater	tendency	to	aggregate	in	an	uncontrolled	way	–	especially	at	
elevated	concentrations.	
	
	
Figure	2.13.	TEM	images	of	C14-DAPMA	(left,	scale	bar:	200	nm)	and	C14-DAPMA	with	
heparin	(right,	scale	bar:	100	nm)	in	aqueous	solution.	
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Figure	2.14.	TEM	images	of	C16-DAPMA	(left,	scale	bar:	100	nm)	and	C16-DAPMA	with	
heparin	(right,	scale	bar:	100	nm	-	inset:	200	nm)	in	aqueous	solution.		
	
	
Figure	2.15.	TEM	images	of	C18-DAPMA	(left,	scale	bar:	200	nm)	and	C18-DAPMA	with	
heparin	(right,	scale	bar:	100	nm)	in	aqueous	solution.		
	
According	to	the	previous	results,	research	proceeded	with	C16-DAPMA	and	C14-DAPMA,	
as	 C18-DAPMA	 revealed	 significant	 solubility	 problems	 in	 the	 physiological	 buffers	 of	
interest.	
	
2.7. Modelling	Heparin	Binding	
Given	the	potential	clinical	relevance	of	self-assembled	nanostructures	for	heparin	binding	
and	 reversal,220	 it	 is	 of	 great	 interest	 to	 verify	whether	 the	 highly	 ordered	 hierarchical	
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nanoscale	aggregates	revealed	by	TEM	for	C14-DAPMA	and	C16-DAPMA	are	preserved	in	
solution.	Therefore,	our	collaborators	at	University	of	Trieste,	Italy,	led	by	Professor	Sabrina	
Pricl	 performed	 Dissipative	 Particle	 Dynamics	 (DPD)	 simulations206,207,217,218,225,226,233	 to	
predict	the	self-assembly	and	spatial	organization	of	these	two	amphiphiles	in	solution	in	
presence	of	heparin	(Figure	2.16).		
	
	
Figure	2.16.	DPD	snapshots	of	C14-DAPMA	(left)	and	C16-DAPMA	(right)	self-assembly	in	
presence	of	heparin	(2:1	binder:heparin	ratio).	The	hydrophobic	micellar	core	is	
highlighted	as	green	and	blue	isosurfaces,	respectively.	Hydrophilic	moieties	of	each	
aggregate	are	shown	as	white	sticks,	while	heparin	molecules	are	shown	as	orange	rods.	
A	continuous	light	grey	field	portrays	the	aqueous	medium.	
	
In	agreement	with	TEM	analysis,	mesoscale	computational	models	reveal	that	both	binders	
self-assemble	 into	 highly	 ordered	 spherical	 nanostructures	 in	 the	 presence	 of	 the	
polyanion.		The	nanoscale	organization	is	characterised	by	face-centred	(fcc)	packing	of	the	
hierarchical	assemblies,	as	evidenced	by	the	relevant	 isodensity	surfaces	of	 the	micellar	
hydrophobic	cores.	The	predicted	 lattice	structures	of	 the	C14-DAPMA	and	C16-DAPMA	
micelles	are	characterised	by	lattice	constants,	a,	of	8.1	nm	and	8.6	nm,	respectively.	Thus,	
the	unit	cell	size	of	the	fcc	structure	of	C16-DAPMA	is	predicted	to	be	slightly	bigger	than	
that	of	C14-DAPMA.	The	corresponding	centre-to-centre	distance	(a/Ö2)	is	5.7	nm	for	C14-
DAPMA	and	6.1	nm	for	C16-DAPMA.	It	 is	worth	reflecting	that	this	 is	 in	agreement	with	
measurements	of	micelle	diameters	achieved	by	DLS	(Table	2.3).	
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2.8. Small	Angle	X-Ray	Scattering	(SAXS)	
The	 nanostructure	 of	 the	 aqueous	 binder-heparin	 complex	 was	 then	 investigated	
experimentally	 by	 small	 angle	 X-ray	 scattering	 for	 C14-DAPMA	 and	 C16-DAPMA,	 in	
collaboration	with	Professor	Mauri	Kostiainen’s	group	at	Aalto	University,	Finland.	A	Debye	
ring	with	a	diffuse	symmetric	halo	without	intensity	differences	was	obtained	from	the	2D	
diffraction	patterns	for	both	binder-heparin	complexes	(Figure	2.17a	inset),	which	is	typical	
for	 polycrystalline	 samples	 with	 isotropic	 orientation	 of	 multiple	 crystals.234	 For	 the	
assembly	formed	between	C14-DAPMA	and	heparin	the	positions	of	the	diffraction	peaks	
were	 at	q	 =	 0.129	 and	0.259	Å-1	which	 in	 terms	of	 crystal	 plane	 reflections	with	Miller	
indices	corresponds	to	(hkl)	=	(111)	and	(222),	assuming	a	face-centred	cubic	(fcc)	structure.	
For	the	assemblies	comprising	C16-DAPMA	and	heparin,	SAXS	measurements	(Figure	2.17)	
showed	diffraction	peaks	at	q	=	0.122,	0.138	and	0.246	Å-1	which	in	terms	of	crystal	plane	
reflections	with	Miller	indices	corresponds	to	(hkl)	=	(111),	(200)	and	(222),	assuming	a	fcc	
structure.	The	additional	observation	of	the	(200)	peak	for	the	C16-DAPMA	complexes,	not	
observed	 for	 those	 formed	 by	 C14-DAPMA,	 may	 be	 suggestive	 of	 a	 greater	 degree	 of	
nanocrystalline	order	for	the	C16-DAPMA	system	or	a	different	form	factor	for	the	micelles.	
This	 would	 be	 in	 agreement	 with	 the	 lower	 CMC	 and	 greater	 heparin	 binding	 ability	
observed	 for	 this	 compound,	 as	 well	 as	 the	 very	 highly	 ordered	 repetitive	 structures	
observed	by	TEM	(Figure	2.14	-	right).	
	
It	has	been	noted	that	 in	the	same	way	atomic	structure	controls	crystallisation	events,	
molecular	 structures	 can	 play	 a	 directing	 role	 in	 the	 formation	 of	 nanocrystalline	
assemblies	via	electrostatic	interactions	between	polyionic	species.235–237	In	this	case,	the	
modification	 of	 lattice	 parameters	 based	 on	 the	 size	 of	 the	molecular	 scale	 surfactant	
building	 block	 is	 a	 clear	 example	 of	 the	 way	 in	 which	 molecular	 parameters	 can	 be	
translated	into	the	packing	of	hierarchical	nanocrystalline	structures.	
	
The	 quadratic	 Miller	 indices	 were	 plotted	 against	 the	 measured	 q(hkl)	 values	 for	 C14-
DAPMA-heparin	 and	 C16-DAPMA-heparin	 complexes,	 as	 shown	 in	 Figure	 2.17b	 and	 c,	
respectively.	 The	 lattice	 constant	a,	was	 then	 estimated	 by	 linear	 regression.	 For	 cubic	
phases	a	=	2π√(h2+k2+l2)/q(hkl),	which	was	determined	to	be	8.5	nm	for	C14-DAPMA	and	8.9	
nm	for	C16-DAPMA,	in	good	agreement	with	the	corresponding	values	obtained	from	the	
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theoretical	calculations.	The	centre-to-centre	distance	(a/Ö2)	of	the	particles	was	6.0	nm	
for	 the	 C14-DAPMA	 and	 6.3	 nm	 for	 the	 C16-DAPMA,	 again	 in	 line	 with	 mesoscale	
predictions.	
	
The	 centre-to-centre	 distances	 are	 also	 in	 agreement	 with	 the	 micellar	 diameters	
determined	by	DLS	methods.		It	should	be	remembered	that	as	a	solution-phase	method,	
DLS	 also	 includes	 the	 solvent	 and	 counterions	 at	 the	micellar	 periphery,	 which	will	 be	
replaced	 by	 polyanion	 once	 heparin	 has	 bound.	 	 As	 such,	 and	 supported	 by	 the	
binder:heparin	complex	organization	predicted	by	simulation,	these	SAXS	data	would	fit	
with	a	view	in	which	self-assembled	cationic	micelles	are	packed	into	a	polycrystalline	array	
by	polyanionic	heparin	in	analogy	to	the	ionic	model	only	using	electrostatically-charged	
nanoscale	building	blocks	instead	of	simple	inorganic	ions.	Most	importantly,	these	SAXS	
results	once	again	confirm	that	the	self-assembled	micelles	retain	their	structural	integrity	
on	 binding	 to	 heparin,	 and	 are	 not	 disrupted,	 even	 on	 formation	 of	 high-affinity	
electrostatic	interactions	with	their	binding	partner.	
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Figure	2.17.	SAXS	characterisation	of	C14-DAPMA	and	C16-DAPMA	in	the	presence	of	
heparin.	a)	Integrated	SAXS	curve	measured	from	self-assembled	C14-DAPMA	and	C16-
DAPMA	in	the	presence	of	heparin.		Inset:	2D-scattering	pattern	of	C14-DAPMA	and	C16-
DAPMA	with	heparin.	b,	c)	Quadractic	Miller	indices	of	assigned	reflections	for	fcc	
structure	versus	measured	q-vector	positions	for	indexed	peaks,	related	with	(b)	C14-
DAPMA	and	(c)	C16-DAPMA,	both	binding	heparin.				
Finally,	the	data	obtained	from	simulations	and	SAXS	were	compared	with	the	TEM	images.	
Figure	2.18a	and	2.19a	show	the	TEM	images	of	C14-DAPMA	and	C16-DAPMA,	respectively,	
binding	to	heparin,	where	it	is	possible	to	distinguish	the	crystal	projection	viewed	along	
the	[110]	zone	axis	(Figures	18b	and	19b,	left).	Analysing	the	line	profile	over	the	crystal	
projection	(marked	in	red)	yields	an	average	period	(ap)	of	4.5	±	0.3	nm,	which	corresponds	
to	 a	 fcc	 lattice	 constant	 (a	 =	 3ap/Ö3)	 of	 7.8	 nm	 for	 C14-DAPMA.	 As	 expected,	 the	
corresponding	values	for	C16-DAPMA	are	slightly	higher	(ap	=	4.6	±	0.3	nm	and	a	=	8.0	nm,	
Figure	2.19).		These	values	are	in	good	agreement	with	the	a	values	obtained	by	DPD	and	
SAXS	and	the	slight	reduction	in	unit	cell	size	could	be	attributed	to	a	drying	effect	on	the	
TEM	grid	or	grid-lattice	interactions	causing	minor	reorganisation.	Calculating	a	fast	Fourier	
transform	(Figures	18b	and	19b	inset)	from	the	crystalline	area	(Figures	18b	and	19b)	and	
filtering	the	inverse	Fourier	transform	from	selected	Fourier	components,	yields	an	image	
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that	represents	the	unit	cell	of	the	crystal	viewed	along	the	[110]	zone	axis	(Figures	18c	and	
19c,	left).	This	can	be	also	confirmed	by	overlaying	the	image	and	a	model	of	the	unit	cell	
(Figures	18c	and	19c,	middle)	shown	in	Figures	18c	and	19c,	right.	Taken	together,	our	data	
indicates	that	the	proposed	hierarchical	nanoscale	assembly	model	is	valid,	and	confirms	
the	 viewpoint	 that	 the	 micellar	 objects	 have	 excellent	 structural	 integrity	 and	 can	 be	
considered	 as	 intact	 nanoscale	 building	 blocks	 throughout	 the	 heparin	 binding	 and	
hierarchical	assembly	process.	
	
	
Figure	2.18.	a)	TEM	image	of	C14-DAPMA	heparin	complex.	b)	A	crystalline	area	(left,	
inset:	fast	Fourier	transform)	and	a	line	profile	analysis	(right)	along	the	red	line.	c)	
Filtered	inverse	Fourier	transform	from	selected	Fourier	components	(left),	overlay	of	the	
image	and	fcc	unit	cell	(middle)	and	model	of	the	fcc	unit	cell	with	key	dimension	(right).	
Micelles	shown	in	yellow,	diameter	reduced	for	clarity.				
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Figure	2.19.	a)	TEM	image	of	C16-DAPMA	heparin	complex.	b)	A	crystalline	area	(left,	
inset:	fast	Fourier	transform)	and	a	line	profile	analysis	(right)	along	the	red	line.	c)	
Filtered	inverse	Fourier	transform	from	selected	Fourier	components	(left),	overlay	of	the	
image	and	fcc	unit	cell	(middle)	and	model	of	the	fcc	unit	cell	with	key	dimension	(right).	
Micelles	shown	in	yellow,	diameter	reduced	for	clarity.				
	
This	is	the	first	such	study	of	a	hierarchical	nanoscale	recognition	process	in	any	heparin	
binding	event	and	we	suggest	that	such	structures	may	be	of	clinical	relevance.	
	
2.9. Degradation	Studies	
To	 gain	 a	 better	 understanding	 of	 how	 these	 heparin	 binders	 behave	 over	 time,	
degradation	 studies	were	 performed	using	 two	different	 approaches	 to	 study	 both	 the	
molecular	degradation	as	well	as	the	disassembly	process	of	C14-DAPMA	and	C16-DAPMA.	
In	order	to	determine	the	molecular	degradation	of	C14-DAPMA	and	C16-DAPMA,	a	mass	
spectrometry	 study	 was	 performed	 over	 time.	 Each	 binder	 was	 dissolved	 in	 buffered	
solution	at	pH	7.5	and	incubated	at	37	°C.	Gly-Ala	dipeptide	was	added	as	internal	standard	
to	 the	 binder	 solutions	 prior	 to	measurement	 and	mass	 spectra	 of	 both	 binders	 were	
obtained	 at	 0	 and	 24	 hours.215	 The	mass	 spectra	 for	 C14-DAPMA	 and	 C16-DAPMA	 are	
shown	in	Figure	2.20	and	Figure	2.21,	respectively.		
	
From	the	obtained	spectra	it	is	possible	to	observe	that	the	molecular	ions	of	both	binders	
remain	fully	intact	after	24	hours,	indicating	that	no	molecular	degradation	of	both	binders	
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occurs	over	this	period	of	time.	Previous	work	from	Smith207,215	group	has	shown	the	design	
of	 degradable	 binders	 with	 ester	 linkages	 that	 are	 easily	 cleaved	 under	 physiological	
conditions.	 By	 replacing	 the	 ester	 with	 an	 amide	 linkage	 in	 the	 C14-DAPMA	 and	 C16-
DAPMA	 it	was	expected	 to	have	a	more	 stable	bond	and	consequently	non-degradable	
compounds	under	these	conditions.	Furthermore,	the	use	of	these	compounds	as	heparin	
binders	was	intended	to	facilitate	the	study	of	multicomponent	systems	with	simple	stable	
structures	that	at	the	same	time	are	effective	heparin	binders.							
	
	
Figure	2.20.	Mass	spectra	of	C14-DAPMA	at	0	(top)	and	24	hours	(bottom)	in	the	
presence	of	Gly-Ala	and	incubated	at	37	°C.		
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Figure	2.21.	Mass	spectra	of	C16-DAPMA	at	0	(top)	and	24	hours	(bottom)	in	the	
presence	of	Gly-Ala	and	incubated	at	37	°C.		
	
After	concluding	that	no	molecular	degradation	occurs	after	24	h	for	C14-DAPMA	and	C16-
DAPMA	the	disassembly	of	both	binders	was	also	tested	using	Nile	Red	encapsulated	 in	
C14-DAPMA	and	C16-DAPMA	micelles.	The	fluorescence	intensity	of	Nile	Red	was	recorded	
at	635	nm	over	time.	This	fluorescence	should	be	maintained	as	long	as	the	hydrophobic	
environment	of	the	micellar	core	remains	existing	in	the	buffer	solution.206	The	obtained	
data	is	shown	in	Figure	2.22	and	Figure	2.23.		
	
Figure	2.22.	Normalised	fluorescence	intensity	of	Nile	Red	at	635	nm	in	the	presence	of	
C14-DAPMA	(circles)	and	C14-DAPMA	with	heparin	(triangles),	over	time.	
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Figure	2.23.	Normalised	fluorescence	intensity	of	Nile	Red	at	635	nm	in	the	presence	of	
C16-DAPMA	(circles)	and	C16-DAPMA	with	heparin	(triangles),	over	time.	
A	gradual	release	of	Nile	Red	from	C14-DAPMA	micelles	was	obtained	(Figure	2.22)	with	a	
half-life	of	approximately	24	hours	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer.	The	presence	
of	heparin	resulted	in	a	similar	release	profile	indicating	that	approximately	50%	of	the	Nile	
Red	was	released	after	24	hours	in	the	absence	and	the	presence	of	heparin.	Given	there	
is	 no	molecular	 scale	 degradation	 it	 seems	 strange	 that	 the	micelles	 should	 apparently	
disassemble	over	time.	We	suggest	that	slow	reorganisations	of	the	micellar	structures	in	
the	presence	of	 the	Nile	Red	probe	may	give	rise	to	 its	exclusion	from	the	hydrophobic	
domain	and	release	into	solution.	
	
Interestingly,	with	the	increase	of	the	hydrocarbon	chain	length	(Figure	2.23)	the	release	
of	 Nile	 Red	 was	 faster,	 with	 a	 half-life	 of	 approximately	 4	 hours.	 However,	 the	 faster	
disassembly	of	C16-DAPMA	was	retarded	with	the	presence	of	heparin	leading	to	the	half-
life	increasing	to	approximately	24	hours.	This	result	suggests	once	more	that	the	formation	
of	stable	self-assembled	nanostructures	when	heparin	is	present,	corroborating	with	the	
highly	ordered	crystalline	nanostructures	observed	by	SAXS	for	these	two	binders	in	the	
presence	of	heparin.				
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2.10. Conclusions	
In	 conclusion,	 three	 self-assembling	 amphiphilic	 molecules	 have	 been	 successfully	
synthesised,	 based	 on	 a	 fatty	 acid	 tail	 and	 an	 amine	 ligand	 to	 bind	 electrostatically	 to	
heparin.	CMC	values	for	the	three	molecules	were	obtained,	with	C18-DAPMA	presenting	
a	higher	value	than	expected	due	to	its	low	solubility	in	buffer	and	C14-DAPMA	showing	a	
higher	CMC	value	than	C16-DAPMA,	since	the	shorter	apolar	chain	contributes	to	a	smaller	
hydrophobic	 effect,	 hence	 requiring	 a	 higher	 concentration	 for	 aggregation	 to	 occur.	
Therefore,	C16-DAPMA	proved	to	be	the	optimal	system	in	terms	of	self-assembly.	MalB	
assays	were	performed	in	order	to	investigate	the	binding	of	the	synthesised	molecules	to	
heparin.	C16-DAPMA	revealed	the	lowest	EC50,	CE50	and	dose,	proving	that	it	corresponds	
to	 the	 most	 effective	 heparin	 binder,	 of	 this	 simple	 family	 of	 compounds.	 DLS	
measurements	 for	 the	 three	 binders	 proved	 the	 existence	 of	 larger	 aggregates	 when	
heparin	was	present	in	solution,	 indicating	once	more	the	effective	interaction	between	
the	binder	and	heparin.	Furthermore,	TEM	images	showed	highly	organised	nanocrystalline	
hierarchical	 assemblies	 when	 C14-DAPMA	 and	 C16-DAPMA	 were	 in	 the	 presence	 of	
heparin.	In	addition,	characterisation	by	mesoscale	simulations	and	SAXS	of	C14-DAPMA	
and	 C16-DAPMA	 with	 heparin	 gave	 new	 insights	 on	 the	 nanoscale	 to	 reveal	 isotropic	
orientation	of	the	crystals	with	a	fcc	structure,	confirming	that	the	micelles	remained	intact	
during	hierarchical	assembly.	This	analysis	was	in	good	agreement	with	the	TEM	images.	
Finally,	a	Nile	Red	release	assay	proved	that	 the	presence	of	heparin	stabilizes	 the	self-
assembled	binders,	most	effectively	for	C16-DAPMA,	which	has	a	half-life	of	ca.	24	hours.	
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3. Orthogonal	 Self-Assembly	 of	 DBS-COOH	 Hydrogels	 with	 C16-
DAPMA	and	Heparin	
Part	of	 the	work	presented	 in	 this	 chapter	was	 carried	out	 in	 conjunction	with	MChem	
student	 Laura	 Hay	 and	 published	 in	 Chem.	 Sci.,	 2017,	 DOI:	 10.1039/C7SC03301J.	
Cytocompatibility	 studies	 were	 performed	 on	 a	 placement	 at	 Nano-FM	 in	 Groningen,	
Netherlands,	as	part	of	the	SmartNet	network.		
 
3.1. Introduction	
Supramolecular	 hydrogels	 are	 desirable	 tissue	 engineering	 scaffolds	 and	 drug	 delivery	
vehicles	due	to	their	ability	to	respond	to	a	variety	of	external	stimuli,	undergoing	sol-gel	
transitions	in	response	to	temperature	or	pH.87,238	Additionally,	hydrogels	are	of	particular	
interest	as	a	consequence	of	their	ability	to	encapsulate	and	deliver	bioactive	molecules	
for	 drug	 delivery	 and	 to	 promote	 cell	 adhesion,	 migration,	 differentiation	 and	
proliferation.239–244	 Therefore,	 the	 self-assembly	 of	 LMWGs	 with	 the	 incorporation	 of	
bioactive	factors	that	can	be	released	in	a	controlled	manner,	can	originate	a	single	system	
with	the	independent	formation	of	supramolecular	materials	that	will	have	its	individual	
biological	functions.	Multicomponent	hydrogels	therefore	have	a	higher	potential	to	mimic	
the	ECM	as	they	can	mimic	the	orthogonal	chemistries	existing	in	natural	systems.245–247	
This	 way,	 multicomponent	 hydrogels	 are	 very	 promising	 nanostructures	 for	 tissue	
engineering.	 Their	 complexity,	 and	 potential	 for	 independent	 roles	 of	 the	 different	
networks	can	give	rise	to	highly	responsive	and	stable	scaffolds	able	to	be	employed	as	
multi-functional	cell	microenvironments.	
	
However,	despite	the	intrinsic	responsiveness	of	LMWGs,	their	inherent	weak	mechanical	
strength	 can	 limit	 their	 applications,	 and	 therefore	a	method	of	 improving	 this	without	
losing	the	responsive	nature	of	such	gels	can	be	achieved	by	integration	of	LMWGs	with	
PGs	 creating	 a	 hybrid	 hydrogel,	 where	 the	 mechanical	 strength	 of	 the	 gel	 is	 greatly	
enhanced.87,98,248–251	The	responsive	nature	of	hybrid	hydrogels	was	proven	when	the	pH	
responsive	 ability	 of	 a	 LMWG,	 1,3:2,4-dibenzylidene-D-sorbitol–p,p’-dicarboxylic	 acid	
(DBS–COOH),	to	assemble	and	dissemble	into	a	hydrogel	in	the	presence	of	the	PG	agarose	
was	 demonstrated	 (Figure	 3.1).87	 Importantly	 this	 highlights	 that	 there	 is	 potential	 to	
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harness	 the	 pH-responsive	 nature	 of	 DBS-COOH	 to	 release	 bioactive	 molecules,	 while	
utilising	the	robustness	of	agarose	to	maintain	structural	integrity.	
	
	
Figure	3.1.	Chemical	structures	of	LMWG	DBS-COOH	and	PG	agarose,	used	in	the	
formation	of	a	hybrid	hydrogel.	
	
Additionally,	 there	 is	 an	 interest	 in	 applying	 heparin,	 which	 has	 clinical	 use	 as	 an	
anticoagulant,182,252	for	transdermal	or	subcutaneous	low-dose	delivery	for	long	term	use	
in	hospital	settings.194,253	Heparin	has	also	been	included	in	gels	with	potential	applications	
in	 tissue	 engineering,	 to	 control	 growth	 factor	 release	 and/or	 encourage	 tissue	
growth.161,162	However,	supramolecular	gels	which	incorporate	heparin	remain	very	rare,	
and	are	restricted	to	gels	based	on	relatively	complex	self-assembling	peptides.202,205,254,255				
	
In	 this	chapter,	pH	responsive	DBS-COOH	hydrogelator	 is	presented	and	the	orthogonal	
self-assembly	 of	 the	 hydrogel	 with	 self-assembled	 C16-DAPMA	 for	 heparin	 binding	 is	
investigated.	 	Additionally,	 the	 incorporation	of	heparin	within	a	two-component	hybrid	
hydrogel	 combining	 a	 polymer	 gelator	 (agarose)	 and	 a	 LMWG	 (DBS-COOH)	 is	 studied.	
Heparin	 release	 from	 the	 multi-component	 systems	 will	 be	 quantified	 and	 the	
cytocompatibility	of	these	systems	tested.		
	
3.2. Synthesis	of	DBS-COOH	Gelator	and	pH-induced	Hydrogelation	
DBS-COOH	was	synthesised	according	to	previously	reported	methodology	from	the	Smith	
group.87	 Firstly,	 D-sorbitol	 was	 condensed	 with	 two	 equivalents	 of	 methyl	 4-
formylbenzoate	 in	the	presence	of	a	catalytic	acid,	specifically	p-toluenesulfonic	acid	(p-
TsOH).	The	reaction	was	carried	at	70	°C	in	a	mixture	of	cyclohexane	and	methanol	to	yield	
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DBS-COOCH3	(Scheme	3.1).	Methanol	was	used	to	solubilize	the	reagents	for	the	reaction	
to	take	place,	while	cyclohexane	allowed	the	product	to	precipitate.		
	
	
Scheme	3.1.	Synthesis	of	DBS-COOCH3.	
	
Following	the	formation	of	DBS-COOCH3,	saponification	of	the	methyl	ester	groups	with	
sodium	hydroxide	(NaOH)	was	carried	out	to	obtain	the	DBS-COOH	derivative,	as	shown	in	
Scheme	3.2.		
	
	
Scheme	3.2.	Synthesis	of	DBS-COOH.	
	
The	ability	of	DBS-COOH	to	form	gels	in	10	mM	Tris-HCl/150	mM	NaCl	(pH	7.4)	was	then	
tested	using	different	concentrations	of	LMWG	(0.2%	w/v,	0.15%	w/v	and	0.1%	w/v).	 In	
order	to	form	supramolecular	hydrogels	with	carboxylic	acid	gelators,	the	pH	values	should	
be	below	the	pKa	of	the	carboxylic	acid	(4-5).	For	this	reason,	hydrogels	were	formed	using	
slow	 acidification	 of	 a	 basic	 solution.	 Initially,	 NaOH	 was	 added	 in	 order	 to	 basify	 the	
solution	 and	 subsequently,	 the	 addition	 of	 glucono-δ-lactone	 (GdL),	 which	 undergoes	
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alkaline	hydrolysis	forming	gluconic	acid	(Scheme	3.3)	slowly	lowers	the	pH,	enabling	the	
formation	of	uniform	homogeneous	gels.			
	
	
Scheme	3.3.	Hydrolysis	of	GdL.	
	
The	 three	 different	 concentrations	 of	 DBS-COOH	 tested,	 resulted	 in	 the	 formation	 of	
homogeneous	gels,	as	shown	in	Figure	3.2.	However,	for	concentrations	of	0.1%	w/v	a	very	
weak	gel	was	 formed,	 easily	 collapsing	when	gently	moving	 the	 vial.	 Therefore,	 studies	
proceeded	using	a	DBS-COOH	concentration	of	0.2%	w/v,	in	order	to	ensure	the	formation	
of	stable	gels.	
	
	
Figure	3.2.	DBS-COOH	gel	formation	using	different	concentration	of	gelator:	0.2%	w/v;	
0.15%	w/v	and	0.1%	w/v	(from	left	to	right)	in	10	mM	Tris-	HCl/	150	mM	NaCl.		
	
3.3. Study	 of	 Orthogonal	 Self-Assembly	 of	 DBS-COOH	 with	 C16-DAPMA	 and	
Heparin	
The	main	aim	of	 this	project	 consists	 in	 studying	 the	 self-assembly	of	multi-component	
hydrogels	with	the	incorporation	of	a	bioactive	factor	-	heparin.	To	gain	initial	insight	into	
multi-component	 systems,	 simple	 visual	 experiments	 of	 gelation	 were	 performed.	
Therefore,	 the	 assembly	 of	 DBS-COOH	 hydrogel	 with	 C16-DAPMA	 micelles	 bound	 to	
heparin	 was	 firstly	 investigated	 by	 testing	 different	 orders	 of	 addition	 of	 heparin-C16-
DAPMA	aggregates	to	verify	their	influence	in	gel	formation.	The	concentration	of	heparin-
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C16-DAPMA	used	was	the	same	as	for	the	TEM	images	in	Chapter	2.	In	a	first	attempt,	a	
solution	of	150	µM	C16-DAPMA/	38	µM	heparin	was	added	into	a	solution	of	DBS-COOH	
(0.2%	w/v)	with	GdL	in	10	mM	Tris-HCl/	150	mM	NaCl	(pH	7.4)	approximately	20	minutes	
after	the	addition	of	GdL.	 It	was	noticed	when	adding	the	C16-DAPMA/heparin	solution	
that	the	gel	was	already	forming,	and	on	the	addition	of	the	binder/heparin	solution	and	
further	agitation	the	conditions	to	form	the	gel	were	disrupted	(Figure	3.3).		
	
	
Figure	3.3.	0.2%	w/v	DBS-COOH	gel	formation	with	addition	of	150	µM	C16-DAPMA	/38	
µM	Heparin	solution	20	minutes	after	the	addition	of	GdL,	in	10	mM	Tris-HCl/	150	mM	
NaCl	(pH	7.4).	
	
The	 same	 test	was	 repeated,	 but	 adding	 the	heparin-C16-DAPMA	 solution	 immediately	
after	 GdL	 or	 before	 the	 GdL	 addition.	 The	 formation	 of	 stable	 gels	 in	 both	 cases	 was	
verified,	with	a	final	pH	of	5.	Therefore,	in	a	first	analysis	it	is	possible	to	conclude	that	the	
orthogonal	 self-assembly	 of	 DBS-COOH	 hydrogels	 in	 the	 presence	 of	 heparin/heparin	
binder	complexes	is	achievable.			
	
The	 following	 studies	 were	 performed	 with	 the	 addition	 of	 the	 heparin	 -	 C16-DAPMA	
solution	immediately	after	the	GdL	using	10	mM	Tris-HCl/	150	mM	NaCl	buffer	(pH	7.4)	as	
medium.	
	
Gel	Formation	with	Different	Concentrations	of	Heparin	
To	test	 the	 influence	of	heparin	alone	on	the	gel	 formation,	different	concentrations	of	
heparin	(38	µM;	50	µM;	100	µM;	150	µM;	300	µM;	400	µM;	500	µM)	were	added	to	DBS-
COOH.	From	all	the	different	concentrations	used	homogeneous	and	stable	gel	formation	
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occurred	 (Figure	3.4),	meaning	 that	 the	presence	of	heparin	does	not	 stop	gelator	 self-
assembly.		
	
	
Figure	3.4.	0.2%	w/v	DBS-COOH	gel	formation	with	38	µM;	50	µM;	100	µM;	150	µM;	300	
µM;	400	µM;	500	µM	(from	left	to	right)	of	heparin.	
	
Gel	Formation	with	Different	Concentrations	of	C16-DAPMA	
The	influence	of	C16-DAPMA	alone	on	DBS-COOH	gel	formation	was	also	tested:	150	µM;	
300	µM;	400	µM;	500	µM;	600	µM;	700µM;	800	µM;	900	µM	and	1000	µM	of	C16-DAPMA	
were	added	to	DBS-COOH	and	unlike	the	addition	of	heparin,	none	of	these	concentrations	
of	 C16-DAPMA	 led	 to	 the	 formation	 of	 gel	 (Figure	 3.5).	 This	 clearly	 indicates	 that	 C16-
DAPMA	has	a	direct	negative	influence	on	the	self-assembly	of	DBS-COOH,	even	though	an	
acidic	pH	was	achieved	(pH	@	5).	We	suggest	that	the	amine	groups	of	C16-DAPMA	may	
interact	with	DBS-COOH	carboxylic	acid	groups	and	thus,	effective	self-assembly	does	not	
take	place	and	consequently	no	gel	is	formed.		
	
	
Figure	3.5.	0.2%	w/v	DBS-COOH	gel	formation	with	150	µM;	300	µM;	400	µM;	500	µM;	
600	µM;	700µM;	800	µM;	900	µM;	1000	µM	(from	left	to	right)	of	C16-DAPMA.	
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Gel	Formation	with	Constant	Concentrations	of	Heparin	and	Different	Concentrations	of	
C16-DAPMA	
Following	the	obtained	results,	gel	formation	was	next	tested	at	constant	concentrations	
of	heparin	but	with	increasing	concentration	of	C16-DAPMA	in	order	to	verify	the	optimum	
charge	ratio	of	these	two	molecules	for	formation	of	stable	gels.	As	the	concentration	of	
150	µM	C16-DAPMA/	38	µM	heparin	has	been	already	 tested,	higher	concentrations	of	
heparin	were	studied:	150	µM,	300	µM,	400	µM	and	600	µM	(Table	3.1).	At	150	µM	heparin	
the	threshold	concentration,	for	formation	of	a	stable	gel,	of	C16-DAPMA	was	450	µM	–	
above	this,	gel	formation	was	disturbed.	For	300	µM	heparin	the	threshold	concentration	
of	C16-DAPMA	was	800	µM,	for	400	µM	heparin	it	was	900	µM	and	for	600	µM	heparin	it	
was	1400	µM.	In	each	case,	excess	C16-DAPMA	led	to	disruption	of	the	gel	–	for	example	
partial	gel	formation,	or	at	higher	concentration,	no	gelation.	
	
Table	3.1.	Test	of	different	heparin/binder	ratio	in	gel	formation.	
[Heparin]	(µM)	 [C16-DAPMA]	(µM)	 Gel	Formation	
	
150	
600	 No	gel	formation	
500	 Unstable	gel	
Below	450	 Stable	gel	
	
300	
Above	1000	 No	gel	formation	
900	 Gel	without	incorporation	of	all	solvent	
Below	800	 Stable	gel	
	
400	
Above	1500	 No	gel	formation	
1400	-1000	 Gel	with	aggregates	
900	 Stable	gel	
	
600	
Above	2100	 No	gel	formation	
2000-1800	 Unstable	gel	
1700-1500	 Gel	with	aggregates	
1400	 Stable	gel	
	
We	note	that	no	gel	forms	in	the	presence	of	excess	C16-DAPMA,	and	suggest	that	this	is	
because	 the	excess	C16-DAPMA	 is	not	binding	 to	heparin	 and	 thus	disrupts	 gelation	as	
observed	for	C16-DAPMA	alone.	We	note	that	as	the	concentration	of	heparin/binder	in	
the	network	 increases	 the	gel	becomes	more	sensitive	 to	 the	excess	of	binder	which	 in	
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molar	terms	becomes	more	significant	(Table	3.2).	Overall,	these	results	suggest	that	the	
DBS-COOH	gel	 is	 tolerant	of	heparin	and	can	also	 tolerate	C16-DAPMA	–	as	 long	as	 the	
surfactant	is	bound	to	the	heparin	within	the	multi-component	system.		
	
Table	3.2.	Binder/Heparin	molar	ratio	and	charge	ratio	+/-	with	increasing	heparin	
concentration.	
[Heparin]	(µM)	 Binder/Heparin	Molar	Ratio	 Charge	ratio	+/-	
38	 4:1	 2.0	
150	 3:1	 1.5	
300	 2.7:1	 1.3	
400	 2.2:1	 1.1	
600	 2.3:1	 1.2	
	
3.3.1. Thermal	Stability	and	Tgel	Determination	
The	thermal	stability	of	the	gels	formed	in	the	previous	section	was	then	tested	by	simple	
reproducible	 tube	 inversion	methodology.	 The	 Tgel	 was	 considered	 as	 the	 temperature	
when	the	gel	starts	to	deform	and	starts	to	slip	down	the	vial	walls	when	it	is	inverted.	
	
For	the	DBS-COOH	hydrogel	(0.2%	w/v)	formed	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	(pH	
7.4)	it	was	possible	to	verify	that	the	Tgel	value	was	over	100	°C,	the	boiling	point	of	the	
solvent,	which	indicate	a	high	thermal	stability.	For	all	different	concentrations	of	heparin	
in	 DBS-COOH	 tested,	 the	 Tgel	 obtained	 was	 over	 100	 °C,	 proving	 that	 the	 presence	 of	
heparin	does	not	adversely	 impact	on	 the	 thermal	 stability	of	 the	gel.	 For	 the	different	
concentrations	of	C16-DAPMA	with	heparin	that	resulted	in	gel	formation,	the	Tgel	values	
again	all	appeared	to	be	above	100	°C,	indicating	that	the	presence	of	heparin	bound	to	
C16-DAPMA	does	not	 significantly	affect	 the	 thermal	 stability	of	 the	gel,	which	 remains	
above	the	boiling	point	of	the	solvent.	
	
3.3.2. Infrared	Characterisation	(IR)	
Detailed	IR	characterisation	was	performed	for	the	gel	formed	with	DBS-COOH	(0.2%	w/v)	
alone,	in	the	presence	of	300	µM	of	heparin	and	in	the	presence	of	300	µM	of	heparin	and	
800	µM	of	C16-DAPMA	(Figure	3.6).	By	comparing	the	spectra	it	is	possible	to	notice	that	
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the	 expected	 peaks	 are	 present	 in	 the	 analysed	 xerogels	 and	 that	 the	 spectra	 broadly	
correspond	to	the	simple	overlap	of	the	three	compounds.	A	broad	band	appears	at	3272	
cm-1	which	is	characteristic	of	the	O-H	stretching	vibration	but	probably	it	has	such	high	
intensity	due	to	some	remaining	solvent	in	the	sample.	C-H	stretches	at	2924	and	2845	cm-
1	are	present,	as	well	as	a	C=O	stretch	at	1775	cm-1.	At	1596	cm-1,	a	C=C	stretch	from	the	
aromatic	rings	of	DBS	is	observed	and	at	1598	cm-1	the	presented	peak	overlaps	with	the	
carboxylate	peak	of	 heparin.	 Between	1400	and	1294	 cm-1	 several	 peaks	 from	 the	DBS	
sugar	are	noticeable.	At	1018	cm-1	a	strong	peak	is	verified,	probably	corresponding	to	the	
overlap	of	 S=O	 stretch	 and	C-O	 stretch.	Due	 to	 the	 fact	 that	 several	 IR	 frequencies	 are	
common	in	the	three	compounds	that	formed	the	gel	an	overlap	of	the	characteristic	peaks	
of	each	molecule	occurred.	This	suggests	that	the	gel	is	self-sorted	and	each	component	
can	behave	independently	in	the	bottom-up	assembled	material.				
	
	
Figure	3.6.	IR	spectra	of	xerogels	formed	by	DBS-COOH	gel	(blue	line);	DBS-COOH	gel	with	
300	µM	of	heparin	(red	line)	and	DBS-COOH	gel	with	800	µM	of	C16-DAPMA	and	300	µM	
of	heparin	(green	line).	
	
3.3.3. Study	of	Gel	Formation	Kinetics	
The	incorporation	of	different	components	within	the	gel	network	raised	our	 interest	 in	
understanding	 how	 the	 presence	 of	 heparin	 and	 heparin-C16-DAPMA	 aggregates	 could	
affect	the	self-assembly	of	DBS-COOH	into	gel	nanofibers.	Knowing	that	DBS-COOH	gelation	
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is	a	slow	process	(at	least	4h,	depending	on	GdL-gelator	ratio)	it	was	possible	to	monitor	
the	kinetics	of	self-assembly	of	DBS-COOH	over	time	using	two	complementary	approaches	
as	described	below.		
	
Nuclear	Magnetic	Resonance	(NMR)	
An	interesting	characteristic	of	the	formation	of	gels	in	NMR	is	that	before	starting	to	self-
assemble,	the	molecules	of	the	gelator	are	mobile	on	the	NMR	timescale	and	hence	present	
a	NMR	spectrum	with	characteristic	resonances.	As	the	gelator	assembles,	however,	the	
molecules	become	immobile	and	hence	disappear	from	the	spectrum.	This	methodology	is	
a	powerful	way	of	obtaining	detailed	information	on	the	kinetics	of	gelation	by	quantifying	
the	peaks	in	spectrum	over	time	by	determining	the	relative	integration	of	the	resonances,	
using	a	mobile	standard	as	internal	reference.	This	test	was	performed	by	recording	NMR	
spectra	every	60	minutes	for	10	hours,	for	samples	in	D2O	containing	only	0.2%	w/v	of	DBS-
COOH;	with	0.2%	w/v	of	DBS-COOH	and	300	µM	of	heparin	and	0.2%	w/v	of	DBS-COOH,	
300	µM	of	heparin	and	800	µM	of	C16-DAPMA	as	shown	in	Figure	3.7.	The	internal	standard	
was	28	mM.		
	
	
Figure	3.7.	%	Gelation	over	time	for	DBS-COOH	(0.2%	w/v)	(blue	circles);	DBS-COOH	(0.2%	
w/v)	with	heparin	(300	µM)	(red	triangles)	and	DBS-COOH	(0.2%	w/v)	in	the	presence	of	
heparin	(300	µM)	and	C16-DAPMA	(800	µM)	(green	squares),	as	monitored	by	NMR	
spectroscopy.	
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For	 the	 DBS-COOH	 sample,	 no	 gel	 formation	 occurred	 for	 the	 first	 hour	 and	 a	 gradual	
increase	in	the	%	gelation	takes	place	over	the	next	seven	hours,	until	all	the	molecules	are	
immobilised,	meaning	 that	 100%	 of	 the	molecules	 formed	 a	 gel	 after	 approximately	 8	
hours.	DBS-COOH	with	300	µM	of	heparin	presented	a	similar	kinetic	profile,	with	a	gradual	
increase	 in	 %	 of	 immobilised	 gelator	 over	 time,	 achieving	 100%	 gelation	 after	
approximately	9	hours.	The	sample	of	DBS-COOH,	300	µM	of	heparin	and	800	µM	of	C16-
DAPMA	 revealed	 equivalent	 behaviour,	 achieving	 100%	 of	 gel	 in	 the	 sample	 after	
approximately	10	hours.	Therefore,	the	presence	of	heparin	and	heparin	with	C16-DAPMA	
appear	to	have	little	impact	on	the	kinetics	of	DBS-COOH	assembly	into	supramolecular	gel	
fibers.	Once	again	this	is	supportive	of	self-sorting	within	this	multi-component	system.	
	
	
Circular	Dichroism	(CD)	
CD	studies	were	then	performed	to	follow	the	nanoscale	organisation	and	assembly	of	the	
nanoscale	 network	 of	 the	 DBS-COOH	 hydrogel,	 DBS-COOH	 hydrogel	 in	 the	 presence	 of	
heparin	and	DBS-COOH	hydrogel	 in	 the	presence	of	both	heparin	and	C16-DAPMA.	 It	 is	
noteworthy	that	this	experiment	was	performed	below	the	gelation	concentration	of	DBS-
COOH	 (0.02%	w/v),	hence	we	observe	 the	assembly	of	organised	nanofibers	within	 the	
sample	but	not	the	complete	formation	of	the	gel-phase	material.	
	
From	 the	 obtained	 data	 (Figure	 3.8),	 in	 each	 case	 the	 presence	 of	 a	 CD	 band	 at	
approximately	260	nm	was	observed,	with	 increasing	 intensity	over	 time.	This	 indicates	
that	π-π	stacking	of	the	aromatic	rings	of	the	gelator	occurs	even	in	the	presence	of	heparin,	
and	C16-DAPMA	with	heparin.	However,	it	is	possible	to	observe	subtle	differences	in	the	
CD	intensities	of	the	different	samples.	
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Figure	3.8.	Kinetic	studies	of	the	growth	of	DBS-COOH	fibrillar	network	over	time,	using	
CD	spectroscopy.	(a)	DBS-COOH	(0.02%	w/v);	(b)	DBS-COOH	(0.02%	w/v)	in	the	presence	
of	heparin	(38	µM)	and	(c)	DBS-COOH	(0.02%	w/v)	in	the	presence	of	C16-DAPMA	(150	
µM)	and	heparin	(38	µM).	
	
The	intensity	of	the	polarized	light	at	260	nm	was	plotted	against	time	for	the	three	tested	
gels	(Figure	3.9)	and	it	became	clear	that	in	the	presence	of	heparin,	the	assembly	of	the	
gelator	 fibers	appears	 to	be	 faster,	 reaching	a	maximum	 intensity	after	4	h	while,	DBS-
COOH	alone	needed	more	than	5	h.	On	the	other	hand,	the	presence	of	both	heparin	and	
C16-DAPMA	revealed	a	slower	change	in	band	intensity,	although	after	6	hours	a	similar	
intensity	was	obtained	for	all	three	different	samples.	It	can	therefore	be	suggested	that	
the	 presence	 of	 heparin	 promotes	 the	 growth	 of	 the	 DBS-COOH	 nanofibers	 while	 the	
presence	of	C16-DAPMA-heparin	complex	appears	to	somewhat	slow	the	rate	of	growth	of	
the	 nanofibers	 but	 does	 not	 prevent	 their	 formation.	We	might	 therefore	 suggest	 that	
there	are	some	direct	interactions	between	self-assembled	DBS	nanofibers	and	the	heparin	
biopolymer	or	that	heparin	helps	the	fibre	nucleation	process.	Furthermore,	the	presence	
of	binder	may	somewhat	inhibit	gel	fibre	assembly;	indeed	we	know	from	the	experiments	
described	above	that	an	excess	of	binder	can	completely	supress	gelation.		
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Figure	3.9.	Absorbed	polarized	light	at	260	nm	of	DBS-COOH	(blue	circles),	DBS-COOH	in	
the	presence	of	heparin	(red	triangles)	and	DBS-COOH	in	the	presence	of	heparin	and	
C16-DAPMA	(green	squares),	over	6	hours.	
	
3.3.4. Mallard	Blue	Diffusion	Assay	
After	 studying	 the	 influence	 of	 incorporating	 C16-DAPMA	 and	 heparin	within	 the	 DBS-
COOH	gel	network,	we	were	 interested	to	obtain	a	better	understanding	of	the	existing	
interactions	between	C16-DAPMA	and	heparin	when	incorporated	within	the	DBS-COOH	
gel.	For	that	purpose,	MalB	(25	µM)	solution	(3	mL)	was	placed	on	top	of	gels	(3	mL)	(Figure	
3.10)	containing	only	DBS-COOH	(0.2%	w/v),	DBS-COOH	(0.2%	w/v)	with	38	µM	heparin	
and	DBS-COOH	(0.2%	w/v)	with	150	µM	C16-DAPMA	and	38	µM	heparin.	The	variations	in	
intensity	of	MalB	in	the	solution	on	top	of	the	three	different	gels	were	then	studied	over	
one	 week	 by	 UV-Vis.	 As	 described	 in	 Chapter	 2,	 MalB	 changes	 significantly	 its	 UV	
absorbance	when	interacting	with	heparin	and	therefore,	when	in	contact	with	the	gel	can	
indicate	the	existence	of	free	heparin.		
		
	
Figure	3.10.	DBS-COOH	gel	with	MalB	solution	on	top.	
	
-250 
-200 
-150 
-100 
-50 
0
50
0 30 60 90 120 150 180 210 240 270 300 330 360
In
te
ns
ity
	a
t	2
60
	n
m
Time	/	min
DBS-COOH
DBS-COOH	+	Heparin
DBS-COOH	+	Heparin	
+	C16-DAPMA
	 	 Chapter	3	
	
113	
	
The	obtained	results	are	plotted	in	Figure	3.11.	It	is	evident	that	the	decrease	of	the	MalB	
concentration	over	time	for	the	three	different	gels,	due	to	natural	dilution	phenomena	as	
the	MalB	is	distributed	between	the	supernatant	and	the	solvent	within	the	gel.	Figure	3.12	
shows	a	DBS-COOH	gel	sample	after	one	week	of	experiment	where	it	is	possible	to	verify	
the	presence	of	blue	 colour	 in	 the	 gel,	 the	diffusion	of	MalB	 into	 the	 gel	 results	 in	 the	
decrease	of	concentration	of	MalB	present	in	the	solution	on	top	of	the	gel.	The	predicted	
dilution	factor	in	the	absence	of	MalB	binding	to	heparin,	is	50%.	
	
	
Figure	3.11.	Normalised	absorbance	of	MalB	at	615	nm	over	time	when	placed	on	top	of	
DBS-COOH;	DBS-COOH	with	heparin	and	DBS-COOH	with	heparin	and	C16-DAPMA.	
	
	
Figure	3.12.	DBS-COOH	gel	with	MalB	solution	on	top	after	1	week.	
	
Using	the	sample	containing	only	DBS-COOH	gel	as	a	control	experiment,	it	is	possible	to	
verify	 that	 the	 sample	 of	 DBS-COOH	 containing	 C16-DAPMA	 and	 heparin	 resulted	 in	 a	
decrease	of	MalB	absorbance	similar	 to	 the	control.	On	the	other	hand,	when	the	DBS-
COOH	 gel	 contains	 heparin	 a	 higher	 decrease	 of	 the	 MalB	 absorbance	 over	 time	 is	
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noticeable,	when	 compared	with	 the	 other	 two	 tested	 gels.	 This	 indicates	 that	MalB	 is	
interacting	with	the	free	heparin	present	in	the	gel,	and	binding	to	heparin	released	from	
the	gel,	resulting	in	a	lower	absorbance	of	MalB.	When	C16-DAPMA	is	present,	MalB	is	no	
longer	able	to	interact	with	heparin	and	thus	its	intensity	over	time	has	a	similar	behaviour	
to	the	control	experiment.	This	provides	clear	evidence	that	the	interactions	between	C16-
DAPMA	and	heparin	are	maintained	when	incorporated	into	the	gels,	indicating	that	in	this	
multi-component	system,	each	individual	component	keeps	its	own	unique	behaviour.		
	
3.3.5. Electron	Microscopy	 	
TEM	 images	 of	 DBS-COOH	 gel,	 DBS-COOH	 gel	 in	 the	 presence	 of	 heparin,	 and	 in	 the	
presence	of	heparin	and	C16-DAPMA	were	obtained,	 in	order	 to	better	understand	 the	
morphology	and	behaviour	of	these	three	different	systems.	
	
TEM	images	of	DBS-COOH	gel	(Figure	3.13)	showed	the	presence	of	intertwined	long	and	
twisted	nanofibers,	proving	the	self-assembly	into	1D	fibers	of	this	gelator	in	water.	When	
heparin	was	added	into	the	gel	(Figure	3.14)	long	nanofibers	were	once	again	observed,	
and	at	a	heparin	concentration	of	38	µM	 it	was	possible	 to	distinguish	 the	existence	of	
some	 differentiated	 structures,	 particularly,	 but	 not	 exclusively	 on	 the	 tips	 of	 the	
nanofibers.	 This	may	 be	 related	 to	 the	 fact	 that	 heparin	 can	 induce	 the	 growth	 of	 the	
nanofibers,	as	already	observed	in	the	CD	studies.	It	is	known	that	in	organogels,	polymers	
can	 adsorb	 onto	 the	 tips	 of	 growing	 gel	 fibers	 and	 modify	 their	 growth	 kinetics	 and	
morphology;	we	suggest	heparin	plays	a	similar	role	here.98		
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Figure	3.13.	TEM	image	of	DBS-COOH	gel	(0.2%	w/v).	Scale	bar:	1	µM.	
	
	
Figure	3.14.	TEM	image	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM).	
Scale	bar:	200	nm.	
	
Figure	3.15	shows	TEM	images	of	DBS-COOH	gel	formed	in	the	presence	of	both	heparin	
and	 C16-DAPMA,	where	 the	 presence	 of	 aggregates	 along	with	 the	 nanofibers	 of	 DBS-
COOH	is	evident.	The	observed	hierarchical	aggregates	should	correspond	to	the	binding	
between	C16-DAPMA	and	heparin	 (as	 discussed	 in	 Chapter	 2).	 Therefore,	 the	 obtained	
images	indicate	that	interactions	between	binder	and	heparin	are	maintained	within	the	
gel	nanostructure,	which	is	in	agreement	with	the	obtained	results	for	the	MalB	assay.	This	
provides	evidence	that	orthogonal	assembly	and	binding	are	maintained	within	the	multi-
component	gel.		
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Figure	3.15.	TEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM)	
and	C16-DAPMA	(150	µM).	Scale	bar:	200	nm.	
	
Scanning	electron	microscopy	(SEM)	was	then	performed.	SEM	images	of	the	DBS-COOH	
gel	(Figure	3.16)	showed	a	network	structure	comprising	nanofibers,	in	agreement	with	the	
TEM	imaging.	In	the	presence	of	heparin	(Figure	3.17)	it	was	possible	to	verify	once	more	
the	formation	of	nanofibers,	with	a	‘spaghetti’	like	structure	and	some	twisted	regions.	It	
is	worth	noting	that	these	heparin-modified	nanostructures	are	narrower	(DBS-COOH	with	
heparin:	49	±	2	nm;	DBS-COOH:	82	±	1	nm)	and	this	again	agrees	with	the	view	that	the	
heparin	 polymer	 interacts	 with	 the	 growing	 self-assembled	 fibres	 and	 modifies	 their	
morphology	and	kinetics	of	growth.98		
	
	
Figure	3.16.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v).	
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Figure	3.17.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM).	
	
SEM	 images	 obtained	 for	 DBS-COOH	 gel	 incorporating	 both	 C16-DAPMA	 and	 heparin	
(Figure	3.18),	only	revealed	the	presence	of	nanofibers	from	the	DBS-COOH	self-assembly;	
it	was	not	possible	 to	distinguish	 the	presence	of	C16-DAPMA	 interacting	with	heparin.	
Interestingly,	 however,	 the	 fibers	 were	 equivalent	 to	 those	 formed	 in	 the	 absence	 of	
heparin	which	would	suggest	that	C16-DAPMA	binds	heparin	and	prevents	its	interaction	
with	 the	growing	DBS-COOH	nanofibers.	The	 fact	 that	 the	concentration	of	gelator	 (4.5	
mM)	used	was	much	higher	to	the	concentration	of	binder	(150	µM)	and	heparin	(38	µM)	
may	be	the	reason	why	it	was	only	possible	to	identify	nanofibers.	Additionally,	it	is	well	
known	that	relatively	soft	self-assembled	micelles	are	difficult	to	image	using	this	technique	
as	they	suffer	from	damage	under	the	electron	beam.		
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Figure	3.18.	SEM	images	of	DBS-COOH	gel	(0.2%	w/v)	in	the	presence	of	heparin	(38	µM)	
and	C16-DAPMA	(150	µM).	
	
3.3.6. Rheology	
The	viscoelastic	properties	of	DBS-COOH	gel	alone,	in	the	presence	of	1	mM	of	heparin	and	
1	mM	of	 heparin	 bound	 to	 2	mM	of	 C16-DAPMA,	were	 then	 studied	by	 rheology.	 This	
technique	allows	us	to	obtain	the	storage	or	elastic	modulus	(G’)	and	the	loss	or	viscous	
modulus	(G’’)	for	a	soft	material,	through	the	application	of	oscillating	strains.	A	gel	 is	a	
solid-like	material	and	thus	it	must	exhibit	a	G’	which	is	an	order	of	magnitude	higher	than	
G’’	and	low	frequency	dependence.256,257		
	
The	application	of	a	range	of	strains	gives	an	indication	of	how	stable	a	material	is,	with	the	
linear	viscoelastic	region	(LVR)	corresponding	to	the	region	where	the	storage	modulus	is	
constant	and	thus	the	sample	is	stable	and	‘solid-like’,	with	its	decrease	indicating	the	loss	
of	the	elastic	properties	and	thus	the	breakdown	of	the	structure	into	a	‘liquid-like’	phase.				
Figure	3.19	shows	the	strain	amplitude	dependence	of	G’	and	G’’	for	a	0.2%	w/v	DBS-COOH	
gel;	it	is	possible	to	observe	a	LVR	up	to	approximately	3%	strain	for	DBS-COOH	alone	or	in	
the	presence	of	heparin,	decreasing	significantly	to	approximately	1%	strain	when	heparin-
C16-DAPMA	aggregates	are	present.	This	suggests	that	when	heparin	and	C16-DAPMA	are	
incorporated	within	the	hydrogel,	the	overall	material	is	less	stable	macroscopically	as	the	
gel	network	breaks	down	at	 lower	strains	than	for	 the	other	two	tested	conditions.	We	
suggest	that	the	presence	of	C16-DAPMA-heparin	hierarchical	aggregates	may	impact	on	
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the	 overall	 stability	 of	 the	 network	 perhaps	 somewhat	 limiting	 nanoscale	 chain	
entanglement	 which	 contributes	 to	 macroscopic	 behaviour	 and	 network	 formation.	
Additionally,	the	incorporation	of	heparin	and	heparin-C16-DAPMA	aggregates	within	the	
gel	 network	 resulted	 in	 a	 decrease	 of	 G’	 value	 from	 approximately	 2600	 Pa	 to	
approximately	 700	 Pa,	 indicating	 that	 the	 addition	 of	 these	 components	 reduced	 the	
stiffness	of	DBS-COOH	gel.		
	
	
Figure	3.19.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBS-COOH	gel	(),	DBS-COOH	gel	with	heparin	(r)	and	DBS-COOH	gel	with	
heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.	
	
In	an	attempt	to	obtain	a	stronger	and	stiffer	gel	network,	agarose	(1%	w/v)	was	mixed	
with	the	DBS-COOH	hydrogelator	(0.2%	w/v)	and	the	mechanical	properties	of	the	hydrid	
hydrogels	tested	in	the	presence	and	absence	of	heparin	(1	mM),	as	shown	in	Figure	3.20.		
DBS-COOH-agarose	hybrid	gels	were	formed	by	applying	a	heat-cool	cycle	to	a	solution	of	
dissolved	DBS-COOH	and	agarose	followed	by	addition	of	GdL	to	induce	pH	change.	The	
addition	of	1%	w/v	of	agarose	to	DBS-COOH	(0.2%	w/v)	resulted	in	a	significant	increase	of	
G’	 value	 from	approximately	 2600	 Pa	 to	 approximately	 7900	 Pa,	meaning	 that	 agarose	
contributes	to	the	formation	of	a	stiffer	gel	network,	while	presenting	a	stability	similar	to	
the	DBS-COOH	hydrogel	 (LVR	approximately	3%).	 The	addition	of	heparin	 to	 the	hybrid	
hydrogel	 gave	 rise	 to	 an	 identical	G’	 value	 and	 LVR.	Once	 again,	 this	 indicates	 that	 the	
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presence	 of	 agarose	 gives	 rise	 to	 a	 more	 robust	 stiffer	 gel,	 with	 G’	 increasing	 from	
approximately	700	Pa	to	7900	Pa.		
		
	
Figure	3.20.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBS-COOH	gel	with	agarose	()	and	DBS-COOH	gel	with	agarose	and	heparin	
(r).	Frequency	=	1	Hz.	
	
The	frequency	dependencies	(Figure	3.21)	indicated	that	all	gels	were	stable	up	to	ca.	10	
Hz.	The	G’	and	G’’	values	were	as	described	in	the	variable	strain	experiments.	The	addition	
of	agarose	(Figure	3.22)	significantly	increased	the	stability	to	frequency	up	to	ca.	50	Hz.	
Once	again	the	G’	and	G’’	values	were	as	described	in	the	variable	strain	experiments.	It	
should	be	noted	that	in	these	experiments,	frequencies	were	increased	to	unusually	large	
values,	 in	order	 to	probe	 the	 response.	 	As	 the	 frequency	 increases,	 the	 timescale	over	
which	properties	are	being	measured	becomes	much	shorter,	and	the	gel	eventually	begins	
to	harden,	leading	to	an	increase	in	G’	and	G”.		Similar	effects	have	been	discussed	in	the	
literature.258,259			
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Figure	3.21.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBS-COOH	gel	(),	DBS-COOH	gel	with	heparin	(r)	and	DBS-COOH	gel	with	heparin	
and	C16-DAPMA	(£).	Amplitude	strain	=	0.1%.	
	
	
Figure	3.22.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBS-COOH	gel	with	agarose	()	and	DBS-COOH	gel	with	agarose	and	heparin	(r).	
Amplitude	strain	=	0.1%.	
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3.4. Release	Studies	
	
Heparin	release:	Buffer	on	top	of	the	gel	
One	of	the	key	aims	of	this	project	is	to	release	heparin	from	hydrogels	that	may	therefore	
act	 as	 a	 vehicle	 for	 heparin	 delivery	 in	 a	 controlled	 manner	 for	 clinical	 purposes	 and	
alternatively,	 to	 understand	 whether	 heparin	 angiogenic	 properties	 can	 promote	 cell	
growth.	Therefore,	the	release	of	heparin	from	DBS-COOH	hydrogels	was	investigated.		
	
Heparin	release	from	the	hydrogels	was	studied	by	placing	1	mL	of	10	mM	Tris-HCl/	150	
mM	NaCl	buffer	on	top	of	3	mL	of	hydrogel	incorporating	1	mM	of	heparin,	as	shown	in	
Figure	3.23.	DBS-COOH	hydrogels	were	prepared	as	described	in	Section	3.2.	in	10	mM	Tris-
HCl/	150	mM	NaCl	buffer.	Aliquots	(65	µL)	of	the	supernatant	buffer	were	removed	over	
time,	 added	 into	MalB	 solution	 (25.84	µM,	1935	µL)	 and	 the	absorbance	measured.	As	
already	discussed,	MalB	acts	as	a	heparin	sensor,225	and	in	the	presence	of	heparin,	the	
MalB	absorbance	band	changes	significantly,	so	if	heparin	is	being	released	into	the	buffer	
solution,	it	is	possible	to	quantify	this	by	means	of	a	calibration	plot	using	known	heparin	
concentrations	added	into	MalB	solution.	
	
	
Figure	3.23.	DBS-COOH	hydrogel	containing	1	mM	of	heparin	with	buffer	on	top	for	
monitoring	the	release	of	heparin.	
	
Results	from	Figure	3.24	show	the	release	of	heparin	from	DBS-COOH	hydrogel	(0.2%	w/v)	
in	the	presence	and	absence	of	C16-DAPMA.	Gradual	release	of	heparin	from	DBS-COOH	
hydrogels	was	 observed	 over	 time,	 reaching	 86%	of	 heparin	 being	 released	 after	 72	 h.	
Pleasingly,	when	C16-DAPMA	was	present	it	was	possible	to	observe	that	no	heparin	was	
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released	over	72	h,	proving	that	it	is	indeed	effectively	binding	to	heparin	and	completely	
preventing	release.	A	triggered	release	could	therefore	eventually	be	achieved,	potentially	
by	degradation	of	the	binder.	
	
	
Figure	3.24.	Heparin	release	from	DBS-COOH	hydrogel	(0.2%	w/v)	with	1	mM	of	heparin	
(p)	and	DBS-COOH	hydrogel	(0.2%	w/v)	with	1	mM	of	heparin	interacting	with	2	mM	of	
C16-DAPMA(¢).	
	
Furthermore,	the	use	of	DBS-COOH	hydrogelator	alone	as	a	heparin	carrier	may	allow	its	
controlled	release	due	to	the	responsiveness	of	DBS-COOH	to	changes	in	(e.g.)	pH	or	by	
controlling	network	density.87	The	DBS-COOH	concentration	was	increased	to	2%	w/v	with	
the	 aim	 of	 limiting	 diffusion	 of	 heparin	 out	 of	 the	 gel,	 so	 that	 release	 would	 only	 be	
achieved	 on	 breakdown	 of	 the	 DBS-COOH	 network.	 The	 same	 procedure	 as	 described	
above	was	followed.	Comparing	release	from	the	0.2%	w/v	and	2%	w/v	DBS-COOH	gels	
(Figure	 3.25)	 shows	 that	 increasing	 the	 DBS-COOH	 concentration	 significantly	 slows	
heparin	release,	stabilising	at	35%	release	after	6	hours	rather	than	continuing	to	increase	
up	to	86%	of	released	heparin.	Increasing	the	concentration	of	gelator	contributed	to	the	
decrease	of	the	pore	size	of	the	gel,	thus	increasing	the	chance	of	the	heparin	becoming	
trapped	in	the	network.162	We	suggest	that	the	heparin	that	is	initially	rapidly	released	is	
that	which	 is	 close	 to	 the	 surface	 of	 the	 gel	 and	hence	 able	 to	 access	 the	 supernatant	
solvent.	Once	this	surface-located	heparin	has	been	released,	the	remainder	is	entrapped	
within	the	dense	gel	network.			
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Figure	3.25.	Heparin	release	from	0.2%	w/v	(p)	and	2%	w/v	()	of	DBS-COOH	hydrogels	
with	1	mM	of	heparin.	
	
We	then	studied	further	the	impact	of	network	density	on	heparin	release.	The	DBS-COOH	
concentration	 was	 increased	 further	 to	 5%	 w/v	 and	 10%	w/v.	 As	 this	 requires	 a	 large	
amount	of	DBS-COOH,	for	the	initial	study	only	2	replicates	of	the	5%	w/v	and	1	replicate	
of	the	10%	w/v	gels	were	produced.	Figure	3.26	shows	the	obtained	results,	where	 it	 is	
possible	to	observe	that	the	use	of	5%	w/v	and	10%	w/v	DBS-COOH	resulted	in	identical	
release	profiles	as	for	2%	w/v,	with	all	 reaching	between	35%-40%	maximum	release	of	
heparin.	 Since	 5%	 w/v	 and	 10%	 w/v	 of	 DBS-COOH	 did	 not	 contribute	 to	 any	 further	
reduction	 in	 release	 of	 heparin	 or	 significant	 changes	 in	 initial	 release	 kinetics	 when	
compared	 to	 2%	w/v,	 a	 concentration	of	 2%	w/v	DBS-COOH	was	 chosen	 for	 all	 further	
release	studies.		
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Figure	3.26.	Heparin	release	from	2%	w/v	(),	5%	w/v	(¿)	and	10%	w/v	(¯)	DBS-COOH	
hydrogels	containing	1	mM	of	heparin.		
	
To	improve	the	strength	of	the	DBS-COOH	hydrogels,	agarose	was	added	to	form	a	hydrid	
hydrogel	 with	 enhanced	 mechanical	 strength	 as	 described	 above,	 while	 keeping	 the	
properties	of	the	LMWG,	such	as	reversibility	and	response	to	external	stimuli.	
	
The	effect	of	agarose	concentration	on	heparin	release	was	firstly	studied	by	preparing	gels	
with	1,	2.5,	5,	7.5	and	10%	w/v	agarose	concentrations	having	1	mM	of	heparin	in	10	mM	
Tris-HCl/	150	mM	NaCl	buffer,	 using	 the	 same	method	as	described	above.	 Figure	3.27	
shows	 that	 as	 agarose	 concentration	 increases,	 heparin	 release	 is	 inhibited.	 With	 the	
increase	in	agarose	concentration,	a	gel	network	will	be	formed	with	smaller	pore	sizes	that	
will	 contribute	 to	 the	 entrapment	 of	 heparin	 and	 consequently	 to	 a	 lower	 release.	
Moreover,	it	is	possible	to	verify	that	1%	w/v	of	agarose	allows	to	the	release	of	93%	of	the	
heparin	indicating	that	at	this	concentration	it	only	has	a	small	influence	on	heparin	release,	
and	hence	only	contributes	to	a	higher	gel	strength	as	intended.			
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Figure	3.27.	Heparin	release	from	1.0%	w/v	(yellow),	2.5%	w/v	(blue),	5.0%	w/v	(orange),	
7.5%	w/v	(green)	and	10%	w/v	(purple)	of	agarose	gels	with	1	mM	of	heparin.	
	
Hybrid	hydrogels	were	then	prepared	using	2%	w/v	DBS-COOH	and	0.5%	w/v	and	1%	w/v	
of	 agarose	 in	 order	 to	 test	 the	 influence	 of	 these	 hybrid	 gels	 on	 heparin	 release	when	
compared	with	DBS-COOH	hydrogels	(2%	w/v).	As	shown	in	Figure	3.28,	the	presence	of	
0.5	 or	 1%	w/v	 of	 agarose	 together	 with	 DBS-COOH	 hydrogelator	 resulted	 in	 the	 same	
heparin	release	profile	as	when	only	DBS-COOH	is	used.	 In	addition,	of	the	two	agarose	
concentrations,	 1%	 w/v	 of	 agarose	 with	 2%	 w/v	 DBS-COOH	 proved	 to	 form	 stronger	
hydrogels,	being	easier	to	handle	without	breaking.	This	indicates	that	the	presence	of	1%	
w/v	of	agarose	allows	the	formation	of	a	more	robust	gel	while	not	affecting	the	release	of	
heparin	that	can	then	be	controlled	by	disruption	of	the	DBS-COOH	nanofibers.					
	
	
Figure	3.28.	Heparin	release	from	DBS-COOH	hydrogel	(2%	w/v)	with	1	mM	of	heparin	in	
the	absence	of	agarose	(p),	with	0.5%	of	agarose	()	and	1%	w/v	of	agarose	(¢).	
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Heparin	Release:	Gel	cylinders		
In	vivo,	heparin	release	would	occur	from	the	entire	gel	surface	rather	than	just	the	top	
face;	thus	in	an	attempt	to	mimic	these	conditions,	release	was	studied	from	gel	cylinders	
containing	2.0%	w/v	DBS-COOH,	1.0%	w/v	agarose,	and	17	mM	heparin	(Figure	3.29).	It	is	
important	 to	note	 that	 the	addition	of	agarose	was	essential	 to	make	these	gels	 robust	
enough	 to	handle	 in	 this	way.	 The	 cylinders	were	each	placed	 in	 35	mL	buffer	 giving	 a	
heparin	concentration	at	full	release	of	ca.	0.5	mM,	within	the	range	quantifiable	by	MalB.	
	
	
Figure	3.29.	Assay	design	for	heparin	release	from	hybrid	gel	cylinders	containing	2.0%	
w/v	DBS-COOH,	1.0%	w/v	agarose	and	17	mM	heparin.	1	mL	gels	were	prepared	in	small	
sample	vials.	The	gel	cylinders	were	then	transferred	to	large	glass	jars	and	35	mL	buffer	
was	added.	65	μL	of	buffer	was	removed	over	time,	added	to	1935	μL	MalB	and	a	UV-
Visible	spectrum	recorded.	
	
Figure	3.30	compares	the	release	of	heparin	from	the	two	different	methods:	gel-in-vial	
and	gel	cylinder.	As	expected	the	hybrid	gel	cylinders	allow	greater	heparin	release	than	
the	 gels	 in	 vials,	 with	 80%	 of	 release	 after	 144	 h	 instead	 of	 40%.	 The	 higher	 release	
percentage	obtained	is	due	to	the	greater	surface	area	to	volume	ratio	of	the	gel	cylinders	
in	contact	with	the	buffer.	When	the	buffer	is	placed	only	on	top	of	the	gel	this	reduces	
significantly	the	surface	area	from	which	heparin	release	can	occur.			
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Figure	3.30.	Different	methods	of	heparin	release	from	DBS-COOH	hydrogel	(2%	w/v)	and	
agarose	(1%	w/v).	():	Buffer	on	top	of	the	gel.	(¢):	Gel	cylinder.	
	
Heparin	Release:	pH	triggered		
The	pH	responsive	assembly	and	disassembly	of	DBS-COOH	in	the	presence	of	agarose	has	
previously	been	reported.87	Prior	to	using	pH	to	achieve	release	of	heparin,	an	NMR	study	
was	carried	out	to	check	that	DBS-COOH	is	still	able	to	disassemble	with	heparin	present.	
Two	hybrid	gels	(0.2%	w/v	DBS-COOH,	0.5%	w/v	agarose)	were	prepared,	in	the	presence	
and	 absence	 of	 heparin.	 Their	 NMR	 spectra	 were	 recorded	 before	 and	 after	 gelation.	
NaOH(aq)	was	then	added	to	the	top	of	each	gel	and	NMR	spectra	recorded	periodically	to	
observe	the	breakdown	of	the	DBS-COOH	(Figure	3.31).		
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Figure	3.31.	NMR	spectra	of	aromatic	protons	of	DBS-COOH	prior	to	gelation,	after	full	
gelation,	and	after	19.5,	26,	45,	and	68/69	hours	exposure	to	NaOH	a)	in	presence	of	
agarose	and	absence	of	heparin,	and	b)	in	presence	of	agarose	and	heparin.	
	
Prior	 to	 gelation	 the	 resonances	 corresponding	 to	 the	 aromatic	 protons	 of	 DBS-COOH	
appear	 as	 a	 duplet	 at	 7.86-7.83	 ppm	 and	 as	 a	 quartet	 at	 7.59-7.56.	 As	 the	 DBS-COOH	
molecules	 self-assemble	 into	 gel	 fibres	 they	 become	 immobile	 on	 the	 NMR	 timescale,	
hence	 the	 peaks	 disappear	 from	 the	 spectrum.	 In	 both	 gels,	 these	 resonances	 then	
reappear	after	treatment	with	NaOH,	indicating	that	the	DBS-COOH	fibres	are	being	broken	
a)	
b)	
	 	 Chapter	3	
	
130	
	
down	into	mobile	DBS-COO-	molecules,	thus	heparin	does	not	 inhibit	the	pH	responsive	
disassembly	of	DBS-COOH	nanofibers.			
	
Subsequently,	 attempts	 were	made	 to	 study	 pH-triggered	 release	 of	 heparin	 from	 the	
hybrid	gels.	1	mL	NaOH(aq)	was	added	to	the	top	of	three	hybrid	gels	(2.0%	w/v	DBS-COOH,	
1.0%	w/v	agarose,	1mM	heparin),	and	after	1	hour	65	μL	supernatant	was	removed	and	
neutralised	with	HCl(aq).	However,	neutralisation	caused	gelation	of	the	supernatant,	due	
to	the	presence	of	DBS-COO-.	This	prevented	its	analysis	by	addition	to	MalB.	Due	to	the	
pH	sensitivity	of	MalB,	neutralisation	is	necessary	to	quantify	heparin	release.	Nonetheless,	
we	are	reasonably	confident	that	heparin	will	be	released	from	the	gel	along	with	DBS-
COO-.	
	
A	milder	base,	pH	9	buffer	(Na2B4O7/HCl),	was	then	trialled	as	this	could	be	added	directly	
to	MalB	without	affecting	its	absorbance.	However,	after	4	weeks	the	DBS-COOH	gel	(pKa	
ca	4-5)	 remained	 intact,	and	so	 it	appears	 that	 this	base	 is	unable	 to	deprotonate	DBS-
COOH	on	a	suitable	timescale.	A	pH	10	buffer	(borax/NaOH)	was	trialled	but	this	was	also	
unable	to	break	down	the	DBS-COOH,	thus	future	experiments	should	seek	to	find	a	base	
able	 to	 disassemble	 DBS-COOH	 on	 an	 appropriate	 timescale,	 while	 still	 allowing	 facile	
quantification	of	heparin	release	using	MalB.		
	
3.5. Cytocompatibility	of	DBS-COOH	Hydrogels	
The	cytocompatibility	of	DBS-COOH	hydrogels	was	then	studied	using	mouse	embryonic	
fibroblasts	(3T3	cells).	Both	2D	and	3D	cellular	microenvironments	were	tested.	For	the	2D	
cell	culture,	the	hydrogels	were	tested	in	96-well	plates,	with	cells	added	on	top	after	the	
gelation	process	occurred	(Figure	3.32).	In	addition,	the	gels	were	also	prepared	in	inserts	
(transwells),	with	cells	seeded	in	the	well	plate	(Figure	3.33).			
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Figure	3.32.	Schematic	representation	of	2D	cell	culture	performed	in	96	well	plates.		
	
	
Figure	3.33.	Schematic	representation	of	2D	cell	culture	performed	in	transwells.	
	
For	 both	 experiments,	 cell	 morphology	 was	 observed	 by	 optical	 microscopy	 and	 using	
phalloidin/	4',6-diamidino-2-phenylindole	(DAPI)	staining.	The	distinction	between	live	and	
dead	cells	was	achieved	by	Calcein	acetomethoxy	(AM)/Propidium	iodide	(PI)	staining.	The	
labelling	of	cell	mitochondria	was	obtained	using	MitoTraker	green	dye	and	the	metabolic	
activity	of	the	cells	studied	using	the	cells	proliferation	reagent:	water	soluble	tetrazolium	
salt	(WST-1).
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3.5.1. 2D	Cell	Culture	with	Cells	on	Top	
2D	cell	culture	was	tested	using	DBS-COOH	hydrogels,	however,	it	was	observed	that	the	
addition	of	culture	medium	(Table	3.3	-	a)	dissolved	the	gel.	The	use	of	very	small	volumes	
of	gel	in	the	wells	can	contribute	to	a	less	stable	network,	which	together	with	the	fact	that	
DBS-COOH	only	forms	stable	gels	at	acidic	pH,	may	explain	why	it	becomes	liquid	when	in	
contact	with	cell	culture	media	(pH	7-7.4).		
	
A	number	of	different	media	were	 tested	 (Table	3.3–	b-e)	 in	order	 to	 verify	 if	 only	 the	
DMEM,	10%	FBS,	1%	P/S	medium	was	disrupting	the	gel.	However,	 the	use	of	different	
media	also	resulted	in	the	dissolution	of	the	DBS-COOH	gels.		
	
Table	3.3.	Media	tested	in	DBS-COOH	gels.	
	 Medium/	Buffer	 Description	
	
a.	
	
DMEM,	10%	FBS,	1%	P/S	
Dulbecco’s	Modified	 Eagle’s	Medium	 (89%	 DMEM	 –	 high	
glucose	 in	3.7	g/L	NaHCO3),	10%	 fetal	bovine	 serum	 (FBS)	
and	1%	Penicillin/Streptomycin	(P/S)	
b.	 NaHCO3	 3.7	g/L,	pH=8.39	
c.	 EBM-2	 Endothelial	basal	medium	
d.	 Mesencult	ACF	 Animal	component	 free	medium	for	human	mesenchymal	
stem	cells	
e.	 DPBS	 Dulbecco’s	phosphate-buffered	saline	
	
Nonetheless,	2D	cell	culture	assays	with	DBS-COOH	gels	were	performed.	Although	on	the	
addition	of	cell	culture	medium	the	gels	became	liquid.	Therefore,	instead	of	having	cells	
growing	 on	 top	 of	 the	 gels,	 they	 were	 growing	 attached	 to	 the	 bottom	 of	 the	 wells.	
Subsequently,	this	assay	only	allows	us	to	understand	how	the	acidic	properties	of	DBS-
COOH	can	affect	the	cells,	and	as	such	it	acts	as	an	effective	toxicity	assay.	2D	experiments	
were	performed	using	a	cell	density	of	50000	cells/mL	and	DBS-COOH	in	the	absence	of	
heparin,	with	1	mM	–	667	µg/mL	and	2	mM	–	1330	µg/mL	of	heparin.	
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Cell	Morphology	
Cell	morphology	was	followed	by	optical	microscopy	and	phalloidin/DAPI	staining.	Optical	
microscopy	of	DBS-COOH	hydrogels	allowed	us	to	identify	on	day	1	the	presence	of	slightly	
oval	cells	and	the	confluence	of	cells	by	day	5	(Figure	3.34).	Images	from	day	7	were	similar	
to	the	ones	from	day	5,	with	cells	starting	to	detach	due	to	the	high	confluency.	Identical	
results	were	observed	for	samples	containing	667	µg/mL,	1330	µg/mL	of	heparin	and	for	
the	control	experiments	(cells	with	medium).	
	
Figure	3.34.	Optical	microscopy	images	of	DBS-COOH	hydrogels	with	cells	on	top,	at	day	1	
and	5.	Magnification:	10x.	
	
Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	cells	in	DBS-COOH	hydrogels	
are	shown	in	Figure	3.35.	Phalloidin	is	a	peptide	stain	that	binds	to	actin	filaments,	whereas	
DAPI	is	a	blue	fluorescent	nucleic	acid	stain	that	specifically	 labels	nuclei,	allowing	more	
detailed	imaging	of	cell	morphology.				
	
On	day	1	 it	 is	possible	to	verify	that	the	cells	are	more	spherical	than	on	day	5,	but	the	
presence	of	some	cell	extensions	are	also	visible,	indicating	adhesion	onto	the	bottom	of	
the	wells.	On	day	5	the	existence	of	stretched	filaments	is	clearly	noticeable,	indicating	a	
good	adhesion	of	cells	to	the	bottom	of	the	wells.	Similar	images	were	obtained	for	samples	
containing	667	µg/mL,	1330	µg/mL	of	heparin	and	for	the	control	experiments.	
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Figure	3.35.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	cells	on	top	of	
DBS-COOH	hydrogels,	at	day	1	and	5.	Magnification:	40x.	
	
Live/Dead	Staining	
Calcein-(AM)	was	used	to	label	live	cells	and	PI	was	used	to	label	dead	cells.	The	former	can	
enter	viable	cells	and	will	undergo	esterase	cleavage	of	AM	groups	only	if	the	cells	are	alive,	
as	esterase	activity	does	not	exist	in	dead	cells.	Fluorescent	calcein	will	then	be	trapped	
inside	the	cells,	allowing	the	labelling	of	live	cells.	On	the	other	hand,	PI	can	only	penetrate	
damaged	cell	membranes	and	thus	only	labels	dead	cells.	
	
Figure	3.36	shows	the	fluorescence	microscopy	images	obtained	for	DBS-COOH	hydrogels	
in	the	absence	and	presence	of	heparin	at	day	1	and	7.	On	day	5,	cells	were	fixed	in	order	
to	 try	 to	have	more	 time	 to	obtain	 fluorescence	microscopy	 images	of	 all	 the	 samples.	
However,	this	did	not	allow	clear	images	to	be	obtained;	it	was	therefore	not	possible	to	
identify	the	cells	under	the	fluorescence	microscope.		
	
From	the	images	it	is	possible	to	observe	that	on	day	1	cells	were	alive	(green	fluorescence)	
and	in	the	presence	of	1330	µg/mL	of	heparin	it	appeared	that	cells	were	more	stretched	
in	comparison	with	the	samples	with	no	heparin	and	667	µg/mL	of	heparin.	Dead	cells	(red	
fluorescence)	were	not	present	on	day	1,	however	it	is	believed	that	they	may	have	been	
washed	off	due	to	the	fact	that	dead	cells	are	not	attached	and	the	samples	were	washed	
twice	with	DPBS.	On	day	7,	cells	were	already	confluent	as	expected,	as	optical	microscopy	
showed	that	on	day	5	confluency	was	achieved.	Thus,	an	optimization	of	the	initial	number	
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of	cells	is	needed.	Importantly,	however	the	cells	were	able	to	live	for	the	7	days	of	assay	
and	proliferate	in	the	presence	of	the	DBS-COOH	disrupted	hydrogels.	This	suggests	that	
DBS-COOH	has	low	cellular	toxicity	which	is	promising	for	this	class	of	material	even	though	
DBS-COOH	could	not	maintain	its	gel	structure	under	cell-growth	medium.	
	
	
Figure	3.36.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	
and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1	and	7.	Magnifcation:	20x.	
	
MitoTracker	Staining	
MitoTracker	green	was	used	to	label	cell	mitochondria	and	Hoechst	stain	was	used	to	stain	
cells	nuclei.	MitoTracker	green	is	a	cell	permeant	dye	that	binds	to	the	thiol	groups	in	the	
mitochondria,	while	Hoechst	dye	is	a	cell	permeable	nucleic	acid	stain.		
	
From	 Figure	 3.37	 it	 is	 possible	 to	 observe	 that	 on	 day	 1,	 no	 significant	 differences	 are	
present	between	the	cell	mitochondria	of	DBS-COOH	hydrogels	with	no	heparin	and	with	
667	µg/mL	of	heparin,	which	are	similar	to	the	control	cells.	However,	when	1330	µg/mL	
of	heparin	is	present,	slightly	more	stretched	cells	appear	to	be	present.	These	differences	
between	cells	under	different	 conditions	are	more	evident	on	day	5.	Despite	 some	cell	
confluency	and	the	fact	that	for	all	the	samples	the	cells	became	more	elongated,	when	
1330	µg/mL	of	heparin	is	present,	the	cell	elongation	appear	to	be	more	obvious,	as	shown	
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in	more	detail	on	Figure	3.38.	This	suggests	the	presence	of	this	concentration	of	heparin	
does	impact	on	cell	growth	and	importantly	morphology.		
	
On	day	7,	it	was	difficult	to	achieve	clear	images	due	to	high	confluency	of	the	cells.	Thus,	
it	was	not	possible	to	obtain	any	more	information	related	with	this	staining	 in	specific,	
only	the	fact	that	cells	appeared	to	continue	to	grow	from	day	5	to	7.			
	
	
Figure	3.37.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
COOH	hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	
µg/mL)	and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1,	5	and	7.	
Magnifcation:	20x.	
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Figure	3.38.	Fluorescence	microscopy	images	of	cell	in	DBS-COOH	hydrogels	with	1330	
µg/mL	heparin	at	day	1	(left)	and	5	(right).	Magnifcation:	20x.	
	
Metabolic	Activity	
Cell	proliferation	reagent	WST-1	was	used	to	determine	the	metabolic	activity	of	the	cells.	
Cellular	enzymes	cleave	tetrazolium	salt	WST-1	to	formazan	dye.	This	way,	when	measuring	
the	dye	absorbance	it	 is	possible	to	correlate	 it	with	the	number	of	metabolically	active	
cells	-	the	higher	the	number	of	viable	cells,	the	higher	the	concentration	of	formazan	dye.	
Figure	3.39	shows	the	absorbance	at	440	nm	of	formazan	in	DBS-COOH	with	no	heparin,	
667	 µg/mL	 of	 heparin	 and	 1330	 µg/mL	 of	 heparin.	 When	 compared	 to	 the	 control	
absorbance	values,	it	is	noticeable	that	at	days	1	and	5	for	all	conditions,	there	is	a	potential	
effect	of	DBS-COOH	on	the	proliferation	of	the	cells,	with	a	higher	metabolic	activity	being	
obtained	in	the	control	assay.	However,	by	day	7	the	cells	have	recovered	and	a	similar	
metabolic	activity	to	control	was	obtained.		
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Figure	3.39.	Absorbance	of	formazan	at	440	nm	with	DBS-COOH	hydrogels,	DBS-COOH	
hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	and	control	(medium	
with	cells),	with	cells	on	top,	at	day	1,	5	and	7.	
	
3.5.2. 2D	Cell	Culture	in	Transwells	
DBS-COOH	hydrogels	were	tested	in	transwells,	with	gels	prepared	in	inserts,	which	were	
placed	on	top	of	medium,	containing	cells	that	were	growing	attached	to	the	well	plates	
(cell	density:	40000	cells/mL).	Once	again,	after	the	gels	were	in	contact	with	cell	culture	
medium	they	broke	down.	
	
Cell	Morphology	
Figure	3.40	shows	the	optical	microscopy	 images	obtained	for	 the	DBS-COOH	hydrogels	
where	it	is	possible	to	observe	the	presence	of	round	and	slightly	oval	cells	on	day	1.	On	
day	5,	the	number	of	cells	on	the	plates	showed	a	reasonable	increase,	and	presented	more	
elongated	shapes.	On	day	7,	cells	were	confluent	and	thus	it	was	difficult	to	obtain	clear	
images.	Similar	results	were	obtained	for	samples	containing	667	µg/mL,	1330	µg/mL	of	
heparin	and	for	the	control	experiments.	
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Figure	3.40.	Optical	microscopy	images	of	DBS-COOH	hydrogels	in	transwells,	at	day	1	
and	5.	Magnification:	10x.	
	
Phalloidin/DAPI	staining	of	cells	with	DBS-COOH	hydrogels	in	transwells	is	shown	on	Figure	
3.41.	The	obtained	results	were	similar	to	the	already	described	2D	cell	culture	with	cells	
on	top	(see	section	3.5.1.).	Comparable	images	were	also	obtained	for	samples	containing	
667	µg/mL,	1330	µg/mL	of	heparin	and	for	the	control	assays.	
	
	
Figure	3.41.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	DBS-COOH	
hydrogels	in	transwells,	at	day	1	and	5.	Magnification:	40x.	
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Live/Dead	Staining	
Live/dead	cells	of	DBS-COOH	hydrogels	in	transwells	can	be	identified	on	Figure	3.42.	On	
day	1	live	cells	are	easily	detected	and	when	667	µg/mL	and	1330	µg/mL	of	heparin	is	within	
the	gels,	it	appears	that	cells	are	slightly	more	elongated	than	when	no	heparin	is	present.	
On	day	5,	cells	from	samples	with	667	µg/mL	and	1330	µg/mL	of	heparin	were	alive	and	
proliferating.	Cells	from	DBS-COOH	hydrogels	with	no	heparin	and	the	control	assay	were	
fixated	on	day	5,	thus	clear	images	were	not	possible	to	obtain.	On	day	7,	we	can	observe	
cells	 in	 high	 confluency	 once	more.	 However,	 cells	 adhere	 and	 proliferate	 over	 7	 days	
indicating	that	the	DBS-COOH	is	non-cytotoxic.		
	
	
Figure	3.42.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-COOH	
hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	667	µg/mL)	
and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	Magnifcation:	20x.	
	
MitoTracker	Staining	
MitoTracker	staining	of	cells	with	DBS-COOH	hydrogels	in	transwells	was	obtained	and	is	
shown	on	Figure	3.43.	On	day	1	it	is	possible	to	observe	that	when	1330	µg/mL	of	heparin	
is	within	the	gel	network,	the	mitochondria	appear	to	be	slightly	more	stretched	(Figure	
3.44	for	a	more	detailed	image)	than	in	the	samples	without	heparin	or	with	667	µg/mL	of	
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heparin.	 On	 day	 5	 and	 7,	 cells	 high	 confluency	 makes	 it	 difficult	 to	 see	 clearly	 the	
mitochondria,	and	as	on	section	3.5.1.	 it	 is	only	possible	to	verify	that	cells	appeared	to	
continue	to	grow	from	day	5	to	7.			
	
	
Figure	3.43.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
COOH	hydrogels,	DBS-COOH	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	
µg/mL)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	Magnifcation:	
20x.	
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Figure	3.44.	Fluorescence	microscopy	images	of	cell	in	DBS-COOH	hydrogels	with	1330	
µg/mL	heparin	at	day	1.	Magnifcation:	20x.	
	
Metabolic	Activity	
Figure	 3.45	 shows	 the	 obtained	 absorbance	 of	 formazan	 for	 DBS-COOH	 hydrogels	 in	
transwells	 assay.	 On	 day	 1,	 the	 metabolic	 activity	 of	 cells	 from	 DBS-COOH	 hydrogels	
without	 heparin	 is	 slightly	 lower	 than	 the	 control,	 while	 when	 heparin	 is	 present	 the	
metabolic	activity	is	similar	to	the	control.	Moreover,	it	is	possible	to	verify	on	day	5,	that	
when	cells	are	in	contact	with	DBS-COOH	hydrogels	without	heparin	and	with	667	µg/mL	
of	heparin,	their	metabolic	activity	is	affected	and	is	not	as	high	as	the	control.	However,	
when	1330	µg/mL	of	heparin	is	present	the	metabolic	activity	is	higher	and	almost	identical	
to	the	control,	indicating	a	potential	positive	influence	of	heparin,	at	this	concentration,	on	
cell	viability.		
	
Despite	the	first	5	days	showing	a	lower	cell	proliferation	for	DBS-COOH	hydrogels	with	no	
heparin	and	667	µg/mL	of	heparin,	on	day	7	the	metabolic	activity	of	cells	increased.	On	
the	other	hand,	when	1330	µg/mL	of	heparin	is	incorporated,	the	metabolic	activity	of	the	
cells	 remains	 practically	 the	 same.	 This	 may	 indicate	 that	 the	 presence	 of	 a	 certain	
concentration	of	heparin	may	have	a	positive	influence	on	cell	proliferation	for	the	first	5	
days	and	as	the	cells	became	confluent	in	the	well	they	were	then	not	able	to	proliferate	
further	from	day	5	to	7.	To	have	a	better	understanding	the	cell	number	should	be	reduced,	
so	the	confluency	of	the	cells	does	not	interfere	with	the	results.	It	should	be	noted	that	
this	result	is	significantly	different	from	the	metabolic	activity	obtained	for	the	‘cells	on	top	
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of	 the	gel’,	where	 in	 the	absence	or	presence	of	heparin	 similar	metabolic	 activity	was	
obtained.	This	may	be	due	to	the	fact	that	when	gels	were	in	transwells	there	was	not	an	
immediate	contact	of	the	cell	medium	with	the	gels	and	therefore	the	acidic	conditions	of	
the	disrupted	gels	did	not	affect	the	cells	in	the	same	extent,	and	the	influence	of	heparin	
was	more	evident	in	the	transwells	experiment.		
	
	
Figure	3.45.	Absorbance	of	formazan	at	440	nm	with	DBS-COOH	hydrogels,	DBS-COOH	
hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	µg/mL)	and	control	(medium	
with	cells),	in	transwells,	at	day	1,	5	and	7.	
	
3.5.3. 3D	Cell	Culture	
The	 incorporation	of	 cells	within	 the	DBS-COOH	network	 could	not	be	achieved,	as	 the	
addition	of	culture	medium	dissolved	the	gel.	Therefore,	3D	cell	culture	assays	were	not	
performed.		
	
3.6. Summary,	Conclusions	and	Future	Work	
LMWG	 DBS-COOH	 was	 successfully	 synthesised	 and	 its	 orthogonal	 self-assembly	 with	
heparin	 and	 C16-DAPMA	 investigated.	With	 the	 addition	 of	 different	 concentrations	 of	
binder	and	heparin	to	DBS-COOH	separately,	it	was	possible	to	verify	that	heparin	did	not	
prevent	the	formation	of	DBS-COOH	gels,	in	contrast	with	the	binder,	which	significantly	
affected	 the	 self-assembly	 of	 DBS-COOH,	 with	 no	 gels	 being	 formed	 at	 any	 tested	
concentration	of	binder,	indicating	the	interaction	of	the	amine	heads	of	C16-DAPMA	with	
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DBS-COOH.	 The	 orthogonal	 self-assembly	 of	 DBS-COOH	 with	 both	 binder	 and	 heparin	
revealed	 that	when	 the	binder	 is	 bound	 to	 heparin,	 gel	 formation	does	 still	 occur.	 The	
presence	of	heparin	and	binder-heparin	 in	DBS-COOH	gels	did	not	altered	the	apparent	
thermal	stability,	which	was	above	100	°C.	IR	spectra	of	the	gel	in	the	presence	of	binder	
and	heparin	showed	the	overlap	of	the	characteristic	vibrations	of	C16-DAPMA,	heparin	
and	 DBS-COOH	 suggesting	 orthogonal	 assembly.	 The	 study	 of	 gel	 formation	 by	 NMR,	
revealed	slight	differences	 in	 the	 formation	of	gel	with	 time,	between	DBS-COOH,	DBS-
COOH	in	the	presence	of	heparin	and	DBS-COOH	in	the	presence	of	heparin	and	binder,	
however	the	three	different	samples	presented	a	gradual	increase	in	the	%	of	gel	over	time	
with	100%	of	gel	being	formed	in	the	samples	after	7	hours.		The	growth	of	the	DBS-COOH	
nanofibers	 was	 also	 studied	 using	 CD	 and	 it	 was	 observed	 that	 heparin	 appeared	 to	
promote	the	growth	of	the	fibers	–	suggesting	that	the	nanofibers	formed	by	DBS-COOH	
nucleate	more	 quickly	 in	 the	 presence	 of	 heparin;	 while	 the	 presence	 of	 heparin	 with	
binder	contributed	to	slower	self-assembly	of	DBS-COOH	gelator	nanofibers	–	which	can	
reflect	greater	difficulty	in	assembling	nanofibers	as	a	result	of	steric	hindrance	provided	
by	the	relative	large	hierarchical	C16-DAPMA-heparin	aggregates.	The	use	of	MalB	solution	
on	top	of	the	gel	allowed	to	prove	that	binder	-	heparin	interactions	are	maintained	within	
the	gel.	TEM	and	SEM	images	of	DBS-COOH	in	the	presence	of	heparin	demonstrated	that	
heparin	alone	has	same	impact	on	the	assembly	and	morphology	of	the	gel.	In	the	presence	
of	 both,	 C16-DAPMA	 and	 heparin	 TEM	 showed	 the	 clear	 presence	 of	 hierarchical	
aggregates	along	with	the	fibers,	proving	once	more	that	the	binder-heparin	interactions	
are	still	present	when	incorporated	in	the	hydrogel.	This	clearly	indicates	that	within	this	
highly	complex	multi-component	material,	orthogonal	 interactions	can	occur	 in	order	to	
generate	 highly	 structured	 potentially	 functional	 nano-composites.	 The	 mechanical	
properties	of	DBS-COOH	confirmed	its	gel-like	characteristics,	that	were	not	significantly	
affected	with	the	incorporation	of	heparin	and	heparin-C16-DAPMA	aggregates,	while	the	
addition	of	agarose	contributed	to	the	formation	of	a	stronger	gel,	which	could	be	handled.	
Therefore,	 it	 is	possible	 to	conclude	 that	DBS-COOH	and	heparin	are	 largely	orthogonal	
while	DBS-COOH	 and	 C16-DAPMA	are	 clearly	 not	 orthogonal.	 Additionally,	mixing	 both	
heparin	and	C16-DAPMA	into	DBS-COOH	leads	to	a	largely	orthogonal	system	in	which	both	
DBS-COOH	and	C16-DAPMA	self-assemble	into	their	own	respective	nanostructures,	with	
heparin	preventing	the	disruptive	effect	of	C16-DAPMA	by	binding	strongly	to	the	micelles.	
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Furthermore,	 the	 release	 of	 heparin	 from	DBS-COOH	 hydrogels	was	 achieved	with	 the	
presence	of	C16-DAPMA	completely	 inhibiting	the	release	of	heparin.	The	 incorporation	
and	release	of	heparin	from	a	hybrid	gel	combining	the	PG	agarose	with	the	LMWG	DBS-
COOH	was	successfully	demonstrated.	Initial	heparin	release	studies	indicate	that	release	
can	 be	 controlled	 either	 by	 changing	 the	 surface	 area	 for	 release,	 or	 by	 altering	 the	
concentration	of	agarose	and/or	DBS-COOH,	resulting	in	a	change	of	pore	size	of	the	gel.	In	
conclusion,	 there	 is	 a	 threshold	 DBS-COOH	 network	 density	 that	 prevents	 heparin	
diffusion,	 limiting	 total	 release,	while	 agarose	has	 a	progressive	effect	on	diffusion	and	
release	of	heparin	with	higher	agarose	loadings	decreasing	heparin	release	kinetics.		NMR	
studies	 indicate	 that	 DBS-COOH	 in	 the	 presence	 of	 heparin	 and	 agarose	 is	 still	 able	 to	
assemble	 and	 disassemble	 in	 response	 to	 pH	 changes,	 releasing	 heparin	 whilst	 still	
maintaining	gel	 integrity.	However,	problems	were	faced	quantifying	this	release	due	to	
the	pH	sensitivity	of	the	MalB	dye.			
	
The	present	study	also	allowed	to	conclude	that	3D	cell	culture	assays	are	not	possible	to	
perform	using	DBS-COOH	gels	as	they	dissolve	in	cell	culture	medium.	In	respect	to	the	2D	
cell	culture	it	is	possible	to	conclude	that	DBS-COOH	hydrogels	are	not	good	candidates,	
once	more	because	they	dissolve	in	cell	culture	medium	and	thus	no	gel	is	present.	On	the	
other	hand,	from	the	obtained	results	it	seems	that	DBS-COOH	is	not	cytotoxic	-	the	cells	
were	able	to	adhere	onto	the	bottom	of	the	wells	and	proliferate,	and	thus	other	biological	
applications	may	be	explored.	However,	we	should	take	into	account	that	the	medium	was	
replaced	 over	 the	 week	 and,	 as	 the	 gels	 dissolved,	 they	 could	 had	 been	 washed	 off,	
specially	for	the	2D	cell	culture	with	cells	on	top.	Moreover,	the	cells	used	are	very	resistant	
and	 the	 use	 of	more	 sensitive	 cells	may	 give	more	 conclusive	 results	 about	DBS-COOH	
cytotoxicity.	The	cytotoxicity	should	therefore	be	investigated	by	optimizing	the	number	of	
cells	used	and	by	using	different	type	of	cells.				
	
Further	studies	could	seek	to	optimise	pH-responsive	heparin	release	by	finding	a	base	able	
to	 deprotonate	 DBS-COOH	 on	 a	 suitable	 timescale,	 while	 still	 allowing	 facile	 heparin	
quantification	using	MalB.	Additionally,	the	fact	that	C16-DAPMA	is	a	very	stable	binder	
may	 make	 it	 difficult	 to	 achieve	 the	 controlled	 release	 of	 heparin	 from	 the	 multi-
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component	 hydrogel	 network.	 It	 can	 easily	 be	 replaced	 by	 a	 heparin	 binder	 with	 a	
degradable	linkage.207		
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4. Orthogonal	 Self-Assembly	 of	 DBS-CONHNH2	 Hydrogels	 with	
C16-DAPMA	and	Heparin	
Cytocompatibility	 studies	 were	 performed	 on	 a	 placement	 at	 Nano-FM	 in	 Groningen,	
Netherlands,	as	part	of	the	SmartNet	network.	
	
4.1. Introduction	
Following	 the	 results	 obtained	 in	 Chapter	 3	 and	 the	 limitations	 observed	 for	 our	 pH	
responsive	LMWG	for	mammalian	cell	culture	in	terms	of	gel	instability,	the	replacement	
of	DBS-COOH	with	a	different	DBS	derivative	was	of	great	 interest.	DBS	hydrazide	(DBS-
CONHNH2	-	Figure	4.1)	has	previously	been	reported	by	the	Smith	group	as	a	LMWG	capable	
of	gelating	water	as	solvent,	and	forming	stable	hydrogels	across	a	wide	range	of	pH	(2-
11.5)	by	applying	a	simple	heat-cool	cycle.88	Therefore,	DBS-CONHNH2	hydrogels	 ideally	
can	provide	a	more	stable	microenvironment	to	which	cells	can	adhere	and	proliferate.	For	
this	 purpose,	 this	 chapter	will	 focus	 on	 the	 properties	 of	 DBS-CONHNH2	 as	 a	 potential	
scaffold	for	cell	growth	and	the	orthogonal	self-assembly	of	the	hydrogel	with	heparin	and	
self-assembled	C16-DAPMA.	As	in	the	previous	Chapter,	the	incorporation	of	heparin	into	
a	 hybrid	 hydrogel	 containing	 agarose	 as	 PG	 and	 DBS-CONHNH2	 as	 LMWG	will	 also	 be	
studied	and	the	release	of	heparin	from	different	multi-component	hydrogels	investigated.	
Additionally,	the	cytocompatibility	of	these	systems	will	be	tested.		
	
	
Figure	4.1.	Chemical	structure	of	LMWG	DBS-CONHNH2.	
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4.2. Synthesis	 of	 DBS-CONHNH2	 Gelator	 and	 Temperature	 Induced	
Hydrogelation	
DBS-CONHNH2	 was	 obtained	 from	 the	 DBS-COOCH3	 derivative	 using	 a	 hydrazination260	
reaction	 as	 previously	 reported	 the	 by	 Smith	 group.88	 DBS-COOCH3	was	 synthesised	 as	
previously	 described	 in	 Chapter	 3.	 The	 reaction	 between	 DBS-COOCH3	 and	 excess	
hydrazine	monohydrate	 resulted	 in	a	white	precipitate	 that	after	 filtration	and	washing	
yielded	 DBS-CONHNH2,	 as	 shown	 in	 Scheme	 4.1.	 All	 characterisation	 data	 for	 DBS-
CONHNH2	were	in	agreement	with	previous	reports.	
	
	
Scheme	4.1.	Synthesis	of	DBS-CONHNH2.	
	
The	gelation	of	the	hydrazide	gelator	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	was	achieved	
using	a	heat-cool	cycle.	The	formation	of	hydrogels	was	obtained	after	heating	the	DBS-
CONHNH2	 solution	 until	 the	 gelator	was	 completely	 dissolved	 and	 a	 clear	 solution	was	
observed,	following	by	cooling	to	room	temperature.	In	order	to	obtain	stable	and	uniform	
gels,	a	concentration	of	0.4%	w/v	of	DBS-CONHNH2	was	used.	This	concentration	of	DBS-
CONHNH2	was	 found	 to	 be	 the	maximum	 concentration	 of	 gelator	 that	 resulted	 in	 the	
formation	 of	 stable	 and	 uniform	 hydrogels.	When	 using	 higher	 concentrations	 of	 DBS-
CONHNH2	 not	 all	 of	 the	 gelator	 was	 dissolved	 upon	 heating,	 resulting	 in	 a	 weak	 and	
unstable	hydrogel.	Heating	the	samples	for	longer	periods	of	time	was	not	possible	as	the	
solutions	started	to	boil.	
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4.3. Study	of	Orthogonal	Self-Assembly	of	DBS-CONHNH2	with	C16-DAPMA	and	
Heparin	
The	 self-assembly	 of	 DBS-CONHNH2	 hydrogels	 incorporating	 heparin,	 and	 heparin	
interacting	with	C16-DAPMA	micelles	were	each	studied	to	understand	how	the	properties	
of	the	individual	nanoarchitectures	are	affected	when	incorporated	into	a	single	system.			
	
C16-DAPMA	Stability	at	High	Temperatures	
DBS-CONHNH2	 hydrogels	 are	 formed	 immediately	 after	 heating,	 thus	 the	 only	 way	 to	
incorporate	heparin	and	heparin-C16-DAPMA	aggregates	within	the	gel	network	was	by	
adding	 them	 to	 the	 solution	before	heating.	 Therefore,	 the	 stability	of	 the	C16-DAPMA	
micelles	at	high	 temperatures	was	 tested,	 to	understand	how	temperature	affects	C16-
DAPMA	self-assembly	and	interactions	with	heparin.		
	
DLS	 studies	 of	 C16-DAPMA	were	 performed	 at	 25	 °C	 and	 70	 °C	 (Table	 4.1).	 From	 the	
obtained	results,	it	is	possible	to	observe	that	the	hydrodynamic	diameter	of	the	micelles	
is	similar	after	heating,	 indicating	that	micellar	size	does	not	appear	to	be	influenced	by	
high	temperatures.	High	zeta	potential	values,	in	the	same	range,	were	also	obtained	for	
the	 two	 different	 temperatures,	 indicating	 that	 heating	 does	 not	 affect	 the	 repulsion	
between	 the	 particles	 and	 the	micelles	 are	 highly	 charged	 at	 70	 °C.	Moreover,	 it	 was	
observed	that	the	increase	in	temperature	contributed	to	a	decrease	of	the	polydispersity	
index,	 indicating	 that	 at	 high	 temperatures	 the	 micelle	 population	 has	 a	 better	
monodispersity.	 This	 is	 in	 line	with	expectation	–	micellar	 assembly	occurs	 through	 the	
entropically	driven	hydrophobic	effect,	which	will	be	favoured	at	elevated	temperatures.					
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Table	4.1.	Average	hydrodynamic	diameter,	zeta	potential	and	polydispersity	index	(PdI)	
of	C16-DAPMA	micelles	at	25	°C	and	70	°C.	
	 Micelles	at	25	°C	 Micelles	at	70	°C	
Z-Ave	(nm)	 6.2	±	1.3	 5.6	±	0.2	
PdI	 0.63	±	0.02	 0.13	±	0.04	
ζ	Potential	(mV)	 51.7	±	2.2	 49.7	±	6.9	
	
The	interactions	between	C16-DAPMA	and	heparin	were	then	studied	at	85	°C	using	a	MalB	
assay.	As	described	in	Chapter	2,	when	free	in	solution,	MalB	presents	a	characteristic	UV-
Vis	band	with	a	maximum	absorbance	at	615	nm.	When	interacting	with	heparin,	this	UV-
Vis	 band	 decreases	 substantially	 in	 intensity.	 Therefore,	 if	 MalB	 is	 displaced	 from	 its	
complex	with	heparin	by	 the	 interaction	of	heparin	with	another	molecule,	 this	 can	be	
easily	verified	by	an	increase	in	the	absorbance.	As	discussed	in	Chapter	2,	C16-DAPMA	is	
an	effective	heparin	binder	at	room	temperature,	and	in	order	to	understand	the	influence	
of	high	temperature	on	heparin-C16-DAPMA	interactions,	a	solution	of	C16-DAPMA	was	
heated	to	85	°C	in	an	oil	bath	and	added	into	a	MalB	solution	with	heparin.	In	addition,	a	
solution	containing	C16-DAPMA	micelles	interacting	with	heparin	was	also	heated	at	85	°C	
for	10	min	and	added	into	a	solution	of	free	MalB.	The	absorbance	spectra	were	recorded	
and	compared	with	the	spectra	obtained	for	the	same	conditions	at	25	°C	(Figure	4.2).		
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Figure	4.2.UV-Vis	spectra	of	MalB	free	in	solution,	with	heparin	and	in	the	presence	of	
C16-DAPMA,	at	25	°C	and	85	°C.	
	
From	the	obtained	results	it	is	evident	that	for	both	situations	tested	at	high	temperature,	
the	 MalB	 band	 absorbance	 increased	 in	 intensity	 when	 the	 C16-DAPMA	 was	 present,	
indicating	that	the	MalB	is	displaced	from	its	complex	and	thus	C16-DAPMA	is	interacting	
with	heparin	at	85	°C.		
	
In	conclusion,	the	characteristics	of	C16-DAPMA	and	its	interactions	with	heparin	do	not	
appear	 to	 be	 affected	 with	 high	 temperatures.	 Therefore,	 studies	 proceeded	 with	 the	
incorporation	of	heparin	and	C16-DAPMA	into	the	DBS-CONHNH2	hydrogels	via	a	heat-cool	
cycle.	
	
Gel	Formation	with	different	Concentrations	of	Heparin	
In	 order	 to	 initially	 and	 quickly	 test	 the	 influence	 of	 heparin	 on	 the	 formation	 of	 the	
hydrazide	gel,	different	concentrations	of	heparin	(38	µM;	150	µM;	300	µM;	400	µM;	600	
µM)	 were	 added	 to	 DBS-CONHNH2.	 From	 all	 concentrations	 tested,	 stable	 and	
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homogeneous	gels	were	obtained,	indicating	that	the	presence	of	heparin	does	not	prevent	
self-assembly	of	the	gelator.	
	
Gel	Formation	with	Different	Concentrations	of	C16-DAPMA	
Different	concentrations	of	C16-DAPMA	(150	µM;	300	µM;	600	µM;	800	µM;	1000	µM;	
1200	µM)	were	also	added	to	DBS-CONHNH2	gels	in	order	to	observe	their	influence	on	gel	
formation.	 Once	 more,	 for	 all	 the	 concentrations	 used,	 the	 formation	 of	 stable	 and	
homogeneous	gels	was	observed.	This	indicates	that	the	presence	of	C16-DAPMA	micelles	
does	not	 interfere	 in	the	self-assembly	of	 the	DBS-CONHNH2	gelator.	This	 is	contrary	to	
what	 was	 observed	 with	 DBS-COOH	 LMWG	 and	 highlights	 our	 previous	 suggestion	 in	
Chapter	3	that	acid-amine	interactions	were	the	reason	C16-DAPMA	inhibited	the	gelation	
of	DBS-COOH.	
	
Gel	Formation	with	Constant	Concentrations	of	Heparin	and	Different	Concentrations	of	
C16-DAPMA	
Gel	 formation	 was	 also	 tested	 by	 keeping	 the	 heparin	 concentration	 constant	 and	
increasing	C16-DAPMA	concentration	in	order	to	verify	the	optimal	charge	ratio	of	these	
two	molecules	for	formation	of	stable	gels.	For	heparin	concentrations	of	150	µM,	300	µM,	
400	µM	and	600	µM	a	maximum	of	600	µM,	1200	µM,	1600	µM	and	2400	µM	of	C16-
DAPMA	was	used,	respectively,	and	concentrations	below	these	values	were	also	tested	
(Table	4.2).	These	maximum	values	correspond	to	charge	ratios	+/-	of	2.	
	
Table	4.2.	Test	of	different	heparin/binder	ratio	in	gel	formation.	
[Heparin]	(µM)	 [C16-DAPMA]	(µM)	 Gel	Formation	
150	 Below	600	 Stable	gel	
300	 Below	1200	 Stable	gel	
400	 Below	1600	 Stable	gel	
	
600	
Above	1600	 Non	uniform	gel	
Below	1500	 Stable	gel	
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It	was	verified	 that	 for	heparin	 concentrations	below	400	µM	 the	use	of	 the	maximum	
concentrations	of	C16-DAPMA	calculated	still	gave	rise	to	the	formation	of	stable	gels,	as	
did	concentrations	below	that.	For	600	µM	of	heparin,	only	concentrations	of	C16-DAPMA	
below	1500	µM	led	to	the	formation	of	stable	gels,	with	higher	concentrations	resulting	in	
gels	with	the	presence	of	aggregates	or	unstable	gels	(Figure	4.3).			
	
	
Figure	4.3.	DBS-CONHNH2	(0.4%	w/v)	gel	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer:	stable	
and	uniform	gel	(left),	non-uniform	gel	(centre)	and	unstable	gel	(right).	
	
Therefore,	 the	 incorporation	 of	 C16-DAPMA	 interacting	with	 heparin	 did	 not	 affect	 gel	
formation,	but	at	higher	heparin/C16-DAPMA	concentrations	non-uniform	or	unstable	gels	
resulted.	This	may	relate	to	the	fact	that	at	higher	heparin/C16-DAPMA	concentrations,	
more	 larger	 aggregates	will	 be	present,	 and	 the	dispersity	of	 these	 aggregates	become	
greater.	We	suggest	the	self-assembly	of	the	DBS-CONHNH2	becomes	more	sensitive	to	the	
excess	aggregates.	Thus,	it	is	believed	that	on	increasing	the	heparin	concentration	a	lower	
molar	ratio	between	C16-DAPMA	and	heparin	is	needed	(Table	4.3),	limiting	the	formation	
of	aggregates	that	may	affect	gel	formation.						
	
Table	4.3.	Binder/Heparin	molar	ratio	and	charge	ratio	+/-	with	increasing	heparin	
concentration.	
[Heparin]	(µM)	 Binder/Heparin	Molar	Ratio	 Charge	ratio	+/-	
38	 4:1	 2.0	
150	 4:1	 2.0	
300	 4:1	 2.0	
400	 4:1	 2.0	
600	 2.5:1	 1.2	
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4.3.1. Thermal	Stability	and	Tgel	Determination	
The	thermal	stability	of	the	gels	formed	in	the	previous	section	was	tested	by	simple	tube	
inversion	methodology.	The	Tgel	was	considered	to	be	the	temperature	when	the	gel	starts	
to	deform	and	starts	to	slip	in	the	vial	walls	when	it	is	turned	upside	down.	
	
DBS-CONHNH2	(0.4%	w/v)	gel	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	presented	a	Tgel	value	
of	86	°C.	For	the	different	concentrations	of	heparin	tested	in	DBS-CONHNH2	gel,	the	Tgel	
values	obtained	were	between	83-86	°C,	proving	that	the	incorporation	of	heparin	does	
not	 affect	 significantly	 the	 thermal	 stability	 of	 the	 gel.	 The	 same	was	 observed	 for	 the	
different	concentrations	of	C16-DAPMA	with	Tgel	 values	also	between	83-86	°C.	For	 the	
different	concentrations	of	C16-DAPMA	with	constant	heparin	concentrations	 (150	µM;	
300	µM;	400	µM;	600	µM)	that	resulted	in	uniform	and	stable	gels,	the	Tgel	values	were	
approximately	66	°C,	below	the	Tgel	value	of	DBSCONHNH2	gel,	indicating	that	the	presence	
of	C16-DAPMA	and	heparin	aggregates	somewhat	affects	the	thermal	stability	of	the	gel,	
consistent	 with	 the	 view	 that	 that	 hierarchical	 aggregates	 may	 somewhat	 hinder	 gel	
network	formation.		
	
4.3.2. Infrared	Characterisation		
IR	characterisation	was	performed	for	the	gel	formed	with	DBS-CONHNH2	(0.4%	w/v)	alone,	
in	the	presence	of	300	µM	of	heparin,	1200	µM	of	C16-DAPMA	and	in	the	presence	of	300	
µM	 of	 heparin	 and	 1200	 µM	 of	 C16-DAPMA	 (Figure	 4.4).	 By	 comparing	 the	 obtained	
spectra,	 it	 is	 possible	 to	 observe	 that	 the	 expected	 peaks	 are	 present	 in	 the	 multi-
component	gel	and	that	the	spectrum	corresponds	to	simple	overlap	of	IR	spectra	of	the	
three	 compounds.	Additionally,	 the	 IR	 spectra	of	DBS-CONHNH2	with	heparin	 and	DBS-
CONHNH2	 with	 C16-DAPMA	 also	 correspond	 to	 the	 overlap	 between	 the	 typical	 IR	
frequencies	of	each	molecule.	In	respect	to	the	multi-component	gel,	a	strong	peak	appears	
at	3182	cm-1	which	is	characteristic	of	the	N-H	stretching.	C-H	stretches	at	2981	and	2943	
cm-1	are	present,	as	well	as	C=O	stretch	at	1629	cm-1.	At	1505	and	1406	cm-1,	C=C	stretches	
from	the	aromatic	rings	of	DBS	is	observed	and	at	1400	cm-1	the	presented	peak	overlaps	
with	the	carboxylate	peak	of	heparin.	Between	1300	and	1120	cm-1	several	peaks	from	DBS	
sugar	are	noticeable.	At	1095	cm-1	a	strong	peak	is	verified	and	probably	corresponding	to	
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the	overlap	of	S=O	stretch	and	C-O	stretch.	Due	to	the	fact	that	several	IR	frequencies	are	
common	in	the	three	compounds	that	formed	the	gel	an	overlap	of	the	characteristic	peaks	
of	each	molecule	occurred.	This	indicates	that	each	component	can	behave	independently	
when	the	gel	is	formed	and	there	are	no	molecular	scale	interactions	between	the	different	
components	in	the	multi-component	gels.		
	
	
Figure	4.4.	IR	spectra	of	xerogels	formed	by	DBS-CONHNH2	gel	(blue	line);	DBS-CONHNH2	
gel	with	300	µM	of	heparin	(red	line);	DBS-CONHNH2	gel	with	1200	µM	C16-DAPMA	
(dashed	orange	line)	and	DBS-CONHNH2	gel	with	1200	µM	of	C16-DAPMA	and	300	µM	of	
heparin	(green	line).	
	
4.3.3. Study	of	Gel	Formation	Kinetics	
Following	 the	 incorporation	 of	 heparin	 and	 C16-DAPMA	 within	 the	 DBS-CONHNH2	 gel	
network,	the	influence	of	the	addition	of	these	components,	individually	and	as	aggregates,	
on	the	self-assembly	kinetics	of	DBS-CONHNH2	nanofibers	was	investigated.		
	
Circular	Dichroism		
CD	studies	were	performed	to	follow	the	kinetics	of	growth	of	the	self-assembled	fibrillary	
network	of	(a)	DBS-CONHNH2,	DBSCONHNH2	in	the	presence	of	(b)	heparin,	as	well	as	in	
the	presence	of	(c)	C16-DAPMA	and	in	the	presence	of	(d)	both	heparin	and	C16-DAPMA.	
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It	 is	 noteworthy	 that	 DBS-CONHNH2	 undergoes	 gelation	 immediately	 after	 heating	 and	
therefore,	the	CD	cuvette	was	incubated	at	90	°C	prior	to	the	transfer	of	its	hydrosol	into	
the	cuvette	and	the	beginning	of	kinetic	measurements.	From	the	obtained	data	(Figure	
4.5)	the	presence	of	an	absorbed	left-handed	circularly	polarized	light	at	approximately	275	
nm	was	observed,	with	increased	intensity	over	time	for	all	the	tested	gels.	This	indicates	
that	π-π	stacking	of	the	aromatic	rings	of	the	gelator	occurs	in	all	cases	consistent	with	the	
formation	of	self-assembled	nanofibers.	However,	it	is	possible	to	observe	differences	in	
the	intensities	of	the	gels.						
	
	
Figure	4.5.	Kinetic	studies	of	the	growth	of	DBSCONHNH2	fibrillar	network	over	time,	
using	CD	spectroscopy.	(a)	DBS-CONHNH2;	(b)	DBS-CONHNH2	in	the	presence	of	heparin;	
(c)	DBS-CONHNH2	in	the	presence	of	C16-DAPMA	and	(d)	DBS-CONHNH2	in	the	presence	
of	C16-DAPMA	and	heparin.	
The	intensity	of	the	CD	band	at	275	nm	was	plotted	against	time	for	the	gels	in	the	four	
different	conditions	(Figure	4.6).	For	all	conditions	rapid	self-assembly	of	the	gelator	fibers	
was	observed,	reaching	a	maximum	intensity	after	approximately	300	seconds.	However,	
the	 presence	 of	 heparin	 led	 to	 a	 decrease	 in	 intensity	 when	 compared	 with	 the	 DBS-
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CONHNH2	gel,	indicating	an	influence	on	fiber	formation,	despite	the	similar	rate	of	fibers	
growth.	Identical	behaviour	was	observed	when	C16-DAPMA	was	present	in	the	gel.	The	
incorporation	of	both	C16-DAPMA	and	heparin	in	the	gel	revealed	a	significant	decrease	of	
the	absorbance	 intensity	when	compared	to	 the	DBS-CONHNH2	gel,	 suggesting	 that	 the	
presence	of	the	aggregates	may	inhibit	gel	fiber	assembly,	specifically	in	terms	of	chirality	
or	helical	twist.	This	corroborates	with	the	lower	Tgel	obtained	for	this	system	that	indicated	
same	influence	of	the	C16-DAPMA	and	heparin	aggregates	on	the	thermal	stability	of	this	
gel.	
	
	
Figure	4.6.	CD	intensity	at	275	nm	of	DBS-CONHNH2,	DBS-CONHNH2	in	the	presence	of	
heparin,	DBS-CONHNH2	in	the	presence	of	C16-DAPMA	and	DBS-CONHNH2	in	the	
presence	of	C16-DAPMA	and	heparin,	over	15	minutes.	
	
4.3.4. Mallard	Blue	Diffusion	Assay	
To	obtain	a	better	understanding	of	 the	 interactions	between	C16-DAPMA	and	heparin	
incorporated	within	the	DBS-CONHNH2	gel,	MalB	(25	µM)	solution	was	placed	on	top	of	
gels	(Figure	4.7)	containing	only	DBS-CONHNH2	(0.3%	w/v),	DBS-CONHNH2	(0.3%	w/v)	with	
38	µM	heparin,	DBS-CONHNH2	(0.3%	w/v)	with	150	µM	C16-DAPMA	and	DBS-CONHNH2	
(0.3%	w/v)	with	150	µM	C16-DAPMA	and	38	µM	heparin.	The	variations	in	intensity	of	MalB	
in	the	solution	on	top	of	the	four	different	gels	were	studied	over	three	days	by	UV-Vis.		
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Figure	4.7.	DBS-CONHNH2	gel	with	MalB	solution	on	top.		
	
Figure	4.8	 shows	 the	DBS-CONHNH2	gel	 sample	after	 three	days	where	 it	 is	possible	 to	
verify	the	presence	of	a	blue	colour	in	the	gel,	which	is	due	to	natural	dilution	phenomena	
that	resulted	in	a	decrease	of	MalB	absorbance	present	in	the	solution	supernatant	(Figure	
4.10).	The	predicted	dilution	factor	in	the	absence	of	MalB	binding	to	heparin,	is	50%.	It	is	
noteworthy	that	of	the	four	tested	samples,	the	only	one	presenting	a	greater	decrease	in	
MalB	absorbance	was	the	gel	with	only	heparin	incorporated	(Figure	4.9).	It	was	observed	
that	instead	of	a	uniform	dispersion	of	MalB	over	the	gel,	a	deep	blue	ring	on	the	surface	
of	the	gel	was	formed,	providing	evidence	that	the	MalB	is	 interacting	with	heparin	and	
thus	does	not	diffuse	into	the	gel	in	the	same	way	as	for	the	other	samples.		
	
	
Figure	4.8.	DBS-CONHNH2	gel	with	MalB	solution	on	top	after	72	h.		
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Figure	4.9.	DBS-CONHNH2	gel	in	the	presence	of	heparin	with	MalB	solution	on	top	after	
72	h.	
	
From	 Figure	 4.10	 and	 using	 the	 sample	 containing	 DBS-CONHNH2	 gel	 as	 a	 control	
experiment,	it	is	possible	to	verify	that	the	samples	with	C16-DAPMA	and	C16-DAPMA	with	
heparin	resulted	in	a	smaller	decrease	of	MalB	absorbance	over	time	when	compared	with	
DBS-CONHNH2	gel,	that	may	correspond	to	the	fact	that	as	the	gels	have	more	components	
within	 the	network	 it	 becomes	more	difficult	 for	 the	MalB	 to	diffuse	 into	 the	 gel,	 thus	
resulting	 in	 a	 lower	 dilution	 and	 higher	 absorbance.	 On	 the	 other	 hand,	 when	 DBS-
CONHNH2	gel	contains	heparin	it	is	noticeable	a	higher	decrease	of	the	MalB	absorbance	
over	 time,	 when	 compared	 with	 DBS-CONHNH2	 gel.	 This	 may	 indicate	 that	 MalB	 is	
interacting	with	the	free	heparin	present	in	the	gel,	and	binding	to	heparin	released	from	
the	gel,	resulting	in	a	lower	absorbance	of	MalB.	Importantly,	when	C16-DAPMA	is	present,	
MalB	no	longer	interacts	with	heparin	and	thus	a	higher	absorbance	is	observed	over	time.	
Therefore,	C16-DAPMA	and	heparin	interactions	are	maintained	when	incorporated	into	
the	multi-component	gel.	
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Figure	4.10.	Normalised	absorbance	of	MalB	at	615	nm	over	time	when	placed	on	top	of	
DBS-CONHNH2;	DBS-CONHNH2	with	heparin;	DBS-CONHNH2	with	C16-DAPMA	and	DBS-
CONHNH2	with	heparin	and	C16-DAPMA.	
	
4.3.5. Electron	Microscopy	
TEM	and	SEM	images	of	DBS-CONHNH2	gel,	DBS-CONHNH2	gel	in	the	presence	of	heparin,	
or	C16-DAPMA	and	 in	 the	presence	of	both	heparin	and	C16-DAPMA	were	obtained,	 in	
order	to	better	understand	the	morphology	and	behaviour	of	these	four	different	systems.	
TEM	 images	 of	 DBS-CONHNH2	 gel	 (Figure	 4.11)	 showed	 the	 presence	 of	 twisted	 and	
branched	 nanofibers,	 proving	 the	 self-assembly	 of	 this	 gelator	 into	 1D	 fibers	 in	 water.	
When	 heparin	 was	 present	 within	 the	 gel	 (Figure	 4.12)	 it	 was	 possible	 to	 observe	 the	
presence	of	 the	twisted	 fibers	as	well	as	 large	unspecific	aggregates	 that	correspond	to	
heparin.	 This	 appears	 to	 indicate	 that	 there	 are	 no	 interactions	 occurring	 between	 the	
gelator	and	heparin	when	the	 former	 is	 self-assembling.	This	 is	 in	contrast	 to	what	was	
observed	with	DBS-COOH	 in	Chapter	3.	The	 incorporation	of	C16-DAPMA	 into	 the	DBS-
CONHNH2	gel	(Figure	4.13)	appears	to	have	a	similar	effect.	Once	more,	 it	 is	possible	to	
distinguish	the	presence	of	nanofibers	along	with	undefined	agglomerates	that	correspond	
to	 self-assembled	 C16-DAPMA	 micelles.	 It	 is	 noteworthy	 that	 due	 to	 the	 difficulty	 of	
imaging	these	micelles	using	TEM,	it	was	hard	to	obtain	images	with	good	quality	and	with	
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clear	micellar	morphology.	Nevertheless,	we	can	conclude	that	no	significant	interactions	
appear	to	occur	between	the	two	components.									
	
	
Figure	4.11.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel.	Scale	bars:	100	nm	(left)	and	
200	nm	(right).	
	
	
Figure	4.12.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	heparin	(38	
µM).	Scale	bars:	1	µM	(left)	and	200	nm	(right).	
	
Chapter	4	
	
	
	
162	
	
Figure	4.13.	TEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM).	Scale	bars	=	200	nm	(left)	and	50	nm	(right).	
	
Figure	4.14	presents	a	TEM	image	of	DBS-CONHNH2	gel	formed	in	the	presence	of	both	
C16-DAPMA	and	heparin,	where	it	is	possible	to	identify	nanofibers	of	DBS-CONHNH2	and	
aggregates.	 The	 observed	 aggregates	 showed	 a	 highly	 organised	 semi	 crystalline	
nanostructure	 (Figure	 4.15),	 characteristic	 of	 the	 hierarchical	 systems	 formed	 by	 C16-
DAPMA	when	 binding	 to	 heparin	 (as	 described	 in	 Chapter	 2).	 Therefore,	 the	 obtained	
images	 proved	 the	maintenance	 of	 the	 interactions	 between	 heparin	 and	 C16-DAPMA	
when	the	gel	is	formed	and	also	provides	evidence	of	the	orthogonal	self-assembly	of	this	
multi-component	gel.					
	
	
Figure	4.14.	TEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM)	and	heparin	(38	µM).	Scale	bar	=	1	µM.	
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Figure	4.15.	TEM	image	of	the	aggregates	observed	in	the	DBS-CONHNH2	(0.4%	w/v)	gel	
in	the	presence	of	C16-DAPMA	(150	µM)	and	heparin	(38	µM).	Scale	bar:	100	nm.	
	
However,	in	addition	to	the	nanofibers	and	hierarchical	aggregates	shown	in	Figure	4.14,	it	
was	 also	 possible	 to	 identify	 some	 large	 and	 aligned	 structures	 (Figure	 4.16)	 that	may	
correspond	 to	 a	 different	 organization	 of	 the	 DBS-CONHNH2	 fibers.	 These	 different	
morphologies	are	better	explained	using	the	SEM	images	described	below.				
	
	
Figure	4.16.	TEM	images	of	Scale	bars	=	500	nm	(left)	and	200	nm	(right).	
	
SEM	 images	of	DBS-CONHNH2	gel	 (Figure	4.17)	 showed	a	network	 structure	comprising	
nanofibers,	which	 supports	 the	 corresponding	 TEM	 images.	 In	 the	 presence	 of	 heparin	
(Figure	4.18)	it	was	possible	to	observe	once	more	the	formation	of	fibers	but	thicker	than	
the	nanofibers	of	DBS-CONHNH2	gel,	presenting	a	width	of	66	±	1	nm	with	heparin	and	38	
±	3	nm	for	the	gel	alone.	This	may	be	due	to	the	fact	that	heparin	is	surrounding	the	fibers	
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on	drying	and	in	this	way	they	become	larger,	however	no	interactions	should	be	occuring	
between	the	two	components	as	shown	in	the	TEM	images.	When	C16-DAPMA	is	present	
in	the	gel	(Figure	4.19)	we	observe	the	existence	of	nanofibers	with	a	similar	width	as	for	
the	DBS-CONHNH2	gel	alone	(40	±	1	nm).	The	detection	of	the	C16-DAPMA	micelles	was	
not	possible	because	they	present	a	very	small	size	average	(6	nm).	It	is	known	that	this	
micelles	are	difficult	 to	 image	using	 this	 technique.	However,	no	 interactions	appear	 to	
exist	 between	 the	C16-DAPMA	and	 the	DBS-CONHNH2,	 as	 the	nanofiber	morphology	 is	
similar	to	that	obtained	for	the	gel	alone,	in	agreement	with	the	TEM	images.						
	
	
Figure	4.17.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel.	
	
Figure	4.18.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	heparin	(38	
µM).	
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Figure	4.19.	SEM	image	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM).	
	
SEM	 images	 of	DBS-CONHNH2	with	 both	 heparin	 and	C16-DAPMA	 incorporated	 (Figure	
4.20)	revealed	the	presence	of	gel	nanofibers	but	also	thicker	structures	(916	±	213	nm)	
that	resemble	needles.	A	closer	look	at	these	structures	showed	what	appears	to	be	a	rigid	
alignment	 of	 gel	 nanofibers.	We	 suggest	 this	 alignment	may	 be	 induced	 by	 the	 highly	
organised	hierarchical	nanostructures	 formed	when	C16-DAPMA	 interacts	with	heparin.	
With	 these	 SEM	 images	 we	 could	 obtain	 a	 better	 understanding	 of	 the	 different	
morphologies	obtained	in	the	corresponding	TEM	images.	This	morphology	would	support	
the	lower	thermal	stability	and	smaller	CD	signal	obtained	for	this	system.	We	propose	that	
the	presence	of	C16-DAPMA	micelles	interacting	with	heparin	has	some	influence	on	the	
self-assembly	and	hierarchical	organisation	of	the	DBS-CONHNH2	fibers.						
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Figure	4.20.	SEM	images	of	DBS-CONHNH2	(0.4%	w/v)	gel	in	the	presence	of	C16-DAPMA	
(150	µM)	and	heparin	(38	µM).	
	
4.3.6. Rheology	
The	viscoelastic	properties	of	DBS-CONHNH2	gel	alone,	in	the	presence	of	1	mM	of	heparin,	
2	mM	of	C16-DAPMA	and	1	mM	of	heparin	bound	to	2	mM	of	C16-DAPMA,	were	each	
studied	by	rheology.	Additionally,	the	viscoelastic	properties	of	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	were	also	studied.	The	addition	of	a	PG	can	help	to	strengthen	the	gel	
network	 of	 LMWGs,	 specifically,	 agarose	 that	 is	 a	 well-known	 biocompatible	 polymer	
gel.97,261,262	As	described	in	Chapter	3,	this	technique	allowed	us	to	understand	how	the	
mechanical	properties	of	DBS-CONHNH2	hydrogels	can	be	affected	by	the	incorporation	of	
heparin	and	C16-DAPMA	and	also	by	the	presence	of	a	strengthening	PG.	To	that	purpose,	
the	storage	or	elastic	modulus	(G’)	and	the	loss	or	viscous	modulus	(G’’)	of	the	material	
were	 obtained,	 through	 the	 application	 of	 oscillating	 strains.	 If	 the	material	 presents	 a	
higher	 G’	 than	 G’’	 with	 low	 frequency	 dependency	 it	 has	 mechanical	 properties	
characteristic	of	a	gel.256,257		
	
Figure	 4.21	 shows	 the	 strain	 amplitude	 dependence	 of	 G’	 and	 G’’	 for	 0.4%	 w/v	 DBS-
CONHNH2	gels,	where	it	is	possible	to	observe	a	LVR	up	to	approximately	1%	strain	when	
C16-DAPMA	is	incorporated	within	the	network	and	approximately	2.5%	for	all	the	other	
conditions.	 These	 results	 indicate	 that	 the	DBS-CONHNH2	gel	with	C16-DAPMA	 is	a	 less	
stable	material	on	the	macroscopic	level,	with	the	disruption	of	its	structure	occurring	at	
lower	strains	than	for	the	other	tested	conditions,	despite	the	presence	of	C16-DAPMA	not	
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affecting	the	stiffness	of	the	gel	network	as	the	G’	value	was	in	fact	slightly	higher	(from	
2150	Pa	for	the	gel	alone	to	2820	Pa	for	the	gel	with	C16-DAPMA).	This	may	be	due	to	the	
fact	that	as	C16-DAPMA	is	a	surfactant	it	forms	some	foam,	which	results	in	the	presence	
of	holes	in	the	gel	(Figure	4.22)	that	will	contribute	to	a	weaker	and	therefore,	less	stable	
macroscopic	 gel	 network.	 However,	 when	 heparin	 or	 heparin/C16-DAPMA	 aggregates	
were	present	within	DBS-CONHNH2	gels,	the	LVR	of	the	gel	was	not	affected,	meaning	that	
the	incorporation	of	these	components	did	not	affect	the	stability	of	the	gel	material.	As	
such	if	the	self-assembling	C16-DAPMA	is	bound	to	heparin,	it	no	longer	limits	the	LVR	of	
the	gel.	
	
Additionally,	and	contrarily	to	what	was	observed	with	DBS-COOH,	the	presence	of	heparin	
and	heparin-C16-DAPMA	aggregates	resulted	in	an	increase	of	G’	from	approximately	2150	
Pa	to	approximately	4100	Pa,	indicating	that	the	addition	of	these	components	increased	
the	stiffness	of	DBS-CONHNH2	gel.			
	
	
Figure	4.21.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBSCONHNH2	gel	(),	DBSCONHNH2	gel	with	heparin	(△),	DBSCONHNH2	gel	
with	C16-DAPMA	(◇)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	
Frequency	=	1	Hz.				
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Figure	4.22.	DBS-CONHNH2	gel	with	C16-DAPMA.	
	
When	1%	w/v	agarose	was	added	into	0.4%	w/v	DBS-CONHNH2	gels	(Figure	4.23),	a	large	
increase	 of	 G’	 from	 approximately	 3800	 Pa	 to	 15000	 Pa	 was	 observed,	 indicating	 the	
presence	of	a	much	stiffer	gel,	resulting	from	the	robustness	of	agarose.	However,	the	LVR	
only	 reaches	approximately	2%	of	 strain.	When	heparin	was	added	 to	DBS-CONHNH2	in	
agarose,	 the	 G’	 decreases	 to	 approximately	 3800	 Pa	 again	 but	 the	 stability	 increases,	
presenting	the	highest	LVR	of	all	tested	materials	(stable	to	approximately	4%	of	strain).		
	
	
Figure	4.23.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	DBSCONHNH2	gel	with	agarose	()	and	DBSCONHNH2	gel	with	agarose	and	
heparin	(△).	Frequency	=	1	Hz.				
	
The	frequency	dependence	of	DBS-CONHNH2	in	the	same	conditions	described	above	was	
also	tested,	as	shown	in	Figure	4.24.	The	incorporation	of	heparin,	C16-DAPMA	or	both,	did	
not	influence	the	gel	mechanical	properties	when	different	frequencies	were	applied	to	the	
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samples,	 exhibiting	 a	 storage	 modulus	 higher	 than	 the	 loss	 modulus	 (G’	 >	 G’’)	 and	 a	
frequency	 independence	 up	 to	 ca.	 25	 Hz.	 Therefore,	 DBS-CONHNH2	 gel	 alone	 and	
incorporating	different	 components	 has	 the	 characteristics	 of	 a	 typical	 gel-like	material	
with	 no	 changes	 in	 the	 viscoelastic	 properties	 from	 0.1	 to	 25	 Hz.	 A	 similar	 frequency	
dependence	was	observed	when	1%	of	agarose	was	added	to	DBS-CONHNH2	gel	and	DBS-
CONHNH2	gel	with	heparin,	as	shown	in	Figure	4.25.	
				
		
	
Figure	4.24.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBSCONHNH2	gel	(),	DBSCONHNH2	gel	with	heparin	(△),	DBSCONHNH2	gel	with	
C16-DAPMA	(¯)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	Amplitude	
strain	=	0.1%.				
	
100
1000
10000
0.1 1 10 100
G'
/	P
a,
G'
'/
	P
a
Frequency/	Hz
Chapter	4	
	
	
	
170	
	
Figure	4.25.	Frequency	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBSCONHNH2	gel	with	agarose	(○)	and	DBSCONHNH2	gel	with	agarose	and	heparin	(
△).	
	
Figure	4.26	shows	the	temperature	dependence	of	the	G’	and	G’’	on	heating	DBS-CONHNH2	
gel	alone,	with	heparin,	with	C16-DAPMA,	and	with	both	heparin	and	C16-DAPMA.	For	DBS-
CONHNH2	gel	it	is	possible	to	observe	the	disruption	of	the	gel	network	at	approximately	
60	°C.	Strangely,	above	65	°C	the	gel	appears	to	recover	its	structure,	with	G’	becoming	
higher	 than	 G’’	 again.	 The	 experiment	 was	 repeated	 to	 verify	 its	 reproducibility	 and	 a	
similar	 result	 was	 obtained.	 This	 may	 indicate	 some	 thermal	 reorganisation	 of	 the	
nanofibers	 and	 the	 ability	 to	 self-heal.	 However,	 further	 studies	 would	 need	 to	 be	
performed	to	ensure	that	this	unusual	feature	is	a	characteristic	of	this	gelator.	In	addition,	
an	identical	temperature	dependence	behaviour	up	to	60	°C	is	observed	when	heparin	is	
incorporated	 within	 the	 gel,	 but	 the	 gel	 structure	 becomes	 completely	 lost	 at	
approximately	60	°C.	For	DBS-CONHNH2	gel	with	C16-DAPMA	the	storage	modulus	remains	
higher	than	the	loss	modulus	from	25	to	80	°C,	indicating	a	solid-like	behaviour	of	the	gel	
across	 the	whole	 temperature	 range	 tested,	however	 it	 is	 possible	 to	observe	a	 steady	
decrease	of	G’	with	the	increase	of	temperature	(G’=3.09x103	Pa	at	25°C	and	G’=1.72x103	
Pa	at	80°C),	 indicating	changes	 in	the	viscoelastic	properties	of	 the	gel	and	possibly	the	
breakdown	 of	 the	 gel	 structure	 at	 higher	 temperatures.	When	 both	 heparin	 and	 C16-
DAPMA	aggregates	are	incorporated	within	the	gel	network,	the	gel	reveals	temperature	
independent	behaviour	across	the	tested	range,	with	G’	higher	than	G’’	from	25	to	80	°C.	
Overall	this	suggests	good	stability	of	these	gels	in	terms	of	mechanical	performance	once	
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both	C16-DAPMA	and	heparin	are	incorporated.	However,	it	should	be	noted	that	these	
values	are	not	in	agreement	with	the	Tgel	values	obtained	in	section	4.3.1.	This	may	be	due	
to	the	fact	that	different	concentrations	of	heparin	and	C16-DAPMA	were	used	along	with	
different	gel	volumes	for	each	experiment.	For	accurate	comparison	identical	experimental	
conditions	would	be	required.					
	
	
Figure	4.26.	Temperature	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	(G’’)	
for	DBSCONHNH2	gel	(),	DBSCONHNH2	gel	with	heparin	(△),	DBSCONHNH2	gel	with	
C16-DAPMA	(◇)	and	DBSCONHNH2	gel	with	heparin	and	C16-DAPMA	(£).	Amplitude	
strain	=	0.1%,	Frequency	=	1	Hz.	
	
4.4. Release	Studies	
To	 understand	 whether	 heparin	 could	 be	 released	 from	 DBS-CONHNH2	 hydrogels	 and	
determine	how	its	release	could	be	controlled,	different	release	assays	were	performed.	
The	release	of	heparin	from	these	LMWG	hydrogels	is	of	great	importance,	as	it	is	intended	
to	 have	 heparin	 contacting	 cells	 in	 a	 controlled	 way	 so	 its	 angiogenic	 properties	 can	
promote	cell	growth.		
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Heparin	release:	Buffer	on	top	of	the	gel	
As	described	on	Chapter	3,	heparin	release	from	the	hydrogels	was	obtained	by	placing	1	
mL	of	buffer	on	top	of	3	mL	of	hydrogel	incorporating	1	mM	of	heparin,	as	shown	in	Figure	
4.27.	 Aliquots	 of	 buffer	 were	 removed	 over	 time,	 added	 into	 MalB	 solution	 and	 the	
absorbance	measured.		
	
	
Figure	4.27.	DBS-CONHNH2	hydrogel	containing	1	mM	of	heparin,	with	10	mM	Tris-HCl/	
150	mM	NaCl	buffer	on	top	for	monitoring	the	release	of	heparin.	
	
Figure	4.28	shows	the	release	profile	of	heparin	from	DBS-CONHNH2	gels	containing	just	
heparin	and	also	those	in	which	heparin	is	interacting	with	C16-DAPMA.	When	just	heparin	
is	 present	 within	 the	 gel	 network,	 it	 is	 possible	 to	 observe	 a	 gradual	 increase	 of	 the	
percentage	of	heparin	being	released	into	the	buffer,	reaching	a	maximum	of	62%	after	72	
hours.	The	incorporation	of	C16-DAPMA	into	the	gel	resulted	in	significantly	lower	heparin	
release	over	time	(only	24%	after	72h).	Therefore,	C16-DAPMA	is	inhibiting	the	release	of	
heparin	 by	 binding	 it	 into	 hierarchical	 aggregates.	 In	 this	way,	 it	 should	 be	 possible	 to	
trigger	 the	 release	 of	 heparin	 by	 degrading	 the	 binder	 or	 adding	 a	 biocompatible	
competitor	that	will	preferentially	interact	with	the	binder,	hence	releasing	the	heparin.	It	
is	worth	noting,	however,	 that	 for	DBS-COOH	 (Chapter	3)	 the	 release	was	0%	 from	 the	
hydrogel	with	heparin-C16-DAPMA	aggregates.	We	suggest	that	the	release	observed	for	
DBS-CONHNH2	hydrogel	in	the	presence	of	heparin	and	C16-DAPMA	is	related	with	the	gel	
preparation	method,	as	when	heating	larger	volumes	of	sample	(3	mL	instead	of	1	mL)	it	
was	possible	to	observe	the	formation	of	foam	which	is	characteristic	of	C16-DAPMA	free	
in	solution.	Consequently,	this	may	indicate	the	presence	of	some	heparin	within	the	gel	
network	that	is	not	interacting	with	the	binder	and	is	released.		
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Figure	4.28.	Heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	
heparin	(▲)	and	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	heparin	interacting	
with	2	mM	C16-DAPMA	(■).	
	
	
In	an	attempt	to	trigger	the	release	of	heparin	from	the	gel	network	when	bound	to	C16-
DAPMA,	negatively	charged	molecules,	such	as	sodium	dodecylsulfonate	(SDS)	and	sodium	
dodecylbenzenesulfonate	(SDBS)	(Figure	4.29	and	4.30)	were	added	to	the	buffer	placed	
on	 top	 of	 the	 hydrogels	 containing	 heparin-C16-DAPMA	 aggregates,	 in	 order	 to	 bind	
electrostatically	 to	 C16-DAPMA	 when	 diffusing	 through	 the	 hydrogel,	 hence	 releasing	
heparin.	However,	when	different	concentrations	of	SDS	and	SDBS	were	added	into	MalB	
solution,	the	same	displacement	profile	as	when	heparin	is	added	to	MalB	was	obtained.	
Therefore,	it	is	not	possible	to	distinguish	if	the	displacement	observed,	would	correspond	
to	the	release	of	heparin,	or	the	presence	of	SDS	or	SDBS.	By	using	the	MalB	method	to	
detect	heparin	release,	it	is	not	possible	to	use	negatively	charged	molecules	to	compete	
with	heparin	and	bind	to	C16-DAPMA.	
	
	
Figure	4.29.	Chemical	structure	of	sodium	dodecylsulfonate.	
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Figure	4.30.	Chemical	structure	of	sodium	dodecylbenzenesulfonate.	
	
A	different	approach	was	tested	by	replacing	the	buffer	adding	on	top	of	 the	hydrogels	
from	10	mM	Tris-HCl/	 150	mM	NaCl	 buffer	 (pH	7.4)	 to	 borax/NaOH	buffer	 (pH	10).	 As	
previously	reported,	DBS-CONHNH2	hydrogels	are	stable	across	a	wide	pH	range,	from	2	to	
11.5,	so	the	change	in	pH	will	not	affect	the	gel	network.88	Additionally,	by	increasing	the	
pH,	 the	 protonated	 C16-DAPMA	 should	 be	 neutralised	 and	 therefore,	 not	 be	 able	 to	
interact	 electrostatically	 with	 heparin	 anymore.	 Figure	 4.31	 compares	 the	 release	 of	
heparin	from	DBS-CONHNH2	hydrogels	in	the	presence	of	C16-DAPMA	when	10	mM	Tris-
HCl/	150	mM	NaCl	buffer	and	borax/NaOH	buffer	are	added	on	top	of	the	hydrogels.	After	
the	first	1.5	hours	the	release	of	heparin	went	from	9%	with	the	7.4	pH	buffer	to	24%	with	
the	pH	10	buffer.	After	3	days,	almost	double	the	percentage	of	heparin	had	been	released	
when	 in	contact	with	 the	pH	10	buffer	 (from	24%	to	42%).	This	 result	 indicates	 that	by	
increasing	the	pH	of	the	buffer	on	top	of	the	hydrogel	it	is	possible	to	increase	the	release	
of	heparin,	therefore	triggering	release	without	damaging	the	gel	network.		
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Figure	4.31.	Heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	
heparin	and	2	mM	of	C16-DAPMA	over	time,	by	adding	10	mM	Tris-HCl/	150	mM	NaCl	
buffer	(pH	7.4)	(¢)	and	borax/NaOH	buffer	(pH	10)	()	on	top	of	the	hydrogel.	
	
We	then	tested	whether	the	addition	of	agarose	had	an	effect	on	heparin	release	(Figure	
4.32).	On	increasing	the	agarose	concentration,	the	release	of	heparin	slows	down	during	
the	first	6	hours,	giving	41%	in	the	absence	of	agarose,	35%	in	the	presence	of	0.5%	agarose	
and	 only	 28%	 release	 in	 the	 presence	 of	 1%	 agarose.	 At	 longer	 times,	 however,	 the	
presence	of	agarose	does	not	show	an	influence	on	the	release,	with	approximately	53%	
of	 heparin	 being	 released	 after	 24	 hours	 for	 all	 three	 different	 hybrid	 gels.	 Thus,	 the	
presence	of	agarose	may	have	an	effect	on	the	kinetics	of	heparin	release	but	does	not	
affect	the	final	equilibrium	amount	of	heparin	being	released	into	the	buffer.			
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Figure	4.32.	Heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	w/v)	with	1	mM	of	
heparin	in	the	absence	of	agarose	(),	with	0.5%	w/v	of	agarose	()	and	1%	w/v	of	
agarose	(■).				
	
Heparin	Release:	Gel	cylinders		
A	different	release	assay	was	performed	using	hybrid	gel	cylinders	containing	0.4%	w/v	of	
DBS-CONHNH2,	 1%	 w/v	 of	 agarose	 and	 17	 mM	 of	 heparin.	 The	 presence	 of	 agarose	
contributes	to	the	formation	of	stiffer	gels,	making	it	possible	to	remove	them	from	the	
vials	and	immerse	them	in	buffer	(Figure	4.33).	By	using	this	method,	the	entire	gel	surface	
is	in	contact	with	the	buffer	rather	than	just	the	top	surface.					
	
	
Figure	4.33.	Hybrid	gel	cylinder	containing	0.4%	w/v	of	DBS-CONHNH2,	1%	w/v	of	agarose	
and	17	mM	of	heparin,	immersed	in	35	mL	of	buffer.	
0
20
40
60
80
100
0 12 24 36 48
%
	R
el
ea
se
d	
He
pa
rin
Time/	h
Chapter	4	
	
	
	
177	
Figure	4.34	compares	the	release	of	heparin	from	the	two	different	assays.	As	expected,	
the	gel	cylinders	resulted	in	a	greater	heparin	release	than	the	hydrogels	with	buffer	just	
on	top,	with	90%	of	heparin	being	released	after	72	hours	for	the	former	method,	instead	
of	64%	of	release	for	the	later	method.	The	fact	that	the	gel	cylinders	have	a	bigger	surface	
area	to	volume	ratio	for	the	release	to	occur,	when	comparing	to	the	hydrogels	in	a	vial	
with	buffer	on	top,	contributes	to	the	greater	amount	of	heparin	being	released	into	the	
buffer.	Furthermore,	the	initial	release	rate	is	higher	with	ca.	60%	being	released	in	the	first	
6	 hours	 compared	 with	 ca.	 30%.	 Therefore,	 by	 controlling	 the	 surface	 area	 of	 DBS-
CONHNH2	hydrogels	in	contact	with	the	release	environment	it	is	possible	to	control	the	
amount	of	heparin	being	released.		
	
	
Figure	4.34.	Different	methods	of	heparin	release	from	DBS-CONHNH2	hydrogel	(0.4%	
w/v)	and	agarose	(1%	w/v).	():	Buffer	on	top	of	the	gel.	(■):	Gel	cylinder.		
	
4.5. Cytocompatibility	of	DBS-CONHNH2	Hydrogels	
The	 cytocompatibility	 of	 DBS-CONHNH2	 hydrogels	was	 studied	 using	mouse	 embryonic	
fibroblasts	(3T3	cells).	As	described	in	Chapter	3,	3D	and	2D	cell	cultures	were	tested	and	
for	the	latter,	the	hydrogels	were	tested	in	96	plates	with	the	cells	added	on	top	of	the	gels	
and	in	transwells	with	the	cells	seeded	on	the	bottom	of	the	well.	The	same	stainings	and	
techniques	used	in	the	study	of	the	cytocompatibility	of	DBS-COOH	hydrogels	(Chapter	3)	
were	used	for	these	DBS-CONHNH2	hydrogels.			
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4.5.1. 2D	Cell	Culture	with	Cells	on	Top	
2D	cell	culture	assays	were	performed	for	DBS-CONHNH2	hydrogels	by	seeding	cells	on	top	
of	the	gels.	Initially	the	number	of	cells	added	per	well	was	based	on	the	standard	number	
used	 in	 the	 laboratory,	as	 there	was	no	 time	during	 the	placement	 to	optimise	 the	cell	
number	 for	 the	 first	 performed	assays.	 Therefore,	 a	 cell	 density	 of	 50000	 cells/mL	was	
initially	used	together	with	an	excess	of	heparin	concentration	(1	mM	-	667	µg/mL	and	2	
mM	-	1330	µg/mL).	
	
Cell	Morphology	
The	morphology	of	cells	on	top	of	DBS-CONHNH2	gels	was	followed	by	optical	microscopy.	
However,	it	was	not	possible	to	identify	any	cells,	once	the	microscope	used	was	inverted	
and	 only	 gels	 could	 be	 observed.	 The	 gels	 were	 not	 transparent	 enough	 to	 allow	 the	
visualization	of	the	cells,	as	shown	in	Figure	4.35.	In	addition,	from	the	control	images	it	
was	possible	 to	observe	 the	existence	of	 cell	 confluency	after	5	days	 indicating	 that	an	
optimization	of	the	cells	number	is	needed,	with	fewer	cells	in	the	initial	culture.	
	
Phalloidin/DAPI	staining	was	not	performed	for	this	cell	culture	method	as	it	was	previously	
seen	that	it	is	not	possible	to	obtain	clear	images	of	the	cells	under	the	microscope.	
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Figure	4.35.	Optical	microscopy	images	of	DBS-CONHNH2	hydrogels	with	cells	on	top	(top)	
and	controls	(medium	with	cells)	at	day	1	and	5	(bottom).	Magnification:	10x.	
	
Live/Dead	Staining	
Live/dead	 staining	 was	 performed	 for	 DBS-CONHNH2	 hydrogels	 and	 DBS-CONHNH2	
hydrogels	 in	 the	 presence	 of	 heparin,	 with	 cells	 on	 top.	 However,	 as	 the	 fluorescence	
microscope	was	also	inverted	it	was	not	possible	to	obtain	clear	images	of	the	cells	(Figure	
4.36).	On	day	1	it	was	possible	to	observe	the	presence	of	cells	but	the	images	were	blurred,	
on	day	5	and	7	it	was	not	possible	to	identify	any	cells,	probably	because	of	the	existing	cell	
confluency	causing	microscope	focus	problems,	making	it	difficult	to	obtain	clear	images	
through	the	dense	gels.			
	
Chapter	4	
	
	
	
180	
	
Figure	4.36.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels,	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	1330	
µg/mL)	and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1	and	5.	Magnification:	
20x.	
MitoTracker	Staining	
In	respect	to	the	MitoTraker	staining,	the	same	problem	was	faced	as	for	live/dead	staining.	
Thus,	it	was	not	possible	to	obtain	clear	images,	as	can	be	observed	on	Figure	4.37.	
	
Figure	4.37.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
CONHNH2	hydrogels,	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL)	and	controls	(medium	with	cells),	with	cells	on	top,	at	day	1	and	5.	
Magnification:	20x.	
Chapter	4	
	
	
	
181	
Metabolic	Activity	
The	metabolic	activity	of	the	cells	on	top	of	DBS-CONHNH2	hydrogels	was	studied	using	cell	
proliferation	reagent	WST-1,	as	described	in	Chapter	3.	The	obtained	results	(Figure	4.38)	
indicate	that	the	presence	of	an	excess	of	heparin	within	the	DBS-CONHNH2	gel	network	
contribute	to	a	lower	metabolic	activity	of	the	cells	over	7	days,	when	compared	with	the	
control	assay.	This	is	in	agreement	with	the	literature,263–265	where	it	is	demonstrated	that	
the	concentration	of	heparin	is	crucial	for	cell	proliferation	and	that	high	concentrations	of	
heparin	result	in	the	inhibition	of	cell	growth.	It	is	worth	noting	that	the	fact	that	there	is	a	
decrease	of	metabolic	activity	from	day	5	to	day	7	for	both	DBS-CONHNH2	hydrogels	and	
the	control	is	due	to	the	confluency	of	the	cells	that	resulting	in	a	lack	of	sites	to	which	cells	
can	 adhere	 and	 therefore	 contributing	 to	 cell	 death.	 Nevertheless,	 the	 increase	 of	 the	
metabolic	activity	from	day	1	to	day	7	when	the	cells	were	in	contact	with	DBS-CONHNH2	
indicates	 that	 this	 gel	 network	 appears	 to	 provide	 excellent	 conditions	 for	 the	 cells	 to	
adhere	onto	the	gel	surface	and	proliferate.	
	
	
Figure	4.38.	Absorbance	of	WST-1	reagent	at	440	nm	with	(from	left	to	right):	DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL,	respectively)	and	control	(medium	with	cells),	with	cells	on	top,	at	day	1,	5	
and	7.	
	
In	 a	 later	 placement,	 cytocompatibility	 studies	 proceeded	 with	 an	 optimization	 of	 the	
number	of	cells,	to	avoid	confluency,	as	well	as	an	optimization	of	heparin	concentration.	
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Thus,	 an	 initial	 cell	 density	 of	 25000	 cell/mL	 was	 used,	 together	 with	 lower	 heparin	
concentrations	 of	 50	 µg/mL,	 25	 µg/mL	 and	 10	 µg/mL.263,266	 Additionally,	 the	
cytocompatibility	 of	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	 heparin-C16-DAPMA	
aggregates	and	of	hybrid	hydrogels	with	DBS-CONHNH2	and	agarose	was	also	studied.	DBS-
CONHNH2	hydrogels	in	the	presence	of	C16-DAPMA	were	not	tested	in	2D	cell	culture	with	
cells	on	top	of	the	gel,	due	to	the	fact	that	the	presence	of	C16-DAPMA	alone	involves	the	
formation	of	foam	and	therefore	the	hydrogel	presents	air	bubbles	and	does	not	have	an	
uniform	surface,	making	 it	 inappropriate	 to	seed	cells.	Therefore,	C16-DAPMA	was	only	
tested	when	interacting	with	heparin.	From	the	studies	described	above	we	knew	that	it	
was	not	possible	to	obtain	clear	 images	from	optical	and	fluorescence	microscopy	using	
DBS-CONHNH2	 hydrogels,	 therefore	 only	 the	 metabolic	 activity	 was	 tested	 for	 these	
optimized	conditions	(Figure	4.39).					
	
	
Figure	4.39.	Absorbance	of	WST-1	reagent	at	440	nm	with	(from	left	to	right):	DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL,	25	
µg/mL	and	10	µg/mL);	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	
and	C16-DAPMA	(140	µg/mL;	DBS-CONHNH2	hydrogels	with	agarose	(1%	w/v);	DBS-
CONHNH2	hydrogels	with	agarose	(1%	w/v)	and	heparin	(50	µg/mL);	agarose	(1%)	and	
control	(medium	with	cells),	with	cells	on	top	of	the	gels,	at	day	1,	3	and	7.	
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From	 the	 obtained	 results,	 it	 is	 possible	 to	 verify	 that	 the	 presence	 of	 appropriate	
concentrations	 of	 heparin	 within	 DBS-CONHNH2	 gel	 network	 can	 slightly	 increase	 the	
metabolic	activity	of	the	cells	over	7	days.	The	presence	of	heparin	within	the	gel	matrix	
can	 therefore,	 potentiate	 cell	 proliferation.	 Conversely,	 the	 presence	 of	 heparin-C16-
DAPMA	impaired	cell	proliferation,	indicating	a	negative	influence	of	the	presence	of	C16-
DAPMA	within	the	gel	or	of	the	C16-DAPMA/heparin	aggregates.	Saturated	fatty	acids	have	
been	reported	to	induce	apoptosisiii	in	different	type	of	cells267–272	with	the	carbon	chain	
length	having	a	direct	influence	on	cell	growth	inhibition	and	inducing	cell	loss.	In	fact,	while	
short	 to	medium	chain	 saturated	 fatty	acids	are	presumably	used	by	cells	as	an	energy	
source,	thus	promoting	cell	growth,	long-chain	saturated	fatty	acids	can	be	involved	in	the	
apoptosis	 of	 cells	 through	 the	 formation	 of	 ceramide,273	 reactive	 oxygen	 species274	 or	
alteration	 of	mitochondrial	membrane	 permeability.275	 Harvey	 et	 al276	 have	 shown	 the	
impact	that	the	chain	length	of	saturated	fatty	acids	can	have	in	endothelial	cell	functions.	
While	medium	 (C6-C12)	 and	 short	 (C4)	 chain	 saturated	 fatty	 acids	 did	 not	 significantly	
affect	cell	growth,	and	short	chain	saturated	fatty	acids	actually	enhanced	cell	proliferation,	
long	chain	(C14-C20)	fatty	acids	contributed	to	an	increase	of	cell	apoptosis	and	necrosisiv.	
Therefore,	the	use	of	palmitic	acid	as	a	building	block	for	heparin	binding	may	contribute	
to	 the	 inhibition	 of	 cell	 growth	 when	 incorporated	 in	 DBS-CONHNH2	 hydrogels.	
Alternatively,	the	adverse	impact	may	be	a	result	of	using	an	amine-modified	fatty	acid,	
due	 to	 the	 high	 affinity	 of	 cationic	molecules	 for	 net	 negative	 charge	 cell	 membranes	
(typically	bacteria	and	cancer	cells)	or	even	mainly	neutral	zwitteronic	cell	membranes	(e.g.	
mammalian	cell	membrane	–	only	5-10%	of	negatively	charged	phospholipids	and	90-95%	
of	 zwitteronic	 phospholipids)	which	 can	be	disrupted	by	 interactions	with	high	positive	
charge	density	molecules.277–279	
	
When	the	cells	were	on	top	of	agarose	their	proliferation	was	completely	inhibited.	This	is	
most	 likely	 due	 to	 the	 absence	 of	 adhesion	 points	 therefore	 preventing	 cell	 growth.	
Although	 agarose	 is	 known	 for	 being	 biocompatible	 and	 having	 mechanical	 properties	
suitable	 for	 cell	 culture,	 one	 of	 its	main	 limitations	 relates	 to	 the	 fact	 that	 it	 does	 not	
																																																						
iii	Apoptosis	describes	the	process	of	programed	cell	death.		
iv	Necrosis	describes	the	premature	death	of	cells	caused	by	external	factors.	
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contain	moieties	associated	with	cellular	adhesion	resulting	in	low	cell	adhesiveness	and	
cell	proliferation.280,281	 	As	agarose	gels	are	transparent	 it	was	possible	to	observe	them	
under	the	optical	microscope,	which	showed	that	the	cells	were	all	aggregated	on	top	of	
the	gel	 in	a	spheroid	shape,	as	shown	 in	Figure	4.40.	This	proves	that	agarose	does	not	
allow	the	cells	to	adhere	and	subsequently	proliferate.	This	feature	probably	had	a	negative	
influence	on	the	metabolic	activity	of	cells	grown	on	hybrid	hydrogels	of	DBS-CONHNH2	
and	agarose,	which	was	significantly	decreased	compared	to	the	DBS-CONHH2	hydrogels	
used	alone.	However,	 it	was	possible	 to	verify	 that	cells	 could	grow	effectively	on	DBS-
CONHNH2	 and	 that	 the	 presence	 of	 heparin	 had	 some	 beneficial	 impact	 on	metabolic	
activity.	
		
	
Figure	4.40.	Optical	microscope	image	of	cells	on	top	of	1%	w/v	agarose	hydrogel	at	day	
3.	
	
Migration	Assay		
As	it	was	not	possible	to	obtain	any	additional	information	from	the	tested	stainings,	it	was	
important	 to	 ensure	 whether	 the	 cells	 were	 adhering	 on	 the	 DBS-CONHNH2	 hydrogel	
surface	or	migrating	into	the	well	and	adhering	on	the	well	surface.	For	that	purpose,	a	cell	
migration	assay	was	performed	by	simply	preparing	DBS-CONHNH2	hydrogels	(100	µL,	80	
µL	and	60	µL	to	test	different	gel	thickness)	in	transwell	inserts	and	adding	cells	on	top	of	
the	 gel	 (Figure	 4.41	 a).282,283	 If	 the	 cells	 migrate	 through	 the	 gel	 they	 will	 cross	 the	
membrane	 and	 adhere	 to	 the	 bottom	 of	 the	 well,	 which	 can	 be	 followed	 by	 optical	
microscopy	(Figure	4.41	b).	Additionally,	to	ensure	that	the	cells	were	not	attached	to	the	
membrane,	the	gels	were	removed	and	the	inserts	rinsed	with	trypsin	to	detach	any	cells	
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that	 were	 attached	 to	 the	 membrane.	 For	 comparison,	 two	 different	 controls	 were	
prepared,	one	where	cells	were	added	into	a	transwell	insert	in	the	absence	of	gel,	with	
medium	added	into	the	well,	and	another	where	cells	where	added	directly	into	the	well.			
	
	
Figure	4.41.	Schematic	representation	of	the	cell	migration	assay.	(a)	DBS-CONHNH2	
hydrogel	was	formed	in	the	transwell	insert	and	cells	were	added	on	top	of	the	hydrogel.	
Medium	was	added	in	the	well.	(b)	Cells	migration	through	the	gel	network	into	the	well.	
Adhesion	of	cells	on	the	bottom	of	the	well	can	be	followed	by	optical	microscopy.	
	
After	 1	 day	 the	 plates	 were	 observed	 under	 the	 optical	 microscope	 but	 no	 cells	 were	
detected	on	the	bottom	of	the	wells,	except	for	the	control	where	cells	were	added	directly	
into	the	well.	After	7	days	the	same	was	observed	and	therefore,	the	gels	were	removed	
and	 the	 filters	 washed	with	 trypsin.	 Again,	 no	 cells	 were	 observed	 in	 the	 wells	 where	
different	volumes	of	DBS-CONHNH2	hydrogels	had	been	present	(Figure	4.42).	This	result	
indicates	that	the	cells	do	not	migrate	through	DBS-CONHNH2	hydrogel	and	therefore	the	
results	obtained	for	the	metabolic	activity	correspond	to	the	cells	attached	on	the	surface	
of	DBS-CONHNH2	hydrogels.						
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Figure	4.42.	Example	of	an	optical	microscope	image	obtained	on	the	migration	assay	for	
the	well	were	DBS-CONHNH2	hydrogels	were	present	(left	–	no	cells	present)	and	control	
(right	-	cells	added	directly	into	the	well	and	attached	to	the	bottom	of	the	well)	after	
washing	the	membrane	with	trypsin,	on	day	7.	
	
4.5.2. 2D	Cell	Culture	in	Transwells	
DBS-CONHNH2	 hydrogels	were	 then	 tested	 in	 transwells,	with	 gels	 prepared	 in	 inserts,	
which	were	placed	on	top	of	medium,	containing	cells	that	were	growing	attached	to	the	
well	plates.	Initially,	a	cell	density	of	40000	cells/mL	was	used,	but	cells	reached	confluency	
before	the	end	of	the	7	days	experiment	(Figure	4.43).	After	optimization	of	the	number	of	
cells,	 a	 cell	 density	 of	 10000	 cell/mL	was	used.	 The	 cytocompatibility	 of	DBS-CONHNH2	
hydrogels	in	the	absence	and	the	presence	of	heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	
was	studied,	as	well	as	DBS-CONHNH2	in	the	presence	of	C16-DAPMA,	and	the	presence	of	
heparin-C16-DAPMA	 aggregates.	 Furthermore,	 the	 cytocompatibility	 of	 the	 hydrid	
hydrogels	composed	of	DBS-CONHNH2	and	agarose	in	the	presence	and	absence	of	heparin	
was	also	studied.		
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Figure	4.43.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
CONHNH2	hydrogels,	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	5	and	5.	Cell	
density:	40000	cells/mL.	Magnification:	20x.	
	
Cell	Morphology	
Optical	microscopy	of	cells	with	DBS-CONHNH2	hydrogels	in	transwells	allowed	us	to	verify	
the	elongation	and	the	increase	of	the	number	of	cells	over	one	week,	(Figure	4.44).	This	
indicates	that	DBS-CONHNH2	hydrogels	do	not	appear	to	be	toxic,	as	cells	can	adhere	and	
grow	when	 in	contact	with	 the	LMWG	hydrogel.	 Similar	 results	were	obtained	 for	DBS-
CONHNH2	hydrogels	with	heparin	and	the	hybrid	hydrogels	(Figure	4.45	and	Figure	4.46,	
respectively),	however,	on	day	3,	cells	were	more	elongated	and	stretched	in	the	presence	
of	heparin	and	in	the	hybrid	hydrogels	than	for	the	DBS-CONHNH2	hydrogels	alone,	which	
may	 indicate	 that	 these	 conditions	 can	 improve	 the	 biocompatibility	 of	 DBS-CONHNH2	
hydrogels	 for	 cells	 to	 adhere	 and	 proliferate.	 Additionally,	 when	 DBS-CONHNH2	 was	
incorporated	 with	 C16-DAPMA	 and	 heparin-C16-DAPMA	 aggregates,	 no	 cells	 were	
observed	 over	 the	 7	 days,	 indicating	 that	 the	 presence	 of	 C16-DAPMA	 is	 toxic	 and	
contributes	 to	 the	 death	 of	 the	 cells,	 which	 agrees	 with	 the	 lack	 of	 metabolic	 activity	
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observed	on	the	previous	experiment.	Even	when	bound	to	heparin	 it	 is	clear	that	C16-
DAPMA	is	still	exhibiting	some	toxicity.	
	
	
Figure	4.44.	Optical	microscopy	images	of	DBS-CONHNH2	hydrogels	in	transwells,	at	day	1	
3	and	7	and	control	(medium	with	cells).	Magnification:	20x.	
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Figure	4.45.	Optical	microscopy	images	of	DBS-CONHNH2	hydrogels	in	the	presence	of	
heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	and	controls	(medium	with	cells),	in	
transwells,	at	day	1,	3	and	7.	Magnifcation:	20x.	
	
Figure	4.46.	Optical	microscopy	images	of	agarose	hydrogels,	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	and	DBS-CONHNH2	and	agarose	hybrid	hydrogels	in	the	presence	of	
heparin	(50	µg/mL)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	
Magnifcation:	20x.	
Chapter	4	
	
	
	
190	
Phalloidin/DAPI	 staining	 as	 shown	 in	 Figure	 4.47,	 corresponds	 to	 the	 tests	 performed	
before	the	optimization	of	the	cell	density	due	to	a	malfunction	of	the	computer	connected	
to	 the	 fluorescence	 microscope	 when	 the	 optimised	 samples	 went	 for	 imaging.	
Nevertheless,	the	obtained	images	reveal	the	presence	of	stretched	actin	filaments	on	cells	
on	day	1,	from	the	DBS-CONHNH2	hydrogel	sample.	On	day	5	elongated	filaments	were	also	
observed,	together	with	cell	confluency,	as	expected.	This	may	indicate	that	DBS-CONHNH2	
hydrogels	do	not	have	a	negative	influence	on	cell	growth,	i.e.,	the	hydrogels	do	not	appear	
toxic	to	the	cells,	as	they	present	a	good	adhesion	and	proliferation.	Similar	results	were	
observed	when	heparin	was	incorporated	within	the	gels	(Figure	4.48).	
	
	
Figure	4.47.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	DBS-
CONHNH2	hydrogels	in	transwells,	at	day	1	and	5.	Magnification:	40x.	
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Figure	4.48.	Fluorescence	microscopy	images	of	phalloidin/DAPI	staining	of	DBS-
CONHNH2	hydrogels	and	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	
and	1330	µg/mL)	in	transwells	at	day	1	and	5.	Magnification:	40x.	
	
Live/Dead	Staining	
Live/dead	staining	images	revealed	the	existence	of	viable	cells	on	day	1,	for	DBS-CONHNH2	
hydrogels,	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	 heparin	 and	 for	 the	 hybrid	
hydrogels	 of	DBS-CONHNH2	 and	 agarose	 (Figure	 4.49,	 4.50	 and	 4.51).	On	 day	 3,	 it	was	
possible	to	observe	elongated	cells,	as	they	were	adhering	to	the	well	and	proliferating.	On	
day	7,	the	number	of	viable	cells	increased	significantly,	indicating	that	these	conditions	do	
not	inhibit	cell	proliferation.	However,	once	again	when	C16-DAPMA	was	present	no	cells	
were	observed	over	the	7	days,	corroborating	the	previously	obtained	results.	Dead	cells	
were	not	present	or	they	were	present	in	a	very	small	number	just	 in	some	samples,	as	
they	may	had	been	washed	off	with	the	DPBS	washes.		
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Figure	4.49.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels	(0.4%	w/v)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	
Magnification:	20x.	
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Figure	4.50.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	DBS-CONHNH2	
hydrogels	in	the	presence	of	heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	and	controls	
(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	Magnification:	20x.	
	
	
Figure	4.51.	Fluorescence	microscopy	images	of	calcein-AM/PI	staining	of	agarose	
hydrogels,	DBS-CONHNH2	and	agarose	hybrid	hydrogels	and	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	controls	(medium	with	cells),	
in	transwells,	at	day	1,	3	and	7.	Magnification:	20x.	
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MitoTracker	Staining	
MitoTracker	 staining	of	 cells	 in	 contact	with	DBS-CONHNH2	hydrogels	 in	 transwells	was	
obtained	and	is	shown	in	Figure	4.52.	Mitochondrial	staining	(green)	was	achieved	over	one	
week,	indicating	that	DBS-CONHNH2	hydrogels	do	not	damage	the	mitochondria	or	reduce	
the	membrane	potential,	otherwise	the	accumulation	of	the	dye	would	not	be	possible.	
Similar	 results	 were	 observed	 when	 DBS-CONHNH2	 was	 incorporated	 with	 heparin	 (50	
µg/mL,	25	µg/mL	and	10	µg/mL)	 (Figure	4.53)	and	when	cells	were	 in	 contact	with	 the	
hybrid	hydrogels	of	DBS-CONHNH2	and	agarose	 in	the	presence	and	absence	of	heparin	
(Figure	 4.54).	 Additionally,	 when	 C16-DAPMA	 was	 present	 within	 the	 gel	 network	 the	
presence	of	cells	was	not	detected,	confirming	the	toxicity	of	C16-DAPMA.		
	
	
Figure	4.52.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
CONHNH2	hydrogels	(0.4%	w/v)	and	controls	(medium	with	cells),	in	transwells,	at	day	1,	
3	and	7.	Magnification:	40x.	
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Figure	4.53.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	DBS-
CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	and	
controls	(medium	with	cells),	in	transwells,	at	day	1,	3	and	7.	Magnification:	40x.	
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Figure	4.54.	Fluorescence	microscopy	images	of	mitotraker/hoechst	staining	of	agarose	
hydrogels,	DBS-CONHNH2	and	agarose	hybrid	hydrogels	and	DBS-CONHNH2	and	agarose	
hybrid	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	controls	(medium	with	cells),	
in	transwells,	at	day	1,	5	and	7.	Magnification:	40x.	
	
Metabolic	Activity	
Metabolic	activity	of	DBS-CONHNH2	hydrogels	(Figure	4.55)	in	transwells	shows	a	slightly	
better	metabolic	activity	after	7	days	when	heparin	(50	µg/mL,	25	µg/mL	and	10	µg/mL)	is	
incorporated	 within	 DBS-CONHNH2	 hydrogels.	 In	 contrast,	 this	 assay	 clearly	 shows	 the	
toxicity	of	C16-DAPMA,	as	the	absence	of	metabolic	activity	proves	that	no	viable	cells	were	
present.	Interestingly,	the	presence	of	agarose	revealed	good	metabolic	activity	over	one	
week.	Comparing	this	result	with	the	obtained	metabolic	activity	when	cells	were	added	to	
the	top	of	agarose,	allows	us	to	conclude	that	agarose	is	not	toxic	to	cells,	but	despite	being	
biocompatible,	 does	 not	 have	 adhesion	 moieties	 with	 which	 cells	 can	 adhere	 and	
proliferate.					
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Figure	4.55.	Absorbance	of	WST-1	reagent	at	440	nm	with	(from	left	to	right):	DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL,	25	
µg/mL	and	10	µg/mL);	DBS-CONHNH2	hydrogels	in	the	presence	of	C16-DAPMA	(140	
µg/mL);	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(50	µg/mL)	and	C16-DAPMA	
(140	µg/mL);	DBS-CONHNH2	hydrogels	with	agarose	(1%	w/v);	DBS-CONHNH2	hydrogels	
with	agarose	(1%	w/v)	and	heparin	(50	µg/mL);	agarose	(1%)	and	control	(medium	with	
cells),	in	transwells,	at	day	1,	3	and	7.	
	
For	 additional	 information,	 Figure	4.56	 shows	 the	metabolic	 activity	before	 cell	 density	
optimization	 of	 DBS-CONHNH2	 hydrogels	 in	 the	 presence	 of	 higher	 concentrations	 of	
heparin	(1	mM	-	667	µg/mL	and	2	mM	-	1330	µg/mL).	The	significant	higher	concentrations	
of	 heparin	 resulted	 in	 a	 decrease	 of	 the	metabolic	 activity	 when	 compared	 with	 DBS-
CONHNH2	hydrogels	 alone,	 after	7	days.	 This	 is	 in	 agreement	with	 the	 lower	metabolic	
activity	 obtained	when	 the	 cells	were	 on	 top	 of	 the	 hydrogels	 using	 the	 same	 heparin	
concentrations,	 indicating	 lower	 biocompatibility	 when	 heparin	 is	 used	 in	 excess.	 This	
confirms	 that	 the	 concentration	 of	 heparin	 incorporated	 in	 DBS-CONHNH2	 hydrogels	 is	
crucial	to	support	and	promote	the	growth	of	cells.				
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Figure	4.56.	Absorbance	of	WST-1	reagent	at	440	nm	with	(from	left	to	right):	DBS-
CONHNH2	hydrogels;	DBS-CONHNH2	hydrogels	in	the	presence	of	heparin	(667	µg/mL	and	
1330	µg/mL)	and	control	(medium	with	cells),	in	transwells,	at	day	1,	5	and	7.	
	
4.5.3. 3D	Cell	Culture		
The	 preparation	 of	 DBS-CONHNH2	 gels	 involves	 the	 heating	 of	 samples	 at	 high	
temperatures	(close	to	the	boiling	point	of	water)	which	creates	harsh	conditions	for	the	
cells	 to	 survive,	with	 gelation	 occurring	within	 seconds.	 Consequently,	 the	 heating	 and	
thereafter	 the	 transfer	 of	 the	 samples	 into	 the	well	 plates	 and	 inserts	 had	 to	 be	 done	
outside	the	cell	culture	hood	with	subsequent	sterilization	by	application	of	UV-light.	The	
fact	 that	 the	gels	were	prepared	 in	non-sterile	conditions,	meant	 it	was	not	possible	 to	
perform	3D	cell	encapsulation	experiments	in	these	DBS-CONHNH2	hydrogels.	
	
	
4.6. Summary,	Conclusions	and	Future	Work	
To	overcome	the	limitations	of	using	DBS-COOH	hydrogels	as	potential	scaffolds	for	tissue	
engineering,	DBS-CONHNH2	LMWG	was	synthesised	and	its	orthogonal	self-assembly	with	
heparin	and	C16-DAPMA	was	studied.	The	incorporation	of	these	two	components	within	
the	gel	network	did	not	inhibit	gelation.	Furthermore,	the	addition	of	heparin-C16-DAPMA	
aggregates	 into	 the	 DBS-CONHNH2	 hydrogels	 resulted	 in	 stable	 and	 uniform	 hydrogels	
using	a	charge	raio	+/-	of	2	at	different	concentrations	of	heparin/binder,	with	a	decrease	
of	the	charge	ratio	+/-		only	being	observed	for	concentrations	of	heparin	higher	than	600	
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µM.	Moreover,	 it	was	 demonstrated	 that	 the	 presence	of	 C16-DAPMA	 interacting	with	
heparin	 in	 the	hydrogel	network	had	a	 significant	effect	on	 the	 thermal	 stability	of	 the	
hydrogel,	 affecting	also	 the	CD	 signal	 intensity.	 IR	 spectra	of	 the	gel	 in	 the	presence	of	
binder	and	heparin	showed	overlap	of	the	characteristic	vibrations	of	C16-DAPMA,	heparin	
and	DBS-CONHNH2	suggesting	effective	self-sorting	at	the	molecular	level.	The	use	of	MalB	
solution	on	top	of	the	gel	allowed	us	to	prove	that	binder	-	heparin	interactions	appear	to	
be	unaffected	when	incorporating	these	two	components	within	the	gel.	By	using	TEM	and	
SEM	the	presence	of	aggregates	characteristic	of	the	C16-DAPMA	interacting	with	heparin	
were	observed,	along	with	nanofibers	but	also	needles	which	were	not	observed	for	the	
gel	 alone.	 This	 indicates	 that	 the	 C16-DAPMA-heparin	 aggregates	 influence	 the	 self-
assembly	of	DBS-CONHNH2	gel	fibers,	changing	its	morphology.	The	mechanical	properties	
of	 the	 hydrogel	 were	 affected	 when	 C16-DAPMA	 alone	 was	 incorporated	 due	 to	 the	
formation	of	foam,	while	the	presence	of	agarose	contributed	to	the	formation	of	stiffer	
and	stronger	gels,	as	expected.	Additionally,	this	study	provides	evidence	that	when	mixing	
heparin,	 C16-DAPMA	 or	 heparin-C16-DAPMA	 aggregates	 with	 DBS-CONHNH2	 into	 one	
single	 system,	 the	 individual	 function	 of	 each	 component	 is	 kept,	 hence	 the	 multi-
component	systems	tested	are	orthogonal.	
	
The	release	of	heparin	 from	DBS-CONHNH2	hydrogels	was	achieved	and	the	addition	of	
agarose	up	to	1%	w/v	did	not	affect	the	maximum	amount	of	heparin	that	can	be	released,	
while	also	allowing	the	formation	of	robust	and	stiffer	gels.	Furthermore,	the	presence	of	
C16-DAPMA	limited	the	release	of	heparin	by	binding	to	it	and	hence	preventing	its	escape	
from	the	gel.	The	addition	of	borax/NaOH	buffer	(pH	10)	on	top	of	DBS-CONHNH2	hydrogels	
incorporating	 heparin-C16-DAPMA	 aggregates,	 contributed	 to	 an	 increase	 of	 heparin	
released	from	the	hydrogel,	which	can	 indicate	that	a	triggered	release	 is	achievable	by	
deprotonating	 the	 positively	 charged	 C16-DAPMA	 that	 consequently	 cannot	 interact	
electrostatically	with	 heparin,	 allowing	 its	 release	 from	 the	 gel.	 Additionally,	 controlled	
release	of	heparin	was	achievable	by	changing	the	surface	area	of	gel	in	contact	with	the	
release	medium.		
	
From	 the	 cytocompatibility	 studies	 performed,	 3D	 cell	 culture	 assays	 could	 not	 be	
performed	due	to	the	preparation	method	of	DBS-CONHNH2	hydrogels	which	required	high	
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temperatures.	 2D	 cell	 culture	 assays	 revealed	 that	 DBS-CONHNH2	 hydrogels	 remained	
stable	 in	 the	 plates	 throughout	 the	 7	 days	 of	 experiment	 and	no	 fluctuation	of	 gels	 or	
disruption	 of	 the	 gel	 network	was	 observed.	 Due	 to	 the	 high	 density	 of	 the	 gel	 it	was	
difficult	to	obtain	clear	fluorescence	microscopy	images	when	the	cells	were	put	on	top	of	
the	gels.	However,	the	metabolic	activity	assay	proved	that	cells	were	able	to	adhere	and	
proliferate	when	on	top	of	DBS-CONHNH2	hydrogels,	with	a	somewhat	higher	metabolic	
activity	being	obtain	when	10-50	µg/mL	of	heparin	was	incorporated	within	the	hydrogel.	
Additionally,	migration	studies	proved	that	cells	did	not	migrate	through	the	gel	and	attach	
to	the	bottom	of	the	plates,	confirming	that	the	obtained	metabolic	activity	corresponded	
to	the	cells	growing	directly	on	top	of	DBS-CONHNH2	hydrogels.	Furthermore,	when	DBS-
CONHNH2	hydrogels	were	tested	alone	and	in	the	presence	of	10-50	µg/mL	of	heparin	in	
transwells,	clear	fluorescence	microscopy	images	were	obtained,	where	it	was	possible	to	
observe	the	presence	of	viable	cells,	able	to	adhere,	stretch	and	proliferate	over	one	week.		
In	 addition,	 cell	 proliferation	 assays	 confirmed	 that	 DBS-CONHNH2	 hydrogels	 are	 not	
cytotoxic,	and	again	the	presence	of	10-50	µg/mL	of	heparin	could	improve	the	metabolic	
activity	of	the	cells.	In	contrast,	the	use	of	higher	concentrations	of	heparin	(667	µg/mL	and	
1330	µg/mL)	proved	 to	have	 the	opposite	 influence,	with	metabolic	 activity	decreasing	
significantly,	 indicating	 that	 the	 concentration	 of	 heparin	 incorporated	 within	 the	 gel	
network	is	crucial	to	support	and	promote	cell	growth.	
	
In	 respect	 to	 the	 hybrid	 hydrogels,	 we	 could	 conclude	 that	 agarose,	 although	
biocompatible,	does	not	have	adhesion	moieties	and	therefore,	cells	are	not	able	to	adhere	
to	the	hybrid	hydrogels	as	effectively	as	when	only	DBS-CONHNH2	is	present.	The	presence	
of	C16-DAPMA	as	heparin	binder	within	the	gel	network	proved	to	be	toxic	to	the	cells,	
with	no	cells	being	detected	using	the	fluorescence	microscope	and	no	metabolic	activity	
being	obtained,	 indicating	that	cells	died	when	 in	contact	with	C16-DAPMA.	Even	when	
bound	to	heparin,	the	C16-DAPMA	still	had	a	negative	influence	on	cell	growth.	
	
Additionally,	for	a	less	extensive	and	faster	cytotoxicity	study,	the	live/dead	staining	and	
the	metabolic	activity	test	in	transwells	should	be	prioritised	as	they	will	be	sufficient	to	
obtain	conclusive	and	valid	information.		
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As	future	work,	further	release	studies	could	be	performed	in	order	to	better	understand	
the	 influence	 of	 pH	 of	 release	 medium	 in	 triggering	 heparin	 release	 from	 the	 gel.	
Additionally,	the	release	assays	could	be	adapted	and	designed	in	order	to	mimic	the	gel	
preparation	 needed	 in	 cell	 culture	 plates.	 It	 would	 be	 of	 great	 interest	 to	 test	 the	
cytotoxicity	of	DBS-CONHNH2	hydrogels	on	different	types	of	cells,	namely	primary	cells	
(e.g.	human	adipose	derived	stem	cells).	Furthermore,	as	C16-DAPMA	proved	to	be	toxic,	
its	replacement	is	crucial.	Smith’s	group	has	since	developed	a	cholesterol-based	heparin	
binder	which	proved	to	have	low	cytotoxicity	and	could	replace	C16-DAPMA.	Also,	the	use	
of	 gelatin	 or	 gelatin-agarose	 conjugates	 as	 PG	 to	 form	 the	 hybrid	 hydrogel	 with	 DBS-
CONHNH2	can	overcome	the	limitation	obtained	with	agarose	hydrogels	by	incorporating	
cell	adhesion	moieties.281,284	It	is	also	worth	noting	that,	DBS-CONHNH2	and	agarose	hybrid	
hydrogels	proved	to	be	biocompatible	so	they	could	be	used	for	different	applications	such	
as	drug	delivery.	Controlled	release	of	heparin	has	significant	relevance	in	a	clinical	setting	
to	avoid	deep	vein	thrombosis.285	
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5. Orthogonal	 Self-Assembly	 of	 Cyclohexane-Based	 Low-
Molecular-Weight	Hydrogels	
The	following	studies	were	performed	on	a	placement	at	Delft	University	of	Technology	in	
Netherlands,	as	part	of	the	SmartNet	network.		
	
5.1. Introduction	
With	the	majority	of	the	reported	applications	of	hydrogels	still	using	polymeric	gelators,	
in	fields	such	as	biomedicine,286–290	food291,292	and	cosmetics,293–295	the	use	of	responsive	
LMWGs	as	potential	alternative	to	polymer	gels	has	become	an	attractive	subject.	The	van	
Esch	research	group	has	widely	studied	the	use	of	LMWGs	as	a	complement	to	or	substitute	
for	polymeric	hydrogels.296–307In	particular,	they	have	designed	a	family	of	effective	LMWGs	
consisting	 of	 a	 triamide	 cyclohexane	 gelating	 scaffold	 with	 the	 addition	 of	 amino	 acid	
substituents	 that	 contribute	 via	 the	 additional	 presence	 of	 hydrogen	 bonding	 and	
hydrophobic	interactions	to	promote	gelation	(Figure	5.1).	296		
	
	
Figure	5.1.	Chemical	structure	of	cyclohexane-based	LMWGs.	Light	grey:	hydrophilic	
regions;	dark	grey:	hydrophobic	regions.	AA:	aminoacid;	X:	hydrophilic	substituent.296	
	
In	this	chapter,	the	assembly	of	a	multi-component	hybrid	system	using	cyclohexane-based	
LMWGs	with	heparin	and	C16-DAPMA	was	studied.	Figure	5.2	shows	the	LMWGs	used	for	
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this	 study	 that	were	previously	 synthesised	by	Vincent	 le	 Sage	 from	Delft	University	 of	
Technology.		
	
	
Figure	5.2.	Chemical	structure	of	cyclohexane-based	hydrogelators.	OG1:	heat-cool	
gelator	and	OG2:	pH	responsive	gelator.	
	
Compound	OG1	is	a	thermoreversible	hydrogelator	capable	of	forming	stable	gels	at	very	
low	 concentrations	 due	 to	 the	 presence	 of	 phenylalanine	 amino	 acids	 that	 provide	
hydrophobic	interactions	fundamental	for	the	gelation	of	water.296	OG2	was	designed	as	a	
LMWG-drug	conjugate	 system.	Specifically,	 it	 is	a	pH	 responsive	gelator	connected	 to	a	
phenylalanyl-aminoquinoline	 that	 can	 be	 enzymatically	 cleaved,	 releasing	 the	
aminoquinoline	group,	through	the	hydrolysis	of	the	amide	into	an	amine.298	The	OG2	gel	
forms	on	raising	the	pH	as	the	protonated	aminoquinoline	 is	converted	 into	the	neutral	
free	base	 form.	 Interestingly,	 the	drug	 is	protected	from	enzymatic	action	while	 the	gel	
nanofibers	are	assembled.	After	applying	a	stimulus	to	disassemble	the	gel	nanofibers	(e.g.	
temperature,	pH)	the	individual	molecules	can	be	enzymatically	cleaved	and	the	drug	can	
be	released	(Figure	5.3).	Both	compounds	have	ethylene	glycol	chains	connected	in	order	
to	control	the	degree	of	hydrophobicity,	introducing	the	degree	of	water	solubility	needed	
to	form	gels.296,298,300		
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Figure	5.3.	Schematic	representation	of	a	two-step	release	system	with	the	dissociation	
of	self-assembled	nanofibers	followed	by	enzymatic	cleavage	for	OG2-drug	conjugate	
hydrogels.	∆:	trigger	of	gel-sol	transition	(temperature,	pH).[Adapted	from	reference	298]	
	
The	goal	was	to	use	self-assembled	C16-DAPMA	micelles	to	interact	with	heparin	and	study	
their	coexistence	within	the	OG1/	OG2	gel	networks.	Studies	were	performed	in	order	to	
better	understand	this	multi-component	supramolecular	system.	
			
5.2. Orthogonal	Self-Assembly	of	Cyclohexane	Hydrogels	with	C16-DAPMA	and	
Heparin	
Firstly,	 heparin,	 C16-DAPMA	 and	 heparin-C16-DAPMA	 aggregates	 were	 incorporated	
within	OG1	and	OG2	hydrogels	to	understand	if	the	addition	of	these	components	inhibited	
the	formation	of	OG1	and	OG2	gels.	The	gelation	of	OG1	in	water	was	achieved	by	cooling	
heated	solutions	of	0.5%	w/v	of	gelator.	The	final	pH	of	the	OG1	gel	was	7.	OG2	hydrogels	
were	obtained	by	acidifying	the	gelator	solution	(0.5%	w/v)	 in	water,	with	HCl	(1	M),	to	
completely	 dissolve	 the	 gelator,	 followed	by	 the	neutralisation	of	 the	 solution	by	 rapid	
addition	of	NaOH	(1	M).	The	final	pH	of	the	OG2	gel	was	between	8-9.	Heparin,	C16-DAPMA	
and	heparin-C16-DAPMA	aggregates	were	added	to	the	LMWG	solutions	prior	to	heating	
for	OG1	and	prior	to	the	addition	of	NaOH	for	OG2,	as	after	heating	and	adding	NaOH	the	
hydrogels	 formed	 immediately.	 The	 final	 pH	 of	 OG1	 and	 OG2	 gels	 in	 the	 presence	 of	
additives	was	the	same	as	for	the	hydrogels	alone.	
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Gel	Formation	with	the	Incorporation	of	Different	Concentrations	of	Heparin	or	C16-DAPMA	
In	 order	 to	 test	 the	 influence	 of	 heparin	 on	 the	 formation	 of	OG1	 and	OG2	hydrogels,	
different	concentrations	of	heparin	(38	µM;	150	µM;	300	µM;	400	µM;	600	µM;	1000	µM)	
were	added	to	the	gelator	solutions.	For	all	the	different	concentrations	tested,	stable	and	
homogeneous	gels	were	obtained,	suggesting	that	the	presence	of	heparin	does	not	inhibit	
gel	formation.	The	same	was	observed	when	different	concentrations	of	C16-DAPMA	(150	
µM;	300	µM;	600	µM;	800	µM;	1000	µM;	1200	µM)	were	added	to	OG1	and	OG2	gels,	with	
stable	and	homogenous	gels	being	formed	in	each	case.			
	
Gel	Formation	with	Constant	Concentrations	of	Heparin	and	Different	Concentrations	of	
C16-DAPMA	
Gel	formation	was	then	tested	by	keeping	the	heparin	concentration	constant	and	varying	
C16-DAPMA	concentration	in	order	to	verify	the	best	charge	ratio	of	these	two	molecules	
for	the	formation	of	stable	gels.	For	the	different	heparin	concentrations	tested,	an	initial	
charge	 ratio	 (+/-)	 of	 2	 was	 used.	 If	 no	 stable/	 homogeneous	 gels	 were	 formed,	 lower	
concentrations	of	C16-DAPMA	were	used	for	the	same	heparin	concentration.		
	
Table	5.1	shows	the	tested	ratios	of	heparin	and	C16-DAPMA	in	OG1	hydrogels,	where	it	is	
possible	 to	verify	 that	 for	a	heparin	concentration	of	150	µM,	the	use	of	 the	maximum	
concentration	of	C16-DAPMA	calculated	lead	to	the	formation	of	stable	gels.	For	heparin	
concentrations	above	300	µM,	charge	ratios	below	2	were	needed	to	allow	the	formation	
of	stable	gels.	The	higher	the	heparin	concentration,	the	lower	the	charge	ratio	between	
heparin	and	C16-DAPMA	needed	to	obtain	stable	and	uniform	gels.	This	may	indicate	that	
on	increasing	the	heparin/C16-DAPMA	concentration,	more	aggregates	will	be	present	and	
the	dispersity	of	these	aggregates	destabilises	the	nanofiber	gel	network.		
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Table	5.1.	Test	of	different	heparin/	binder	ratios	on	OG1	gel	formation.	
[Heparin]	(µM)	 [C16-DAPMA]	(µM)	 Gel	Formation	 Charge	ratio	+/-	
150	 Below	600	 Stable	gel	 2	
	
300	
Above	1100	 Non	uniform	gel	 	
1.7	
Below	1000	 Stable	gel	
	
400	
Above	900	 Non	uniform	gel	 	
1	
Below	800	 Stable	gel	
	
600	
Above	1300	 Non	uniform	gel	 	
1	
Below	1200	 Stable	gel	
	
The	incorporation	of	different	heparin	and	C16-DAPMA	ratios	within	OG2	hydrogels	(	Table	
5.2)	revealed	that	the	use	of	a	charge	ratio	of	2	for	all	the	different	heparin	concentrations	
tested,	resulted	in	the	formation	of	stable	gels.	Unlike	the	OG1	hydrogels,	the	increase	of	
the	heparin/	C16-DAPMA	concentrations	within	the	OG2	network	did	not	appear	to	affect	
gel	 stability,	 which	may	 indicate	 a	 higher	 loading	 capacity	 of	 OG2	 hydrogels	 than	OG1	
hydrogels,	or	less	sensitivity	to	an	excess	of	C16-DAPMA.			
	
	Table	5.2.	Test	of	different	heparin/	binder	ratios	in	OG2	gel	formation.	
[Heparin]	(µM)	 [C16-DAPMA]	(µM)	 Gel	Formation	 Charge	ratio	+/-	
150	 Below	600	 Stable	gel	 2	
300	 Below	1200	 Stable	gel	 2	
400	 Below	1600	 Stable	gel	 2	
600	 Below	2400	 Stable	gel	 2	
	
	
5.2.1. Thermal	Stability	and	Tgel	Determination	
The	 thermal	 stability	 of	 the	 gels	 formed	 in	 the	 previous	 sections	 was	 tested	 by	 the	
“dropping	ball	method”,	where	a	steel	ball	is	placed	on	top	of	the	gel	and	the	temperature	
monitored	 by	 placing	 the	 gels	 in	 a	 heating	 block	 (Figure	 5.4).308	 The	 Tgel	 value	 was	
considered	the	temperature	at	which	the	steel	ball	started	to	fall	through	the	gel.	OG1	gel	
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(0.5%	 w/v)	 in	 water	 presented	 a	 Tgel	 value	 of	 65	 °C.	 The	 incorporation	 of	 different	
concentrations	of	heparin,	C16-DAPMA	and	heparin/C16-DAPMA	aggregates	 resulted	 in	
the	observations	of	 the	 same	Tgel	 value,	 indicating	 that	 the	presence	of	 these	different	
components	had	no	effect	on	the	thermal	stability	of	the	OG1	gel.		
	
The	OG2	gel	(0.5%	w/v)	in	water	presented	a	Tgel	value	of	72	°C.		The	presence	of	heparin	
in	the	gel	yielded	materials	with	Tgel	values	of	approximately	78	°C,	that	can	be	considered	
as	 the	 same	Tgel	 range	 as	 for	 the	 gel	 alone,	 indicating	 that	 heparin	does	not	 appear	 to	
significantly	affect	the	thermal	stability	of	OG2	gels.	When	C16-DAPMA,	or	heparin	bound	
to	 C16-DAPMA	 were	 incorporated	 within	 the	 gel,	 the	 Tgel	 values	 decreased	 to	
approximately	50	°C,	indicating	that	C16-DAPMA	and	heparin/C16-DAPMA	aggregates	do	
influence	the	thermal	stability	of	OG2	hydrogels.								
	
	
Figure	5.4.	Dropping	ball	method:	Steel	balls	are	placed	on	top	of	gels,	that	subsequently	
are	placed	in	a	heating	block,	where	the	temperature	is	monitored	and	recorded.	
	
5.2.2. Transmission	Electron	Microscopy	
TEM	 images	 of	 the	OG1	 gel,	 the	OG1	 gel	 in	 the	 presence	 of	 heparin,	 as	well	 as	 in	 the	
presence	 of	 C16-DAPMA	 and	 heparin-C16-DAPMA	 aggregates	 were	 obtained	 to	 gain	 a	
better	understanding	of	the	morphology	of	these	different	systems.		
	
TEM	images	of	the	OG1	hydrogel	(Figure	5.5)	showed	the	presence	unbranched	nanofibers	
with	a	diameter	of	13.6	±	1.6	nm.	In	the	presence	of	heparin	(Figure	5.6),	the	OG1	hydrogel	
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showed	 a	 different	 morphology,	 with	 what	 appeared	 to	 be	 rigid	 alignment	 of	 the	
nanofibers	(12.7	±	1.0	nm)	being	induced	by	heparin,	resulting	in	thicker	structures	that	
resemble	needles.	In	addition,	when	C16-DAPMA	is	added	into	the	OG1	hydrogels	(Figure	
5.7),	it	also	appears	to	influence	the	self-assembly	of	OG1,	contributing	to	the	formation	of	
significantly	thinner	(4.4	±	0.4	nm	in	diameter)	and	longer	unbranched	nanofibers,	when	
compared	to	the	OG1	hydrogel	alone.			
	
Figure	5.8,	shows	the	OG1	hydrogel	in	the	presence	of	heparin	bound	to	C16-DAPMA	using	
phosphotungstic	acid	(4.2%)	stain	and	a	gold	grid,	where	it	is	possible	to	see	the	presence	
of	both	nanofibers	and	the	typical	organised	aggregates	of	heparin	interacting	with	C16-
DAPMA.	However,	it	must	be	noted	that	these	conditions	for	imaging	did	not	result	in	very	
clear	 images.	 It	 was	 difficult	 to	 identify	 the	 gel	 nanofibers	 and	 for	 that	 reason,	 all	 the	
imaging	 was	 repeated	 using	 uranyl	 acetate	 stain	 in	 a	 copper	 grid	 as	 described	 in	 the	
experimental	part.	However,	using	this	approach	the	stain	did	not	set	properly	or	reveal	
clear	images.	Nevertheless,	it	is	possible	to	conclude	that	the	incorporation	of	heparin-C16-
DAPMA	aggregates	did	not	prevent	the	nanofiber	assembly	and	the	interactions	between	
heparin	 and	 C16-DAPMA	 remain	 present,	 as	 the	 typical	 hierarchically-organised	 and	
aligned	nanostructures	of	heparin-C16-DAPMA	aggregates	were	observed.	
	
	
Figure	5.5.	TEM	images	of	OG1	(0.5%	w/v)	gel.	Scale	bars:	1	µm	(left)	and	500	nm	(right).	
Chapter	5	
	
	
	
209	
	
Figure	5.6.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	heparin	(38	µM).	Scale	
bars:	1	µm	(left)	and	200	nm	(right).	
	
Figure	5.7.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	C16-DAPMA	(150	µM).	
Scale	bars:	500	nm	(left)	and	200	nm	(right).	
	
Figure	5.8.	TEM	images	of	OG1	(0.5%	w/v)	gel	in	the	presence	of	heparin(38µM)	and	C16-
DAPMA	(150	µM).		
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The	morphology	of	OG2	gels	was	also	analysed	by	TEM	imaging	as	shown	in	Figure	5.9,	
where	 it	 is	possible	 to	observe	 the	presence	of	unbranched	and	 long	nanofibers	with	a	
diameter	of	4.8	±	0.3	nm,	proving	self-assembly	of	the	gelator	into	1D	fibers	in	water.	When	
heparin	was	present	(Figure	5.10)	it	was	possible	to	once	again	verify	the	presence	of	these	
long	unbranched	nanofibers	(5.7	±	0.5	nm	in	diameter)	and	unspecific	polymer	aggregates	
that	may	correspond	to	heparin.	The	morphology	of	the	nanofibers	does	not	appear	to	be	
significantly	affected	by	 the	presence	of	heparin	and	no	 interactions	are	believed	 to	be	
happening	between	the	gelator	and	the	heparin.	On	the	other	hand,	when	C16-DAPMA	
was	incorporated	into	the	OG2	gel	network,	two	different	nanofiber	morphologies	were	
identified,	as	 shown	 in	Figure	5.11,	with	no	visible	presence	of	 the	self-assembled	C16-
DAPMA	micelles.	While	the	unbranched	long	nanofibers	were	still	present	(5.2	±	0.2	nm	in	
diameter);	branched	and	shorter	nanofibers	were	also	observed	(9.2	±	0.7	nm	in	diameter).	
This	 may	 indicate	 that	 the	 C16-DAPMA	 is	 not	 self-assembling	 into	 micelles	 and	 may	
coassemble	 with	 the	 OG2	 molecules	 contributing	 to	 the	 different	 morphology	 being	
observed.309	This	is	consistent	with	the	observation	that	C16-DAPMA	lowers	the	Tgel	value	
of	 OG2	 as	 described	 above	 and	 suggests	 this	may	 be	 underpinned	 by	 a	morphological	
change.	
	
When	both	heparin	 and	C16-DAPMA	were	 incorporated	within	 the	 gel	 network	 (Figure	
5.12)	it	was	possible	to	observe	the	presence	of	aggregates	along	with	OG2	nanofibers	(7.5	
±	1.2	nm	in	diameter).	However,	in	these	aggregates,	the	presence	of	the	well-organized	
hierarchical	 nanostructures	 characteristic	 of	 C16-DAPMA	 interacting	 with	 heparin	 (as	
described	in	Chapter	2)	were	not	observed,	and	it	was	therefore	not	possible	to	confirm	
that	the	interactions	remain	intact.	Additionally,	it	is	noticeable	that	the	presence	of	the	
heparin/C16-DAPMA	aggregates	 somewhat	 influenced	 the	 length	of	 the	 fibers,	 that	are	
significantly	shorter	 than	the	typical	 long	nanofibers	of	 the	self-assembled	OG2	gelator.	
Once	again	this	supports	the	observation	of	a	lower	Tgel	value	on	this	material.	
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Figure	5.9.	TEM	images	of	OG2	(0.5%	w/v)	gel.	Scale	bars:		1	µm	(left)	and	500	nm	(right).	
	
Figure	5.10.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	heparin	(38	µM).	Scale	
bars:	500	nm	(left)	and	200	nm	(right).	
	
Figure	5.11.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	C16-DAPMA	(150	µM).	
Scale	bars:	500	nm	(left)	and	200	nm	(right).	
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Figure	5.12.	TEM	images	of	OG2	(0.5%	w/v)	gel	in	the	presence	of	heparin(38µM)	and	
C16-DAPMA	(150	µM).	Scale	bars:	200	nm	(left)	and	100	nm	(right).	
	
5.2.3. Rheology	Studies	
The	influence	of	the	incorporation	of	C16-DAPMA	and	heparin	within	the	OG1	and	OG2	gel	
networks	was	studied	by	rheology.	For	that	purpose,	the	strain	dependence	of	G’	and	G’’	
for	 0.5%	 w/v	 OG1	 hydrogels	 was	 measured	 and	 is	 presented	 on	 Figure	 5.13.	 The	
incorporation	 of	 different	 components	 (0.3	 mM	 of	 heparin,	 1.2	 mM	 of	 C16-DAPMA	
individually	and	bound)	within	the	OG1	gel	matrix	did	not	significantly	affect	the	stability	
of	the	gel	and	in	each	case	a	LVR	up	to	approximately	1.3%	of	strain	was	obtained.	This	
agrees	with	the	earlier	observation	that	the	additives	also	have	minimal	impact	on	other	
macroscopic	properties	such	as	thermal	stability.				
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Figure	5.13.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	OG1	gel	(),	OG1	gel	with	heparin	(△),	OG1	gel	with	C16-DAPMA	(◇)	and	OG1	
gel	with	heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.				
	
Figure	5.14	 follows	the	change	 in	 rheological	performance	of	OG1	over	 time	and	hence	
shows	the	gelation	kinetics	of	OG1	hydrogels.	As	the	gelation	of	OG1	occurs	within	seconds,	
when	the	measurement	was	started	the	gel	was	already	formed	and	thus	a	constant	G’	
value	 was	 obtained.	 Only	 for	 the	 sample	 containing	 heparin	 and	 C16-DAPMA	 was	 it	
possible	to	observe	an	increase	of	G’	from	608	Pa	at	0	minutes	to	1281	Pa	at	5	minutes,	
indicating	that	the	incorporation	of	the	hierarchical	aggregates	may	slightly	slow	down	the	
gelation	 kinetics	 of	OG1	 hydrogels.	 In	 addition,	 the	 presence	 of	 C16-DAPMA	 in	 the	 gel	
resulted	in	the	highest	G’	value,	meaning	that	the	fibril	network	is	stiffer	when	compared	
to	the	other	tested	conditions.	This	result	corroborates	the	obtained	TEM	images,	where	
the	incorporation	of	C16-DAPMA	molecules	appeared	to	promote	the	self-assembly	of	the	
OG1	gelator	into	thinner	and	longer	fibers	that	may	result	in	a	denser	and	stronger	gel.				
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Figure	5.14.	Time	sweep	oscillatory	rheology	measurements	(frequency	=	1Hz	and	0.5%	
strain)	for	OG1	gel	(),	OG1	gel	with	heparin	(△),	OG1	gel	with	C16-DAPMA	(◇)	and	
OG1	gel	with	heparin	and	C16-DAPMA	(£).			
	
Figure	5.15	shows	the	strain	dependence	of	G’	and	G’’	for	0.5%	w/v	OG2	hydrogels	that	
exhibited	a	similar	LVR	when	alone,	incorporated	with	0.3	mM	of	heparin	and	0.3	mM	of	
heparin	bound	to	1.2	mM	of	C16-DAPMA	(up	to	approximately	1.8%	of	strain).	However,	
when	 1.2	 mM	 of	 C16-DAPMA	 was	 present	 within	 the	 gel	 the	 LVR	 decreased	 to	
approximately	1%	strain,	indicating	that	the	incorporation	of	C16-DAPMA	contributes	to	a	
less	stable	gel.	This	 is	 in	agreement	with	TEM	imaging	which	showed	an	 impact	of	C16-
DAPMA	on	OG2	nanofibre	morphology,	and	is	also	in	agreement	with	other	macroscopic	
properties	such	as	thermal	stability.	
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Figure	5.15.	Strain	amplitude	dependence	of	the	storage	modulus	(G’)	and	loss	modulus	
(G’’)	for	OG2	gel	(),	OG2	gel	with	heparin	(△),	OG2	gel	with	C16-DAPMA	(◇)	and	OG2	
gel	with	heparin	and	C16-DAPMA	(£).	Frequency	=	1	Hz.				
	
Figure	5.16	shows	the	kinetic	rheological	data	for	OG2	gelation.	The	OG2	hydrogel	has	a	
gradual	 increase	 of	 G’	 over	 60	 minutes,	 with	 the	 first	 10	 minutes	 showing	 the	 most	
significant	increase	(from	268	Pa	at	0	min	to	1072	Pa	at	10	min).	When	heparin	is	added	to	
the	hydrogel	a	similar	profile	of	gelation	is	obtained,	with	a	slightly	lower	G’	value	after	60	
minutes	(1559	Pa	compared	to	2481	Pa	from	OG2	hydrogel	alone).	When	heparin	bound	
to	C16-DAPMA	is	present,	a	faster	gelation	process	appears	to	happen	during	the	first	15	
minutes	(G’	increases	from	268	Pa	at	0	min	to	2243	Pa	at	15	min),	and	after	that	G’	becomes	
constant.	After	60	minutes	a	similar	G’	to	the	OG2	hydrogel	is	obtained,	indicating	a	faster	
gelation	but	the	formation	of	materials	with	similar	overall	stifness.	The	incorporation	of	
C16-DAPMA	results	 in	faster	gelation,	reaching	the	maximum	G’	value	after	10	minutes,	
but	the	gel	is	significantly	weaker	(G’	=	695	Pa	at	60	minutes).	Indeed,	as	observed	by	TEM,	
shorter	nanofibers	were	formed	when	C16-DAPMA	was	added	into	the	OG2	gel,	explaining	
the	fact	that	the	gelation	process	is	faster	and	the	formation	of	branched	nanofibers	can	
contribute	to	a	weaker	gel,	with	lower	thermal	stability.	The	more	rapid,	but	less	effective	
assembly	in	the	presence	of	C16-DAPMA	suggests	that	this	additive	is	intimately	involved	
in	the	assembly	process	as	described	above.	
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Figure	5.16.	Time	sweep	oscillatory	rheology	measurements	(frequency	=	1Hz	and	0.5%	
strain)	for	OG2	gel	(),	OG2	gel	with	heparin	(△),	OG2	gel	with	C16-DAPMA	(◇)	and	
OG2	gel	with	heparin	and	C16-DAPMA	(£).			
	
5.3. Release	Studies	
The	release	of	heparin	from	OG1	and	OG2	hydrogels	was	then	studied.	Furthermore,	the	
influence	 of	 agarose	 when	 added	 to	 OG1/OG2	 hydrogelators	 to	 form	 hybrid	 gels	 and	
subsequently	 release	 heparin	 was	 also	 investigated.	 The	 same	 release	 experiments	 as	
described	in	Chapters	3	and	4	were	performed	for	OG1	and	OG2	hydrogels.	Therefore,	one	
experiment	consisted	on	placing	10	mM	Tris-HCl/	150	mM	NaCl	buffer	(1	mL)	on	top	of	the	
gel	(3	mL)	and	collecting	aliquots	of	buffer	over	time	and	the	second	experiment	consisted	
of	forming	gel	cylinders	(1	mL)	which	requires	the	presence	of	agarose	and	placing	them	in	
a	jar	with	buffer	(35	mL)	as	receiving	medium.	
	
Heparin	release	from	OG1	hydrogels	
Figure	 5.17	 shows	 the	 release	 profile	 obtained	 for	 0.5%	w/v	OG1	 hydrogels	 containing	
either	1	mM	of	heparin	or	1	mM	of	heparin	with	2	mM	of	C16-DAPMA	also	present.	When	
only	heparin	is	present	within	the	OG1	gel	network	it	was	possible	to	observe	a	gradual	
increase	of	heparin	being	released	over	the	first	24	hours,	with	56%	of	heparin	released	
over	 that	period	of	 time.	After	24	hours,	 the	 release	of	heparin	 is	essentially	complete,	
reaching	a	total	of	59%	release	after	72h.	When	C16-DAPMA	was	interacting	with	heparin	
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within	the	gel	network	the	release	of	heparin	was	inhibited	as	expected,	with	only	10%	of	
heparin	being	released	after	72h,	clearly	demonstrating	the	efficacy	of	C16-DAPMA	binding	
to	 heparin	 even	 after	 being	 incorporated	 within	 OG1	 gel	 network,	 and	 hence	 limiting	
heparin	release.	
	
	
Figure	5.17.	Heparin	release	from	OG1	hydrogel	(0.5%	w/v)	containing	1	mM	of	heparin	(
▲)	and	1	mM	of	heparin	with	2	mM	of	C16-DAPMA	(¢).	
	
The	 same	 experiment	 was	 performed	 to	 verify	 how	 heparin	 release	 is	 affected	 when	
incorporated	 into	a	hybrid	hydrogel	 consisting	of	0.5%	w/v	OG1	as	 LMWG	and	1%	w/v	
agarose	 as	 PG.	When	 comparing	 the	 release	 of	 heparin	 from	 OG1	 hydrogel	 and	 OG1-
agarose	hybrid	hydrogel	(Figure	5.18),	an	identical	release	profile	was	obtained	for	both	
conditions,	with	59%	and	62%	heparin	released	after	72	h,	from	OG1	hydrogel	and	OG1-
agarose	hybrid	hydrogel,	respectively.	This	indicates	that	the	addition	of	1%	w/v	of	agarose	
to	 OG1	 hydrogels	 allows	 to	 obtain	 a	 stiffer,	 more	 robust	 and	manipulatable	 hydrogel,	
without	adversely	affecting	the	release	of	heparin.		
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Figure	5.18.	Heparin	release	from	OG1	hydrogel	(0.5%	w/v)	with	1	mM	of	heparin	in	the	
absence	of	agarose	()	and	in	the	presence	of	1%	w/v	of	agarose	(¢).	
	
Figure	5.19	compares	the	release	of	heparin	from	0.5%	w/v	OG1-agarose	hybrid	hydrogels	
containing	1	mM	of	heparin	when	buffer	was	placed	on	 top	of	 the	gel,	and	when	a	gel	
cylinder	was	 immersed	 in	 buffer.	When	using	 the	OG1-agarose	 hybrid	 gel	 cylinder,	 the	
amount	of	 released	heparin	 increased	 to	97%	after	72	hours,	 compared	with	62%	total	
release	obtained	with	the	previous	method.	This	proves	once	again	that	the	greater	the	
surface	area	to	volume	ratio	of	the	gel	in	contact	with	buffer,	the	more	of	the	heparin	can	
be	released,	suggesting	that	some	of	the	heparin	effectively	becomes	trapped	within	the	
gel	nanostructure	if	it	is	too	far	away	from	the	gel	surface.	
						
	
Figure	5.19.	Different	methods	of	heparin	release	from	OG1	hydrogel	(0.5%	w/v).	():	
Buffer	on	top	of	the	gel.	(■):	Gel	cylinder.	
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Heparin	release	from	OG2	hydrogels	
Heparin	release	from	OG2	hydrogels	with	buffer	added	on	top	is	shown	on	Figure	5.20.	A	
gradual	increase	on	the	release	of	heparin	was	observed	over	time,	reaching	a	maximum	
of	67%	after	72	hours.	Despite	the	fact	that	OG1	hydrogels,	in	the	same	conditions,	resulted	
in	a	lower	total	release	of	heparin	after	72	hours,	it	is	worth	noting	that	after	6	hours,	47%	
of	heparin	was	released	from	the	OG1	gels,	 instead	of	only	33%	from	the	OG2	gel.	This	
indicates	a	faster	initial	release	of	heparin	in	OG1	hydrogels	but	a	lower	total	amount	of	
heparin	that	can	be	released,	when	compared	with	OG2	gels.	This	indicates	that	the	kinetics	
of	release	are	better	for	OG1	but	the	thermodynamics	of	release	are	better	for	OG2.	This	
may	be	a	 result	of	 the	change	 in	morphology	of	 the	OG1	nanofibers	 in	 the	presence	of	
heparin	observed	by	TEM,	with	the	junction	of	the	fibers	into	a	needle	shape	contributing	
to	 a	 different	 heparin	 release	 profile	 and	 leading	 to	 more	 of	 the	 heparin	 becoming	
effectively	permanently	entrapped.	 Interestingly,	when	C16-DAPMA	was	present	within	
the	gel	network,	it	did	not	inhibit	the	release	of	heparin,	as	expected,	and	a	very	similar	
release	of	heparin	was	obtained	as	when	only	heparin	was	present	(Figure	5.20).	This	may	
be	due	to	the	fact	that	when	NaOH(aq)	is	added	to	form	the	gel,	after	acidifying	the	sample,	
the	pH	of	the	hydrogel	is	not	neutral	but	between	8-9	(measured	by	placing	pH	test	paper	
inside	the	gel),	which	can	contribute	to	the	deprotonation	of	C16-DAPMA	that	can	then	no	
longer	interact	electrostatically	with	heparin.	This	agrees	with	the	triggered	release	assay	
performed	in	Chapter	4,	when	a	pH	10	buffer	was	added	on	top	of	the	gel	to	obtain	the	
release	of	heparin	when	C16-DAPMA	was	effectively	binding	to	heparin.	Additionally,	this	
is	 supported	 by	 the	 fact	 that	 the	well-organised	 hierarchical	 crystalline	 nanostructures	
characteristic	of	heparin	interacting	with	C16-DAPMA	could	not	be	observed	by	TEM.	We	
suggest	that	the	agglomerates	observed	by	TEM	probably	correspond	to	heparin	alone	and	
that	C16-DAPMA	in	this	system	is	intimately	involved	in	OG2	assembly	and	does	not	get	
involved	in	heparin	binding.	
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Figure	5.20.	Heparin	release	from	OG2	hydrogel	(0.5%	w/v)	containing	1	mM	of	heparin	(
▲)	and	1mM	of	heparin	and	2	mM	of	C16-DAPMA	(¢).	
	
Surprisingly,	 the	 use	 of	 agarose	 to	 prepare	 hybrid	 hydrogels	 with	 OG2	 resulted	 in	 the	
formation	of	 very	unstable	 gels	or	partial	 gels.	 Therefore,	 it	was	not	possible	 to	obtain	
hybrid	 hydrogels	 using	 OG2	 and	 agarose.	 It	 is	 believed	 that	 the	 fact	 that	 OG2	 is	 a	 pH	
responsive	gelator	and	needs	to	initially	be	acidified	at	pH	2	contributed	to	the	hydrolysis	
of	agarose	and	thus	prevented	the	formation	of	uniform,	stable	and	stiff	hybrid	gels.		
	
5.4. Positively	Charged	Cyclohexane	LMWG	
A	 different	 approach	 to	 release	 heparin	 in	 a	 controlled	 manner	 involves	 the	 direct	
interaction	 of	 heparin	 with	 negatively	 charged	 nanofibers	 that	 can	 degrade	 or	 can	 be	
enzymatically	 cleaved.	 An	 example	 of	 heparin	 directly	 interacting	 with	 nanofibers	 was	
already	described	in	Chapter	1	–	Section	1.6.195	Another	example	was	reported	by	Xu	and	
coworkers	with	the	development	of	a	heparinized	Cu(OH)2	nanofibrous	membrane.	It	was	
confirmed	that	the	negatively	charged	heparin	was	successfully	immobilised	onto	positive	
charged	 Cu(OH)2	 nanofibers	 by	 electrostatic	 interactions.	 The	 system	 exhibited	 good	
hemocompatibility	 and	 very	 good	 antibacterial	 activities	 against	 Escherichia	 coli	 and	
Staphyloccocus	aureus.310	However,	the	release	of	heparin	from	the	triggered	degradation	
of	self-assembled	nanofibers	was,	to	the	best	of	our	knowledge,	not	tested	yet.	
	
During	the	placement,	a	new	hydrogelator	was	synthesised	by	Vincent	le	Sage	(Figure	5.21)	
with	a	similar	structure	to	OG2	but	with	one	of	the	ethylene	glycol	chains	changed	in	order	
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to	add	an	amine	group	and	obtain	a	positively	charged	gelator	that	can	potentially	interact	
directly	with	heparin.	As	the	phenylalanyl-aminoquinoline	can	be	enzymatically	cleaved,	
the	 triggered	 release	 of	 heparin	 could	 then	 be	 easily	 achieved.	 Therefore,	 further	
characterisation	and	release	assays	were	performed	with	this	gelator	to	better	understand	
the	ability	of	this	gelator	to	bind	heparin	and	release	it.	
	
	
Figure	5.21.	Positively	charged	cyclohexane	gelator	(OG+).	
	
OG+	 hydrogels	 (0.5%	 w/v)	 could	 be	 obtained	 using	 two	 different	 approaches,	 one	 by	
acidifying	the	gelator	solution	in	water,	with	HCl	(1	M),	to	completely	dissolve	the	gelator,	
followed	by	neutralisation	of	the	solution	by	NaOH	(1	M)	and	the	other	by	dissolving	the	
gelator	 in	 DMSO	 and	 adding	 0.1	 M	 Tris-HCl	 buffer,	 pH	 7.75	 (mixture	 ratio	 of	 1:9	
DMSO:buffer).		
	
TEM	images	of	OG+	hydrogel	and	OG+	hydrogel	in	the	presence	of	heparin	were	obtained	
using	the	first	method	of	preparation	described	above,	and	are	shown	in	Figure	5.22	and	
5.23.	OG+	nanofibers	presented	a	similar	morphology	to	OG2	nanofibers	with	unbranched	
and	 elongated	 nanofibers	 having	 a	 diameter	 of	 6.8	 ±	 0.8	 nm.	 When	 heparin	 was	
incorporated	within	the	gel	 it	was	possible	to	observe	the	presence	of	needle-like	semi-
crystalline	structures	that	may	correspond	to	heparin	(Figure	5.23	-	top).	When	obtaining	
more	detailed	 images	of	 these	nanostructures	 (Figure	5.23	 -	bottom)	 it	was	possible	 to	
clearly	 observe	 the	 presence	 of	 what	 appear	 to	 be	 nanofibers	 wrapped	 around	 larger	
fibrillar	 objects.	 In	 a	 first	 conclusion,	 it	 appears	 that	 these	 are	 OG+	 nanofibers	 that	
effectively	 bind	 to	 heparin	 and	may	 as	 well	 have	 an	 influence	 in	 the	 organization	 and	
packing	of	heparin	into	a	needle-like	morphology.	This	fascinating	hierarchical	nanoscale	
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architecture	 supports	 the	 view	 that	 interactions	 can	 be	 established	 between	 OG+	 and	
heparin.				
	
Figure	5.22.	TEM	image	of	OG+	(0.5%	w/v)	gel.	Scale	bar:	200	nm.	
	
	
	
Figure	5.23.	TEM	images	of	OG+	gel	(0.5%	w/v)	in	the	presence	of	heparin	(78	µM).	Scale	
bars:	2	µm	(top);	200	nm	(bottom	left)	and	100	nm	(bottom	right).		
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The	 OG+	 gelator	was	 designed	 so	 it	 can	 bind	 directly	 to	 heparin	 and	 be	 enzymatically	
cleaved	by	a-chymotrypsin	(a-chy),	resulting	in	the	release	of	heparin.	Therefore,	heparin	
release	 from	OG+	hydrogels	was	 tested	by	using	1	mL	of	gel	 samples	 (1:9	DMSO:buffer	
preparation	method)	and	placing	1	mL	buffer	on	top	of	the	hydrogels.	Aliquots	of	buffer	
were	 collected	 over	 time	 and	 added	 to	 MalB	 to	 detect	 the	 presence	 of	 heparin	 (as	
described	in	Chapter	3).	Three	different	conditions	were	tested	and	the	obtained	results	
are	shown	in	Figure	5.24	(it	should	be	noted	that	this	experiment	was	performed	with	only	
one	gel	sample	per	condition	and	in	the	future,	it	should	be	repeated	in	triplicate).		
	
	
Figure	5.24.	Heparin	release	from	OG+	hydrogels:	()	OG+	hydrogel	with	heparin	without	
a-chy;	(¯)	OG+	hydrogel	with	heparin	and	a-chy	at	room	temperature;	(¿)	OG+	
hydrogel	with	heparin	and	a-chy	at	37	°C.	
	
Firstly,	OG+	hydrogel	in	the	presence	of	1	mM	of	heparin	was	monitored	to	confirm	that	
the	gel	nanofibers	were	effectively	binding	to	heparin	and	therefore,	no	release	of	heparin	
was	being	obtained	by	a	possible	excess	of	the	concentration	of	heparin	used.	Over	the	
period	of	6	hours	it	was	observed	that	no	release	of	heparin	was	detected,	indicating	that	
OG+	effectively	binds	to	heparin	as	previously	seen	in	the	TEM	images.	This	is	the	first	time	
in	this	thesis	we	have	observed	a	gel	which	completely	inhibits	heparin	release	without	the	
requirement	 for	 C16-DAPMA	 assemblies	 to	 be	 present.	 Moreover,	 as	 the	 heparin	
agglomerates	 appear	 to	 be	 wrapped	 by	 the	 gel	 nanofibers,	 the	 fact	 that	 a	 higher	
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concentration	of	heparin	is	being	used	when	compared	to	the	TEM	samples,	did	not	appear	
to	affect	the	binding	efficiency	and	no	excess	of	heparin	appears	to	be	free	within	the	gel	
network.		
	
We	then	added	900	µL	of	a-chy	in	0.1	M	Tris-HCl	buffer,	pH	7.75	to	100	µL	DMSO	solution	
of	OG+	gelator	with	heparin.	The	enzyme	concentration	after	mixing	with	DMSO	was	40	
µM.	As	described	in	the	introduction,	a-chy	needs	a	stimulus,	such	as	temperature,	to	start	
the	 enzymatic	 cleavage	 and	 as	 reported	 	 by	 van	 Bommel	 at	 al.,298	 an	 increase	 in	
temperature	contributes	to	an	increase	in	enzymatic	hydrolysis.	Therefore,	the	experiment	
was	performed	by	keeping	one	sample	at	room	temperature	(RT	-	21-25	°C)	and	another	
at	37	°C	to	verify	the	effect	of	temperature	in	the	activation	of	the	enzymatic	cleavage	and	
consequently	the	release	of	heparin.	When	the	gel	was	kept	at	room	temperature	a	release	
of	12%	of	heparin	was	obtained	after	6	hours.	At	37	°C	a	significant	increase	in	the	release	
of	 heparin	 was	 obtained,	 with	 approximately	 double	 the	 percentage	 of	 heparin	 being	
release	after	30	minutes	(from	6%	at	RT	to	11%	at	37	°C)	up	to	triple	release	after	6	hours	
(form	12%	at	RT	to	37%	at	37	°C).	Therefore,	the	release	of	heparin	from	OG+	hydrogels	
was	achieved	through	the	enzymatic	cleavage	of	the	phenylalanyl-aminoquinoline	moiety	
and	 by	 increasing	 the	 temperature	 a	 higher	 percentage	 of	 heparin	 is	 released.	 This	
therefore	 indicates	that	controlled	breakdown	of	gel	nanostructures	can	 induce	heparin	
release	when	the	gel	nanofibers	and	heparin	are	mutually	interacting.	This	indicates	the	
potential	of	well-defined	hydrogels	to	achieve	controlled	heparin	release.				
	
5.5. Summary,	Conclusions	and	Future	Work		
The	orthogonal	self-assembly	of	OG1	and	OG2	hydrogelators	with	heparin	and	C16-DAPMA	
was	 investigated.	With	 respect	 to	 the	OG1	hydrogel,	 the	presence	of	heparin	 and	C16-
DAPMA	 contribute	 to	 different	 nanofiber	 morphologies,	 however	 with	 no	 evident	
influence	in	the	stability	of	the	gels	(similar	Tgel	and	LVR	values).	On	the	other	hand,	the	
incorporation	 of	 C16-DAPMA	 or	 heparin	 bound	 to	 C16-DAPMA	 in	 OG2	 hydrogels	
significantly	 changed	 the	 morphology	 of	 the	 nanofibers,	 affecting	 the	 mechanical	
properties	of	the	nanofibrils	and	the	gelation	kinetics.	It	was	proposed	that	C16-DAPMA	is	
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intimately	involved	in	OG2	assembly	and	that	the	pH	of	the	gel	prevents	its	interaction	with	
heparin.		
	
Release	of	heparin	from	both	hydrogels	was	successfully	demonstrated.	Additionally,	it	was	
possible	to	obtain	a	hybrid	hydrogel	with	OG1	and	agarose	with	equivalent	heparin	release	
and	 thus	controlling	 the	 release	of	heparin	 from	OG1	hybrid	hydrogels	by	changing	 the	
surface	 area	 to	 volume	 ratio.	 The	presence	of	C16-DAPMA,	 switched	off	 the	 release	of	
heparin	from	OG1	hydrogels	as	expected.		
	
Conversely,	the	use	of	agarose	with	OG2	gelators	inhibited	the	formation	of	a	stable	gel	
and	thus	limited	the	use	of	different	release	assays.	We	proposed	this	was	a	result	of	the	
pH	 changes	 used	 to	 form	 the	 gel.	Moreover,	 the	 presence	 of	 C16-DAPMA	within	 OG2	
hydrogels	did	not	 inhibit	heparin	release,	confirming	that	C16-DAPMA	is	not	 interacting	
with	heparin,	probably	due	to	the	basic	conditions	of	the	hydrogel	causing	deprotonation	
of	C16-DAPMA.		
	
OG+,	a	positively	charged	LMWG	proved	to	effectively	and	directly	bind	to	heparin,	with	
TEM	images	showing	gel	nanofibers	wrapped	around	heparin	aggregates.	The	release	of	
heparin	 was	 inhibited	 by	 this	 gel-binding	 event	 and	 was	 only	 achievable	 by	 enzymatic	
cleavage	of	 the	gelator	 leading	 to	breakdown	of	 the	gel	nanofibers,	with	an	 increase	 in	
temperature	contributing	to	a	higher	percentage	of	released	heparin.		
	
Future	work	could	seek	to	test	the	release	of	heparin	from	OG2	hydrogels	by	enzymatic	
cleavage,	using		a-chy.	Additionally,	it	would	be	interesting	to	test	the	release	of	heparin	
from	OG+	using	a-chy	at	different	temperatures	than	the	ones	tested	(between	25-45	°C),	
to	obtain	a	release	profile	dependent	on	temperature.	It	would	also	be	interesting	to	test	
the	maximum	loading	capacity	of	heparin	within	OG+	hydrogels	by	simply	testing	at	which	
concentration	heparin	starts	being	released	to	the	buffer	on	top	of	the	OG+	hydrogel	using	
MalB.	We	suggest	that	a	gelator	such	as	OG+	has	considerable	potential	for	the	controlled	
release	of	heparin	for	future	applications	in	tissue	engineering.	
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6. Conclusions	and	Future	Work	
6.1. Conclusions		
Initially,	a	family	of	simple	self-assembling	surfactant	molecules	based	on	saturated	fatty	
acids	was	 reported	and	 their	 ability	 to	bind	 to	heparin	was	 investigated.	Modifying	 the	
hydrophobic	chain	length	offers	a	mechanism	for	tuning	the	ability	of	these	compounds	to	
self-assemble	into	micellar	aggregates,	with	C16-DAPMA	being	the	optimal	system	in	terms	
of	 CMC.	 Furthermore,	 this	 compound	 is	 also	 the	 most	 effective	 heparin	 binder	 as	
determined	by	MalB	displacement	assays	–	it	is	suggested	that	this	indicates	the	synergy	
between	surfactant	self-assembly	and	polyanion	binding.		For	the	first	time,	the	nanoscale	
aggregates	formed	on	binding	between	SAMul	cationic	spherical	micelles	and	polyanionic	
cylindrical	 heparin	 were	 structurally	 characterised.	 In	 particular,	 C14-DAPMA	 and	 C16-
DAPMA	 formed	 highly	 organised	 nanocrystalline	 assemblies	 as	 observed	 by	 TEM.		
Characterisation	by	mesoscale	simulations	and	SAXS	further	confirmed	that	the	micelles	
remained	 intact	 during	 hierarchical	 assembly	 and	were	 packed	 in	 a	 face-centred	 cubic	
manner	on	contact	with	heparin.	 	The	assemblies	formed	by	the	most	effective	system,	
C16-DAPMA	 showed	 the	 highest	 degree	 of	 crystalline	 order	 revealed	 by	 the	 distinct	
diffraction	 peaks.	 These	 self-assembling	micelles	 present	 high	 stability	 even	when	 they	
form	very	strong	electrostatic	interactions	with	heparin,	indicating	they	can	be	considered	
as	distinct	building	blocks	for	nanoscale	assembly	even	in	very	competitive	conditions.	
	
In	 Chapter	 3,	 a	 simple	 multi-component	 approach	 to	 hybrid	 hydrogels	 with	 two	 self-
assembling	 components	 (DBS-COOH	 and	 C16-DAPMA)	 and	 two	 polymeric	 components	
(heparin	 and	agarose)	was	used	and	 the	 impact	of	 each	 component	on	 the	others	was	
characterised.		This	is	the	first	time	such	a	detailed	study	has	been	performed	in	a	multi-
component	gel	of	this	complexity.	The	self-assembly	of	DBS-COOH	is	slightly	modified	on	
the	nanoscale	by	heparin,	completely	disrupted	by	C16-DAPMA	and	unaffected	by	agarose.		
However,	 if	 the	 heparin	 is	 bound	 to	 self-assembled	multivalent	 C16-DAPMA,	 then	 the	
assembly	 of	 DBS-COOH	 still	 takes	 place,	 and	 although	 the	 presence	 of	 the	 hierarchical	
heparin/C16-DAPMA	 aggregates	 has	 some	 minor	 impacts	 on	 gel	 performance,	 the	
components	are	largely	orthogonal	to	one	another.	The	PG	reinforces	all	materials	when	
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present,	and	dominates	macroscopic	behaviour.		DBS-COOH	retains	pH	responsiveness	and	
can	 be	 disassembled	 in	 the	 presence	 of	 the	 other	 components	 introducing	 triggered	
response	characteristics	to	these	hybrid	hydrogels.	The	release	of	heparin	from	the	DBS-
COOH	gel	network	was	achieved,	with	the	presence	of	C16-DAPMA	inhibiting	it	completely	
and	the	presence	of	the	PG	not	affecting	the	release	while	contributing	to	the	formation	of	
a	 more	 robust	 gel	 network.	 Cytocompatibility	 studies	 revealed	 that	 DBS-COOH	 is	 not	
cytotoxic,	hence	promising	for	biological	applications.				
	
The	same	multi-component	approach	and	characterisation	was	used	in	Chapter	4,	using	a	
different	LMWG	–	DBS-CONHNH2.	The	self-assembly	of	DBS-CONHNH2	was	unaffected	by	
the	 incorporation	of	heparin,	C16-DAPMA	and	agarose.	However,	 if	heparin	 is	bound	to	
C16-DAPMA	 the	 morphology	 of	 the	 gel	 fibers	 is	 affected,	 although	 the	 hierarchical	
organised	nanostructures	of	heparin-C16-DAPMA	aggregates	remain	intact	within	the	gel	
network.	 When	 the	 PG	 is	 present,	 DBS-CONHNH2	 self-assembly	 is	 unaffected	 and	 it	
contributes	to	the	formation	of	robust	gels.	The	release	of	heparin	from	the	DBS-CONHNH2	
gel	 network	 was	 achieved,	 and	 once	 again	 the	 presence	 of	 C16-DAPMA	 inhibited	 its	
release,	while	the	presence	of	the	PG	did	not	affect	release.	A	change	in	pH	of	the	release	
medium	contributed	to	triggered	release	of	heparin.	Cytocompatibility	studies	confirmed	
that	DBS-CONHNH2	hydrogels	are	not	cytotoxic,	and	cells	were	able	to	adhere	on	to	the	gel	
surface	and	proliferate,	with	the	metabolic	activity	of	the	cells	being	enhanced	when	10-
50	 µg/mL	 of	 heparin	 was	 incorporated	 within	 the	 gel	 network.	 However,	 C16-DAPMA	
proved	 to	be	cytotoxic	 for	 cells,	 and	agarose,	although	non-cytotoxic,	does	not	present	
adhesion	moieties	for	cells	to	adhere.	
	
In	Chapter	5,	multi-component	hydrogel	systems	using	cyclohexane	based	LMWGs	(OG1	
and	OG2)	were	reported.	The	self-assembly	of	OG1	is	slightly	affected	by	heparin	and	C16-
DAPMA	and	unaffected	by	agarose,	with	the	release	of	heparin	from	both	OG1	hydrogel	
and	OG1-agarose	hybrid	hydrogel	successfully	achieved	and	inhibited	by	the	presence	of	
C16-DAPMA.	The	self-assembly	of	OG2	is	unaffected	by	heparin	and	SAMul	C16-DAPMA,	
but	 was	 altered	 by	 the	 presence	 of	 heparin	 bound	 to	 C16-DAPMA,	 with	 changes	 in	
morphology,	and	inhibited	by	agarose.	The	release	of	heparin	over	time	from	OG2	hydrogel	
is	achievable,	however	the	presence	of	C16-DAPMA	does	not	inhibit	the	release	of	heparin	
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due	 to	 deprotonation	 of	 the	 heparin	 binder	 as	 the	 gel	 is	 formed	 by	 basification.	
Additionally,	a	positively	charged	cyclohexane-based	LMWG	–	OG+	was	introduced.	OG+	
directly	binds	to	heparin	as	a	consequence	of	its	positive	charge,	as	demonstrated	by	TEM	
images,	 and	 its	 triggered	 release	 can	 be	 obtained	 by	 enzymatic	 cleavage	 of	 the	 OG+	
hydrogel.		
	
With	 these	 studies,	 it	 was	 possible	 to	 gain	 fundamental	 insights	 into	multi-component	
systems	and	conclude	that	this	strategy	is	a	powerful	way	of	formulating	multi-functional	
materials	and	tuning	desired	characteristics	for	bioactive	release	of	heparin	and	potential	
cell	growth.			
	
6.2. Future	Work	
As	 future	work,	 triggered	heparin	 release	under	physiologically	 relevant	 conditions	 and	
multi-component	 hybrid	 gels	 should	 be	 studied,	which	 ultimately	may	have	 biomedical	
applications.	Studies	can	proceed	to	further	explore	the	pH	responsiveness	of	DBS-COOH	
and	 OG2	 hydrogels	 to	 release	 bioactive	 molecules	 by	 testing	 different	 bases	 or	 acids,	
respectively.	Different	heparin	binders,	such	as	cholesterol-based	SAMul	binders,	can	also	
be	 tested	 in	order	 to	optimise	 the	cytocompatibility	of	 the	multi-component	hybrid	gel	
systems	while	enabling	a	triggered	release	response	through	degradation	of	the	binders.	
DBS-CONHNH2	 and	 agarose	 hybrid	 hydrogels	 have	 good	 biocompatibility	 making	 them	
good	candidates	for	topical	drug	delivery	and	therefore	in	vitro	release	testing	(e.g.	cells	
Franz	diffusion)	may	be	performed.	To	better	understand	their	potential	as	3D	scaffolds	for	
cell	growth,	different	PGs	should	be	tested	along	with	different	types	of	mammalian	cells.	
Additionally,	 the	 release	of	heparin	 from	OG+	hydrogel	network	by	enzymatic	 cleavage	
should	be	performed	in	more	detail	in	order	to	understand	how	temperature	can	tune	the	
release	of	heparin	from	this	gel	system,	and	the	impacts	of	this	on	cell	growth.	
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7. Experimental	
	
7.1. General	Reagents	and	Methods	
All	 reagents	 were	 purchased	 from	 commercial	 sources	 and	 used	 directly	 without	 any	
further	 purification,	with	 the	 exception	 of	MalB	 dye	which	was	 synthesised	 in	 the	DKS	
laboratory	 following	 known	 methods.225	 Heparin,	 sodium	 salt,	 from	 porcine	 intestinal	
mucosa	(MW	13,500-15,000	Da)	was	purchased	from	Merck.	a-Chymotrypsin	from	bovine	
pancreas	 (MW	40,000	Da)	was	purchased	 from	Sigma.	Thin	 layer	chromatography	 (TLC)	
was	 performed	 on	Merck	 aluminium-backed	 plates	 coated	 with	 0.25	 nm	 silica	 gel	 60.	
Preparative	 gel	 permeation	 chromatography	 (GPC)	 was	 performed	 on	 Biobeads	 SX-1	
supplied	by	Bio-Rad.	ESI	mass	spectra	were	recorded	on	a	Bruker	Daltonics	Micro-Tof	mass	
spectrometer.	 Fluorescence	 spectra	 were	 obtained	 with	 a	 Hitachi	 F-4500	 fluorimeter.	
Infrared	 spectra	 were	 recorded	 on	 Shimadzu	 IRPrestige-21	 FT-IR	 spectrometer.	 UV-Vis	
absorbance	was	recorded	on	a	Shimadzu	UV-2401PC	spectrophotometer.	TEM	and	SEM	
images	were	obtained	by	Meg	Stark	at	Biology	Technology	Faculty,	University	of	York,	using	
a	FEI	Tecnai	12	Bio	TWIN	operated	at	120	kV	for	the	TEM	images	and	a	JEOL	JSM-7600F	
operated	at	3	kV	for	the	SEM	images.	Thermal	stability	was	recorded	on	a	Huber	Ministat	
230	circulator	oil	bath.	Kinetic	studies	were	performed	on	a	Bruker	AV500	spectrometer	
(1H	 500	 MHz)	 and	 a	 Jasco	 J810	 CD	 spectrophotometer.	 DLS	 and	 zeta	 potential	
measurements	 were	 recorded	 on	 a	 Zetasizer	 Nano	 ZS.	 SAXS	 was	 performed	 by	 Ville	
Liljeström	 at	 the	 Department	 of	 Applied	 Physics,	 School	 of	 Science,	 Aalto	 University	
(Finland),	 using	 a	 SAXS	 setup	 consisting	 of	 a	 rotating	 anode	 microfocus	 X-ray	 source	
(Bruker),	a	Montel	multilayer	focusing	monochromator	(Incoatec)	and	four	collimating	slits	
(JJ	X-ray).	Rheology	studies	were	performed	on	a	Kinexus	Pro+	rheometer	from	Malvern	
instruments,	and	on	a	AR-G2	rheometer	from	TA	instruments.	Optical	microscopy	images	
were	 recorded	by	a	Nikon	Eclipse	TS100	 inverted	microscope.	Fluorescence	microscopy	
images	were	obtained	using	a	Leica	DMIL	inverted	microscope.		
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7.2. Synthesis		
Synthesis	of	tert-Butyl	3-((3-aminopropyl)(methyl)amino)propyl	carbamate	(Mono	Boc-
Protected	DAPMA)311		
	
	
	
	
Molecular	Formula:	C12H27N3O2	
Molecular	Weight:	245.36	
	
N,N-Di-(3-aminopropyl)-N-methylamine	(50	mL,	310	mmol)	was	dissolved	in	250	mL	of	THF	
and	cooled	to	0	°C.	Di-(tert-butyl)dicarbonate	(12.0	g,	55.0	mmol)	was	dissolved	in	THF	and	
added	drop	wise	over	2	h,	to	the	previous	solution.	The	reaction	was	then	quenched	with	
water	 (5	 mL).	 The	 solvent	 was	 removed	 by	 rotary	 evaporation	 and	 the	 product	 was	
dissolved	in	NaOH(aq)	 (pH>10)	and	extracted	with	DCM.	The	organic	 layers	were	washed	
with	citric	acid,	and	the	pH	adjusted	to	4-5.	The	aqueous	layers	were	then	basified	with	
NaOH	(5	M)	pH>10	and	the	compound	was	extracted	with	DCM.	The	organic	layers	were	
dried	with	MgSO4	and	 filtered.	The	 final	product	was	evaporated	by	 rotary	evaporation	
resulting	in	a	colourless	oil	(4.9	g,	20.0	mmol,	36%).		
1H	NMR	(400	MHz,	DMSO-d6)	δ:	6.77	(br	t,	J	=	5.2	Hz,	NH,	1H);	2.88	(q,	CH2NHCO,	J	=	6.8	Hz,	
2H);	2.50	(t,	CH2NH2,	J	=	6.4	Hz,	2H);	2.25-2.18	(m,	CH2N(CH3),	4H);	2.04	(s,	N(CH3),	3H);	
1.60-1.54	(m,	CH2CH2NH2,	2H);	1.49-1.39	(m,	CH2CH2N(CH3),	2H);	1.33	(s,	C(CH3),	9H).	13C	
NMR	(100	MHz,	DMSO-d6)	δ:	156.09	(CONH);	77.79	(CCH3);	55.59,	55.42	(CH2NCH3);	42.34	
(NCH3);	 38.89	 (CH2NHCO);	 38.74	 (CH2NH2);	 31.16	 (CH2CH2NHCO);	 28.78	 (CCH3);	 27.72	
(CH2CH2NH2).	 HRMS:	 Calcd.	 [M+H]+	 (C12H28N3O2)	m/z	 =	 246.2176.	 Found	 [M+H]+	m/z	 =	
246.2180.	
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Coupling	of	Myristic	Acid	and	DAPMA	(mono	Boc-protected	C14-DAPMA)	
	
	
	
Molecular	Formula:	C26H53N3O3	
Molecular	Weight:	455.72	
	
Myristic	 acid	 (1.00	 g,	 4.40	mmol)	was	 dissolved	 in	 DCM	 (65	mL).	 O-(Benzotriazol-1-yl)-
N,N,Nʹ,Nʹ-tetramethyluronium	 tetrafluoroborate	 (TBTU)	 (1.41	 g,	 4.40	 mmol)	 and	
triethylamine	 (5.4	mL)	were	added	 to	 the	mixture	and	 it	was	 stirred	 for	5	min	at	 room	
temperature.	Mono	Boc-protected	DAPMA	(1.08	g,	4.4	mmol)	was	dissolved	in	DCM	(65	
mL),	added	to	the	mixture	and	the	reaction	was	stirred	overnight.	The	solvent	was	removed	
by	rotary	evaporation	and	the	product	dissolved	in	EtOAc	(50	mL)	and	washed	with	NaHSO4	
(2	x	15	mL,	1.33	M),	NaHCO3	(2	x	15	mL,	saturated),	deionised	water	(3	x	15	mL)	and	brine	
(15	mL,	saturated).	The	organic	layer	was	collected,	dried	with	MgSO4,	filtered	and	dried	
under	 vacuum.	 The	 product	 was	 purified	 by	 GPC	 column	 (Bio-beads,	 100%	 DCM).	 The	
obtained	product	was	a	beige	solid	(800	mg,	1.80	mmol,	41%).		
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CDCl3)	δ:	6.81	(br	s,	NH,	1H);	5.12	
(br	s,	NHBoc,	1H);	3.30	(q,	CH2NHCO,	J	=	6.0	Hz,	2H);	3.17	(q,	CH2NHBoc,	J	=	5.2	Hz,	2H);	
2.55	(t,	CH2N(CH3),	J	=	6.4	Hz,	4H);	2.31	(s,	N(CH3),	3H);	2.16	(t,	CH2CONH,	J	=	7.2	Hz,	2H);	
1.75-1.69	(m,	CH2CH2N(CH3),	4H);	1.59-1.56	(m,	CH2CH2CONH,	2H);	1.42	(s,	C(CH3)3,	9H);	
1.23	(s,	CH2CH2CH2,	20H);	0.86	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	 13C	NMR	(100	MHz,	CDCl3)	δ:	
176.75	(CONH);	156.92	(OCONH);	77.13	(C(CH3)3);	54.13,	53.86	(CH2NCH3);	39.22	(NCH3);	
36.16	 (CH2NHCO);	 35.52	 (CH2CONH);	 31.99,	 29.74,	 29.44	 (all	CH2);	 28.42	 (CCH3);	 25.79,	
24.84,	 24.55,	 22.76	 (all	CH2);	 14.20	 (CH3CH2).	 νmax	 (cm-1)	 (solid):	 3397m,	 2924s,	 1691m,	
1633m,	1555m,	1514m,	1365m,	1172m,	1049w,	722w.	HRMS:	Calcd.	[M+H]+	(C26H54N3O3)	
m/z	=	456.4160.	Found	[M+H]+	m/z	=	456.4162.	
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Coupling	of	Palmitic	Acid	and	DAPMA	(mono	Boc-protected	C16-DAPMA)	
	
	
	
Molecular	Formula:	C28H57N3O3	
Molecular	Weight:	483.44	
	
Palmitic	acid	(1.00	g,	3.90	mmol)	was	dissolved	in	DCM	(65	mL).	TBTU	(1.25	g,	3.90	mmol)	
and	triethylamine	(5.4	mL)	were	added	to	the	mixture	and	it	was	stirred	for	5	min	at	room	
temperature.	Mono	Boc-protected	DAPMA	(950	mg,	3.90	mmol)	was	dissolved	in	DCM	(65	
mL),	added	to	the	mixture	and	the	reaction	was	stirred	overnight.	The	solvent	was	removed	
by	rotary	evaporation	and	the	product	dissolved	in	EtOAc	(50	mL)	and	washed	with	NaHSO4	
(2	x	15	mL,	1.33	M),	NaHCO3	(2	x	15	mL,	saturated),	deionised	water	(3	x	15	mL)	and	brine	
(15	mL,	saturated).	The	organic	layer	was	collected,	dried	with	MgSO4,	filtered	and	dried	
under	 vacuum.	 The	 product	 was	 purified	 by	 GPC	 column	 (Bio-beads,	 100%	 DCM).	 The	
obtained	product	was	an	orange	gummy	solid	(1.18	g,	2.40	mmol,	62%).		
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CDCl3)	δ:	7.26	(br	s,	NH,	1H);	5.56	
(br	s,	NHBoc,	1H);	3.41	(q,	CH2NHCO,	J	=	5.2	Hz,	2H);	3.32	(q,	CH2NHBoc,	J	=	4.8	Hz,	2H);	
3.18	(t,	CH2N(CH3),	J	=	6.4	Hz,	4H);	2.88	(s,	N(CH3),	3H);	2.32	(t,	CH2CONH,	J	=	7.6	Hz,	2H);	
2.09-2.02	(m,	CH2CH2N(CH3),	4H);	1.68-1.65	(m,	CH2CH2CONH,	2H);	1.51	(s,	C(CH3)3,	9H);	
1.33	(s,	CH2CH2CH2,	24H);	0.96	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	 13C	NMR	(100	MHz,	CDCl3)	δ:	
176.36	(CONH);	156.88	(OCONH);	77.15	(C(CH3)3);	54.23,	53.98	(CH2NCH3);	39.41	(NCH3);	
36.21	 (CH2NHCO);	 35.76	 (CH2CONH);	 31.99,	 29.78,	 29.43	 (all	CH2);	 28.42	 (CCH3);	 25.81,	
24.98,	 24.66,	 22.75	 (all	CH2);	 14.19	 (CH3CH2).	 νmax	 (cm-1)	 (solid):	 3300w,	 3017w,	 2936s,	
2845s;	1671s,	1647s,	1538m,	1456m,	1390m,	1272m,	1250s,	1171s,	1046s,	867w,	723w.	
HRMS:	Calcd.	[M+H]+	(C28H58N3O3)	m/z	=	484.4473.	Found	[M+H]+	m/z	=	484.4474.	
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Coupling	of	Stearic	Acid	and	DAPMA	(mono	Boc-protected	C18-DAPMA)	
	
	
	
Molecular	Formula:	C30H61N3O3	
Molecular	Weight:	511.47	
	
Stearic	acid	(1.00	g,	3.50	mmol)	was	dissolved	in	DCM	(65	mL).	TBTU	(1.25	g,	3.90	mmol)	
and	triethylamine	(5.4	mL)	were	added	to	the	mixture	and	it	was	stirred	for	5	min	at	room	
temperature.	Mono	Boc-protected	DAPMA	(860	mg,	3.50	mmol)	was	dissolved	in	DCM	(65	
mL),	added	to	the	mixture	and	the	reaction	was	stirred	overnight.	The	solvent	was	removed	
by	rotary	evaporation	and	the	product	dissolved	in	EtOAc	(50	mL)	and	washed	with	NaHSO4	
(2	x	15	mL,	1.33	M),	NaHCO3	(2	x	15	mL,	saturated),	deionised	water	(3	x	15	mL)	and	brine	
(15	mL,	saturated).	The	organic	layer	was	collected,	dried	with	MgSO4,	filtered	and	dried	
under	 vacuum.	 The	 product	 was	 purified	 by	 GPC	 column	 (Bio-beads,	 100%	 DCM).	 The	
obtained	product	was	a	light	orange	gummy	solid	(1.13	g,	2.20	mmol,	63%).	
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CDCl3)	δ:	7.15	(br	s,	NH,	1H);	5.47	
(br	s,	NHBoc,	1H);	3.30	(q,	CH2NHCO,	J	=	4.8	Hz,	2H);	3.20	(q,	CH2NHBoc,	J	=	4.4	Hz,	2H);	
3.10	(t,	CH2N(CH3),	J	=	6.4	Hz,	4H);	2.81	(s,	N(CH3),	3H);	2.22	(t,	CH2CONH,	J	=	8.0	Hz,	2H);	
1.99-1.93	(m,	CH2CH2N(CH3),	4H);	1.55-1.54	(m,	CH2CH2CONH,	2H);	1.40	(s,	C(CH3)3,	9H);	
1.22	(s,	CH2CH2CH2,	28H);	0.85	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	 13C	NMR	(100	MHz,	CDCl3)	δ:	
176.60	(CONH);	156.93	(OCONH);	77.15	(C(CH3)3);	54.14,	53.89	(CH2N(CH3));	39.27	(N(CH3));	
36.16	(CH2NHCO);	35.59	(CH2CONH);	31.99,	29.78,	29.43	(all	CH2);	28.42	(C(CH3)3);	25.80,	
24.86,	 24.57,	 22.75	 (all	CH2);	 14.19	 (CH3CH2).	 νmax	 (cm-1)	 (solid):	 3404m,	 2917s,	 1649m,	
1526m,	 1467m,	 1366m,	 1170m,	 1054s,	 722w.	HRMS:	Calcd.	 [M+H]+	 (C30H62N3O3)	m/z	 =	
512.4798.	Found	[M+H]+	m/z	=	512.4786.	
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Boc	Group	Removal	to	yield	C14-DAPMA	
	
	
	
Molecular	Formula:	C21H47Cl2N3O	
Molecular	Weight:	428.52	
	
Mono	Boc-protected	C14-DAPMA	(800	mg,	1.80	mmol)	was	dissolved	in	MeOH	(50	mL)	and	
HCl	gas	was	applied	for	approximately	15	seconds.	The	mixture	was	stirred	for	3	hours	and	
the	solvent	was	removed	by	rotaty	evaporation.	The	product	C14-DAPMA	was	a	beige	solid	
(617	mg,	1.40	mmol,	78%).	
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CD3OD-d4)	δ:	4.96	(br	s,	NH,	1H);	
3.65	(s,	NH2,	2H);	3.08	(t,	CH2N(CH3),	J	=	7.2	Hz,	4H);	2.91	(s,	NCH3,	3H);	2.27	(t,	CH2CO,	J	=	
7.2	Hz,	2H);	2.21-2.13	(m,	CH2CH2N(CH3),	4H);	2.04-1.96	(m,	CH2CH2CO,	2H);	1.64-1.60	(m,	
CH2CH2CO,	2H);	1.32-1.29	(m,	CH2CH2CH2,	22H);	0.90	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	13C	NMR	
(100	MHz,	CD3OD-d4)	δ:	177.16	(CONH);	55.29,	54.24	(CH2N(CH3));	40.51	(N(CH3));	37.90	
(CH2CO);	37.31	(CH2NHCO);	36.94	(CH2NH2);	33.05,	30.75,	30.46,	26.99,	25.44,	23.72,	23.43	
(all	CH2);	14.51	(CH3CH2).	νmax	(cm-1)	(solid):	3352w,	3306w,	2918s,	1638m,	1554m,	1470m,	
1090w,	 722w.	 HRMS:	 Calcd.	 [M+H]+	 (C21H46N3O)	m/z	 =	 356.3635.	 Found	 [M+H]+	m/z	 =	
356.3623.	
	
Boc	Group	Removal	to	yield	C16-DAPMA	
	
	
	
Molecular	Formula:	C23H51Cl2N3O	
Molecular	Weight:	456.58	
	
MonoBoc-protected	C16-DAPMA	(750	mg,	1.60	mmol)	was	dissolved	in	MeOH	(50	mL)	and	
HCl	gas	was	applied	for	approximately	15	seconds.	The	mixture	was	stirred	for	3	hours	and	
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the	 solvent	was	 removed	 by	 rotaty	 evaporation.	 The	 product	 C16-DAPMA	was	 a	 sticky	
orange	solid	(578	mg,	1.30	mmol,	82%).	
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CD3OD-d4)	δ:	4.99	(br	s,	NH,	1H);	
3.35	(s,	NH2,	2H);	3.08	(t,	CH2N(CH3),	J	=	7.2	Hz,	4H);	2.90	(s,	NCH3,	3H);	2.27	(t,	CH2CO,	J	=	
7.6	Hz,	2H);	2.20-2.12	(m,	CH2CH2N(CH3),	4H);	2.03-1.96		(m,	CH2CH2CO,	2H);	1.63-1.60	(m,	
CH2CH2CO,	2H);	1.32-1.28	(m,	CH2CH2CH2,	24H);	0.90	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	13C	NMR	
(100	MHz,	CD3OD-d4)	δ:	175.96	(CONH);	54.02,	52.96	(CH2N(CH3));	39.20	(N(CH3));	36.62	
(CH2CO);	35.93	(CH2NHCO);	35.67	(CH2NH2);	31.77,	29.51,	29.18,	25.68,	24.18,	22.44,	22.13	
(all	CH2);	13.22	(CH3CH2).	νmax	(cm-1)	(solid):	3389w,	3254w,	2917s,	1634m,	1548m,	1468m,	
1056s,	 721w.	 HRMS:	 Calcd.	 [M+H]+	 (C23H50N3O)	m/z	 =	 384.3948.	 Found	 [M+H]+	m/z	 =	
384.3961.	
	
Boc	Group	Removal	to	yield	C18-DAPMA	
	
	
Molecular	Formula:	C25H55Cl2N3O	
Molecular	Weight:	484.64	
	
MonoBoc-protected	C18-DAPMA	(800	mg,	1.60	mmol)	was	dissolved	in	MeOH	(50	mL)	and	
HCl	gas	was	applied	for	approximately	15	seconds.	The	mixture	was	stirred	for	3	hours	and	
the	solvent	was	removed	by	rotary	evaporation.	The	product		C18-DAPMA	was	a	slightly	
sticky	light	orange	solid	(431	mg,	0.89	mmol,	57%).	
Rf	=	0.3	(90:10:1	DCM/MeOH/Et3N).	1H	NMR	(400	MHz,	CD3OD-d4)	δ:	4.91	(br	s,	NH,	1H);	
3.31	(s,	NH2,	2H);	3.08	(t,	CH2N(CH3),	J	=	7.6	Hz,	4H);	2.90	(s,	NCH3,	3H);	2.25	(t,	CH2CO,	J	=	
7.6	Hz,	2H);	2.17-2.09	(m,	CH2CH2N(CH3),	4H);	1.99-1.92	(m,	CH2CH2CONH,	2H);	1.65-1.54	
(m,	CH2CH2CO,	2H);	1.35-1.21	(m,	CH2CH2CH2,	28H);	0.90	(t,	CH3CH2,	J	=	6.8	Hz,	3H).	 13C	
NMR	(100	MHz,	CD3OD-d4)	δ:	177.89	 (CONH);	55.23,	54.26	 (CH2N(CH3));	40.47	 (N(CH3));	
37.90	(CH2NHCO);	37.74	(CH2NH2);	36.55	(CH2CO);	33.08,	30.81,	30.64,	27.02,	25.22,	23.74,	
23.45	(all	CH2);	14.50	(CH3CH2).	νmax	(cm-1)	(solid):	3385w,	3243w,	2916s,	1641m,	1543m,	
1468m,	1059s,	721w.	HRMS:	Calcd.	[M+H]+	(C25H54N3O)	m/z	=	412.4261.	Found	[M+H]+	m/z	
=	412.4267.	
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Synthesis	of	1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dimethylester	(DBS-COOCH3)87	
	
	
	
Molecular	Formula:	C24H26O10	
Molecular	Weight:	474.15	
	
D-Sorbitol	 (3.08	g,	16.9	mmol),	cyclohexane	(35	mL)	and	methanol	(10	mL)	were	mixed,	
and	stirred	for	20	min,	at	50	°C	under	N2	atmosphere.	Methyl	4-formylbenzoate	(4.71	g,	
28.7	mmol)	and	p-toluene	sulfonic	acid	hydrate	(1.00	g)	were	dissolved	in	methanol	(20	
mL)	and	stirred	for	20	min	(RT).	The	mixture	was	added	drop	wise	to	the	D-sorbitol	solution.	
The	reaction	temperature	was	then	increased	to	70	°C	and	stirred	for	approximately	3	h.	
The	 product	 was	 washed	 with	 methanol	 (3	 x	 100	 mL),	 dried	 under	 vacuum	 for	
approximately	1	h	and	then	air-dried	overnight.	To	ensure	that	mono	and	tri-substitued	
derivates	were	removed,	the	compound	was	washed	with	boiling	water	(4	x	100	mL)	and	
DCM.	The	obtained	product	was	a	white	powder	(6.10	g,	12.9	mmol,	89%).		
1H	NMR	(400	MHz,	DMSO-d6)	δ:	8.00-7.97	(m,	ArH,	4H);	7.61	(t,	ArH,	J	=	8.4	Hz,	4H);	5.76	
(s,	ArCH,	2H);	4.91	(d,	CHOH,	J	=	5.2Hz,	1H);	4.46	(br,	CHOH,	1H);	4.22-4.15	(m,	sugar,	3H	
(overlap));	3.91	(m,	sugar,	1H);	3.88	(m,	sugar,	1H);	3.85	(s,	OCH3,	6H);	3.78	(br,	sugar,	1H);	
3.63-3.61	(m,	sugar,	1H);	3.50-3.45	(m,	sugar,	1H).	13C	NMR	(100	MHz,	DMSO-d6)	δ:	166.52	
(COO);	143.84	(Ar-C);	143.57	(Ar-C);	130.28	(Ar-C);	130.22	(Ar-C);	129.56	(Ar-C);	129.47	(Ar-
C);	127.02	(Ar-C);	99.05	(Acetal-C);	98.97	(Acetal-C);	78.08	(CH);	70.69	(CH);	69.83	(CH2);	
69.04	(CH);	68.10	(CH);	63.14	(CH2);	52.74	(CH3).	νmax	(cm-1)	(solid):	3249m,	2954m,	1724s,	
1616w,	 1580w,	 1512w,	 1278s,	 1018s,	 856m,	 836m,	 750s,	 708m.	HRMS:	Calcd.	 [M+Na]+	
(C24H26O10)	m/z	=	497.1418.	Found	[M+Na]+	m/z	=	497.1416.	
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Synthesis	of	1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dicarboxylic	acid	(DBS-COOH)87	
	
	
	
Molecular	Formula:	C22H22O10	
Molecular	Weight:	446.41	
	
DBS-COOCH3	(1.20	g,	2.50	mmol)	was	dissolved	in	methanol	(35	mL).	NaOH(aq)		(35	mL,	1	
M)	was	added	to	the	solution	and	the	mixture	was	heated	overnight	at	80	°C	under	reflux.	
The	 solvent	was	 removed	by	 rotary	 evaporation,	 and	50	mL	of	water	were	 added.	 The	
mixture	was	acidified	to	pH	3	using	NaHSO4,	resulting	in	the	formation	of	a	white	gel.	The	
product	was	then	filtered,	washed	with	deionised	water	(4	x	100	mL)	and	dried	under	high	
vacuum	oven	at	50	°C		for	1	day.	The	obtained	product	was	a	white	powder	(0.82	g,	1.80	
mmol,	73%).	
1H	NMR	(400	MHz,	DMSO-d6)	δ:	12.99	(br	s,	COOH,	2H);	7.98	(d,	ArH,	J	=	6.8	Hz,	4H);	7.59	
(t,	ArH,	,	J	=	8.4	Hz,	4H);	5.74	(s,	ArCH,	2H);	4.25-4.17	(m,	sugar,	3H	(overlap));	4.00	(s,	sugar,	
1H);	3.90	(d,	sugar,	J	=	9.2	Hz,1H);	3.81-3.79	(m,	sugar,	1H);	3.64	(d,	sugar,	J	=	10.8	Hz,	1H);	
3.49-3.48	(m,	sugar,	1H).	13C	NMR	(100	MHz,	DMSO-d6)	δ:	167.12	(COOH);	142.91	(Ar-C);	
142.64	 (Ar-C);	 130.97	 (Ar-C);	 130.91	 (Ar-C);	 129.17	 (Ar-C);	 129.08	 (Ar-C);	 126.31	 (Ar-C);	
98.65	(Acetal-C);	98.57	(Acetal-C);	77.58	(CH);	70.16	(CH);	69.32	(CH2);	69.04	(CH);	68.51	
(CH);	67.62	 (CH);	62.58	 (CH2).	 νmax	 (cm-1)	 (solid):	 3394m,	 2865m,	 1689s,	 1613w,	 1577w,	
1511w,	1290m,	1091s,	856m,	832m,	751m,	703m.	HRMS:	Calcd.	[M+Na]+	(C22H22O10)	m/z	=	
469.1105.	Found	[M+Na]+	m/z	=	469.1118.	
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Synthesis	of	1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dihydrazide	(DBS-CONHNH2)88	
	
	
	
Molecular	Formula:	C22H26N4O8	
Molecular	Weight:	474.46	
	
DBS-COOCH3	 (1.10	 g,	 2.32	mmol)	 was	 dissolved	 in	 tetrahydrofuran	 (40	mL).	 Hydrazine	
monohydrate	(6.19	g,	0.12	mol)	was	added	to	the	solution	and	the	mixture	was	heated	
overnight	 at	 65	 °C	 under	 reflux.	 The	 product	was	 then	 filtered,	washed	with	 deionised	
water	 (3	 x	 100	mL)	 and	 dried	 under	 high	 vacuum	 oven	 at	 80	 °C	 	 and	 pulverized.	 The	
obtained	product	was	a	white	powder	(0.88	g,	1.85	mmol,	80%)	.	
1H	NMR	(400	MHz,	DMSO-d6)	δ:	9.81	(s,	CONHNH2,	2H);	7.83	(d,	ArH,	,	J	=	6.8	Hz,	4H);	7.52	
(t,	ArH,	,	J	=	8.8	Hz,	4H);	5.71	(s,	ArCH,	2H);	4.93	(d,	J	=	6.0	Hz,	CHOH,	1H);	4.51	(s,	CONHNH2,	
4H);	4.47	(t,	J	=	11.6	Hz,	CH2OH,	1H);	4.23-4.16	(m,	sugar,	3H	(overlap));	3.98	(s,	sugar,	1H);	
3.87	(d,	J	=	9.6	Hz,	sugar,	1H);	3.78-3.77	(m,	sugar,	1H);	3.63-3.59	(m,	sugar,	1H);	3.47-3.44	
(m,	sugar,	1H).	13C	NMR	(100	MHz,	DMSO-d6)	δ:	165.66	(C=O);	141.25	(Ar-C);	140.98	(Ar-C);	
133.50	(Ar-C);	133.42	(Ar-C);	126.77	(Ar-C);	126.69	(Ar-C);	126.06	(Ar-C);	98.76	(Acetal-C);	
98.69	(Acetal-C);	77.56	(CH);	70.12	(CH);	69.32	(CH2);	68.47	(CH);	67.67	(CH);	62.61	(CH2).	
νmax	(cm-1)	(solid):	3294m,	2869w,	1664s,	1506w,	1163m,	1093s,	848m,	830m,	754m.HRMS:	
Calcd.	[M+Na]+	(C22H26N4O8)	m/z	=	497.1643.	Found	[M+Na]+	m/z	=	497.1670.	
	
7.3. Chapter	2	–	Characterisation	and	Assay	Methods	
Nile	Red	Assay223	
Nile	Red	 solution	 (2.5	mM)	was	prepared	 in	ethanol.	A	blank	 solution	was	prepared	by	
placing	1	mL	of	phosphate	buffer	saline,	PBS	(0.01	M,	pH	7.4)	into	a	cuvette	and	adding	1	
µL	of	Nile	Red	solution.		A	stock	solution	of	binder	was	prepared	in	PBS.	Different	amounts	
of	stock	solution	(1000	µL;	900	µL;	800	µL;	700	µL;	600	µL;	500	µL;	400	µL;	300	µL;	200	µL;	
	 	 Chapter	7	
	
	
	
239	
100	µL)	were	added	to	cuvettes	and	the	volume	was	made	up	to	1	mL	with	PBS.	1	µL	of	Nile	
Red	 was	 added	 to	 all	 the	 cuvettes.	 The	 fluorescence	 was	 recorded	 with	 an	 excitation	
wavelength	 of	 550	 nm	 and	 an	 emission	 wavelength	 of	 635	 nm.	 The	 procedure	 was	
performed	 for	 C14-DAPMA	 (stock	 solution	 concentration:	 225	 µM),	 C16-DAPMA	 (stock	
solution	concentration:	100	µM)	and	C18-DAPMA	(stock	solution	concentration:	175	µM).	
The	data	were	obtained	in	triplicate	for	each	binder.										
	
MalB	Assay226		
MalB	(25	µM)	solution	was	prepared	in	Tris-HCl	(10	mM)	and	NaCl	(150	mM),	wrapped	with	
foil	to	avoid	contact	with	direct	light	and	incubated	at	50	°C	for	24	hours.	Heparin	(27	µM)	
was	added	to	the	MalB	solution,	after	it	cooled	down.	2	mL	of	MalB	(25	µM),	heparin	(27	
µM)	solution	in	Tris-HCl	(10	mM)	and	NaCl	(150	mM)	was	placed	in	a	cuvette	and	titrated	
with	binder	stock	solution	to	give	a	suitable	charge	ratio	for	the	binder	and	heparin	in	the	
cuvette.	Binder	stock	solution	consisted	of	the	solution	of	MalB	and	heparin	in	Tris-HCl	(10	
mM)	and	NaCl	(150	mM)	with	a	concentration	of	binder	that	resulted	in	a	cuvette	charge	
ratio	(+	:	-)	of	0.1,	after	the	addition	of	10	µL	of	binder	stock	solution.	After	each	addition	
of	the	binder	stock	solution,	the	cuvette	was	stirred	to	ensure	mixing	and	the	absorbance	
recorded	at	615	nm.	This	procedure	was	performed	in	triplicate	for	each	binder.	
	
Dynamic	Light	Scattering	(DLS)	and	Zeta	Potential	
The	binder	(1	mg/mL)	was	dissolved	in	10	mM	Tris-HCl/	150	mM	NaCl	(pH	7.4).	1	mL	of	the	
sample	was	filtered	using	a	syringe	filter	PTFE	0.45	µM	and	placed	in	a	disposable	cuvette.	
DLS	 measurements	 were	 carried	 out	 at	 25	 oC,	 in	 triplicate	 with	 11-15	 runs	 per	 single	
measurement.	 The	 procedure	 was	 performed	 for	 C14-DAPMA,	 C16-DAPMA	 without	
sonication	and	C18-DAPMA	after	sonicated	for	30	minutes.	The	same	procedure	was	also	
performed	for	each	binder	in	the	presence	of	heparin	(charge	ratio	+/-:	2)	(Table	7.1).	
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Table	7.1.	Binder/Heparin	ratios	used	in	DLS	measurements.	
Sample	 Concentration	(mM)	
C14-DAPMA/Heparin	 2.33/0.580	
C16-DAPMA/Heparin	 2.19/0.550	
C18-DAPMA/Heparin	 2.06/0.520	
		
Zeta	potential	measurements	were	obtained	using	 the	 samples	previously	prepared	 for	
DLS.	The	samples	were	transferred	to	a	zeta	capillary	cell	(DTS1070)	until	the	electrodes	
were	 fully	covered	with	 the	solution	and	ensuring	 that	no	air	bubbles	were	 formed.	An	
electric	field	was	applied	using	a	4	mW	He-Ne	laser	at	633	nm	and	the	experiments	were	
performed	in	triplicate	with	11-15	runs	per	single	measurement.		
	
TEM	Imaging	
In	order	 to	obtain	TEM	 images,	10	µL	of	each	sample	 (Table	7.2)	 in	ultra-pure	H2O	was	
placed	on	a	copper	grid	(standard)	with	Formvar	and	carbon	support	film.	Excess	sample	
was	 removed	with	 filter	 paper	 then	 the	 sample	was	 allowed	 to	 stand	 for	 5	minutes.	 A	
negative	stain	(1%	uranyl	acetate)	was	applied	to	the	grid	while	wet	to	allow	the	stain	to	
run	across	the	grid.		The	grid	was	then	left	to	rest	for	20	minutes	before	recording	images.			
	
Table	7.2.	Concentrations	of	C14-DAPMA,	C16-DAPMA,	C18-DAPMA	with	and	without	
heparin	used	to	record	TEM	images	in	water.	
Sample	 Concentration	(µM)	
C14-DAPMA	 200	
C16-DAPMA	 150	
C18-DAPMA	 150	
C14-DAPMA	/	Heparin	 200/50	
C16-DAPMA	/	Heparin	 150	/	38	
C18-DAPMA	/	Heparin	 150	/	38	
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SAXS	
A	sample	of	C16-DAPMA	with	heparin	was	prepared	by	mixing	10	µl	of	C16-DAPMA	(7.36	
mg/ml)	in	10	mM	Tris-HCl/	150	mM	NaCl	with	10	µl	of	heparin	(2.64	mg/ml)	also	in	10	mM	
Tris-HCl/	150	mM	NaCl.	The	sample	formed	a	white	precipitate	and	SAXS	was	measured	
from	 the	 precipitate.	 C14-DAPMA	with	 heparin	 was	 prepared	 by	 mixing	 15	 µl	 of	 C14-
DAPMA	(7.08	mg/ml)	in	10	mM	Tris-HCl/	150	mM	NaCl	with	15	µl	of	heparin	(2.92	mg/ml)	
in	10	mM	Tris-HCl/	150	mM	NaCl.	The	sample	formed	a	white	precipitate	and	SAXS	was	
measured	from	the	precipitate.	
	
The	wet	precipitate	was	sealed	between	two	Kapton	foils	during	SAXS	measurements.	The	
sample	environment	was	evacuated	in	order	to	reduce	scattering	from	air.	The	final	spot	
size	at	 the	 sample	position	was	 roughly	1	mm	 in	diameter.	The	 scattered	 intensity	was	
collected	using	a	Hi-Star	2D	area	detector	(Bruker).	Sample-to-detector	distance	was	0.59	
m,	 and	 silver	 behenate	 standard	 sample	 was	 used	 for	 calibration	 of	 the	 length	 of	 the	
scattering	vector	q.	One-dimensional	SAXS	data	were	obtained	by	azimuthally	averaging	
the	2D	 scattering	data.	 The	magnitude	of	 the	 scattering	vector	q	 is	 given	by	q= 4π	 sin (θ)
λ
,	
where	2θ	is	the	scattering	angle.	
	
Degradation	Assay	-	Mass	Spectrometry	
C14-DAPMA	and	C16-DAPMA	were	dissolved	in	in	ammonium	carbonate	(10	mM,	pH	7.5)	
to	give	a	concentration	of	450	μM	and	200	μM,	respectively.	250	μL	of	this	binder	solution	
was	combined	with	250	μL	of	a	Gly-Ala	standard	(1	mM,	in	10	mM	ammonium	carbonate)	
for	mass	spectrometric	analysis.	Following	incubation	of	the	binder	solution	for	24	hours	
at	37	°C,	the	same	analysis	was	repeated.		
	
Degradation	Assay	-	Fluorescence206		
C14-DAPMA	and	C16-DAPMA	were	dissolved	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	to	
give	a	concentration	of	225	μM	and	100	μM,	respectively.	In	a	cuvette,	an	aliquot	(1	mL)	of	
each	solution	was	mixed	with	Nile	red	(1	μL,	2.5	mM	in	ethanol).	Following	inversion	to	
ensure	mixing,	fluorescence	intensity	at	635	nm	was	recorded	over	time	using	a	550	nm	
excitation	wavelength.	 For	 the	degradation	experiment	 in	 the	presence	of	 heparin,	 the	
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binder	 stock	 solution	 was	 additionally	 endowed	 with	 a	 heparin	 concentration	
corresponding	to	a	+/-	charge	ratio	of	2.	This	procedure	was	performed	 in	 triplicate	 for	
each	binder.	
	
7.4. Chapters	3	and	4	–	Characterisation	and	Assay	Methods	
DBS-COOH	and	DBS-CONHNH2	Gel	Formation	
DBS-COOH	gel	was	prepared	with	different	gelator	concentrations	(0.1%	w/v;	0.15%	w/v;	
0.2%	w/v)	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer,	pH	7.4.	0.5	mL	of	solvent	was	added	to	
DBS-COOH	powder	(0.50	mg;	0.75	mg;	1.0	mg,	respectively)	and	sonicated.	20	µL	of	0.5	M	
NaOH(aq)	was	added	to	dissolve	all	the	solid.	The	solution	was	then	transferred	to	a	vial	
with	GdL	(4	mg,	44.9	mM),	followed	by	shaking	to	dissolve.	The	vials	were	allowed	to	stand	
overnight.		
	
DBS-CONHNH2	gel	was	prepared	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer,	pH	7.4.	0.5	mL	of	
solvent	was	added	 to	DBS-CONHNH2	powder	 (2	mg)	and	sonicated	 for	20	minutes.	The	
solution	was	heated	until	complete	dissolution	of	the	gelator	and	a	transparent	solution	
was	observed.	The	sample	was	allowed	to	cool	down	at	room	temperature.		
	
DBS-COOH	and	DBS-CONHNH2	–	Agarose	Hybrid	Gel	Formation	
The	required	amount	of	DBS-COOH	(2	mg)	were	added	to	10	mM	Tris-HCl/	150	mM	NaCl,	
pH	7.4	(1	mL)	and	sonicated	for	10	minutes.	30	µL	of	0.5	M	NaOH(aq)	was	added	to	dissolve	
all	the	solid.	The	solution	was	transferred	to	a	vial	containing	agarose	(10	mg),	heated	to	
90	 °C	 in	 a	 thermoregulated	 oil	 bath	 to	 dissolve	 agarose,	 cooled	 to	 50	 °C,	 and	 then	
transferred	to	a	vial	containing	GdL	(8	mg,	44.9	mM),	followed	by	shaking	to	dissolve.	The	
vials	were	allowed	to	stand	overnight.		
	
The	required	weight	of	agarose	(5	mg)	and	DBS-CONHNH2	(2	mg)	were	jointly	dissolved	in	
10	mM	Tris-HCl/	150	mM	NaCl,	pH	7.4	(0.5	mL).	After	sonicating	the	mixture,	the	solution	
was	 heated	 until	 complete	 dissolution	 of	 the	 gelators	 and	 a	 transparent	 solution	 was	
observed.	The	sample	was	allowed	to	cool	down	at	room	temperature.				
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DBS-COOH	and	DBS-CONHNH2	Gel	Formation	with	Different	Concentrations	of	Heparin	
and	C16-DAPMA	
DBS-COOH	gel	was	prepared	with	a	minimum	concentration	of	heparin	(38	µM)	and	C16-
DAPMA	(150	µM)	in	order	to	verify	the	influence	on	gel	formation	and	the	best	order	of	
addition.	DBS-COOH	gel	was	prepared	in	10	mM	Tris-HCl/	150	mM	NaCl,	pH	7.4.	0.5	mL	of	
solvent	was	added	to	DBS-COOH	powder	(2.0	mg)	and	sonicated.	30	µL	of	0.5	M	NaOH(aq)	
was	added	to	dissolve	all	solid.	Solutions	of	C16-DAPMA	and	heparin	were	prepared	with	
three	 times	 higher	 concentration	 than	 the	 intended	 final	 concentration,	 to	 allow	 for	
subsequent	dilutions.	0.5	mL	of	C16-DAPMA	solution	(600	µM)	was	then	added	to	0.5	mL	
of	heparin	solution	(152	µM)	and	stirred	to	ensure	the	binding.	The	previous	mixture	was	
added	 in	 different	 orders	 to	 the	 DBS-COOH	 solution:	 1)	 The	 DBS-COOH	 solution	 was	
transferred	to	a	vial	with	GdL	(8	mg,	44.9	mM),	followed	by	shaking	to	dissolve	and	0.5	mL	
of	the	solution	of	C16-DAPMA	and	heparin	was	added	after	approximately	20	minutes;	2)	
0.5	mL	of	the	solution	of	C16-DAPMA	and	heparin	was	added	to	the	DBS-COOH	solution,	
stirred	to	ensure	mixing	and	transferred	to	a	vial	with	GdL	(8	mg,	44.9	mM),	followed	by	
shaking	to	dissolve;	3)	The	DBS-COOH	solution	was	transferred	to	a	vial	with	GdL	(8	mg,	
44.9	mM),	followed	by	shaking	to	dissolve	and	0.5	mL	of	the	solution	of	C16-DAPMA	and	
heparin	was	immediately	added.	The	vials	were	allowed	to	stand	overnight.	Addition	order	
3)	was	used	in	the	following	sections.	
	
DBS-COOH	gel	was	prepared	with	different	concentrations	of	heparin	(38	µM;	50	µM;	100	
µM;	150	µM;	300	µM;	400µM;	500	µM)	in	10	mM	Tris-HCl/	150	mM	NaCl,	pH	7.4.		0.5	mL	
of	10	mM	Tris-HCl/	150	mM	NaCl	was	added	to	DBS-COOH	powder	(2.0	mg)	and	sonicated.	
30	µL	of	0.5	M	NaOH(aq)	was	added	to	dissolve	all	solid.	Solutions	of	heparin	were	prepared	
with	double	the	intended	final	concentration,	to	allow	for	subsequent	dilution.	The	DBS-
COOH	solution	was	transferred	to	a	vial	with	GdL	(8	mg,	44.9	mM),	followed	by	shaking	to	
dissolve	 and	 0.5	mL	 of	 heparin	 solution	was	 immediately	 added	 and	 stirred	 to	 ensure	
mixing.	The	vials	were	allowed	to	stand	overnight.	
	
DBS-CONHNH2	gel	was	prepared	with	different	concentrations	of	heparin	(38	µM;	150	µM;	
300	µM;	400	µM;	600	µM)	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer.	DBS-CONHNH2	powder	
(2	mg)	was	mixed	with	0.25	mL	of	buffer	and	sonicated	for	20	min.		Solutions	of	heparin	
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were	 prepared	 with	 double	 the	 intended	 final	 concentration,	 to	 allow	 for	 subsequent	
dilution.	0.25	mL	of	heparin	solution	was	added	into	the	DBS-CONHNH2	solution,	followed	
by	heating	and	shaking	until	a	clear	solution	was	obtained.	The	sample	was	allowed	to	cool	
down	at	room	temperature.		
	
DBS-COOH	and	DBS-CONHNH2	gels	were	prepared	with	different	concentrations	of	C16-
DAPMA	(150	µM;	300	µM;	600	µM;	800	µM;	1000	µM;	1200	µM)	in	10	mM	Tris-HCl/	150	
mM	NaCl	buffer.	This	followed	the	procedure	explained	above.	
	
DBS-COOH	gel	was	prepared	with	 solutions	 containing	a	 fixed	concentration	of	heparin	
(150	µM)	and	different	C16-DAPMA	concentrations	(100	µM;	150	µM;	200	µM;	250	µM;	
300	µM;	350	µM;	400	µM;	450	µM;	500	µM;	600	µM).	0.5	mL	of	10	mM	Tris-HCl/	150	mM	
NaCl	 (pH	7.4)	was	added	 to	DBS-COOH	powder	 (2.0	mg)	and	sonicated.	30	µL	of	0.5	M	
NaOH(aq)	 was	 added	 to	 dissolve	 all	 solid.	 A	 solution	 of	 C16-DAPMA	 and	 heparin	 was	
prepared	 with	 three	 times	 the	 intended	 final	 concentration,	 to	 allow	 for	 subsequent	
dilutions.	0.5	mL	of	C16-DAPMA	solution	was	then	added	to	0.5	mL	of	heparin	solution	and	
stirred	to	ensure	binding.	The	DBS-COOH	solution	was	transferred	to	a	vial	with	GdL	(8	mg,	
44.9	mM),	followed	by	shaking	to	dissolve	and	0.5	mL	of	C16-DAPMA/heparin	solution	was	
immediately	added	and	stirred	to	ensure	mixing.	
	
DBS-CONHNH2	gel	was	prepared	with	solutions	containing	a	fixed	concentration	of	heparin	
(150	µM)	and	different	C16-DAPMA	concentrations	(150	µM;	300	µM;	400	µM;	500	µM;	
600	µM).	0.25	mL	of	10	mM	Tris-HCl/	150	mM	NaCl	(pH	7.4)	was	added	to	DBS-CONHNH2	
powder	 (2.0	mg)	 and	 sonicated	 for	 20	min.	A	 solution	of	C16-DAPMA	and	heparin	was	
prepared	 with	 three	 times	 the	 intended	 final	 concentration,	 to	 allow	 for	 subsequent	
dilutions.	0.25	mL	of	C16-DAPMA	solution	was	then	added	to	0.25	mL	of	heparin	solution	
and	stirred	to	ensure	binding.	C16-DAPMA/heparin	solution	(0.25	mL)	was	added	into	the	
DBS-CONHNH2	solution	and	stirred	to	ensure	mixing.	The	sample	was	heated	until	a	clear	
solution	was	observed	and	allowed	to	cool	down	at	room	temperature.	The	same	study	
was	performed	for	both	gelators	with	double	the	concentration	of	heparin	(300	µM)	and	
different	C16-DAPMA	concentrations	(500	µM;	800	µM;	1000	µM;	1100	µM;	1200	µM),	as	
well	as	for	400	µM	of	heparin	with	different	concentrations	of	C16-DAPMA	(500	µM;	900	
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µM;	1000	µM;	1200	µM;	1500	µM;	1600	µM)	and	600	µM	of	heparin	with	the	following	
concentrations	of	C16-DAPMA:	1400	µM;	1500	µM;	1600	µM;	1800	µM;	2000	µM;	2200	
µM;	2400	µM.	
	
C16-DAPMA	Stability	at	High	Temperatures	
C16-DAPMA	(1	mg/mL)	was	dissolved	in	10	mM	Tris-HCl/	150	mM	NaCl	(pH	7.4).	1	mL	of	
the	sample	was	filtered	using	a	syringe	filter	 (PTFE	0.45	µM)	and	placed	 in	a	disposable	
cuvette.	DLS	measurements	were	carried	at	25oC	and	70	°C,	in	triplicate	with	11-15	runs	
per	single	measurement.	Zeta	potential	measurements	were	obtained	using	the	samples	
previously	prepared	for	DLS.	The	samples	were	transferred	to	a	zeta	capillary	cell	(DTS1070)	
until	the	electrodes	were	fully	covered	with	the	solution	and	ensuring	that	no	air	bubbles	
were	formed.	An	electric	field	was	applied	using	a	4	mW	He-Ne	laser	at	633	nm	and	the	
experiments	were	performed	in	triplicate	with	11-15	runs	per	single	measurement.		
	
MalB	(25	µM)	solution	was	prepared	as	previously	described.	A	solution	of	C16-DAPMA	
(2.4	mM)	 in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	was	heated	to	85	°C	 for	10	min.	The	
binder	solution	(100	µL)	was	added	to	the	MalB	solution	containing	100	µL	of	heparin	(0.6	
mM)	and	the	absorbance	was	measured.		
A	solution	of	1.2	mM	of	C16-DAPMA	and	0.3	mM	of	heparin	was	prepared	in	buffer	and	
heated	at	85	°C	for	10	min.	An	aliquot	(200	µL)	was	added	into	the	MalB	solution	and	the	
absorbance	recorded.				
	
Thermal	Stability	and	Tgel	Determination		
Thermal	 stability	 and	 Tgel	 values	 for	 DBS-COOH	 and	 DBS-CONHNH2	 were	 obtained	 by	
reproducible	tube	inversion	methodology.	All	the	samples	with	different	concentrations	of	
heparin,	C16-DAPMA	and	heparin-C16-DAPMA	aggregates	that	resulted	in	gel	formation	
were	placed	 into	a	thermo-controlled	oil	bath,	with	an	 initial	temperature	of	25	°C.	The	
temperature	was	set	to	rise	until	100	°C.	After	each	increase	of	ca.	5	°C,	the	tubes	were	
removed	from	the	bath	and	turned	upside	down.	The	stability	of	the	gels	was	observed	and	
the	Tgel	was	considered	as	the	temperature	when	the	gel	started	to	run	down	the	sides	of	
the	vial.			
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Infrared	
DBS-COOH	 (Table	 7.3)	 and	 DBS-CONHNH2	 (Table	 7.4)	 gel	 samples	 were	 prepared	 for	
infrared	by	removing	solvent	from	the	samples	under	high	vacuum.	The	resulting	powder	
was	placed	into	the	infrared	spectrometer	and	the	spectra	recorded.	
	
Table	7.3.	Concentrations	of	DBS-COOH,	C16-DAPMA	and	heparin	used	to	record	infrared	
spectra.	
Sample	 Concentration	(mM)	
DBS-COOH	 4.5	
DBS-COOH/Heparin	 4.5/0.3	
DBS-COOH/Heparin/C16-
DAPMA	
4.5/0.30/0.80	
	
Table	7.4.	Concentrations	of	DBS-CONHNH2,	C16-DAPMA	and	heparin	used	to	record	
infrared	spectra.	
Sample	 Concentration	(mM)	
DBS-CONHNH2	 8.4	
DBS-CONHNH2/Heparin	 8.4/0.3	
DBSCONHNH2/C16-DAPMA	 8.4/1.2	
DBS-CONHNH2/Heparin/C16-
DAPMA	
8.4/0.3/1.2	
	
NMR	Characterisation	of	DBS-COOH	Kinetics	
DBS-COOH	gel	was	prepared	by	adding	D2O	(0.7	mL)	to	DBS-COOH	(1.4	mg)	and	sonicating.	
20	µL	of	NaOH(aq)	(0.5	M)	was	added	to	dissolve	all	solid	and	DMSO	(1.4	µL)	was	added	as	
an	internal	standard.	The	solution	was	then	transferred	to	a	vial	containing	GdL	(5.6	mg,	
44.9	mM),	followed	by	shaking.	The	sample	was	then	immediately	transferred	to	a	NMR	
tube	and	placed	in	the	spectrometer,	with	spectra	recorded	every	30	minutes	for	10	hours.	
The	kinetics	of	DBS-COOH	gel	formation	with	300	µM	heparin	were	obtained	by	adding	D2O	
(0.5	mL)	to	DBS-COOH	(2.0	mg)	and	sonicating.	30	µL	of	NaOH(aq)	 (0.5	M)	was	added	to	
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dissolve	all	solid	and	DMSO	(2.0	µL)	was	added	as	an	internal	standard.	The	solution	was	
then	transferred	to	a	vial	containing	GdL	(8	mg,	44.9	mM),	followed	by	shaking.	0.5	mL	of	
heparin	(600	µM)	in	D2O	was	added	to	the	DBS-COOH	solution,	stirred	and	immediately	
transferred	to	a	NMR	tube	and	placed	in	a	spectrometer,	with	spectra	recorded	every	30	
minutes	for	10	hours.	The	same	procedure	was	performed	for	the	kinetics	of	DBS-COOH	
with	300	µM	of	heparin	and	800	µM	of	C16-DAPMA.						
	
Circular	Dichroism		
The	DBS-COOH	CD	sample	was	prepared	by	adding	10	mM	Tris-HCl/	150	mM	NaCl	(500	µL)	
to	DBS-COOH	(0.2	mg)	and	sonicating.	5	µL	of	NaOH(aq)	(0.5	M)	was	added	to	dissolve	all	
solid	and	then	the	solution	was	transferred	to	a	vial	containing	GdL	(1	mg),	followed	by	
shaking.	400	µL	of	sample	were	immediately	transferred	to	a	CD	cuvette	(1	mm	pathlength)	
and	placed	in	the	CD	spectrometer,	with	spectra	recorded	every	5	minutes	for	5	hours	and	
a	further	reading	after	6	hours.	The	same	procedure	was	performed	in	the	presence	of	38	
µM	of	heparin	and	150	µM	of	C16-DAPMA/	38	µM	heparin.	
	
The	DBS-CONHNH2	CD	sample	was	prepared	by	adding	10	mM	Tris-HCl/	150	mM	NaCl	(500	
µL)	to	DBS-CONHNH2	(0.6	mg)	and	sonicating.	The	sample	was	heated	until	a	clear	solution	
was	formed	and	400	µL	of	sample	were	immediately	transferred	to	a	1	mm	quartz	cuvette	
(incubated	in	a	cell	holder	at	90	°C)	and	placed	in	the	spectrometer.	The	temperature	was	
set	to	cool	down	to	20	°C	(5	°C/min	ramp)	while	spectra	were	recorded	every	30	seconds	
for	15	minutes.	The	same	procedure	was	performed	in	the	presence	of	38	µM	of	heparin,	
150	µM	of	C16-DAPMA	and	150	µM	of	C16-DAPMA/	38	µM	heparin.	
	
MalB	Diffusion	Assay	
DBS-COOH	gel	(0.2%	w/v)	or	DBS-CONHNH2	gel	(0.3%	w/v)	with	38	µM	heparin,	150	µM	
C16-DAPMA	 and	 38	 µM	 heparin	 and	 DBS-CONHNH2	 gel	 (0.3%	w/v)	 with	 150	 µM	 C16-
DAPMA	were	prepared	in	10	mM	Tris-HCl/	150	mM	NaCl.	3	mL	of	25	µM	MalB	solution	
were	carefully	placed	on	top	of	the	gels	and	the	absorbance	measured	at	different	times	
(0h,	1h,	2h,	3h,	4h,	5h,	6h,	7h,	24h,	48h,	72h,	168h)	by	collecting	2	mL	of	the	MalB	solution	
and	 replacing	 it	 after	 the	measurement.	 Data	were	 obtained	 in	 triplicate.	 A	 calibration	
curve	of	MalB	was	plotted	and	the	obtained	UV-Vis	absorbance	at	615	nm	fitted	against	it.		
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Electron	Microscopy	
DBS-COOH	 (Table	7.5)	and	DBS-CONHNH2	 (Table	7.6)	gel	 samples	 for	TEM	 images	were	
prepared	 in	 ultra-pure	 H2O	 and	 images	 obtained	 by	 adding	 one	 microspatula	 of	 each	
sample	 on	 a	 copper	 grid	 (standard)	with	 Formvar	 and	 carbon	 support	 film.	 The	 excess	
sample	was	removed	with	filter	paper	then	allowed	to	set	for	5	minutes.	A	negative	stain	
(1%	uranyl	acetate)	was	applied	to	the	grid	while	wet	to	allow	the	stain	to	run	across	the	
grid.		The	grid	was	left	to	rest	for	30	minutes	before	taking	images.		
To	obtain	SEM	images	(Table	7.5	and	7.6),	the	gels	were	freeze	fried	on	bits	of	copper	shim.	
After	mounting	the	samples	on	stubs	they	were	sputter	coated	with	approximately	5	nm	
of	Au/Pd	and	the	images	recorded.		
	
Table	7.5.	Concentrations	of	DBS-COOH,	C16-DAPMA	and	heparin	used	to	record	TEM	
and	SEM	images	of	gels	prepared	in	ultra-pure	H2O.	
Sample	 Concentration	(mM)	
DBS-COOH	 4.5	
DBS-COOH/Heparin	
4.5/0.038	
4.5/0.30	
DBS-COOH/Heparin/C16-
DAPMA	
4.5/0.038/0.15	
4.5/0.30/0.80	
	
	
Table	7.6.	Concentrations	of	DBS-CONHNH2,	Heparin	and	C16-DAPMA	used	to	record	
TEM	and	SEM	images	of	gels	prepared	in	ultra-pure	water.	
Sample	 Concentration	(mM)	
DBS-CONHNH2	 8.4	
DBS-CONHNH2/Heparin	 8.4/0.038	
DBSCONHNH2/C16-DAPMA	 8.4/0.15	
DBS-CONHNH2/Heparin/C16-
DAPMA	
8.4/0.038/0.15	
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Rheology	
The	 following	 measurements	 were	 performed	 in	 a	 Malvern	 Instrument	 Kinexus	 pro+	
rheometer.	
DBS-COOH	(0.2%	w/v)	and	DBS-CONHNH2	(0.4%	w/v)	hydrogels	were	prepared	in	10	mM	
Tris-HCl/	150	mM	NaCl	buffer	(d	=	20	mm,	h	=	0.5	cm)	on	the	lower	plate	of	the	equipment	
with	a	bottomless	vial	as	template	to	obtain	the	intended	gel	dimensions.	The	viscoelastic	
properties	were	measured	by	applying	dynamic	strain	sweeps	(f	=	1	Hz),	dynamic	frequency	
sweeps	(Y	=	0.1%)	and	temperature	variation	(f	=	1	Hz,	Y	=	0.1%).	The	measurements	were	
carried	out	with	a	parallel	geometry	plate	(d	=	20	mm)	and	a	gap	of	0.5	mm.	The	same	
procedure	 was	 performed	 for	 DBS-COOH	 and	 DBS-CONHNH2	 hydrogels	 incorporating	
heparin	 (1	mM),	C16-DAPMA	(2	mM),	heparin/C16-DAPMA	aggregates	and	agarose	(1%	
w/v).	
	
Release	Studies		
• Release	Assay	-	Aliquots	
DBS-COOH	 (0.2%	 w/v,	 2%	 w/v,	 5%	 w/v	 and	 10%	 w/v)	 and	 DBS-CONHNH2	 (0.4%	 w/v)	
hydrogels	(3	mL)	containing	1	mM	of	heparin;	1	mM	of	heparin	and	2	mM	of	C16-DAPMA;	
and	agarose	(0.5%	w/v	and	1%	w/v)	with	heparin	(1	mM)	were	prepared	in	10	mM	Tris-
HCl/	 150	mM	NaCl	 buffer	 (pH	 7.4),	 followed	by	 the	 addition	 of	 1	mL	 of	 buffer	 on	 top.	
Aliquots	of	65	µL	of	buffer	were	collected	over	time,	added	into	1935	µL	of	MalB	solution	
(25.84	µM)	and	the	UV-Vis	absorbance	recorded.	The	data	were	obtained	in	triplicate.	A	
calibration	curve	of	heparin	was	obtained	by	adding	65	µL	of	known	heparin	concentrations	
into	1935	µL	of	MalB	solution	and	the	absorbance	spectra	obtained.	The	same	procedure	
was	followed	for	the	release	of	heparin	(1	mM)	from	agarose	gels	(2.5%	w/v,	5.0%	w/v,	
7.5%	w/v	and	10%	w/v).		
	
• Release	Assay	-	Gel	Cylinder	
DBS-COOH	(2%	w/v)	and	DBS-CONHNH2	(0.4%	w/v)	hydrogels	were	prepared	with	1%	w/v	
of	agarose	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	incorporating	17	mM	of	heparin.	The	
gel	cylinders	(approx.	dimensions:	radius	5	mm,	height	14	mm)	were	removed	from	the	vial	
carefully	using	a	spatula	and	placed	into	a	glass	jar	(100	mL).	Buffer	solution	was	added	(35	
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mL,	10	mM	Tris-HCl/	150	mM	NaCl)	to	the	jar	and	aliquots	of	65	µL	of	buffer	were	collected	
over	 time	after	gently	swirling	of	 the	solution	and	added	 into	1935	µL	of	MalB	solution	
(25.84	µM)	for	UV-Vis	absorbance	measurement.	The	data	were	obtained	in	triplicate.	A	
calibration	curve	of	heparin	was	obtained	by	adding	65	µL	of	known	heparin	concentrations	
into	1935	µL	of	MalB	solution	and	the	absorbance	spectra	obtained.	
	
7.5. Chapter	3	and	4	-	Cytocompatiblity	Studies	
Cell	Line	(3T3	cells:	mouse	embryonic	fibroblasts)	
Mouse	fibroblast	3T3	cells	were	expanded	in	a	T75	flask	with	Dulbecco’s	Modified	Eagle’s	
Medium	(89%	DMEM	–	high	glucose	and	3.7	g/L	NaHCO3),	10%	fetal	bovine	serum	(FBS)	
and	1%	Penicillin/Streptomycin.	To	obtain	the	cells,	 the	medium	was	removed	from	the	
T75	flask	and	the	cells	washed	with	10	mL	Dulbecco’s	phosphate	buffered	saline	(DPBS)	
warmed	at	37	°C.	Trypsin/EDTA	(1.5	mL)	was	added	and	the	cells	 incubated	at	37	°C	for	
approximately	5	min.	When	cell	detachment	was	observed	(by	optical	microscopy),	trypsin	
was	neutralised	with	3.5	mL	of	DMEM,	10%	FBS,	1%	P/S	and	the	cell	suspension	collected	
into	a	50	mL	tube.	The	cells	were	counted	in	a	Neubauer	Chamber	by	mixing	20	µL	of	cell	
suspension	with	180	µL	of	trypan	blue	by	optical	microscopy.		
	
DBS-COOH	Gel	Preparation	
DBS-COOH	gel	was	prepared	by	adding	2	mg	of	gelator	to	1	mL	of	10	mM	Tris-HCl/	150	mM	
NaCl	(pH	7.4),	followed	by	sonication.	30	µL	of	0.5	M	NaOH(aq)	was	added	to	dissolve	all	
solid.	The	solution	was	then	transferred	to	a	vial	with	GdL	(8	mg,	44.9	mM),	followed	by	
shaking	to	dissolve.	The	solution	was	immediately	transferred	into	the	well	plates	(50	µL	in	
each	well	of	the	96	well	plates	and	100	µL	in	the	inserts).	The	same	procedure	was	followed	
to	prepare	the	gels	with	1	mM	and	2	mM	of	heparin,	by	adding	a	solution	of	heparin	in	10	
mM	Tris-HCl/	150	mM	NaCl	with	the	appropriate	concentration.		
	
DBS-CONHNH2	Gel	Preparation	
DBS-CONHNH2	gel	was	prepared	in	10	mM	Tris-HCl/	150	mM	NaCl	buffer	(pH	7.4).	0.5	mL	
of	 buffer	 was	 added	 to	 DBS-CONHNH2	 powder	 (2	 mg).	 The	 solution	 was	 heated	 until	
complete	dissolution	of	the	gelator	and	a	transparent	solution	was	observed.	The	solution	
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was	immediately	transferred	into	the	well	plates	(50	µL	in	each	well	of	the	96	well	plates	
and	100	µL	in	the	inserts).	The	same	procedure	was	done	to	prepare	the	gels	with	different	
concentrations	of	heparin,	C16-DAPMA	and	agarose,	by	adding	a	solution	of	heparin	or	
C16-DAPMA	in	10	mM	Tris-HCl/	150	mM	NaCl	with	the	appropriate	concentration	and	by	
weighing	agarose	together	with	DBS-CONHNH2	powder.			
	
2D	Cell	Culture:	Gels	with	Cells	on	Top	
Gels	were	prepared	in	96	well	plates	(50	µL	of	gel/	well)	and	sterilised	by	applying	UV	light	
for	20	min.	After	gelation,	the	cells	were	seeded	on	top	of	the	gels.	The	desired	number	of	
cells	 (to	 obtain	 the	 following	 cell	 density:	 50000	 cells/mL	 or	 25000	 cells/ml	 after	
optimisation)	was	added	into	a	2	mL	Eppendorf	and	centrifuged	at	1800	rpm	for	6	min	at	
25	°C,	followed	by	the	removal	of	the	supernatant.	The	cells	were	re-suspended	in	DMEM	
-	10%	FBS	-	1%	P/S	and	100	µL	added	on	top	of	each	gel	in	the	well.		
	
2D	Cell	Culture:	Gels	in	Transwells	
Gels	were	prepared	in	the	inserts	(100	µL	of	gel/	insert)	and	sterilised	by	applying	UV	light	
for	 20	min.	After	 gelation,	 the	 cells	were	 seeded	on	 the	bottom	of	 the	wells	 and	both	
compartments	(well	and	inserts)	were	filled	with	medium.		
The	desired	number	of	cells	(to	obtain	the	following	cell	density:	40000	cells/mL	or	10000	
cells/mL	after	optimisation)	was	added	into	a	2	mL	Eppendorf	and	centrifuged	at	1800	rpm	
for	6	min	at	25	°C,	followed	by	the	removal	of	the	supernatant.	The	cells	were	re-suspended	
in	DMEM	-	10%	FBS	-	1%	P/S	and	500	µL	added	to	each	well.		
	
Cell	Morphology:	Optical	Microscopy	
The	morphology	 of	 the	 cells	 placed	 on	 top	 of	 the	 gels	 and	with	 gels	 in	 transwells	was	
followed	by	placing	the	96	plates	and	the	transwell	plates	under	the	optical	microscope	
and	recording	images	over	the	days	of	the	experiment.	
	
Cell	Morphology:	Phalloidin/	DAPI	Staining	
The	medium	was	removed	from	the	culture	wells.	Paraformaldehyde	(PFA)	was	added	to	
each	well	(100	µL	or	200	µL	into	96	well	plates	or	24	well	plates,	respectively)	and	incubated	
at	room	temperature	for	1	h.	PFA	was	removed	and	the	samples	washed	twice	with	DPBS	
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for	approximately	15	min.	Triton-X100	(0.5%	in	PBS	-	100	µL	or	200	µL	into	96	well	plates	
or	24	well	plates,	respectively)	was	added	to	each	well	and	incubated	at	room	temperature	
for	 1h.	 Triton-X100	 was	 removed	 and	 the	 samples	 washed	 twice	 with	 DPBS	 for	
approximately	15	min.	The	plates	were	incubated	overnight	at	4	°C	with	100	µL	or	200	µL	
of	 phalloidin	 -	 tetramethylrhodamine	 B	 isothiocyanate	 (TRITC)	 diluted	 in	 PBS	 1:23.	 The	
samples	were	washed	twice	with	DPBS	for	approximately	15	min	and	incubated	with	100	
µL	or	200	µL	(96	well	plates	or	24	well	plates,	respectively)	of	5	µg/mL	DAPI	in	DPBS	for	45	
min	at	room	temperature.	The	samples	were	washed	twice	with	DPBS	for	approximately	
15	min	and	the	images	collected	from	a	fluorescence	microscope.	
	
Live/Dead	Staining	
The	medium	was	removed	from	the	culture	wells.	The	plates	were	incubated	with	13.3	µM	
calcein-	acetoxymethyl	(AM)	and	4.8	µM	propidium	iodide	(PI)	in	cell	culture	medium	for	
60	min	at	37	°C.	The	staining	solution	was	removed	and	the	samples	washed	twice	with	
DPBS	for	approximately	15	min.	Some	gels/cells	were	fixed	with	100	µL	or	200	µL	(96	well	
plates	or	24	well	plates,	respectively)	of	4%	PFA	in	PBS	(0.01	M,	pH	7.4)	for	1h.	The	samples	
were	washed	twice	with	DPBS	for	approximately	15	min	and	the	pictures	were	collected	
from	a	fluorescence	microscope.			
	
MitoTracker	Staining	
The	medium	was	removed	from	the	culture	wells.	The	plates	were	incubated	with	0.4	µM	
of	MitoTracker	Green	and	10.8	µM	of	Hoechst	diluted	in	culture	medium,	for	90	min	at	37	
°C.	The	staining	solution	was	removed	and	the	samples	washed	with	DPBS	for	30	min	at	
room	temperature.	DPBS	(twice	the	sample	volume)	was	added	to	the	cells	and	the	images	
collected	from	a	fluorescence	microscope.		
	
Metabolic	Activity	
WST-1	 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene	 disulfonate)	
was	added	to	each	well	(10%	of	the	total	volume	–	5	µL	for	gels	in	96	well	plates	and	10	µL	
for	gels	in	transwells),	followed	by	incubation	of	the	plates	at	37	°C	for	2	h.	The	gels	were	
then	disrupted	by	pipetting	them	up	and	down,	transferred	into	Eppendorfs	and	frozen.	
Later,	 the	 samples	 were	 thawed	 (protecting	 them	 from	 light)	 and	 homogenized.	 The	
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samples	were	centrifuged	at	13800	rpm,	for	5	min.	The	supernatant	(80	µL)	was	collected	
and	added	into	a	new	96	well	plate.	The	absorbance	was	measured	at	440	nm.		
	
Migration	Assay	
Different	 volumes	 (100	µL,	 80	µL	 and	60	µL)	 of	DBS-CONHNH2	hydrogels	 (0.4%	w/v)	 in	
transwells	were	 prepared	 as	 described	 above.	 Cells	 (cell	 density:	 10000	 cells/mL)	were	
added	on	 top	of	 the	 gels	 (double	 the	 volume	of	 the	 gels).	 Two	different	 controls	were	
prepared:	200	µL	of	cells	in	medium	was	added	to	the	insert,	or	200	µL	of	cells	in	medium	
was	added	directly	to	the	bottom	of	the	well	without	the	presence	of	the	insert.	The	inserts	
were	washed	with	trypsin	to	detach	any	cells	from	the	membrane.	The	presence	of	cells	on	
the	bottom	of	the	wells	was	followed	by	optical	microscopy	over	7	days.	
	
7.6. Chapter	5	–	Characterisation	and	Assay	Methods	
OG1	and	OG2	Gel	Formation78,298	
The	OG1	 gel	was	 prepared	by	 adding	 1	mL	of	water	 into	 5	mg	of	 gelator	 powder.	 The	
solution	was	heated	until	 the	gelator	was	dissolved	and	allowed	 to	 cool	down	at	 room	
temperature.	The	final	pH	of	the	OG1	gel	was	7.	
	
The	OG2	gel	was	prepared	by	adding	0.8	mL	of	water	into	5	mg	of	gelator	powder	and	0.1	
mL	 of	 HCl	 (1	M)	was	 added	 to	 completely	 dissolve	 the	 gelator.	 The	 solution	was	 then	
neutralised	by	adding	0.1	mL	of	NaOH	 (1	M)	and	gently	 shaken.	The	gel	 formation	was	
observed	immediately	after	the	neutralisation	of	the	gelator	solution	(final	pH	8-9).	
	
OG1	and	OG2	Gel	Formation	with	Different	Concentrations	of	Heparin	and	C16-DAPMA	
OG1	and	OG2	gels	were	prepared	with	different	concentrations	of	heparin	(38	µM;	150	
µM;	300	µM;	400	µM;	600	µM;	1000	µM)	in	water.	The	OG1	gel	was	prepared	by	adding	1	
mL	of	heparin	 solution	 into	5	mg	of	 gelator	powder.	 The	 solution	was	heated	until	 the	
gelator	 dissolved	 and	 allowed	 to	 cool	 down	 at	 room	 temperature.	 The	 OG2	 gel	 was	
prepared	by	adding	0.8	mL	of	heparin	solution	into	5	mg	of	gelator	powder	and	0.1	mL	of	
HCl	(1	M)	to	completely	dissolve	the	gelator.	The	solution	was	then	neutralised	by	adding	
0.1	mL	of	NaOH	(1	M)	and	gently	shaken.	Gel	formation	was	observed	immediately	after	
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neutralisation	of	the	gelator	solution.	Dilutions	from	the	addition	of	the	acid	and	base	were	
taken	into	account	when	preparing	the	heparin	solutions,	in	order	to	have	the	appropriate	
final	concentration.		
	
OG1	and	OG2	gels	were	prepared	with	different	concentrations	of	C16-DAPMA	(150	µM;	
300	µM;	600	µM;	800	µM;	1000	µM;	1200	µM)	in	water.	The	same	procedure	explained	
above	was	followed.	
	
OG1	 and	 OG2	 gels	 were	 prepared	 with	 solutions	 containing	 a	 fixed	 concentration	 of	
heparin	 and	different	 C16-DAPMA	 concentrations.	 An	 initial	 charge	 ratio	 (+/-)	 of	 2	was	
tested	 and	 if	 no	 stable/	 homogeneous	 gels	were	 formed,	 lower	 concentrations	of	 C16-
DAPMA	were	used	for	the	same	heparin	concentration.	As	explained	above,	all	calculations	
for	the	concentrations	used	took	into	account	the	dilutions	needed	for	the	gel	preparation.						
	
OG1	and	OG2	“Dropping	Ball”	Method	for	Tgel	Determination298		
A	stainless	steel	ball	(65	mg,	2.5	mm	in	diameter)	was	placed	on	top	of	the	gel,	previously	
prepared	 in	 a	 2	mL	 glass	 vial.	 The	 vial	was	 subsequently	 placed	 in	 a	 heating	 block	 and	
monitored	 by	 a	 CCD	 camera.	 The	 temperature	 of	 the	 heating	 block	 was	 increased	 by	
1°C/min	and	the	Tgel	value	was	considered	to	be	the	temperature	at	which	the	steel	ball	
started	to	fall	through	the	gel.	
	
OG1	and	OG2	Transmission	Electron	Microscopy	
OG1	and	OG2	gel	samples	for	TEM	images	(Table	7.7)	were	prepared	in	ultra-pure	H2O	and	
obtained	 by	 adding	 one	microspatula	 of	 each	 sample	 on	 a	 copper	 grid	 (standard)	with	
Formvar	and	carbon	support	film.	The	excess	of	sample	was	removed	with	filter	paper	then	
allowed	to	set	for	5	minutes.	A	negative	stain	(1%	uranyl	acetate)	was	applied	to	the	grid	
while	wet	to	allow	the	stain	to	run	across	the	grid.		The	grid	was	left	to	rest	for	30	minutes	
before	taking	images.	
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Table	7.7.	Concentrations	of	OG1,	OG2,	Heparin	and	C16-DAPMA	used	to	obtain	TEM	
images	of	gels	prepared	in	ultra-pure	water.	
Components	 Concentration	(mM)	
OG1	 5.9	
OG2	 7.5	
Heparin	 0.038	
C16-DAPMA	 0.15	
Heparin/C16-DAPMA	 	0.038	/	0.15	
	
OG1	and	OG2	Rheology	
The	following	measurements	were	performed	in	a	TA	Instruments	AR2000	rheometer.	
OG1	gelator	(5	mg)	was	added	to	water	(1	mL)	and	transfered	with	a	pipette	to	the	lower	
plate	 of	 the	 rheometer	 that	 was	 previously	 heated.	 The	 sample	 was	 heated	 on	 the	
rheometer	plate,	followed	by	decreasing	the	temperature	to	25°C.		
	
OG2	 hydrogels	 (0.5%	 w/v)	 were	 prepared	 by	 addition	 of	 0.8	 mL	 of	 water	 into	 a	 vial	
containing	the	gelator	powder,	that	was	then	completely	dissolved	by	the	addition	of	0.1	
mL	of	HCl	(1	M).	NaOH	(0.1	mL,	1	M)	was	added	into	a	syringe,	followed	by	the	addition	of	
the	dissolved	gelator	solution	and	the	mix	immediately	added	into	the	lower	plate	of	the	
equipment,	to	ensure	a	homogeneous	mixture	of	the	base	with	the	acidic	gelator	solution.	
The	measurements	started	immediately	after	sample	loading.	
	
The	 viscolelastic	 properties	 of	 OG1	 and	 OG2	 hydrogels	 were	 measured	 by	 applying	 a	
dynamic	 strain	 sweep	 (f	 =	 1Hz)	 and	 a	 dynamic	 time	 sweep	 (f	 =	 1	 Hz,	 Y	 =	 0.5%).	 The	
measurements	were	carried	out	with	a	parallel	geometry	plate	(d	=	40	mm)	and	a	gap	of	
0.8	mm.	The	same	procedure	was	performed	for	OG1	and	OG2	hydrogels	 incorporating	
heparin	 (0.3	mM),	 C16-DAPMA	 (1.2	mM)	 and	 heparin	 (0.3	mM)/C16-DAPMA	 (1.2	mM)	
aggregates.					
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OG1	and	OG2	Release	Assays	
The	release	of	heparin	from	OG1	and	OG2	hydrogels	was	performed	following	the	same	
procedures	described	for	the	DBS-COOH	and	DBS-CONHNH2	hydrogels.	
	
OG+	Gel	Formation		
OG+	gel	formation	was	obtained	using	two	different	approaches.	One	method	consisted	in	
adding	0.8	mL	of	water	into	5	mg	of	gelator	powder	and	0.1	mL	of	HCl	(1	M)	was	added	to	
completely	dissolve	 the	gelator.	 The	 solution	was	 then	neutralised	by	adding	0.1	mL	of	
NaOH	 (1	M)	and	gently	 shaken.	 The	gel	 formation	was	observed	 immediately	 after	 the	
neutralisation	of	the	gelator	solution.	In	a	second	approach,	5	mg	of	gelator	was	dissolved	
in	0.1	mL	of	DMSO,	followed	by	the	addition	of	0.9	mL	of	0.1	M	Tris-HCl	buffer,	pH	7.75	
(mixture	 ratio	 of	 1:9	DMSO:buffer).	 Gel	 formation	was	 observed	 immediately	 after	 the	
addition	of	the	buffer	solution.	
	
OG+	Gel	Formation	with	Heparin	
OG+	gel	was	prepared	by	adding	0.8	mL	of	heparin	solution	(0.078	or	1	mM)	into	5	mg	of	
gelator	powder	and	0.1	mL	of	HCl	(1	M)	to	completely	dissolve	the	gelator.	The	solution	
was	then	neutralised	by	adding	0.1	mL	of	NaOH	(1	M)	and	gently	shaken.	Gel	formation	
was	observed	immediately	after	the	neutralisation	of	the	gelator	solution.	Dilutions	from	
the	addition	of	 the	acid	and	base	were	 taken	 into	account	when	preparing	 the	heparin	
solutions,	in	order	to	have	the	appropriate	final	concentration.		
	
Alternatively,	0.1	mL	of	heparin	(0.078	or	1	mM)	dissolved	in	DMSO	was	added	to	5	mg	of	
gelator,	followed	by	the	addition	of	0.9	mL	of	0.1	M	Tris-HCl	buffer,	pH	7.75	(mixture	ratio	
of	1:9	DMSO:buffer).	Gel	 formation	was	observed	 immediately	after	the	addition	of	the	
buffer	solution.	
	
OG+	Transmission	Electron	Microscopy	
OG+	 hydrogels	 (0.5%	w/v)	 were	 prepared	 using	 the	 first	method	 described	 above	 and	
following	the	same	procedure	as	described	for	the	TEM	images	of	OG1	and	OG2.	When	in	
the	presence	of	heparin,	a	heparin	concentration	of	0.078	mM	was	used.		
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OG+	Release	Assays	
OG+	hydrogels	were	prepared	following	the	second	method	of	gel	preparation	previously	
described.	Buffer	solution	(1	mL	of	10	mM	Tris-HCl/	150	mM	NaCl)	was	placed	on	top	of	1	
mL	 of	 OG+	 hydrogels	 (0.5%	 w/v)	 containing	 1	 mM	 of	 heparin.	 Release	 assays	 of	 OG+	
hydrogels	in	the	presence	of	a-chy	enzyme	(from	bovine	pancreas,	type	II,	³	40	units/mg	
protein)	were	conducted	using	1	mL	samples	that	were	prepared	by	adding	enzyme	stock	
solution	(900	µL,	a-chy	in	0.1	M	Tris-HCl	buffer,	pH	7.75)	to	a	DMSO	solution	of	OG+	with	
heparin	(1	mM	in	1	mL	of	sample).	1	mL	of	10	mM	Tris-HCl/	150	mM	NaCl	was	placed	on	
top	of	the	gels.	The	experiment	using	the	enzyme	was	performed	at	room	temperature	and	
at	37	°C.	Aliquots	(65	µL)	of	buffer	were	removed	over	time	and	added	to	MalB	solution	
(1935	µL)	and	the	absorbance	at	615	nm	obtained.	
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Abbreviations	
1D	 	 	 One-dimensional	
2D	 	 	 Two-dimensional	
3D	 	 	 Three-dimensional	
a-chy		 	 	 a-	chymotrypsin	
A	 	 	 Alanine	
AgNPs	 	 	 Silver	nanoparticles	
AM		 	 	 Acetoxymethyl	
ASC	 	 	 Adipose	tissue	derived	stem	cells	
AuNPs	 	 	 Gold	nanoparticles	
BMP-2		 	 Bone	morphogenic	protein-2	
Boc	 	 	 tert-Butyl	Dicarbonate  
br	 	 	 broad	(NMR) 	
CD	 	 	 Circular	Dichroism	
CE50	 	 	 Charge	excess	
CGC	 	 	 Critical	Gelation	Concentration	
ChS-F	 	 	 Chondroitin	sulfate	
CMC	 	 	 Critical	Micelle	Concentration	
CN	 	 	 Cavernous	nerve	
D	 	 	 Aspartic	acid	
d	 	 	 doublet	(NMR)	
DAPI	 	 	 4',6-diamidino-2-phenylindole	
DAPMA	 	 N,N-Di-(3-aminopropyl)-N-methylamine	
DBS	 	 	 1,3:2,4-dibenzylidene-D-Sorbitol	
DBS-COOCH3	 	 1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dimethylester	
DBS-COOH	 	 1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dicarboxylic	acid	
DBS-CONHNH2	 1,3:2,4-dibenzylidene-D-Sorbitol-p,p’-dihydrazide	
DCM	 	 	 Dichloromethane	
DLS	 	 	 Dynamic	Light	Scattering	
DMEM		 	 Dulbecco’s	Modified	Eagle’s	Medium	
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DOPC	 	 	 Dioleoylphosphocholine	
DPBS	 	 	 Dulbecco’s	phosphate	buffered	saline	
DPD	 	 	 Dissipative	Particle	Dynamics	
E	 	 	 Glutamic	Acid	
EC50	 	 	 Effective	concentration	
ECM	 	 	 Extracellular	matrix	
EGF	 	 	 Epidermal	growth	factor	
FBS	 	 	 Fetal	bovine	serum	
FDM	 	 	 Fibroblast-derived	extracellular	matrix	
FGF	 	 	 Fibroblast	growth	factor	
FGFR	 	 	 Fibroblast	growth	factor	receptor	
Fmoc	 	 	 9-fluorenylmethoxycarbonyl	
Fmoc-FF	 	 Fmoc-diphenylalanine	
G’		 	 	 Storage	or	elastic	modulus	
G’’	 	 	 Loss	or	viscous	modulus	
GAG	 	 	 Glycosaminoglycans	
GdL	 	 	 Glucono-d-lactone	
GF	 	 	 Growth	factors	
GNF	 	 	 Glycosyl-nucleosyl-fluorinated	
GPC	 	 	 Gel	permeation	chromatography	
HCEC	 	 	 Human	corneal	endothelial	cells		
HUVEC		 	 Human	umbilical	vein	endothelial	cells	
IR	 	 	 Infrared	
K	 	 	 Lysine	
LMWG		 	 Low	molecular	weight	gelator	
LMWH		 	 Low-molecular-weight	heparin	
LVR	 	 	 Linear	viscoelastic	region	
m	 	 	 medium	(IR)	
m	 	 	 multiplet	(NMR) 	
MalB	 	 	 Mallard	Blue	
MDP	 	 	 Multidomain	peptide	
NIR	 	 	 Near-infrared	
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NMR	 	 	 Nuclear	Magnetic	Resonance		
PA	 	 	 Peptide	amphiphile	
PBS	 	 	 Phosphate	buffer	saline	
PdI	 	 	 Polydispersity	index		
PEG	 	 	 Poly(ethylene	glycol)	
PEG-AMI	 	 Maleimide-terminated	poly(ethylene	glycol)	
PEGDM	 	 Poly(ethylene	glycol)	dimethacrylate	
PFA	 	 	 Paraformaldehyde	
PG	 	 	 Polymer	gelator	
PlGF-1	 	 	 Placental	growth	factor-1	
P/S	 	 	 Penicillin/Streptomycin	
p-TsOH	 	 p-Toluenesulfonic	acid		
q	 	 	 quartet	(NMR) 	
RGD	 	 	 Arginine-glycine-aspartic	acid		
s	 	 	 strong	(IR)	
s	 	 	 singlet	(NMR)	
SAMul	 	 	 Self-assembling	multivalency	
SAXS	 	 	 Small	Angle	X-Ray	Scattering	
SDS	 	 	 Sodium	dodecylsulfonate	
SDBS	 	 	 Dodecylbenzenesulfonate	
SEM	 	 	 Scanning	Electron	Microscopy	
SHH	 	 	 Sonic	hedgehog	
t	 	 	 triplet	(NMR) 	
TBTU	 	 	 O-(Benzotriazol-1-yl)-N,N,Nʹ,Nʹ-tetramethyluronium	
tetrafluoroborate	
TEM	 	 	 Transmission	Electron	Microscopy	
Tgel	 	 	 Critical	gelation	temperature	
TGFb	 	 	 Transforming	growth	factor	beta		
TLC	 	 	 Thin	layer	chromatography	
TRITC	 	 	 Tetramethylrhodamine	B	isothiocyanate	
V	 	 	 Valine	
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VEGF	 	 	 Vascular	endothelial	growth	factor	
w	 	 	 weak	(IR)	
WST-1	 	 	 Tetrazolium	salt	
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